{"meta":{"query_hash":"4aa5585a87ca","filters":{"venue":"SKIN The Journal of Cutaneous Medicine"},"cohort_total":247,"direct_labels_cover":0,"predictions_cover":247,"exported":247,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/4aa5585a87ca","api":"https://metacan.xera.ac/api/v1/cohort?venue=SKIN+The+Journal+of+Cutaneous+Medicine"},"results":[{"id":"W2765131124","doi":"10.25251/skin.2.supp.54","title":"Omalizumab Retreatment of Patients with Chronic Idiopathic Urticaria/Spontaneous Urticaria (CIU/CS) Following Return of Symptoms: Primary Results of the Optima Study","year":2018,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Urticaria and Related Conditions","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Novartis Pharmaceuticals Canada; European Academy of Allergy and Clinical Immunology","keywords":"Medicine; Chronic urticaria; Omalizumab; Dermatology; Primary care; Immunology; Immunoglobulin E; Antibody; Family medicine","score_opus":0.005904810974161413,"score_gpt":0.23462561414136235,"score_spread":0.22872080316720095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765131124","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962871,0.0027102414,0.000036178702,0.00010424252,0.000030672887,0.00005421028,0.00012848673,0.000008955916,0.0006400108],"genre_scores_gemma":[0.9987087,0.00062624103,0.00010318909,0.00010121534,0.00005917615,0.000027327085,0.00017311997,0.0000020751465,0.00019896233],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99959797,0.00017528469,0.00003819061,0.00005160885,0.0000715579,0.0000653539],"domain_scores_gemma":[0.9992092,0.00025745927,0.00025161495,0.00006014642,0.000041349344,0.00018029004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013992072,0.00031325666,0.001367615,0.00026927114,0.0002567395,0.0005743338,0.00030938254,0.00051562063,0.0008385289],"category_scores_gemma":[0.0016834346,0.00020415524,0.0009640428,0.00019781342,0.00025150168,0.0004457803,0.00018232645,0.0007521288,0.0002504426],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.31729218,0.014496198,0.34155712,0.0019283596,0.0052051414,0.0012089811,0.0006270533,0.00070660014,0.013623022,0.00020209383,0.004290255,0.29886305],"study_design_scores_gemma":[0.036347724,0.07424082,0.87956345,0.00017641607,0.0028716158,0.001835333,0.00027933702,0.0010501294,0.0013188047,0.00016946782,0.0021000367,0.000046770267],"about_ca_topic_score_codex":0.00068712584,"about_ca_topic_score_gemma":0.0012000079,"teacher_disagreement_score":0.0013992072,"about_ca_system_score_codex":0.00029832483,"about_ca_system_score_gemma":0.0003017172,"threshold_uncertainty_score":0.0073997974},"labels":[],"label_agreement":null},{"id":"W2788512183","doi":"10.25251/skin.2.supp.52","title":"Omalizumab Dose Step-Up and Treatment Response in Patients with Chronic Idiopathic/Spontaneous Urticaria (CIU/CSU): Results from the OPTIMA Study","year":2018,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Urticaria and Related Conditions","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Novartis Pharmaceuticals Canada; Novartis Pharma","keywords":"Omalizumab; Medicine; Chronic urticaria; Dermatology; Pediatrics; Immunology; Immunoglobulin E; Antibody","score_opus":0.009935159998666033,"score_gpt":0.253629792716605,"score_spread":0.24369463271793898,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2788512183","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941857,0.004252983,0.00006342981,0.00014781991,0.00002480141,0.0000579293,0.0004207144,0.000017206406,0.0008295458],"genre_scores_gemma":[0.9985856,0.00042668826,0.00017168048,0.00011418633,0.00003635105,0.00003772043,0.00042817,0.000003821961,0.00019582851],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993325,0.00029685578,0.00006696006,0.00010349201,0.00012905266,0.00007115955],"domain_scores_gemma":[0.9988022,0.00037325334,0.00048350918,0.00009605476,0.00006099536,0.00018396095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013025264,0.00033689322,0.0010633892,0.0002938179,0.00021287618,0.00064854324,0.00036233367,0.00060619414,0.00097223034],"category_scores_gemma":[0.0018542592,0.0002303626,0.0008591634,0.00034150938,0.00019310118,0.00040088117,0.00020696207,0.00092513487,0.00026955394],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24612358,0.006289164,0.55795115,0.0010471714,0.0066424375,0.0003507729,0.0003517314,0.0011964063,0.0098391,0.00019675703,0.0049360287,0.16507567],"study_design_scores_gemma":[0.017559187,0.015115975,0.9614492,0.00009724149,0.002157046,0.0004423884,0.000079865495,0.0010663153,0.0006992152,0.00013407545,0.0011650149,0.00003436971],"about_ca_topic_score_codex":0.00046572223,"about_ca_topic_score_gemma":0.00079142174,"teacher_disagreement_score":0.0013025264,"about_ca_system_score_codex":0.00031782253,"about_ca_system_score_gemma":0.00016771046,"threshold_uncertainty_score":0.006888509},"labels":[],"label_agreement":null},{"id":"W2788759478","doi":"10.25251/skin.2.supp.11","title":"Patient Preferences for Vehicle and Overall Preference of Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam and Gel in the PSO-INSIGHTFUL Study","year":2018,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of British Columbia","funders":"","keywords":"Betamethasone dipropionate; Preference; Dermatology; Psychology; Medicine; Mathematics; Statistics","score_opus":0.2444633296620573,"score_gpt":0.39722299043489334,"score_spread":0.15275966077283604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2788759478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99818015,0.0006599927,0.000029327131,0.00011304692,0.000011529685,0.000017409373,0.0003928478,0.0000013408338,0.00059437874],"genre_scores_gemma":[0.99925333,0.00018529409,0.000035358902,0.000060492275,0.000008624716,0.000008653453,0.00025544167,6.7564304e-7,0.00019212236],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99964595,0.00018011134,0.00004401792,0.0000375407,0.00005377811,0.00003862448],"domain_scores_gemma":[0.9982254,0.00088468,0.00052490097,0.00006046786,0.000050457496,0.0002541501],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009402301,0.0001891306,0.00038673752,0.00021054615,0.000109474866,0.0005057009,0.00014826536,0.00047338547,0.0055268267],"category_scores_gemma":[0.003640974,0.00010357374,0.0009209048,0.00030407825,0.00016536808,0.00037160714,0.0001493658,0.00054343627,0.00028503325],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13054706,0.002205166,0.7891877,0.0005483959,0.003178552,0.0005987552,0.00036097458,0.0010660624,0.002735591,0.00046533326,0.0032877878,0.06581859],"study_design_scores_gemma":[0.009265623,0.020564878,0.95870405,0.00018034129,0.002454777,0.0012799717,0.00090166304,0.00286778,0.0007748565,0.00055073027,0.002359471,0.00009580932],"about_ca_topic_score_codex":0.0007646013,"about_ca_topic_score_gemma":0.0013037882,"teacher_disagreement_score":0.0055268267,"about_ca_system_score_codex":0.0001904066,"about_ca_system_score_gemma":0.00016908557,"threshold_uncertainty_score":0.018489122},"labels":[],"label_agreement":null},{"id":"W2789068895","doi":"10.25251/skin.2.supp.4","title":"Clinical Efficacy or Tildrakizumab in Patients with Chronic Plaque Psoriasis Over 2 Years of Treatment: Results from Long-Term Extensions to 2 Phase 3 Clinical Studies","year":2018,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Plaque psoriasis; Medicine; Psoriasis; Term (time); Dermatology; Clinical efficacy; Internal medicine; Physics","score_opus":0.04899517628077045,"score_gpt":0.37599208035405723,"score_spread":0.3269969040732868,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789068895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97563756,0.019611595,0.0002666536,0.0004427016,0.0001651139,0.00076818024,0.00080935535,0.00007030175,0.0022283958],"genre_scores_gemma":[0.9899351,0.005682393,0.000414141,0.00073897716,0.00027712542,0.0005425521,0.0010829038,0.000015288411,0.0013115038],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9989743,0.0004610887,0.00006492221,0.00013636373,0.00014861181,0.00021466614],"domain_scores_gemma":[0.9986866,0.0003092885,0.00036403042,0.00011451983,0.000109771514,0.00041580995],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032561508,0.001064239,0.0022697202,0.0004317379,0.000542147,0.0009161492,0.00044411296,0.0013033517,0.0025345278],"category_scores_gemma":[0.0016441694,0.0003798268,0.002030929,0.0004693063,0.0006238626,0.0009156426,0.00028122397,0.00208375,0.000601162],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.69848675,0.027948512,0.0212201,0.0017495304,0.0054329033,0.00032785634,0.00038300658,0.0011013817,0.030037971,0.00013968379,0.0035117676,0.2096605],"study_design_scores_gemma":[0.4382498,0.41269347,0.13851155,0.00027519022,0.0028640795,0.00050030235,0.00013599687,0.0006661598,0.0019283622,0.0001919772,0.0039160545,0.000067061184],"about_ca_topic_score_codex":0.0013919703,"about_ca_topic_score_gemma":0.003118463,"teacher_disagreement_score":0.0032561508,"about_ca_system_score_codex":0.00067739433,"about_ca_system_score_gemma":0.0008372906,"threshold_uncertainty_score":0.017220438},"labels":[],"label_agreement":null},{"id":"W2793020549","doi":"10.25251/skin.2.supp.13","title":"Psoriasis Patients on Chronic Biologic Therapy May Benefit from Additional Treatment-Study Design and Baseline Characteristics","year":2018,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Pharmaceutical studies and practices","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"LEO Pharma; Valeant Pharmaceuticals International; Regeneron Pharmaceuticals; Celgene; Amgen; Pfizer; Allergan; Eli Lilly and Company","keywords":"Psoriasis; Baseline (sea); Medicine; Plaque psoriasis; Physical therapy; Internal medicine; Dermatology; Biology","score_opus":0.06000297180320597,"score_gpt":0.3419998588694396,"score_spread":0.28199688706623366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793020549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95963204,0.0073128976,0.003849149,0.002758868,0.00043753115,0.0018856685,0.008410165,0.000047094956,0.015666531],"genre_scores_gemma":[0.98531544,0.001112849,0.0015737405,0.0014575346,0.00029917923,0.0013618619,0.0035163404,0.000010495615,0.0053526335],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989278,0.0005304675,0.00014361227,0.00014410041,0.00011502773,0.00013904917],"domain_scores_gemma":[0.9986093,0.00040418416,0.00046982145,0.00017974089,0.00014424321,0.0001925703],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021827132,0.00032694158,0.00060173817,0.0003093421,0.00054498203,0.00066769455,0.00033525133,0.00055759406,0.012184056],"category_scores_gemma":[0.0033782895,0.00017849106,0.0009258994,0.0006973087,0.00026019363,0.00075195957,0.00023187757,0.0005847876,0.0012037113],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.081328586,0.005221556,0.7332185,0.0013538131,0.0020441199,0.00060081854,0.00018904224,0.00046110974,0.005427105,0.0010882054,0.015061556,0.15400565],"study_design_scores_gemma":[0.010015408,0.0210043,0.934209,0.00043860567,0.0017020251,0.001464479,0.000290568,0.0010942947,0.002188088,0.002839859,0.024713412,0.000039972172],"about_ca_topic_score_codex":0.000829217,"about_ca_topic_score_gemma":0.0028518129,"teacher_disagreement_score":0.012184056,"about_ca_system_score_codex":0.00045073536,"about_ca_system_score_gemma":0.0007831741,"threshold_uncertainty_score":0.040759742},"labels":[],"label_agreement":null},{"id":"W2890005351","doi":"10.25251/2.5.7","title":"Nab-paclitaxel/Gemcitabine Induced Acquired Ichthyosis","year":2018,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Skin and Cellular Biology Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"","keywords":"Ichthyosis; Gemcitabine; Paclitaxel; Medicine; Dermatology; Endocrine system; Disease; Drug; Oncology; Internal medicine; Chemotherapy; Pharmacology; Hormone","score_opus":0.01681145973259187,"score_gpt":0.29562266937997045,"score_spread":0.2788112096473786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890005351","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96273917,0.010194316,0.0034302187,0.00072911015,0.00020019943,0.00015157224,0.00021205754,0.00022460005,0.022118958],"genre_scores_gemma":[0.99280435,0.0035367482,0.00070743496,0.00030482627,0.000071292874,0.000010990466,0.00006922223,0.000017324928,0.0024779332],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9998745,0.000021868076,0.000013215438,0.000023928242,0.00003131468,0.000035125544],"domain_scores_gemma":[0.9998313,0.000038488884,0.00006132665,0.000017708899,0.000015194329,0.000035993817],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000083146755,0.00031792195,0.0002785595,0.00038741296,0.0003165498,0.000387986,0.00019628125,0.0004588637,0.0010748125],"category_scores_gemma":[0.00041172796,0.00011661981,0.000308108,0.000293457,0.00028996394,0.00031311065,0.00027578245,0.00064683304,0.00033251676],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001023535,0.000046865498,0.01047862,0.00015042882,0.000024295883,0.96111536,0.00010276812,0.00019325981,0.014886596,0.0003318902,0.00043876196,0.012128768],"study_design_scores_gemma":[0.000011709055,0.00013697898,0.007694736,0.000020789175,0.000026304628,0.9807334,0.00006244105,0.00037854738,0.006496445,0.00015567205,0.004276652,0.0000063208035],"about_ca_topic_score_codex":0.0005230104,"about_ca_topic_score_gemma":0.00082939083,"teacher_disagreement_score":0.0010748125,"about_ca_system_score_codex":0.00040492282,"about_ca_system_score_gemma":0.00024571715,"threshold_uncertainty_score":0.0035956502},"labels":[],"label_agreement":null},{"id":"W2899771516","doi":"10.25251/skin.2.6.5","title":"Efficacy of a Silicone-Based Gel Containing Pracaxi Oil (Pentaclethra macroloba) for Treating Post-Surgical Scars","year":2018,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatologic Treatments and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Scars; Silicone; Surgery; Silicone oil; Randomized controlled trial","score_opus":0.022799221518680992,"score_gpt":0.3523882437653737,"score_spread":0.32958902224669273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2899771516","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99845886,0.00071099924,0.000117213436,0.00003230753,0.000037990576,0.00032211252,0.000053034815,0.000007687664,0.00025978513],"genre_scores_gemma":[0.9970796,0.0010299999,0.0005328379,0.00007136278,0.00009107866,0.0003313888,0.00013157696,0.000002837109,0.00072937936],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.999696,0.00013242454,0.000032082822,0.000043662483,0.00005216553,0.00004368847],"domain_scores_gemma":[0.999446,0.00020331141,0.00014273211,0.000037084137,0.000036414203,0.00013444664],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072032126,0.00048230303,0.0008198719,0.0003446688,0.00025407836,0.00027658898,0.0004455396,0.0006039439,0.0018080359],"category_scores_gemma":[0.0007278548,0.0002594668,0.0005155536,0.000168062,0.0005135207,0.00039922487,0.00021147905,0.00068211986,0.00019153628],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6285669,0.10691526,0.004894256,0.0014941936,0.00043945675,0.00020174036,0.00023242505,0.00030768994,0.17098847,0.0001508676,0.0003362373,0.085472465],"study_design_scores_gemma":[0.03811426,0.94220084,0.009877442,0.000025643209,0.00018486948,0.00010523475,0.00005734127,0.00016638944,0.008904088,0.000029786357,0.00032286794,0.000011310565],"about_ca_topic_score_codex":0.00046828677,"about_ca_topic_score_gemma":0.0009970621,"teacher_disagreement_score":0.0018080359,"about_ca_system_score_codex":0.00016149359,"about_ca_system_score_gemma":0.00038252884,"threshold_uncertainty_score":0.0060485005},"labels":[],"label_agreement":null},{"id":"W2982882356","doi":"10.25251/skin.3.supp.36","title":"Long-Term Efficacy of Certolizumab Pegol Dosed at 400 mg Every Two Weeks in Patients with Plaque Psoriasis: Pooled 128-Week Data from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2)","year":2019,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre de Recherche Dermatologique du Québec Métropolitain","funders":"","keywords":"Certolizumab pegol; Medicine; Psoriasis; Plaque psoriasis; Term (time); Internal medicine; Gastroenterology; Dermatology; Adalimumab; Disease","score_opus":0.029787239770012654,"score_gpt":0.29823996114461543,"score_spread":0.2684527213746028,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982882356","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8959015,0.09487818,0.001370661,0.00082214177,0.00053419144,0.0008696616,0.0025859862,0.00015339561,0.0028842583],"genre_scores_gemma":[0.98421246,0.011005838,0.0006221872,0.0006519857,0.00035200277,0.0003419112,0.0019469273,0.000026375368,0.000840341],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99840134,0.00084111537,0.00016248284,0.00023769093,0.00016057196,0.0001968335],"domain_scores_gemma":[0.9965739,0.0013897755,0.0008533338,0.0004198562,0.00025040103,0.00051270874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0063418085,0.0012351224,0.0047561997,0.0005110942,0.00042084412,0.0013833711,0.00081760786,0.0018446854,0.0022473694],"category_scores_gemma":[0.0040147947,0.00071938557,0.0053216796,0.000638181,0.00077259965,0.0013703456,0.00045724987,0.0031157355,0.00054429134],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89232403,0.0020963834,0.0071175415,0.002671082,0.028364567,0.00012274533,0.00012112766,0.0018172055,0.0062006577,0.00007407437,0.0016387316,0.05745196],"study_design_scores_gemma":[0.667159,0.19672623,0.09090821,0.000581179,0.036431998,0.00037660362,0.00014117344,0.0014860242,0.0023923274,0.0003964075,0.0032700174,0.00013089334],"about_ca_topic_score_codex":0.0010558234,"about_ca_topic_score_gemma":0.002106926,"teacher_disagreement_score":0.0063418085,"about_ca_system_score_codex":0.0006984024,"about_ca_system_score_gemma":0.0007192279,"threshold_uncertainty_score":0.033539116},"labels":[],"label_agreement":null},{"id":"W2984127608","doi":"10.25251/skin.3.supp.35","title":"Bimekizumab provides rapid and sustained improvements in quality of life that correlate with clinical outcomes in patients with moderate to severe plaque psoriasis: 60 week results from a randomized , double blinded , Phase 2b extension study","year":2019,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Plaque psoriasis; Medicine; Double blinded; Randomized controlled trial; Quality of life (healthcare); Psoriasis; Physical therapy; Surgery; Dermatology; Alternative medicine; Pathology; Nursing","score_opus":0.032285454393292966,"score_gpt":0.30489723420023906,"score_spread":0.2726117798069461,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2984127608","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936155,0.003144818,0.00038391532,0.00036686752,0.00016622304,0.0007086372,0.00048169497,0.00009936731,0.0010330111],"genre_scores_gemma":[0.99427634,0.0016722141,0.00079475815,0.00069447584,0.00036656173,0.00055075315,0.0006008239,0.000025416439,0.0010186209],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99927264,0.00036083502,0.00004663528,0.000093763985,0.00008989065,0.00013630302],"domain_scores_gemma":[0.998835,0.00036306545,0.00028986324,0.00013411496,0.000065337605,0.00031261955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023789066,0.0011612551,0.002349858,0.000340468,0.00030003994,0.00101159,0.000673272,0.0013407066,0.0038764111],"category_scores_gemma":[0.0015733457,0.0005923324,0.0014274279,0.00033452053,0.0009059828,0.0009565473,0.00037766545,0.0031719364,0.0007789877],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8704093,0.032274984,0.0025371464,0.0008816294,0.0012008913,0.00007208833,0.00010990073,0.00052522786,0.014443423,0.00011121836,0.0023205918,0.075113565],"study_design_scores_gemma":[0.7660791,0.21664976,0.013994811,0.00004002173,0.0004228179,0.00009741965,0.000033841225,0.00048577358,0.0013603332,0.00012167613,0.0006886418,0.00002578028],"about_ca_topic_score_codex":0.00049850857,"about_ca_topic_score_gemma":0.00071409135,"teacher_disagreement_score":0.0038764111,"about_ca_system_score_codex":0.00034561378,"about_ca_system_score_gemma":0.0005844778,"threshold_uncertainty_score":0.012967885},"labels":[],"label_agreement":null},{"id":"W2985177726","doi":"10.25251/skin.3.supp.12","title":"An oral, selective tyrosine kinase 2 inhibitor, BMS-986165, improves quality of life in psoriasis: results from a Phase 2 study","year":2019,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Probity Medical Research","funders":"","keywords":"Psoriasis; Tyrosine-kinase inhibitor; Medicine; Phase (matter); Pharmacology; Quality of life (healthcare); Chemistry; Internal medicine; Dermatology; Cancer; Organic chemistry","score_opus":0.021637576214507306,"score_gpt":0.3057167029094791,"score_spread":0.2840791266949718,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2985177726","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.981293,0.012664924,0.0005004863,0.0006276212,0.00013834724,0.0007884981,0.0009166464,0.00012061731,0.0029498336],"genre_scores_gemma":[0.9836535,0.01025046,0.0010519328,0.0010423649,0.00026306658,0.00053186034,0.0016305345,0.000031783482,0.0015445867],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9998035,0.000077665485,0.000011296883,0.000024349636,0.000037182694,0.000046053603],"domain_scores_gemma":[0.9997093,0.00008434321,0.000058760113,0.000023810753,0.000021857582,0.00010193955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00086575985,0.00090707035,0.0015503656,0.00028368775,0.0002463608,0.00053749635,0.0004526167,0.00066697906,0.0034697852],"category_scores_gemma":[0.00042063455,0.00026977735,0.0009762369,0.00037845402,0.00043777176,0.0004895605,0.00016917185,0.002092708,0.0005816521],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.492672,0.05881061,0.0055936426,0.0024003563,0.0031530461,0.00040186822,0.00014539852,0.0018030463,0.08263611,0.00025080744,0.006801732,0.3453313],"study_design_scores_gemma":[0.52636474,0.42180318,0.03616256,0.00012943611,0.0019070402,0.0005909997,0.00008593441,0.0012905016,0.0071107396,0.0002868611,0.004227886,0.00004002481],"about_ca_topic_score_codex":0.0007899838,"about_ca_topic_score_gemma":0.00200068,"teacher_disagreement_score":0.0034697852,"about_ca_system_score_codex":0.00032011356,"about_ca_system_score_gemma":0.00051742286,"threshold_uncertainty_score":0.011607647},"labels":[],"label_agreement":null},{"id":"W2985715279","doi":"10.25251/skin.3.supp.15","title":"Tapinarof Cream for the Treatment of Plaque Psoriasis: Efficacy and Safety by Baseline Disease Characteristics and Skin Type in a Phase 2b Randomized Study","year":2019,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of British Columbia","funders":"","keywords":"Plaque psoriasis; Medicine; Dermatology; Randomized controlled trial; Psoriasis; Disease; Internal medicine","score_opus":0.011130336037182963,"score_gpt":0.27348718798880434,"score_spread":0.2623568519516214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2985715279","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888509,0.0042395215,0.00060686097,0.0003921649,0.00024495213,0.0029899075,0.0012296897,0.00009529003,0.0013506188],"genre_scores_gemma":[0.98486626,0.0042446153,0.0016539625,0.0008622184,0.0005583117,0.003609461,0.001468165,0.00005348673,0.002683575],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9990771,0.00044572676,0.00004316201,0.0001599602,0.000107137676,0.00016692404],"domain_scores_gemma":[0.9984975,0.00047555935,0.00027549366,0.00016012327,0.000116546056,0.00047486255],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022992317,0.0021962936,0.004050664,0.00052867737,0.00049979007,0.0013938725,0.0011659175,0.0018558211,0.008017661],"category_scores_gemma":[0.0019596769,0.0010569195,0.0019299478,0.00064325053,0.0014943307,0.0015979824,0.00048205277,0.0037360555,0.0010813634],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97320324,0.010797451,0.0005228531,0.00036865825,0.00064607325,0.00002913779,0.00003996387,0.00021078439,0.003092709,0.00006780317,0.00044034488,0.010580938],"study_design_scores_gemma":[0.9141771,0.08202711,0.0023353768,0.000024023815,0.0004071771,0.000031679607,0.000017761146,0.0002669397,0.00027365962,0.000106748026,0.00031695294,0.000015494752],"about_ca_topic_score_codex":0.0010358731,"about_ca_topic_score_gemma":0.001768706,"teacher_disagreement_score":0.008017661,"about_ca_system_score_codex":0.00077042455,"about_ca_system_score_gemma":0.0012688985,"threshold_uncertainty_score":0.026821733},"labels":[],"label_agreement":null},{"id":"W2986283446","doi":"10.25251/skin.3.supp.38","title":"Nail Outcome Improvements with Certolizumab Pegol in Moderate to Severe Plaque Psoriasis: Results from Phase 3 Trials","year":2019,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre de Recherche Dermatologique du Québec Métropolitain","funders":"","keywords":"Certolizumab pegol; Medicine; Plaque psoriasis; Psoriasis; Nail (fastener); Dermatology; Outcome (game theory); Internal medicine; Infliximab; Tumor necrosis factor alpha; Materials science","score_opus":0.03094004696178332,"score_gpt":0.2977013145001826,"score_spread":0.2667612675383993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2986283446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7530582,0.2183189,0.0017115813,0.0050678225,0.001118655,0.002538283,0.003301515,0.00034649292,0.014538627],"genre_scores_gemma":[0.9535778,0.036554758,0.0012320862,0.0030806107,0.0005352936,0.0008128764,0.0013376727,0.000027833146,0.0028411003],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9995189,0.00022043823,0.00003398846,0.00006100968,0.000078407495,0.000087323686],"domain_scores_gemma":[0.9991241,0.0003927982,0.00019820857,0.000047672966,0.00008955192,0.00014763969],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016899004,0.00063362037,0.0015021655,0.0002109979,0.00024524948,0.0007604727,0.00035447234,0.00079203816,0.0048262347],"category_scores_gemma":[0.0016252395,0.00016153009,0.0018565597,0.00028101922,0.00037821653,0.00049942033,0.00020076762,0.0018305045,0.0005656888],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5045062,0.006064697,0.0047429865,0.012224786,0.00914214,0.00020680131,0.0001643475,0.0012952873,0.013437808,0.0005146006,0.016496101,0.43120426],"study_design_scores_gemma":[0.72056764,0.17463215,0.06171346,0.0032454836,0.010245369,0.000765346,0.00023655356,0.0014320667,0.0045860433,0.0022150476,0.020281909,0.000078916375],"about_ca_topic_score_codex":0.00081175874,"about_ca_topic_score_gemma":0.0019976052,"teacher_disagreement_score":0.0048262347,"about_ca_system_score_codex":0.0004451355,"about_ca_system_score_gemma":0.00046749666,"threshold_uncertainty_score":0.016145408},"labels":[],"label_agreement":null},{"id":"W2986312172","doi":"10.25251/skin.3.supp.39","title":"Safety of Certolizumab Pegol in Plaque Psoriasis: Pooled 96-Week Data from Three Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1, CIMPASI-2 and CIMPACT)","year":2019,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Probity Medical Research","funders":"","keywords":"Certolizumab pegol; Placebo; Medicine; Psoriasis; Plaque psoriasis; Randomized controlled trial; Multicenter study; Internal medicine; Dermatology; Adalimumab; Pathology; Alternative medicine","score_opus":0.028946586606599847,"score_gpt":0.2972223779139177,"score_spread":0.2682757913073179,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2986312172","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8637459,0.12023051,0.0036885117,0.0011388442,0.0007246833,0.002568325,0.0043783966,0.00033963812,0.0031851735],"genre_scores_gemma":[0.9795521,0.014225807,0.0013657439,0.0007159655,0.00048263674,0.00079277717,0.0021136329,0.000047045378,0.0007043938],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99758446,0.0013491941,0.00027212515,0.00036468025,0.00028725975,0.00014225692],"domain_scores_gemma":[0.9932806,0.0029326791,0.0021183456,0.0006066155,0.00051752455,0.000544193],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008733111,0.0013563288,0.004256478,0.000587333,0.00042402578,0.0013243499,0.0008109319,0.002149747,0.0033576156],"category_scores_gemma":[0.00764849,0.00079859147,0.005025735,0.0006975676,0.0008926615,0.0014142711,0.00043188833,0.002615171,0.0006266401],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9094241,0.0013449531,0.004545648,0.004323327,0.022580609,0.00007487448,0.000090478105,0.0012338117,0.007294633,0.00007842619,0.0013117654,0.04769734],"study_design_scores_gemma":[0.78782445,0.12129296,0.050845068,0.00064216665,0.030531552,0.00039161122,0.00009374955,0.0013146977,0.0039651976,0.00052503013,0.0024749222,0.00009861309],"about_ca_topic_score_codex":0.00051592937,"about_ca_topic_score_gemma":0.0006079936,"teacher_disagreement_score":0.008733111,"about_ca_system_score_codex":0.0005374987,"about_ca_system_score_gemma":0.0007041341,"threshold_uncertainty_score":0.046185672},"labels":[],"label_agreement":null},{"id":"W2987175910","doi":"10.25251/skin.3.supp.37","title":"Certolizumab Pegol for Treatment of Plaque Psoriasis: Pooled Three-Year Efficacy Outcomes from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2)","year":2019,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre de Recherche Dermatologique du Québec Métropolitain","funders":"","keywords":"Certolizumab pegol; Medicine; Plaque psoriasis; Psoriasis; Dermatology; Internal medicine; Oncology; Adalimumab; Disease","score_opus":0.038676375836139795,"score_gpt":0.3220570760310816,"score_spread":0.28338070019494177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2987175910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83734596,0.14487174,0.0022771992,0.0018703679,0.000885875,0.0022672745,0.0060152444,0.0002447035,0.004221621],"genre_scores_gemma":[0.97248095,0.018630233,0.0012331276,0.0012763996,0.00059250474,0.0009094603,0.0040144688,0.000049485818,0.0008133192],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99776304,0.0012937249,0.00020573758,0.00028693984,0.0002503252,0.00020011065],"domain_scores_gemma":[0.99543387,0.0020837525,0.0012687314,0.0003980159,0.00030215096,0.0005135048],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008851249,0.001289631,0.004590121,0.0006312795,0.0003680203,0.0017517079,0.0007651581,0.0017991995,0.002519952],"category_scores_gemma":[0.0058771227,0.0006174113,0.008016114,0.0008087711,0.0006041598,0.001311939,0.0005804825,0.0029097176,0.00044356906],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88200986,0.0009710522,0.0067581614,0.0034138993,0.049182788,0.00009738129,0.00008244341,0.002128409,0.0033953758,0.00012297735,0.0025427546,0.049294833],"study_design_scores_gemma":[0.7612652,0.074110106,0.08328254,0.00086756324,0.071451485,0.0003405999,0.0001132536,0.0023209094,0.0017274424,0.0007525966,0.0036333099,0.00013497754],"about_ca_topic_score_codex":0.0011721066,"about_ca_topic_score_gemma":0.002229066,"teacher_disagreement_score":0.008851249,"about_ca_system_score_codex":0.0007554855,"about_ca_system_score_gemma":0.0009774812,"threshold_uncertainty_score":0.04681039},"labels":[],"label_agreement":null},{"id":"W2987595422","doi":"10.25251/skin.3.supp.14","title":"Influence of baseline demographics/disease characteristics on efficacy of an oral selective TYK2 inhibitor, BMS-986165, in patients with moderate to severe plaque psoriasis: Phase 2, randomized, placebo-controlled trial","year":2019,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Cytokine Signaling Pathways and Interactions","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Probity Medical Research","funders":"","keywords":"Medicine; Randomized controlled trial; Demographics; Placebo; Plaque psoriasis; Internal medicine; Psoriasis; Dermatology; Pathology; Alternative medicine","score_opus":0.007098689643237144,"score_gpt":0.2681841225595791,"score_spread":0.26108543291634195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2987595422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98295283,0.01208627,0.0002919314,0.00049629377,0.00040728893,0.0009259978,0.000612091,0.000052970216,0.002174308],"genre_scores_gemma":[0.99219793,0.0038582056,0.00039818246,0.000585651,0.00041488025,0.0007573765,0.00059869664,0.0000098824885,0.0011791626],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9996493,0.00016090457,0.000035583944,0.000060531023,0.000036118465,0.000057506113],"domain_scores_gemma":[0.99947435,0.00017701232,0.00012362284,0.000032112195,0.0000335542,0.00015923157],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010533545,0.0011299332,0.0023508943,0.00023861474,0.00030242017,0.00088843616,0.00047436653,0.0011605633,0.0037629749],"category_scores_gemma":[0.0011437257,0.00042719117,0.0014909691,0.0003131689,0.00060373324,0.00078296824,0.00022989634,0.0019498763,0.00050622824],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96843845,0.0027668325,0.0019123515,0.0010021473,0.00197521,0.00003884587,0.000028633043,0.00025314366,0.0028191737,0.00007337891,0.000594695,0.020097103],"study_design_scores_gemma":[0.89776176,0.08493623,0.01241628,0.00009783335,0.002281648,0.000060464517,0.00003514498,0.0006551636,0.000634007,0.00019500157,0.0009021662,0.00002418658],"about_ca_topic_score_codex":0.0004346939,"about_ca_topic_score_gemma":0.0010584067,"teacher_disagreement_score":0.0037629749,"about_ca_system_score_codex":0.00038297568,"about_ca_system_score_gemma":0.0005671886,"threshold_uncertainty_score":0.012588382},"labels":[],"label_agreement":null},{"id":"W2989334748","doi":"10.25251/skin.3.supp.26","title":"Long-term Efficacy, Safety, and Patient-Reported Outcomes in a Phase 2 Study of Brodalumab","year":2019,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Term (time); Medicine; Phase (matter); Intensive care medicine; Chemistry; Physics","score_opus":0.11277680321458737,"score_gpt":0.4069110720091389,"score_spread":0.2941342687945515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2989334748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935673,0.0026019968,0.00023354741,0.00043176516,0.000116620184,0.0011073387,0.0009519075,0.00001802498,0.000971472],"genre_scores_gemma":[0.99339795,0.0011627988,0.00046745167,0.0007983394,0.00019702056,0.0012290062,0.0013257693,0.000011799877,0.0014098731],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9986583,0.00072028226,0.00007252827,0.0001641282,0.00013374818,0.00025103986],"domain_scores_gemma":[0.99722254,0.000834268,0.0006723812,0.0002948831,0.00022763558,0.00074824283],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0047854558,0.0010161046,0.0018464124,0.0003071211,0.00052866683,0.0014670019,0.0007075075,0.0014650046,0.00421866],"category_scores_gemma":[0.003274708,0.00051573716,0.0022578903,0.00030344343,0.0009241861,0.0011771577,0.0003676018,0.0036888234,0.0007668662],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.91133815,0.03144395,0.008093161,0.0005668167,0.0028516015,0.0001536579,0.00015036661,0.00096762227,0.0069638677,0.00012356734,0.0017823784,0.035564844],"study_design_scores_gemma":[0.559195,0.3904795,0.044205602,0.00009782144,0.0017482359,0.00017612697,0.00007659889,0.00082055543,0.001291312,0.00016840211,0.001682011,0.00005880444],"about_ca_topic_score_codex":0.0007760171,"about_ca_topic_score_gemma":0.001383976,"teacher_disagreement_score":0.0047854558,"about_ca_system_score_codex":0.0009358266,"about_ca_system_score_gemma":0.0011476693,"threshold_uncertainty_score":0.025308251},"labels":[],"label_agreement":null},{"id":"W2989489239","doi":"10.25251/skin.3.supp.17","title":"Maintenance of Response With up to 4 Years of Continuous Guselkumab Treatment: Results From the VOYAGE 1 Phase 3 Trial","year":2019,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Phase (matter); Medicine; Physics","score_opus":0.012942369372670017,"score_gpt":0.31888104224857944,"score_spread":0.3059386728759094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2989489239","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96786,0.021811403,0.0008370243,0.0016246873,0.0005030338,0.0007605521,0.0021511964,0.00020696744,0.004245198],"genre_scores_gemma":[0.987145,0.0042963694,0.0008355767,0.0015871702,0.0002332752,0.00075679837,0.0023222864,0.000055116696,0.0027685135],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9994085,0.00023460454,0.000024146777,0.00009619248,0.000048496095,0.00018802006],"domain_scores_gemma":[0.9984713,0.0004572967,0.0003086594,0.00021070834,0.000075987504,0.00047610365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021171889,0.00082039204,0.0023414365,0.00025675172,0.0004748287,0.001427158,0.0007761539,0.0014000116,0.0048964894],"category_scores_gemma":[0.0015259527,0.000255811,0.0023578685,0.00038739617,0.000785955,0.0017043371,0.00041555756,0.0040741796,0.0010986761],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.76267487,0.007369186,0.0042483406,0.0017852344,0.0038245842,0.00014627213,0.00022901144,0.0020500359,0.011836394,0.0004651443,0.0076920283,0.19767894],"study_design_scores_gemma":[0.74984807,0.1861152,0.047468964,0.00048549776,0.0022152974,0.00046034047,0.00015534053,0.0014516282,0.0024679773,0.0012600513,0.007994294,0.000077289995],"about_ca_topic_score_codex":0.0007226514,"about_ca_topic_score_gemma":0.0017100949,"teacher_disagreement_score":0.0048964894,"about_ca_system_score_codex":0.00085125165,"about_ca_system_score_gemma":0.0007154625,"threshold_uncertainty_score":0.01638037},"labels":[],"label_agreement":null},{"id":"W2990965204","doi":"10.25251/skin.3.6.20","title":"Reply: Terra Firma-Forme Dermatosis, Keratotic Form","year":2019,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Genetic and rare skin diseases.","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"","keywords":"Dermatology; Medicine; Art","score_opus":0.004164474139625888,"score_gpt":0.22426806103967611,"score_spread":0.22010358690005022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990965204","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012345772,0.0047549526,0.00025799483,0.8981248,0.09280628,0.00005504921,0.00031377928,0.000082046245,0.0023705019],"genre_scores_gemma":[0.017370027,0.0070946957,0.00063940795,0.84025884,0.11897017,0.00011894314,0.00033848122,0.00004818357,0.015161346],"study_design_codex":"not_applicable","study_design_gemma":"case_report","domain_scores_codex":[0.99913776,0.00027134753,0.00018764942,0.00013133691,0.0001454111,0.00012651777],"domain_scores_gemma":[0.99738127,0.0014058771,0.00014046615,0.00012605361,0.0006233537,0.00032303963],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013458584,0.0009541766,0.0013033679,0.0007867609,0.0011119525,0.0012942491,0.0015800776,0.021955691,0.009918524],"category_scores_gemma":[0.010541662,0.00065247936,0.0010450633,0.0006459468,0.0019338727,0.0024282502,0.00081035873,0.018024921,0.006637537],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018673096,0.000032870226,0.0010611728,0.00023391821,0.000028332503,0.009930192,0.00009129251,0.00010384306,0.0004253042,0.0010026613,0.9798819,0.0070217643],"study_design_scores_gemma":[0.0003320027,0.00018447252,0.006088392,0.0006106508,0.00012724205,0.039526895,0.0008538232,0.0006757774,0.00076911063,0.0067633763,0.9439249,0.00014341545],"about_ca_topic_score_codex":0.0027995594,"about_ca_topic_score_gemma":0.0023663186,"teacher_disagreement_score":0.021955691,"about_ca_system_score_codex":0.0013535918,"about_ca_system_score_gemma":0.0010382724,"threshold_uncertainty_score":0.033180714},"labels":[],"label_agreement":null},{"id":"W2993441120","doi":"10.25251/skin.3.6.2","title":"Transitioning Between Biologics","year":2019,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Adverse effect; Intensive care medicine; Biologic Agents; Plaque psoriasis; Psoriasis; Internal medicine; Dermatology; Disease","score_opus":0.014640119302499015,"score_gpt":0.2405203201935189,"score_spread":0.2258802008910199,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2993441120","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13518195,0.68786216,0.035643175,0.035250466,0.0060145864,0.0017749114,0.0009328441,0.0011414706,0.09619852],"genre_scores_gemma":[0.6485152,0.23078048,0.054116897,0.03967915,0.003936498,0.0012230608,0.0012057687,0.000249363,0.020293573],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972433,0.0009890725,0.00049622735,0.00038912054,0.00069195393,0.00019037501],"domain_scores_gemma":[0.99438334,0.0026993428,0.0014366896,0.00038693353,0.0006349645,0.00045865634],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034914631,0.00032283852,0.00079373666,0.000834539,0.00054342125,0.0017155511,0.0008803324,0.001311957,0.009197526],"category_scores_gemma":[0.01031028,0.00022198078,0.0014370087,0.00052303233,0.00064664165,0.002238953,0.001030115,0.0035330127,0.0029094478],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023836112,0.0010458505,0.0048868544,0.0067820568,0.00026895714,0.00085303513,0.0005837721,0.00035250693,0.006084968,0.0059980066,0.020170229,0.95059013],"study_design_scores_gemma":[0.0015447405,0.006582984,0.013126575,0.010413489,0.0012876969,0.008145449,0.0012101068,0.0005980297,0.012894991,0.019402865,0.9246814,0.000111742374],"about_ca_topic_score_codex":0.0005195331,"about_ca_topic_score_gemma":0.0006832324,"teacher_disagreement_score":0.009197526,"about_ca_system_score_codex":0.00071053935,"about_ca_system_score_gemma":0.0010932304,"threshold_uncertainty_score":0.030768812},"labels":[],"label_agreement":null},{"id":"W3003414630","doi":"10.25251/skin.4.supp.46","title":"Long-Term Safety of Certolizumab Pegol in Plaque Psoriasis: Pooled Analysis over 3 Years from Three Phase 3, Randomized, Placebo-Controlled Studies","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"UCB Pharma; National Institute for Health and Care Research; Manchester Biomedical Research Centre; Dermira","keywords":"Certolizumab pegol; Medicine; Placebo; Term (time); Randomized controlled trial; Psoriasis; Plaque psoriasis; Internal medicine; Dermatology; Adalimumab; Alternative medicine; Pathology; Disease; Physics","score_opus":0.017923057379120415,"score_gpt":0.28185330641825046,"score_spread":0.26393024903913004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3003414630","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.59438336,0.3889111,0.005010721,0.0010215997,0.0011717771,0.0022098154,0.0046361526,0.00024386437,0.0024115965],"genre_scores_gemma":[0.9576959,0.03470662,0.0013936723,0.001018677,0.00065028475,0.0010695495,0.002846332,0.000051387844,0.00056755694],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99423933,0.0026814353,0.0010185738,0.0009624011,0.0007106666,0.00038756145],"domain_scores_gemma":[0.987329,0.0055309786,0.0041920897,0.0011836918,0.0012046385,0.0005595808],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015229229,0.0019199654,0.009053198,0.0010546785,0.00063720404,0.002586724,0.0010156013,0.0026401484,0.0022625087],"category_scores_gemma":[0.012874209,0.0010164256,0.017258532,0.0014564305,0.00097158586,0.0018446302,0.0009369204,0.0026986084,0.00034469657],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6305916,0.00075034675,0.012631876,0.015032195,0.2954571,0.00016485635,0.00011881418,0.0016743026,0.0035674502,0.00011556197,0.0012558491,0.038640074],"study_design_scores_gemma":[0.29409242,0.05291542,0.09800958,0.0020026704,0.5438738,0.00048403515,0.00017634165,0.0013953352,0.0020865875,0.0008358992,0.0039390116,0.00018883026],"about_ca_topic_score_codex":0.00095477357,"about_ca_topic_score_gemma":0.0015611753,"teacher_disagreement_score":0.015229229,"about_ca_system_score_codex":0.001036335,"about_ca_system_score_gemma":0.0011877748,"threshold_uncertainty_score":0.080540776},"labels":[],"label_agreement":null},{"id":"W3004321152","doi":"10.25251/skin.4.supp.60","title":"Safety, Pharmacokinetics, and Efficacy of Efinaconazole 10% Topical Solution for the Treatment of Onychomycosis in Pediatric Patients","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Nail Diseases and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mediprobe Research (Canada); University of Toronto","funders":"","keywords":"Pharmacokinetics; Medicine; Dermatology; Pharmacology","score_opus":0.018450507292060808,"score_gpt":0.2905141314512494,"score_spread":0.27206362415918856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004321152","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99331737,0.0048123985,0.0003495763,0.00016856383,0.000018894129,0.00005963624,0.00033021835,0.000021564341,0.00092169974],"genre_scores_gemma":[0.9979603,0.0013238292,0.00019174516,0.000077245044,0.000025572848,0.00002338649,0.0002219985,0.000005569259,0.00017032646],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995833,0.00020239658,0.000031526582,0.000047589467,0.00009416436,0.00004102774],"domain_scores_gemma":[0.9989374,0.0004289966,0.0003588765,0.00006199029,0.0001003329,0.00011227691],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00067544205,0.00026250622,0.00059649505,0.0001775136,0.00014399311,0.00031075298,0.00019109793,0.0003763425,0.00066514045],"category_scores_gemma":[0.0021847093,0.00012800978,0.00028713426,0.00021331852,0.00024684117,0.00031035888,0.00007515491,0.0007037209,0.0001516427],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13054818,0.005105674,0.2980536,0.0012164237,0.0010542908,0.0030803138,0.00079746114,0.0042125187,0.10378638,0.00077921496,0.004352643,0.44701326],"study_design_scores_gemma":[0.0056379368,0.13202088,0.809759,0.0002635048,0.0013139041,0.0069913343,0.0004940649,0.0049965596,0.03097839,0.00026107868,0.0072199213,0.000063371794],"about_ca_topic_score_codex":0.001221812,"about_ca_topic_score_gemma":0.0012493487,"teacher_disagreement_score":0.001221812,"about_ca_system_score_codex":0.00039425603,"about_ca_system_score_gemma":0.0005500828,"threshold_uncertainty_score":0.0035721064},"labels":[],"label_agreement":null},{"id":"W3023963563","doi":"10.25251/skin.4.3.4","title":"Enhancing Patient Compliance for Usage of Laundry Detergents Free of Dyes and Perfumes: Potential Impact of Better Cleaning Performance","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Skin Protection and Aging","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Laundry; Sensitive skin; Compliance (psychology); Free access; Medicine; Business; Dermatology; Computer science; Waste management; Psychology; World Wide Web; Engineering","score_opus":0.02408597449184304,"score_gpt":0.28284296534816117,"score_spread":0.25875699085631815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3023963563","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95610815,0.008990068,0.002128267,0.012548473,0.00030181298,0.00058173866,0.00041343254,0.00019494205,0.018733151],"genre_scores_gemma":[0.9855182,0.002990836,0.004461825,0.0033484115,0.00018192346,0.00037624754,0.00023837747,0.00003843026,0.002845596],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99592894,0.0020736973,0.00045441338,0.00026148173,0.0008034358,0.00047807794],"domain_scores_gemma":[0.9926601,0.0029535275,0.0021834855,0.00028552598,0.0010192824,0.00089803705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036250025,0.0002243967,0.0006228924,0.00038403278,0.00074819726,0.0011506928,0.00043809027,0.00095076615,0.007191697],"category_scores_gemma":[0.016799929,0.000132128,0.0011124855,0.0005166585,0.00021938139,0.0010355179,0.00091797626,0.0012738846,0.00089777174],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018133094,0.008966398,0.37344554,0.0025825,0.00042614783,0.0011991198,0.0019519776,0.00045250278,0.0037369523,0.00067745143,0.009288948,0.59545904],"study_design_scores_gemma":[0.0010294754,0.01683333,0.9101285,0.0031953766,0.0010365839,0.0035536755,0.004245076,0.0031848515,0.005600281,0.0019016284,0.04911214,0.00017905899],"about_ca_topic_score_codex":0.0014172265,"about_ca_topic_score_gemma":0.0024490475,"teacher_disagreement_score":0.007191697,"about_ca_system_score_codex":0.00054488285,"about_ca_system_score_gemma":0.002170243,"threshold_uncertainty_score":0.02405858},"labels":[],"label_agreement":null},{"id":"W3084505162","doi":"10.25251/skin.4.supp.69","title":"Efficacy of Tapinarof Cream by Body Region in Subjects With Plaque Psoriasis in a Phase 2b Randomized Controlled Study","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Phytochemistry Medicinal Plant Applications","field":"Agricultural and Biological Sciences","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"","keywords":"Plaque psoriasis; Randomized controlled trial; Medicine; Dermatology; Psoriasis; Internal medicine","score_opus":0.013928592941656437,"score_gpt":0.25692015283320085,"score_spread":0.24299155989154442,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3084505162","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97933686,0.007847604,0.00088964525,0.00063867227,0.00068856357,0.0070062894,0.00142042,0.00015098526,0.002020967],"genre_scores_gemma":[0.9798054,0.005646009,0.0017123466,0.0011424051,0.0006967032,0.006469497,0.0011309936,0.00004069583,0.0033559883],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99929714,0.00032416984,0.000044927212,0.00014235919,0.00006692973,0.00012444305],"domain_scores_gemma":[0.99902296,0.00031859614,0.00016926437,0.00009543821,0.00009793001,0.00029593715],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018878334,0.0019266146,0.004303103,0.00061124295,0.0006069755,0.001202043,0.0010480189,0.0020592012,0.010172475],"category_scores_gemma":[0.0016390911,0.0010540853,0.001991972,0.0006266784,0.0013330259,0.0013146595,0.00042710753,0.0031924967,0.001228367],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.978509,0.008800002,0.0003058982,0.00067733094,0.0006893555,0.000028833669,0.000033628545,0.00011492919,0.0027697408,0.000048168462,0.00037844616,0.007644612],"study_design_scores_gemma":[0.94490534,0.05271236,0.0013415025,0.000026060312,0.0003878445,0.000011949409,0.000017347069,0.00012879838,0.00016640777,0.000051759103,0.00024027113,0.0000103055045],"about_ca_topic_score_codex":0.0010664145,"about_ca_topic_score_gemma":0.0020657436,"teacher_disagreement_score":0.010172475,"about_ca_system_score_codex":0.0006187432,"about_ca_system_score_gemma":0.0010769063,"threshold_uncertainty_score":0.034030378},"labels":[],"label_agreement":null},{"id":"W3084796437","doi":"10.25251/skin.4.supp.31","title":"Safety of Long-Term Proactive Management with Fixed-Dose Combination Calcipotriene 0.005% and Betamethasone Dipropionate 0.064% Foam in Patients with Psoriasis Vulgaris: Results of a Phase III, Multicentre, Randomized, 52-Week, Vehicle-Controlled Trial","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"LEO Pharma","keywords":"Betamethasone dipropionate; Medicine; Psoriasis; Randomized controlled trial; Dermatology; Surgery","score_opus":0.009909449047611192,"score_gpt":0.2376766184769342,"score_spread":0.227767169429323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3084796437","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98332006,0.012592233,0.0003503015,0.0005387314,0.00027997754,0.0007822484,0.00048496248,0.00008214903,0.0015693093],"genre_scores_gemma":[0.9930354,0.0030885288,0.000523162,0.00068166293,0.00031533922,0.00071168627,0.00054945494,0.000012664965,0.0010820953],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9995127,0.00020599931,0.000037628633,0.00010238555,0.00006108912,0.000080149344],"domain_scores_gemma":[0.99911124,0.00026698154,0.0002244994,0.000067177585,0.000064599306,0.00026557472],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012790383,0.0009623748,0.0022847468,0.00030376008,0.00037648622,0.0009696046,0.0010301694,0.0020529141,0.0037511666],"category_scores_gemma":[0.001293094,0.0005271841,0.0015017606,0.00037171147,0.0009317394,0.0010165558,0.00026037454,0.0026462725,0.0006499599],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9493953,0.0067550247,0.0014007493,0.0008523071,0.001665662,0.00004960847,0.000055713626,0.00031361176,0.004152704,0.00006405393,0.0006777613,0.03461766],"study_design_scores_gemma":[0.89206,0.100040734,0.0053987075,0.00006375422,0.00087282795,0.000066317865,0.000038513874,0.0003439548,0.00046772743,0.00009958292,0.00053133816,0.000016618915],"about_ca_topic_score_codex":0.0009537725,"about_ca_topic_score_gemma":0.0014872474,"teacher_disagreement_score":0.0037511666,"about_ca_system_score_codex":0.00064757414,"about_ca_system_score_gemma":0.0007400714,"threshold_uncertainty_score":0.012548864},"labels":[],"label_agreement":null},{"id":"W3085427446","doi":"10.25251/skin.4.5.25","title":"Norman Orentreich: Father of Hair Modern Transplantation","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Hair Growth and Disorders","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"U.S. Navy; York University","keywords":"Transplantation; Art; Psychoanalysis; Medicine; Psychology; Internal medicine","score_opus":0.015460385247458052,"score_gpt":0.24912535440307318,"score_spread":0.23366496915561513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3085427446","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.30267486,0.104397245,0.0092076175,0.35062736,0.04371287,0.00029675633,0.0045311926,0.00094814075,0.18360405],"genre_scores_gemma":[0.77966076,0.03348978,0.002709468,0.025740271,0.009758421,0.00011292357,0.0010456693,0.0002925606,0.14719011],"study_design_codex":"case_report","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996301,0.000079325815,0.000027583732,0.00009784982,0.00007824515,0.00008688232],"domain_scores_gemma":[0.999305,0.00031451913,0.000069036745,0.000055222597,0.00008074794,0.00017541624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004224547,0.00075684924,0.0008098257,0.0009472589,0.0010655457,0.00089363597,0.0007870271,0.003404311,0.018721908],"category_scores_gemma":[0.002802427,0.00028968818,0.00033567369,0.0005119274,0.0009096178,0.0013658337,0.00065944553,0.0028837891,0.0037766062],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005528908,0.00025141358,0.011581847,0.00031262173,0.00011016135,0.8167198,0.0009526508,0.00033154045,0.0043262336,0.017753385,0.09648449,0.050622985],"study_design_scores_gemma":[0.0000888884,0.00024087532,0.010991411,0.0005021953,0.0000933062,0.7696431,0.0007548564,0.00046840787,0.0039523146,0.013361515,0.19981521,0.00008796877],"about_ca_topic_score_codex":0.0016850245,"about_ca_topic_score_gemma":0.001475865,"teacher_disagreement_score":0.018721908,"about_ca_system_score_codex":0.00047936098,"about_ca_system_score_gemma":0.00076511106,"threshold_uncertainty_score":0.06263101},"labels":[],"label_agreement":null},{"id":"W3085571220","doi":"10.25251/skin.4.supp.42","title":"Tildrakizumab Efficacy by Metabolic Syndrome Status in Psoriasis: Post Hoc Analysis of 3-Year Data from the Phase 3 Resurface 1 And Resurface 2 Studies","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"XBiotech; Kyowa Kirin Pharmaceutical Development; National Institutes of Health; Incyte; Dermira; Valeant Pharmaceuticals International; Celgene; Allergan; Eli Lilly and Company; Bristol-Myers Squibb; Amgen","keywords":"Post-hoc analysis; Psoriasis; Post hoc; Medicine; Internal medicine; Dermatology","score_opus":0.040734554695007204,"score_gpt":0.31283860531457386,"score_spread":0.27210405061956666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3085571220","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914349,0.0043095723,0.0007108012,0.00016090194,0.00013234676,0.00039822818,0.0016363448,0.00004710152,0.0011698516],"genre_scores_gemma":[0.99666864,0.00051260786,0.00029708803,0.00013969353,0.00008952902,0.00032295013,0.0010171934,0.000026460211,0.0009258264],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9952335,0.0028742922,0.00029048734,0.00052351184,0.00036238498,0.0007159764],"domain_scores_gemma":[0.9940304,0.0032334593,0.0010597488,0.0008014582,0.0003864196,0.0004884359],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008578146,0.0012764911,0.004055087,0.0005173659,0.0006170292,0.001725589,0.00083636044,0.0010393338,0.0032497451],"category_scores_gemma":[0.0041267425,0.00051720813,0.006481163,0.0006603351,0.0006747771,0.0015730731,0.00069138804,0.0024882818,0.00041235506],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92296636,0.0017342485,0.030001663,0.00050506,0.021181373,0.00009595737,0.00010549675,0.0016759787,0.0076269973,0.00009734419,0.0011398335,0.012869656],"study_design_scores_gemma":[0.15349324,0.22871251,0.53705627,0.0001770477,0.05733253,0.0003205177,0.00037885687,0.0070145004,0.009428178,0.00077497296,0.0050958334,0.00021557896],"about_ca_topic_score_codex":0.0012431666,"about_ca_topic_score_gemma":0.0029257594,"teacher_disagreement_score":0.008578146,"about_ca_system_score_codex":0.0006580753,"about_ca_system_score_gemma":0.00094033306,"threshold_uncertainty_score":0.045366168},"labels":[],"label_agreement":null},{"id":"W3085734793","doi":"10.25251/skin.4.supp.48","title":"Dupilumab Decreases Blood Biomarkers in Adolescents With Moderate-to-Severe Atopic Dermatitis: Data From a Phase 3 Trial (LIBERTY AD ADOL)","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Sanofi Genzyme; Forskningsrådet om Hälsa, Arbetsliv och Välfärd; LEO Pharma; Galderma; Incyte; Pfizer Pharmaceuticals; Valeant Pharmaceuticals International; Les Laboratories Pierre Fabre; Regeneron Pharmaceuticals; Kyowa Hakko Kirin; Eli Lilly and Company","keywords":"Atopic dermatitis; Dupilumab; Medicine; Dermatology","score_opus":0.028430559652954792,"score_gpt":0.29233794816178915,"score_spread":0.2639073885088344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3085734793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96165687,0.030324258,0.0003513537,0.0014596634,0.00035823588,0.0005402001,0.001255148,0.0001241058,0.0039301915],"genre_scores_gemma":[0.9870675,0.007375171,0.0008120498,0.0015998186,0.00028381203,0.0003240892,0.0009430117,0.00001331954,0.0015812677],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99977726,0.00011965479,0.000011650578,0.000024788544,0.000025304107,0.00004131032],"domain_scores_gemma":[0.9994054,0.0002269337,0.00011307531,0.00002455954,0.000047701305,0.00018245296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007729064,0.00060615945,0.0008624722,0.0001450675,0.00019850835,0.0006108458,0.00029764444,0.0006119235,0.0034672883],"category_scores_gemma":[0.0008222504,0.00017555515,0.0010150046,0.00017100284,0.00023213969,0.00034493572,0.00013307543,0.0018676389,0.00044914542],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5963576,0.010834397,0.021110578,0.0038288934,0.0057409857,0.00037551366,0.00017775512,0.0012277842,0.017545428,0.000314714,0.01662878,0.3258576],"study_design_scores_gemma":[0.6124119,0.22559538,0.13400412,0.00070974004,0.0044282083,0.0012480451,0.00019220095,0.0024900667,0.0051629078,0.00045012828,0.013238814,0.00006838048],"about_ca_topic_score_codex":0.00074853067,"about_ca_topic_score_gemma":0.0029200437,"teacher_disagreement_score":0.0034672883,"about_ca_system_score_codex":0.00036931335,"about_ca_system_score_gemma":0.000372664,"threshold_uncertainty_score":0.011599243},"labels":[],"label_agreement":null},{"id":"W3086123339","doi":"10.25251/skin.4.supp.45","title":"Durable Efficacy of Certolizumab Pegol Dosed at 400 mg Every Two Weeks Over 128 Weeks in Patients with Plaque Psoriasis Enrolled in Three Phase 3 Trials (CIMPASI-1, CIMPASI-2 and CIMPACT)","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre de Recherche Dermatologique du Québec Métropolitain","funders":"UCB Pharma; Dermira","keywords":"Certolizumab pegol; Plaque psoriasis; Medicine; Psoriasis; Internal medicine; Dermatology; Gastroenterology","score_opus":0.021227095897562276,"score_gpt":0.27338008013662973,"score_spread":0.25215298423906746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3086123339","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9765396,0.012437645,0.00096429064,0.0020694898,0.00035671002,0.0008083387,0.0019425742,0.00031988605,0.0045614596],"genre_scores_gemma":[0.9918494,0.00229704,0.0006444261,0.0011736001,0.00019820692,0.0002539795,0.0014039142,0.000027812575,0.002151638],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99965334,0.00012721005,0.000018324632,0.00006968648,0.000035036817,0.00009634506],"domain_scores_gemma":[0.9991817,0.00023102394,0.0001819552,0.000086443586,0.000053196247,0.0002656061],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015532619,0.00048672492,0.0015061385,0.00018541464,0.000297771,0.00073130126,0.00037985248,0.0011740648,0.004597345],"category_scores_gemma":[0.0012895457,0.0002721406,0.0012549667,0.00026753917,0.0003820136,0.0008039786,0.00018788142,0.0027711226,0.0008333626],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5316292,0.013274172,0.007876786,0.0014378435,0.0025151256,0.00039252115,0.0002706427,0.0025389201,0.04926961,0.00038950777,0.011640437,0.37876526],"study_design_scores_gemma":[0.57506263,0.3347921,0.06859086,0.00023245031,0.001510766,0.0007174728,0.00010826864,0.0019363778,0.0076095914,0.00066273956,0.008713239,0.000063555955],"about_ca_topic_score_codex":0.0008055381,"about_ca_topic_score_gemma":0.0016359859,"teacher_disagreement_score":0.004597345,"about_ca_system_score_codex":0.0004558746,"about_ca_system_score_gemma":0.0006113123,"threshold_uncertainty_score":0.015379608},"labels":[],"label_agreement":null},{"id":"W3086473472","doi":"10.25251/skin.4.supp.49","title":"Long-Term Effect of Dupilumab With Concomitant Topical Corticosteroids on POEM in Adults With Moderate-to-Severe Atopic Dermatitis: LIBERTY AD CHRONOS Trial","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health; Queen's University","funders":"LEO Pharma; Sanofi Genzyme; American Academy of Dermatology; Incyte; Dermira; Kiniksa Pharmaceuticals; Celgene; Galderma; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Coherus Biosciences; Amgen; Regeneron Pharmaceuticals","keywords":"Dupilumab; Atopic dermatitis; Concomitant; Dermatology; Medicine; Term (time); Internal medicine","score_opus":0.008855377549419742,"score_gpt":0.25195703451807683,"score_spread":0.2431016569686571,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3086473472","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9667212,0.026710708,0.00018586752,0.0011167175,0.00058720517,0.00039636352,0.0008178098,0.000056393175,0.0034078024],"genre_scores_gemma":[0.9873717,0.005933383,0.00052232575,0.0016648917,0.0006033681,0.00045950004,0.0010736333,0.000011179366,0.002360059],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.999711,0.0001106409,0.000019699426,0.00005445118,0.000029995126,0.00007415543],"domain_scores_gemma":[0.9994518,0.00012943106,0.00009960622,0.000037937654,0.000029950597,0.0002513558],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009579103,0.0007421443,0.0017187585,0.00018052667,0.00037983095,0.0010039605,0.0005592353,0.0011328835,0.0032841377],"category_scores_gemma":[0.0008285014,0.00026617953,0.0015810536,0.0002071747,0.00061407295,0.001010283,0.0003449745,0.002856852,0.00055034115],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.869988,0.0049484596,0.0056937328,0.0025920456,0.003126437,0.00029340916,0.00014221847,0.0005504799,0.004812922,0.00049654656,0.004481345,0.10287436],"study_design_scores_gemma":[0.8283306,0.13367094,0.026616301,0.00041705425,0.002763847,0.00060114893,0.000171592,0.001017926,0.0007860472,0.0004477201,0.0051273997,0.000049526014],"about_ca_topic_score_codex":0.00074153626,"about_ca_topic_score_gemma":0.002432531,"teacher_disagreement_score":0.0032841377,"about_ca_system_score_codex":0.00057004235,"about_ca_system_score_gemma":0.00062406686,"threshold_uncertainty_score":0.010986507},"labels":[],"label_agreement":null},{"id":"W3086665346","doi":"10.25251/skin.4.supp.32","title":"Long-Term Proactive Management of Psoriasis Vulgaris with Fixed-Dose Combination of Calcipotriene 0.005% and Betamethasone Dipropionate 0.064% Foam: Results from a Phase III Randomized Controlled Trial","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"LEO Pharma","keywords":"Betamethasone dipropionate; Medicine; Randomized controlled trial; Psoriasis; Dermatology; Surgery","score_opus":0.01589909687135234,"score_gpt":0.2637209916648256,"score_spread":0.24782189479347327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3086665346","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9587684,0.03336976,0.0006588051,0.0008924128,0.00080349675,0.0020818464,0.0006460774,0.00014009698,0.0026390103],"genre_scores_gemma":[0.98243743,0.009689168,0.0013991655,0.0012751927,0.00066031324,0.0019195231,0.00085479364,0.000016779235,0.001747618],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99949217,0.00020346668,0.000046090045,0.00009995682,0.00007502716,0.0000832189],"domain_scores_gemma":[0.99921465,0.00025235166,0.0001735612,0.00004975102,0.000059171693,0.0002505056],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012911501,0.00096096244,0.0028374754,0.00036476075,0.00045971217,0.0009732724,0.0010670638,0.001794282,0.004883088],"category_scores_gemma":[0.0012651858,0.000509938,0.0018283825,0.0004720546,0.0009692453,0.0010155279,0.00031067623,0.0028637103,0.00070437073],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9409658,0.008181608,0.0009454861,0.0021859086,0.0028510084,0.000057214245,0.00005879821,0.00029929273,0.0026652594,0.00010062656,0.00094408647,0.04074497],"study_design_scores_gemma":[0.93096685,0.06377326,0.002933763,0.00011666464,0.0009966549,0.00004769159,0.000030565814,0.00024255775,0.00022299017,0.000088481305,0.0005678486,0.000012806],"about_ca_topic_score_codex":0.0014881401,"about_ca_topic_score_gemma":0.0027891158,"teacher_disagreement_score":0.004883088,"about_ca_system_score_codex":0.00069225795,"about_ca_system_score_gemma":0.000816503,"threshold_uncertainty_score":0.016335547},"labels":[],"label_agreement":null},{"id":"W3086667064","doi":"10.25251/skin.4.supp.67","title":"Duration of Response and Progression-Free Survival with Sonidegib 200 Mg Once Daily Until Disease Progression or Start of New Antineoplastic Therapy in Patients with Locally Advanced Basal Cell Carcinoma: Results of the 42-Month, Randomized, Double-Blind","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Nonmelanoma Skin Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"","keywords":"Oncology; Internal medicine; Medicine; Progression-free survival; Disease; Duration (music); Overall survival","score_opus":0.01571963843424404,"score_gpt":0.2695627125944479,"score_spread":0.25384307416020385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3086667064","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942047,0.0035983329,0.00017816733,0.00018600207,0.00012552436,0.0003102186,0.00042979463,0.00002675273,0.0009404904],"genre_scores_gemma":[0.9955188,0.001598281,0.00032589323,0.00026297523,0.00019369934,0.0004947706,0.00048425526,0.000010250584,0.0011110945],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.998909,0.0006545599,0.00006805999,0.00014964594,0.00007613631,0.00014257981],"domain_scores_gemma":[0.9982657,0.0006457059,0.00040951217,0.00014834151,0.00006675303,0.00046406902],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023852626,0.00089175184,0.0018527462,0.0004472858,0.00027516522,0.0006450935,0.000703959,0.0012824031,0.0038487036],"category_scores_gemma":[0.0021024544,0.00050037785,0.0019552165,0.0003800057,0.0008507939,0.0011391123,0.00038888067,0.0026580822,0.00043725688],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97054684,0.0048565115,0.0017812091,0.0003340729,0.001007806,0.000016805667,0.000051950265,0.0004735824,0.0025787586,0.000040305054,0.00042686507,0.017885247],"study_design_scores_gemma":[0.6243225,0.3420021,0.027198823,0.00007981869,0.0023603172,0.00006514948,0.000070285016,0.0011278735,0.0016853666,0.00018801964,0.0008578512,0.00004185219],"about_ca_topic_score_codex":0.0011785997,"about_ca_topic_score_gemma":0.0025312402,"teacher_disagreement_score":0.0038487036,"about_ca_system_score_codex":0.0007067561,"about_ca_system_score_gemma":0.00086852495,"threshold_uncertainty_score":0.012875199},"labels":[],"label_agreement":null},{"id":"W3086843644","doi":"10.25251/skin.4.5.22","title":"Plant Fiber Contaminants in Morgellons Disease Skin Samples","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Body Image and Dysmorphia Studies","field":"Psychology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services","funders":"","keywords":"Contamination; Fiber; Environmental science; Environmental chemistry; Biology; Chemistry; Materials science; Composite material; Ecology","score_opus":0.0349688850334671,"score_gpt":0.297023505548507,"score_spread":0.26205462051503986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3086843644","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99394834,0.0007197582,0.00022625337,0.000099521625,0.000038196646,0.000091572554,0.0012088218,0.000013870039,0.0036536346],"genre_scores_gemma":[0.99321127,0.0005226238,0.00068743026,0.00013297048,0.00002125688,0.000046666166,0.0010243974,0.000008272919,0.004345022],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9995598,0.00008422804,0.000041770574,0.000084092564,0.00014962099,0.000080392885],"domain_scores_gemma":[0.9996731,0.000091755006,0.000045654673,0.000020467745,0.0001366941,0.000032284162],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036460377,0.00024291649,0.0001802073,0.00094323093,0.0005164945,0.00043944817,0.00017379702,0.00045437936,0.005351189],"category_scores_gemma":[0.0005632433,0.000103576596,0.00016192024,0.0005040281,0.0002995224,0.00013277477,0.00022727401,0.0001963844,0.000680662],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003157907,0.0006358457,0.33521342,0.00084628817,0.00011881387,0.007091048,0.0018949889,0.00009995251,0.6122925,0.00018132578,0.0015641242,0.036903758],"study_design_scores_gemma":[0.00004642477,0.0048550265,0.860353,0.00023464113,0.00014341915,0.009269264,0.0038358527,0.00018522171,0.10857635,0.000080763486,0.012402085,0.000017976177],"about_ca_topic_score_codex":0.0046072816,"about_ca_topic_score_gemma":0.004324448,"teacher_disagreement_score":0.005351189,"about_ca_system_score_codex":0.00019908212,"about_ca_system_score_gemma":0.00021854149,"threshold_uncertainty_score":0.01790148},"labels":[],"label_agreement":null},{"id":"W3099895352","doi":"10.25251/skin.4.supp.71","title":"Roflumilast Cream (ARQ-151) Improved Itch Severity and Itch-Related Sleep Loss in Adults With Chronic Plaque Psoriasis in a Phase 2b Study","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Probity Medical Research","funders":"","keywords":"Plaque psoriasis; Medicine; Dermatology; Roflumilast; Sleep (system call); Psoriasis; Internal medicine; COPD","score_opus":0.006867902839453745,"score_gpt":0.2579631344631116,"score_spread":0.2510952316236578,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3099895352","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890877,0.0056074304,0.00024330261,0.0003741782,0.00017283221,0.0016640383,0.00091632584,0.00010132945,0.001832878],"genre_scores_gemma":[0.98984516,0.0035666411,0.00084364,0.0009632333,0.00027802694,0.0013888865,0.0010717919,0.000023957538,0.0020186068],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99963236,0.00015262979,0.000025795312,0.0000626017,0.000043901025,0.00008283006],"domain_scores_gemma":[0.99957734,0.000107046464,0.00007713459,0.000045492012,0.000047843605,0.00014516033],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014164688,0.0010914011,0.0020824298,0.00030016617,0.00034561713,0.00063687796,0.00060540374,0.00095502235,0.0055422457],"category_scores_gemma":[0.0008351496,0.0004896454,0.0015569904,0.0002734264,0.0005200531,0.000706618,0.0002338226,0.002300386,0.0009952352],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.75978804,0.059776925,0.0065829894,0.0029456594,0.0041007563,0.0002624922,0.00024007849,0.00062667887,0.033663135,0.00014169914,0.0038267456,0.1280448],"study_design_scores_gemma":[0.68791693,0.27271503,0.034451008,0.00009999685,0.0013095335,0.00022119441,0.0000842392,0.0004884452,0.0010851719,0.000079403166,0.0015160794,0.000032876265],"about_ca_topic_score_codex":0.001342018,"about_ca_topic_score_gemma":0.0031647978,"teacher_disagreement_score":0.0055422457,"about_ca_system_score_codex":0.00039607438,"about_ca_system_score_gemma":0.00057688635,"threshold_uncertainty_score":0.01854068},"labels":[],"label_agreement":null},{"id":"W3101035693","doi":"10.25251/skin.4.supp.97","title":"Efficacy and Safety of Tralokinumab with Concomitant Topical Corticosteroids in North American Adults with Moderate-to-Severe Atopic Dermatitis: A Subanalysis of the ECZTRA 3 Trial","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Atopic dermatitis; Concomitant; Medicine; Dermatology; Internal medicine","score_opus":0.008115933252582475,"score_gpt":0.2339562603275287,"score_spread":0.22584032707494622,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3101035693","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98465294,0.0132016875,0.00008766699,0.00029092032,0.000103936196,0.00016192894,0.00044146457,0.000012008814,0.0010475103],"genre_scores_gemma":[0.99642015,0.0021844816,0.00011448092,0.0002609626,0.0001142862,0.0001216554,0.0004093564,0.000003605438,0.00037104022],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99909246,0.00046971493,0.00008398322,0.00015477196,0.0000862998,0.000112761576],"domain_scores_gemma":[0.998963,0.0003324859,0.0003610543,0.000082329,0.00006653937,0.0001944978],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016285247,0.0005602372,0.0013656393,0.00020166991,0.0003157769,0.0009246133,0.00041851093,0.00067098363,0.0018804041],"category_scores_gemma":[0.0016882088,0.0003097984,0.0026440825,0.0003818499,0.00041524137,0.00072373275,0.00025646572,0.00189106,0.0002586066],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.91067004,0.0020253945,0.025660133,0.0018987186,0.015645878,0.00014671565,0.00013986147,0.00062292075,0.0038555905,0.00014329034,0.0016769338,0.037514362],"study_design_scores_gemma":[0.56603473,0.110092506,0.28181362,0.0005881287,0.031638376,0.0008629775,0.00039413047,0.0018317769,0.0014879897,0.00047173534,0.0046932185,0.00009078886],"about_ca_topic_score_codex":0.0014190705,"about_ca_topic_score_gemma":0.0050415043,"teacher_disagreement_score":0.0018804041,"about_ca_system_score_codex":0.0006660964,"about_ca_system_score_gemma":0.00066633296,"threshold_uncertainty_score":0.008612514},"labels":[],"label_agreement":null},{"id":"W3101280111","doi":"10.25251/skin.4.supp.104","title":"Dupilumab Provides Acceptable Long-Term Safety and Efficacy in Children Aged ≥ 6 to < 12 Years with Uncontrolled, Severe Atopic Dermatitis","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Valeant Pharmaceuticals International; Sanofi Genzyme; National Institute for Health and Care Research; Regeneron Pharmaceuticals; Sanofi","keywords":"Dupilumab; Atopic dermatitis; Medicine; Dermatology","score_opus":0.006721026400807642,"score_gpt":0.23449303160400473,"score_spread":0.22777200520319707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3101280111","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9615996,0.023421807,0.00079365855,0.0010540149,0.00020152672,0.00016271535,0.002332561,0.00017331484,0.010260812],"genre_scores_gemma":[0.9931329,0.0033218814,0.0004376127,0.00036529262,0.000086376494,0.000043438667,0.0008784549,0.000015021168,0.0017190546],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99983907,0.00004317166,0.000012163617,0.000021907063,0.000026523227,0.00005705555],"domain_scores_gemma":[0.9994454,0.00016694386,0.00013443541,0.000026762422,0.000065559594,0.0001609339],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038946554,0.00023092689,0.0006323197,0.00010585913,0.0002436344,0.00042184102,0.00016865163,0.00033515866,0.0053132484],"category_scores_gemma":[0.00097002136,0.00007101588,0.0004648868,0.00014074586,0.00014582099,0.0003076759,0.00013929683,0.0006391917,0.0010554001],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.065411046,0.003287799,0.22950672,0.002579287,0.0010802724,0.004470419,0.0003934796,0.0008500116,0.049511403,0.00041654168,0.024717331,0.61777574],"study_design_scores_gemma":[0.0066200853,0.074382894,0.8299071,0.0008988436,0.0014328428,0.016558262,0.00065854244,0.0011990279,0.0212731,0.000249863,0.0467453,0.00007418578],"about_ca_topic_score_codex":0.0018589239,"about_ca_topic_score_gemma":0.006778523,"teacher_disagreement_score":0.0053132484,"about_ca_system_score_codex":0.00031803804,"about_ca_system_score_gemma":0.00042345564,"threshold_uncertainty_score":0.017774582},"labels":[],"label_agreement":null},{"id":"W3102280768","doi":"10.25251/skin.4.supp.96","title":"Efficacy and Safety of Tralokinumab Monotherapy in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Results from Two 52-Week, Phase 3 Trials (ECZTRA 1 and ECZTRA 2)","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre de Recherche Dermatologique du Québec Métropolitain; Université Laval; Probity Medical Research; University of Toronto","funders":"","keywords":"Atopic dermatitis; Medicine; Dermatology; Phase (matter); Physics","score_opus":0.01976814871375346,"score_gpt":0.28888757321425,"score_spread":0.26911942450049653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3102280768","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98276055,0.012649389,0.00028886858,0.0005512258,0.00011880111,0.00057785073,0.0013012006,0.00009241956,0.001659776],"genre_scores_gemma":[0.99179006,0.00385278,0.0006853643,0.000709186,0.00015160303,0.0003736827,0.0013064904,0.000018180335,0.001112717],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9995696,0.00017821223,0.00004063281,0.00007603272,0.00005812743,0.00007735278],"domain_scores_gemma":[0.99919945,0.00021794795,0.00021015292,0.000064113075,0.00007216054,0.00023625784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018425576,0.00090202026,0.0015752338,0.0002393991,0.00036927726,0.0008773792,0.00054209115,0.0011316604,0.0027330571],"category_scores_gemma":[0.0011380597,0.00035186688,0.0017439082,0.0002685284,0.00049048883,0.0008196922,0.00016530155,0.0023103752,0.00073139986],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7220711,0.01681011,0.010745722,0.0029251338,0.005068228,0.00031007366,0.00040492867,0.0019986734,0.056610834,0.00015918478,0.005958827,0.17693716],"study_design_scores_gemma":[0.60458446,0.29693672,0.08420981,0.00019788896,0.0027367978,0.0008905305,0.00012413396,0.001361318,0.0047074794,0.00018956618,0.003975925,0.00008540621],"about_ca_topic_score_codex":0.00081540365,"about_ca_topic_score_gemma":0.0028360821,"teacher_disagreement_score":0.0027330571,"about_ca_system_score_codex":0.0005808408,"about_ca_system_score_gemma":0.0006893398,"threshold_uncertainty_score":0.009744525},"labels":[],"label_agreement":null},{"id":"W3102502247","doi":"10.25251/skin.4.supp.75","title":"Tapinarof Cream 1% QD for the Treatment of Plaque Psoriasis: Efficacy and Safety in Two Pivotal Phase 3 Trials","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Phytochemistry Medicinal Plant Applications","field":"Agricultural and Biological Sciences","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada); Probity Medical Research; University of British Columbia","funders":"","keywords":"Plaque psoriasis; Psoriasis; Medicine; Dermatology; Phase (matter); Clinical trial; Internal medicine; Physics","score_opus":0.06043474788367265,"score_gpt":0.3426864154785979,"score_spread":0.28225166759492526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3102502247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91660726,0.054974366,0.002603449,0.0032393676,0.0009896685,0.007466379,0.0038669456,0.000421879,0.009830725],"genre_scores_gemma":[0.95298105,0.030173935,0.0029356664,0.0026874589,0.000507233,0.0032337138,0.0024853759,0.000072131515,0.0049233935],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9996444,0.00015104646,0.000020264002,0.00005419082,0.000052162686,0.00007793877],"domain_scores_gemma":[0.9992167,0.00026653678,0.00015052925,0.00006247501,0.00007826561,0.00022548913],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001956882,0.0014429649,0.002008034,0.0003759977,0.00037373274,0.001240442,0.0007004694,0.0018198963,0.006825051],"category_scores_gemma":[0.0013090383,0.0005507972,0.0019256868,0.0004374024,0.00074243214,0.0009586447,0.00022728098,0.0030319428,0.0012427582],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.71941984,0.025384367,0.0015889301,0.0054060034,0.003373686,0.00037299283,0.00037652825,0.0016193199,0.03808392,0.00067229953,0.010081695,0.1936204],"study_design_scores_gemma":[0.8045804,0.17717093,0.0063842987,0.00038699323,0.0012222697,0.00037942574,0.000085356754,0.0008642235,0.0020334169,0.0005226521,0.0063153794,0.000054671313],"about_ca_topic_score_codex":0.0008698977,"about_ca_topic_score_gemma":0.0027325088,"teacher_disagreement_score":0.006825051,"about_ca_system_score_codex":0.000619286,"about_ca_system_score_gemma":0.0009851204,"threshold_uncertainty_score":0.022832096},"labels":[],"label_agreement":null},{"id":"W3102615618","doi":"10.25251/skin.4.supp.82","title":"Efficacy and Safety of Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Results from BE VIVID, a 52-Week Phase 3, Randomized, Double-Blinded, Ustekinumab- and Placebo-Controlled Study","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Probity Medical Research","funders":"UCB Pharma; AstraZeneca","keywords":"Ustekinumab; Double blinded; Medicine; Placebo; Plaque psoriasis; Psoriasis; Dermatology; Randomized controlled trial; Internal medicine; Pathology; Disease; Alternative medicine","score_opus":0.019812991342659063,"score_gpt":0.25553552177184496,"score_spread":0.2357225304291859,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3102615618","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9844862,0.0110372305,0.00042294696,0.00056888716,0.00019666759,0.0007427503,0.0005739325,0.00008008724,0.0018912778],"genre_scores_gemma":[0.993826,0.0026356904,0.000628828,0.0007761436,0.00023484057,0.00046675393,0.00055199803,0.000014062149,0.00086573686],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9994492,0.000287699,0.000040312512,0.00007189759,0.00006895918,0.000081943945],"domain_scores_gemma":[0.9992531,0.00022291148,0.00016732949,0.000059132784,0.00004627755,0.00025130896],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019005492,0.0007885747,0.002557053,0.0002450597,0.0003801077,0.0008635877,0.00062612345,0.0013521204,0.002597054],"category_scores_gemma":[0.001523415,0.0005520544,0.0013590339,0.0002574464,0.0006992362,0.00087375724,0.00028728816,0.0025765968,0.000547329],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89714605,0.010277577,0.003992056,0.0013751436,0.0018310485,0.00010177907,0.00012844369,0.0006022372,0.014692426,0.0001782548,0.0019094764,0.06776553],"study_design_scores_gemma":[0.8391411,0.13491015,0.020447936,0.00008258972,0.0010409585,0.00023040235,0.000058336507,0.0007717229,0.001405245,0.00027708913,0.0016028464,0.000031707394],"about_ca_topic_score_codex":0.00046104804,"about_ca_topic_score_gemma":0.00083853176,"teacher_disagreement_score":0.002597054,"about_ca_system_score_codex":0.00040929503,"about_ca_system_score_gemma":0.000667981,"threshold_uncertainty_score":0.010051191},"labels":[],"label_agreement":null},{"id":"W3103492266","doi":"10.25251/skin.4.supp.105","title":"Atopic Dermatitis (AD) Disease History With AD Treatment History in a Cohort of AD Patients Treated With Dupilumab From a Real-World Registry (PROSE)","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Dupilumab; Atopic dermatitis; Medicine; Cohort; Dermatology; Disease; Medical history; Internal medicine","score_opus":0.011736130041749625,"score_gpt":0.22529670160066187,"score_spread":0.21356057155891225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3103492266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99664956,0.00028563265,0.00006934548,0.00003726587,0.000010146674,0.00001863593,0.0021452901,0.000004517475,0.0007796518],"genre_scores_gemma":[0.99779344,0.0001299718,0.00007530977,0.00005625587,0.000020653777,0.000024719688,0.0016476195,0.0000034778643,0.00024852378],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994966,0.00010859264,0.00005459871,0.00018554223,0.000077387274,0.00007733776],"domain_scores_gemma":[0.99884844,0.00017662399,0.00055718696,0.00014788595,0.00010699953,0.0001628546],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056840794,0.00021168747,0.00034612557,0.0007116819,0.0005448122,0.00085009617,0.00028870167,0.00034170982,0.003658979],"category_scores_gemma":[0.0016390113,0.0003128057,0.0004657009,0.0010522683,0.00021219955,0.00067735947,0.00044940753,0.00060961803,0.0004285864],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004121157,0.000053095777,0.99763894,0.000018149318,0.0000984091,0.00011579822,0.000035269037,0.00002557861,0.00013533523,0.00002564649,0.00038556714,0.0010559825],"study_design_scores_gemma":[0.000039147526,0.00015827722,0.9982079,0.000011308797,0.00008598673,0.0007437551,0.000120680896,0.0001415852,0.00005254349,0.000028441347,0.0004047965,0.0000055490127],"about_ca_topic_score_codex":0.0033920023,"about_ca_topic_score_gemma":0.0032908297,"teacher_disagreement_score":0.003658979,"about_ca_system_score_codex":0.0002393676,"about_ca_system_score_gemma":0.00034652522,"threshold_uncertainty_score":0.012240529},"labels":[],"label_agreement":null},{"id":"W3103502969","doi":"10.25251/skin.4.supp.95","title":"Efficacy and Safety of Ruxolitinib Cream for the Treatment of Atopic Dermatitis: Results From Two Phase 3, Randomized, Double-Blind Studies","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Incyte","keywords":"Ruxolitinib; Atopic dermatitis; Double blind; Medicine; Dermatology; Randomized controlled trial; Internal medicine; Alternative medicine; Myelofibrosis; Pathology; Placebo","score_opus":0.05448425355856354,"score_gpt":0.3643731436587562,"score_spread":0.3098888901001927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3103502969","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97032934,0.019484486,0.0016785614,0.0005181795,0.00043978562,0.004413408,0.0012508264,0.00016466218,0.0017207043],"genre_scores_gemma":[0.98460937,0.0069735534,0.0021536043,0.0008277103,0.00050773635,0.00281683,0.0010401714,0.00004013077,0.0010308966],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99834454,0.00088108156,0.00018934517,0.00023888132,0.00018305206,0.00016310094],"domain_scores_gemma":[0.99732035,0.0012149968,0.00064652145,0.0002627794,0.00019509699,0.00036028016],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046840296,0.0015149356,0.0040806024,0.0004913695,0.0006489368,0.0012621894,0.0011550323,0.0024410123,0.0041879476],"category_scores_gemma":[0.0035057785,0.00075890037,0.002716588,0.0005110345,0.0014868843,0.0015696707,0.00031692028,0.0027949188,0.00082091097],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94693905,0.008914887,0.0005682901,0.001673765,0.0020250173,0.00004539854,0.00008361425,0.00028310463,0.009311096,0.000072292714,0.0005241466,0.029559355],"study_design_scores_gemma":[0.920344,0.07305656,0.0030270978,0.00006738975,0.0012657251,0.00006103963,0.000020606505,0.0002833164,0.0012604648,0.00009264182,0.0004955731,0.0000254545],"about_ca_topic_score_codex":0.00055522297,"about_ca_topic_score_gemma":0.001122478,"teacher_disagreement_score":0.0046840296,"about_ca_system_score_codex":0.0006696373,"about_ca_system_score_gemma":0.000984716,"threshold_uncertainty_score":0.02477181},"labels":[],"label_agreement":null},{"id":"W3103727622","doi":"10.25251/skin.4.supp.83","title":"Efficacy and Safety of Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Results from BE READY, a 56-Week Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study with Randomized Withdrawal","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Double blinded; Medicine; Randomized controlled trial; Placebo; Plaque psoriasis; Psoriasis; Internal medicine; Dermatology; Alternative medicine; Pathology","score_opus":0.016129608752117178,"score_gpt":0.25199327768949914,"score_spread":0.23586366893738198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3103727622","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97844374,0.012960356,0.00094149454,0.000885829,0.00048535998,0.0026599388,0.0010704935,0.00015942953,0.0023933789],"genre_scores_gemma":[0.9886445,0.0034614573,0.0014752238,0.0014424989,0.0004992346,0.0019021103,0.0007595703,0.000038004706,0.001777437],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9991078,0.00045275426,0.00006456114,0.00012808025,0.00010225656,0.0001445076],"domain_scores_gemma":[0.9987004,0.00041214895,0.00028937284,0.00013113201,0.00009447292,0.00037233575],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027423212,0.001102942,0.0038380215,0.00039636713,0.00064444245,0.0012172878,0.00082148175,0.0022443815,0.0054152654],"category_scores_gemma":[0.002169327,0.00079837,0.0023614888,0.00036261705,0.0013350912,0.0014428626,0.0004050757,0.00366304,0.0010358992],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95564055,0.007326066,0.0007636426,0.0008979152,0.00085038855,0.00004011655,0.000060930433,0.00020582663,0.0062811966,0.0000879496,0.0008660291,0.02697943],"study_design_scores_gemma":[0.91319424,0.08172454,0.0031617435,0.000046308796,0.00043027828,0.00004400917,0.000024105657,0.00019066753,0.0005631836,0.00012435546,0.00048015296,0.00001640826],"about_ca_topic_score_codex":0.0005068881,"about_ca_topic_score_gemma":0.00090859097,"teacher_disagreement_score":0.0054152654,"about_ca_system_score_codex":0.00042276288,"about_ca_system_score_gemma":0.0008848727,"threshold_uncertainty_score":0.018115878},"labels":[],"label_agreement":null},{"id":"W3104685239","doi":"10.25251/skin.4.supp.93","title":"The Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Atopic Dermatitis: Phase 2 Proof-of-Concept Study","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada); Probity Medical Research; Queen's University","funders":"","keywords":"Atopic dermatitis; Roflumilast; Proof of concept; Medicine; Dermatology; Computer science; Internal medicine","score_opus":0.012590369743052426,"score_gpt":0.2879166144450862,"score_spread":0.27532624470203376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3104685239","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96584857,0.014185819,0.0028926858,0.0009557077,0.00083420455,0.008859785,0.0026125875,0.00030206735,0.003508567],"genre_scores_gemma":[0.96786034,0.009845781,0.005343337,0.0014055053,0.00053580943,0.0070126103,0.0021824446,0.000087670924,0.0057265153],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9992362,0.00035179482,0.0000425689,0.000120235134,0.000103306134,0.00014600351],"domain_scores_gemma":[0.9991559,0.00025133725,0.00015982396,0.00011663347,0.00009854698,0.00021780276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00286155,0.001796032,0.002527138,0.00043403739,0.00043632917,0.0014330832,0.0013924032,0.0016956467,0.007179512],"category_scores_gemma":[0.0013451619,0.0008974851,0.0021503435,0.00035824327,0.0011598394,0.0014134403,0.00032888263,0.004178675,0.0016928981],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.60515547,0.12966101,0.0008997092,0.005572935,0.0020757627,0.00033376677,0.00039246897,0.0014406512,0.14067896,0.00062159053,0.0058520357,0.10731573],"study_design_scores_gemma":[0.30508864,0.66919905,0.004166768,0.00016489907,0.0009765787,0.00031929213,0.00010630999,0.00080333324,0.012162085,0.00030384443,0.0066546067,0.000054592383],"about_ca_topic_score_codex":0.0006449906,"about_ca_topic_score_gemma":0.0014112379,"teacher_disagreement_score":0.007179512,"about_ca_system_score_codex":0.000734708,"about_ca_system_score_gemma":0.0017078958,"threshold_uncertainty_score":0.02401781},"labels":[],"label_agreement":null},{"id":"W3104939465","doi":"10.25251/skin.4.supp.102","title":"Efficacy and Safety of Tralokinumab Plus Concomitant Topical Corticosteroids (TCS) in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Results from the 32-Week, Phase 3 ECZTRA 3 Trial","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Concomitant; Atopic dermatitis; Medicine; Dermatology; Randomized controlled trial; Internal medicine","score_opus":0.015531852107486319,"score_gpt":0.2618408314692068,"score_spread":0.24630897936172047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3104939465","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860307,0.01081964,0.00016821225,0.0004632066,0.00014211789,0.0003116985,0.00065545033,0.00004513102,0.0013638661],"genre_scores_gemma":[0.9942017,0.0030444495,0.00034104165,0.0005219453,0.00014811101,0.00023999992,0.0006443762,0.000009038053,0.00084928906],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99968374,0.00013561806,0.000026546028,0.000058455735,0.00003822136,0.000057393747],"domain_scores_gemma":[0.99939716,0.00016239582,0.00016773275,0.000042286472,0.000042442298,0.00018795645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001184426,0.0008067237,0.0012578795,0.00017085079,0.0002902895,0.0008668731,0.00045428018,0.0008437146,0.0024520888],"category_scores_gemma":[0.0009810812,0.00028340874,0.0017600524,0.00023626507,0.00047420585,0.0007533158,0.00018200494,0.0023348648,0.0005042951],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.883515,0.005569623,0.006571682,0.0021196126,0.0045105475,0.00017267377,0.00016681667,0.0012663426,0.011261576,0.00015922995,0.0029197508,0.08176712],"study_design_scores_gemma":[0.7815207,0.15340534,0.053477127,0.0002530229,0.0040384913,0.0006480569,0.00013510755,0.0014598938,0.0015565623,0.0003295607,0.0031146475,0.000061481056],"about_ca_topic_score_codex":0.00081893656,"about_ca_topic_score_gemma":0.0028721744,"teacher_disagreement_score":0.0024520888,"about_ca_system_score_codex":0.0005643465,"about_ca_system_score_gemma":0.00061806064,"threshold_uncertainty_score":0.00820303},"labels":[],"label_agreement":null},{"id":"W3105819045","doi":"10.25251/skin.4.supp.113","title":"A Comparative Clinical Demonstration of the Spreadability of Tazarotene Lotion 0.045% versus Trifarotene Cream 0.005%","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Horticultural and Viticultural Research","field":"Agricultural and Biological Sciences","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bausch Health; Ortho Dermatologics","keywords":"Lotion; Tazarotene; Spreadability; Dermatology; Medicine; Chemistry; Pharmacology; Food science","score_opus":0.11917702147513479,"score_gpt":0.35474508486735823,"score_spread":0.23556806339222344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3105819045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994276,0.0017397907,0.0008618434,0.00011877802,0.00013875359,0.00043737955,0.00016940062,0.0000369509,0.0022210549],"genre_scores_gemma":[0.9975992,0.0003986311,0.0004073739,0.00005864375,0.00007911717,0.000077527075,0.00010486242,0.000008237793,0.0012664803],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99932826,0.00033221027,0.00004044834,0.000114873306,0.00010266358,0.0000815134],"domain_scores_gemma":[0.99704343,0.0016933142,0.00028400356,0.00029882797,0.00024508964,0.00043536682],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013731152,0.0005329372,0.0006159545,0.00055037916,0.000311287,0.0003654278,0.0005323328,0.0008029355,0.0064717685],"category_scores_gemma":[0.0026339102,0.0002754684,0.00038735478,0.00026446217,0.001045611,0.000826134,0.00022733386,0.0009998807,0.00083665334],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29819775,0.022397628,0.0019231953,0.00056276354,0.00021391307,0.00046291272,0.00030188204,0.00044276073,0.62758285,0.0002703538,0.00049249385,0.04715148],"study_design_scores_gemma":[0.013147548,0.87435645,0.018623332,0.000024827303,0.00025620428,0.00066798815,0.00017013372,0.0012583463,0.09003265,0.000108483306,0.0013240314,0.000029907713],"about_ca_topic_score_codex":0.00067604386,"about_ca_topic_score_gemma":0.0007194925,"teacher_disagreement_score":0.0064717685,"about_ca_system_score_codex":0.0002260213,"about_ca_system_score_gemma":0.0002946724,"threshold_uncertainty_score":0.021650255},"labels":[],"label_agreement":null},{"id":"W3106177555","doi":"10.25251/skin.4.supp.70","title":"Roflumilast Cream (ARQ-151) 0.15% and 0.3% Improved Burden of Signs and Symptoms in Adults With Chronic Plaque Psoriasis in a Phase 2b Study","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Probity Medical Research","funders":"","keywords":"Plaque psoriasis; Medicine; Roflumilast; Dermatology; Psoriasis; Pediatrics; Internal medicine; COPD","score_opus":0.008240515777240696,"score_gpt":0.23637852521625272,"score_spread":0.22813800943901202,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3106177555","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98699737,0.006191306,0.0003449222,0.00061423454,0.00019253626,0.0015217115,0.0010919964,0.00016429267,0.0028815512],"genre_scores_gemma":[0.9884112,0.0036467111,0.0010425365,0.0010782712,0.0003117108,0.0010459119,0.0014113921,0.000036319743,0.003016036],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99951744,0.00021783049,0.000025557994,0.00007263623,0.000049307895,0.00011724375],"domain_scores_gemma":[0.9995536,0.00011387097,0.00006698395,0.00004601251,0.000039966715,0.00017960623],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001722582,0.0011878426,0.002094263,0.00031917653,0.00037026213,0.0007076626,0.0006922012,0.0013679101,0.0052411584],"category_scores_gemma":[0.00074722717,0.00057803246,0.0013297929,0.00030731998,0.0006685357,0.00081145874,0.00023686868,0.0027486675,0.0011292816],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7646841,0.060173817,0.0035807951,0.0016698872,0.0022749451,0.0002919674,0.00026069157,0.0008291554,0.05019479,0.00022248722,0.0051517496,0.11066572],"study_design_scores_gemma":[0.64550394,0.33331826,0.015943535,0.00006044299,0.000743369,0.00023111662,0.00005304425,0.00043708182,0.0016450343,0.00010321873,0.0019332196,0.000027773047],"about_ca_topic_score_codex":0.0012871407,"about_ca_topic_score_gemma":0.0029548767,"teacher_disagreement_score":0.0052411584,"about_ca_system_score_codex":0.0004451293,"about_ca_system_score_gemma":0.0006968287,"threshold_uncertainty_score":0.017533422},"labels":[],"label_agreement":null},{"id":"W3107702560","doi":"10.25251/skin.4.supp.28","title":"BMS-986165, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor: Evaluation of Changes in Laboratory Parameters in Response to Treatment in a Phase 2 Trial in Psoriasis Patients","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Fungal Biology and Applications","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Probity Medical Research","funders":"Bristol-Myers Squibb","keywords":"Psoriasis; Medicine; Internal medicine; Tyrosine-kinase inhibitor; Tyrosine kinase 2; Pharmacology; Dermatology; Platelet-derived growth factor receptor; Receptor","score_opus":0.043463487994055444,"score_gpt":0.35541407204063863,"score_spread":0.31195058404658316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3107702560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9823815,0.008786598,0.0004540393,0.0009351697,0.00026434395,0.0015744753,0.0015768503,0.00017197189,0.0038550345],"genre_scores_gemma":[0.98532224,0.0058524087,0.0011248273,0.0010481394,0.0003417934,0.0013315276,0.0021889969,0.000025445812,0.002764684],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997292,0.0001214116,0.000019267294,0.0000410169,0.00003540234,0.000053697153],"domain_scores_gemma":[0.9996087,0.0000842877,0.00006569192,0.0000231986,0.000027758337,0.000190405],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011599201,0.0010913563,0.0016553489,0.00034868237,0.00032636576,0.0007409768,0.0004951825,0.00103343,0.004996983],"category_scores_gemma":[0.0006270091,0.00036427722,0.0010539517,0.00046047027,0.0005292781,0.00077991403,0.00021997686,0.00265592,0.0008518013],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.78728026,0.025887426,0.0035645824,0.0015153537,0.0016701175,0.00032970236,0.00012960659,0.001421788,0.043059655,0.00024703707,0.0050942316,0.12980033],"study_design_scores_gemma":[0.70867205,0.26811436,0.013281107,0.00006938636,0.0006730993,0.00032911816,0.000054817985,0.0011823055,0.0046685156,0.00016178002,0.0027611153,0.00003228677],"about_ca_topic_score_codex":0.00069127436,"about_ca_topic_score_gemma":0.0019386598,"teacher_disagreement_score":0.004996983,"about_ca_system_score_codex":0.00044228786,"about_ca_system_score_gemma":0.00080115243,"threshold_uncertainty_score":0.0167166},"labels":[],"label_agreement":null},{"id":"W3118983962","doi":"10.25251/skin.5.supp.20","title":"Long-Term Improvements in Health-Related Quality of Life of Patients with Moderate to Severe Plaque Psoriasis Treated with Certolizumab Pegol: Results from the CIMPASI-1 and CIMPASI-2 Phase 3 Trials","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto","funders":"","keywords":"Certolizumab pegol; Medicine; Plaque psoriasis; Psoriasis; Term (time); Quality of life (healthcare); Internal medicine; Dermatology; Infliximab; Disease","score_opus":0.18406156033160762,"score_gpt":0.3994468664925963,"score_spread":0.2153853061609887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3118983962","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9486609,0.04557111,0.0003041249,0.0016896706,0.00022533945,0.00032413466,0.001296519,0.000020678754,0.0019075269],"genre_scores_gemma":[0.98840964,0.008903295,0.0002546475,0.0006975155,0.0001915784,0.00018399296,0.0009783295,0.000004190922,0.00037683014],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99915266,0.00053953694,0.000054183278,0.000074432486,0.00008309018,0.00009601748],"domain_scores_gemma":[0.9982566,0.00075258594,0.00051498995,0.00006941817,0.00009869632,0.00030763185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002922855,0.0005076017,0.0012874937,0.00020146083,0.00019582626,0.0008884896,0.00032616637,0.0008000474,0.0019071074],"category_scores_gemma":[0.002984009,0.0001900819,0.0031281551,0.00037206744,0.0004354726,0.00057417183,0.00027088152,0.0021676456,0.00019900962],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.75688666,0.005482936,0.033936486,0.004099981,0.01949061,0.00016972324,0.0001782495,0.001968596,0.0033206125,0.00035627975,0.0044274786,0.1696825],"study_design_scores_gemma":[0.5653317,0.1356068,0.26860467,0.0013998651,0.018057209,0.00045942704,0.0002165591,0.001839316,0.0013025588,0.0010433058,0.0060431543,0.000095403935],"about_ca_topic_score_codex":0.00091764086,"about_ca_topic_score_gemma":0.0016064324,"teacher_disagreement_score":0.002922855,"about_ca_system_score_codex":0.0005135569,"about_ca_system_score_gemma":0.00057763763,"threshold_uncertainty_score":0.01545769},"labels":[],"label_agreement":null},{"id":"W3119199869","doi":"10.25251/skin.5.supp.9","title":"Specifically Targeting Interleukin-13 with Tralokinumab Improved Sleep in Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Trials in Patients with Atopic Dermatitis","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"","keywords":"Atopic dermatitis; Placebo; Medicine; Double blind; Randomized controlled trial; Placebo-controlled study; Internal medicine; Dermatology; Alternative medicine; Pathology","score_opus":0.014391379861997315,"score_gpt":0.2972541463484196,"score_spread":0.28286276648642233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3119199869","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9526938,0.031574555,0.0015159762,0.0012771419,0.0018937353,0.007358203,0.0013591966,0.00020969787,0.0021177714],"genre_scores_gemma":[0.9769514,0.00976209,0.002053453,0.0012774034,0.0005388722,0.0067987917,0.0006893165,0.000028093882,0.0019005386],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99918777,0.00039187435,0.0000962832,0.00013902914,0.000065133805,0.00011996039],"domain_scores_gemma":[0.9989667,0.00042026147,0.00022100122,0.00007900961,0.00010366084,0.00020940523],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026285932,0.0015108234,0.0036554588,0.00042185228,0.00063324854,0.0011281859,0.0008258259,0.0017898132,0.005963369],"category_scores_gemma":[0.002358563,0.0006584451,0.0034197029,0.00051674637,0.0010687287,0.0011133676,0.0003195681,0.0033107277,0.0006664428],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96913797,0.0038023405,0.00038608673,0.0022697875,0.0030296103,0.000028025697,0.00005516043,0.00018929069,0.00265482,0.00007621633,0.0006321748,0.017738542],"study_design_scores_gemma":[0.96461964,0.03228711,0.0012094931,0.00007649989,0.0010156819,0.000017590226,0.000019372588,0.0001341385,0.00024397926,0.000057331246,0.00030739975,0.000011754418],"about_ca_topic_score_codex":0.0010204308,"about_ca_topic_score_gemma":0.0034981854,"teacher_disagreement_score":0.005963369,"about_ca_system_score_codex":0.0007442757,"about_ca_system_score_gemma":0.000979835,"threshold_uncertainty_score":0.019949436},"labels":[],"label_agreement":null},{"id":"W3119812808","doi":"10.25251/skin.5.supp.15","title":"Bimekizumab Efficacy and Safety versus Adalimumab in Patients with Moderate to Severe Plaque Psoriasis: Results from a Multicenter, Randomized, Double-Blinded Active Comparator-Controlled Phase 3 Trial (BE SURE)","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Probity Medical Research","funders":"UCB Pharma; European Academy of Dermatology and Venereology","keywords":"Medicine; Adalimumab; Plaque psoriasis; Double blinded; Multicenter study; Randomized controlled trial; Psoriasis; Internal medicine; Dermatology; Pathology; Placebo; Alternative medicine","score_opus":0.02438267293933946,"score_gpt":0.2821770173124763,"score_spread":0.25779434437313686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3119812808","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97025025,0.018199114,0.0010004493,0.0014978686,0.0009826289,0.0029432504,0.001641682,0.00018516179,0.0032996067],"genre_scores_gemma":[0.9852941,0.0037580896,0.0021556488,0.0020391487,0.00090509123,0.0025956933,0.001125878,0.000049744856,0.0020766316],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9990496,0.0004762468,0.000077725286,0.00018345406,0.0000834316,0.00012943093],"domain_scores_gemma":[0.99857473,0.0004851524,0.00036645107,0.000120982724,0.000096320895,0.0003563695],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031586513,0.0012229244,0.003668664,0.00032737292,0.00064703496,0.0016975623,0.00084004365,0.0021522986,0.006677728],"category_scores_gemma":[0.0029046435,0.00075969775,0.0026898754,0.00038582517,0.0011105514,0.0015656122,0.00046418273,0.003450007,0.0010751929],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9811762,0.002302458,0.00047575252,0.0006732722,0.0010918864,0.00002133441,0.00003906755,0.00014148229,0.0018358126,0.000079017496,0.000810837,0.011352897],"study_design_scores_gemma":[0.96839285,0.027909061,0.0020247523,0.00004555834,0.0006183239,0.00003153682,0.000016017604,0.00017927108,0.00021066745,0.0001580964,0.00040136155,0.000012475415],"about_ca_topic_score_codex":0.00053881854,"about_ca_topic_score_gemma":0.000888402,"teacher_disagreement_score":0.006677728,"about_ca_system_score_codex":0.0005912044,"about_ca_system_score_gemma":0.0008160769,"threshold_uncertainty_score":0.022339165},"labels":[],"label_agreement":null},{"id":"W3120199534","doi":"10.25251/skin.5.supp.18","title":"Bimekizumab for the Treatment of Moderate to Severe Plaque Psoriasis with Scalp, Nail and Palmoplantar Involvement Through 52 Weeks: Post-Hoc Analysis from the BE VIVID Phase 3 Trial","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Probity Medical Research","funders":"UCB Pharma; European Academy of Dermatology and Venereology","keywords":"Post-hoc analysis; Scalp; Medicine; Dermatology; Nail (fastener); Psoriasis; Post hoc; Dentistry; Internal medicine; Structural engineering; Engineering","score_opus":0.02446779732439922,"score_gpt":0.27520131174977336,"score_spread":0.2507335144253741,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120199534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.978741,0.0113042975,0.00091566605,0.0008607602,0.00042010195,0.001027681,0.0022551047,0.00011452028,0.0043608956],"genre_scores_gemma":[0.98950034,0.0026933223,0.0008827384,0.0007624656,0.00025134502,0.0008305282,0.0016105623,0.00004316108,0.0034254899],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9991009,0.00051137904,0.000036658876,0.0001150762,0.000060087503,0.00017576737],"domain_scores_gemma":[0.9989373,0.0004313937,0.00018112478,0.00012571657,0.0000676952,0.00025683283],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002980762,0.0009520153,0.0029246828,0.00019932809,0.00032668578,0.0012495689,0.0006402062,0.000881075,0.0053032786],"category_scores_gemma":[0.0019197033,0.0004516149,0.0030611735,0.00030570631,0.0004427166,0.0009982289,0.00039163817,0.0034656622,0.0007991681],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9673456,0.0017506334,0.0014104637,0.0006926719,0.0034543874,0.000040664723,0.000046499066,0.00083991024,0.0022801545,0.00013786671,0.0019329444,0.020068191],"study_design_scores_gemma":[0.88249457,0.089648426,0.017315414,0.00013575067,0.0046725464,0.00013477352,0.00006602332,0.0014231128,0.0008152081,0.0006274576,0.0026312054,0.000035529723],"about_ca_topic_score_codex":0.0008929023,"about_ca_topic_score_gemma":0.0023078674,"teacher_disagreement_score":0.0053032786,"about_ca_system_score_codex":0.00053502835,"about_ca_system_score_gemma":0.00085268245,"threshold_uncertainty_score":0.017741263},"labels":[],"label_agreement":null},{"id":"W3120229153","doi":"10.25251/skin.5.1.16","title":"Toluidine blue for extramammary Paget’s disease in Mohs micrographic surgery","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Cancer and Skin Lesions","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University Health Centre","funders":"McGill University","keywords":"Extramammary Paget's disease; Medicine; Toluidine; Paget Disease; Mohs surgery; Staining; Dermatology; Surgery; Pathology; Disease; Chemistry","score_opus":0.02265867169664513,"score_gpt":0.28611245384520917,"score_spread":0.263453782148564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120229153","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9221273,0.039840527,0.012532057,0.0036537207,0.00082960736,0.00012026965,0.00011139111,0.00045157655,0.020333491],"genre_scores_gemma":[0.9846721,0.005668647,0.006079341,0.0006211184,0.00030543664,0.000015737944,0.000045197194,0.000024087887,0.0025683055],"study_design_codex":"case_report","study_design_gemma":"observational","domain_scores_codex":[0.9998227,0.00004377943,0.00002011749,0.000024657396,0.000054909982,0.00003386944],"domain_scores_gemma":[0.9996387,0.00014977485,0.00010119391,0.00003667056,0.000038499453,0.000035145],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025890413,0.000385611,0.00020463545,0.0007050067,0.00026747235,0.00035241892,0.00028850738,0.0009825756,0.0021609622],"category_scores_gemma":[0.00081999926,0.00020326527,0.00021465942,0.00028429047,0.0005286348,0.00048227957,0.00026801787,0.0005899601,0.00071789324],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005820222,0.00024389334,0.07123634,0.0009839133,0.000047166755,0.6984664,0.00048445686,0.00024073142,0.13786964,0.00079944986,0.0040622596,0.084983625],"study_design_scores_gemma":[0.00002389479,0.00053496734,0.025290474,0.00015732362,0.000048086673,0.92579436,0.00023192371,0.0007463033,0.034968793,0.00041131125,0.011775772,0.000016770897],"about_ca_topic_score_codex":0.00038514644,"about_ca_topic_score_gemma":0.00082067196,"teacher_disagreement_score":0.0021609622,"about_ca_system_score_codex":0.00016580526,"about_ca_system_score_gemma":0.00019129318,"threshold_uncertainty_score":0.0072291493},"labels":[],"label_agreement":null},{"id":"W3120319462","doi":"10.25251/skin.5.supp.21","title":"Bimekizumab Safety in Patients with Moderate to Severe Psoriasis: Analysis of Pooled Data from Phase 2 and 3 Clinical Trials","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Pooled analysis; Psoriasis; Clinical trial; Medicine; Phase (matter); Dermatology; Internal medicine; Meta-analysis; Chemistry","score_opus":0.05098681300665635,"score_gpt":0.34998676432880144,"score_spread":0.2989999513221451,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120319462","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.69208556,0.28995466,0.003379132,0.0015363618,0.00071538746,0.0015682707,0.005237514,0.00014763967,0.00537545],"genre_scores_gemma":[0.9710401,0.022570258,0.0010447626,0.0011082303,0.0005534056,0.0006322219,0.0024110847,0.000028954903,0.00061095605],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9966624,0.0020613768,0.00037283788,0.00037728637,0.0003268004,0.00019928729],"domain_scores_gemma":[0.9941566,0.0031906574,0.0015742956,0.0004260917,0.00033215273,0.00032017662],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009150303,0.0008073778,0.004237829,0.00057664333,0.00028015647,0.0015455612,0.00051918585,0.0009895015,0.0023309428],"category_scores_gemma":[0.007506708,0.00044190412,0.006404683,0.0010162416,0.00041234485,0.0009318041,0.00043553047,0.0016358934,0.00027441778],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.619615,0.0010527994,0.04346833,0.01701043,0.16369064,0.0002264585,0.00013704228,0.0033127633,0.0057583144,0.00042207167,0.005929152,0.13937704],"study_design_scores_gemma":[0.46997556,0.07853507,0.20724617,0.0027451192,0.2156482,0.0013678012,0.00019784726,0.0037622321,0.0030517182,0.0026859243,0.0145990895,0.00018529325],"about_ca_topic_score_codex":0.0002641074,"about_ca_topic_score_gemma":0.0007478434,"teacher_disagreement_score":0.009150303,"about_ca_system_score_codex":0.00045177698,"about_ca_system_score_gemma":0.00076515117,"threshold_uncertainty_score":0.048391998},"labels":[],"label_agreement":null},{"id":"W3120762381","doi":"10.25251/skin.5.1.15","title":"A Case Report of a Primary Cutaneous Adenoid Carcinoma: A Diagnostic and Management Challenge","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Salivary Gland Tumors Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Adenoid cystic carcinoma; Medicine; Distant metastasis; Surgical excision; Metastasis; Neoplasm; Pathology; Adenoid; Carcinoma; Radiology; Cancer; Internal medicine","score_opus":0.018560229466235603,"score_gpt":0.2573513841221511,"score_spread":0.2387911546559155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120762381","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.767615,0.08164584,0.04221447,0.037092183,0.007079454,0.0014554565,0.001411242,0.0015590313,0.05992741],"genre_scores_gemma":[0.9570207,0.011006218,0.013157809,0.0052464786,0.007545299,0.0002071915,0.00022453627,0.00013251633,0.0054592476],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99856395,0.00022234577,0.00019266478,0.00037182507,0.00026228259,0.00038694416],"domain_scores_gemma":[0.9967456,0.0010739231,0.0006108193,0.00041977275,0.00022178283,0.0009279509],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007470876,0.003369263,0.0022706015,0.00550414,0.0046106116,0.003861388,0.0021737164,0.01096334,0.0040425886],"category_scores_gemma":[0.0051872614,0.0019998003,0.0020474985,0.0036246136,0.003073036,0.004999508,0.003475736,0.0075298427,0.0023972895],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009819513,0.000023621407,0.00071871764,0.000033575543,0.0000057988086,0.9971521,0.00008605312,0.00005439106,0.00024655845,0.00019425857,0.00036105854,0.0011140228],"study_design_scores_gemma":[0.0000036174804,0.00001553612,0.00037150443,0.000015101742,0.0000061457526,0.99864763,0.000057551362,0.000095372976,0.00009033022,0.00013944741,0.00055122154,0.0000066058165],"about_ca_topic_score_codex":0.0022076955,"about_ca_topic_score_gemma":0.0029014607,"teacher_disagreement_score":0.01096334,"about_ca_system_score_codex":0.0020751513,"about_ca_system_score_gemma":0.001436287,"threshold_uncertainty_score":0.015056372},"labels":[],"label_agreement":null},{"id":"W3120771989","doi":"10.25251/skin.5.supp.16","title":"Bimekizumab versus Ustekinumab Efficacy Across Subgroups of Patients with Moderate to Severe Plaque Psoriasis: Results from the Multicenter, Randomized, Double-Blinded Phase 3 BE VIVID Trial","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; McMaster University","funders":"","keywords":"Ustekinumab; Plaque psoriasis; Medicine; Double blinded; Psoriasis; Internal medicine; Randomized controlled trial; Multicenter study; Dermatology; Pathology; Placebo; Disease; Alternative medicine","score_opus":0.03190225859256773,"score_gpt":0.2984405727850189,"score_spread":0.26653831419245116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120771989","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868484,0.0066634086,0.00050255226,0.0010467728,0.00045616602,0.0014445223,0.0010549254,0.000075256954,0.0019080446],"genre_scores_gemma":[0.9914724,0.0019679314,0.0009388785,0.0010713723,0.0004937714,0.0017415597,0.0009912128,0.000026591371,0.0012962017],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9987392,0.00072215026,0.00008158796,0.00020408323,0.000084382234,0.00016867364],"domain_scores_gemma":[0.99845326,0.00050146756,0.00037500256,0.00016761127,0.00009321404,0.00040936298],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028638793,0.001751321,0.004053462,0.00031321487,0.000661986,0.0015979512,0.00095050846,0.0019656192,0.0049388874],"category_scores_gemma":[0.0029920507,0.0007103,0.0026702555,0.00044488642,0.0012108935,0.001575191,0.00059350504,0.0037196758,0.000861686],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9860103,0.0019816596,0.0008210771,0.0002936902,0.0010583492,0.00001646346,0.000044702083,0.00013637872,0.0014406311,0.00006832172,0.00054148264,0.0075869863],"study_design_scores_gemma":[0.9592353,0.033975754,0.004173582,0.000039737373,0.001081102,0.000035768087,0.000041089468,0.00028743193,0.0002842052,0.00029674981,0.0005318683,0.000017507962],"about_ca_topic_score_codex":0.0006882941,"about_ca_topic_score_gemma":0.0014164026,"teacher_disagreement_score":0.0049388874,"about_ca_system_score_codex":0.0007620484,"about_ca_system_score_gemma":0.0010491122,"threshold_uncertainty_score":0.016522288},"labels":[],"label_agreement":null},{"id":"W3121057262","doi":"10.25251/skin.5.supp.3","title":"Interim Analysis of Phase 2 Results for Cemiplimab in Patients with Metastatic Basal Cell Carcinoma (mBCC) who Progressed on or are Intolerant to Hedgehog Inhibitors (HHIs)","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Hedgehog Signaling Pathway Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Regeneron Pharmaceuticals; Sanofi","keywords":"Basal cell carcinoma; Interim; Vismodegib; Internal medicine; Oncology; Medicine; Interim analysis; Basal cell; Clinical trial; History","score_opus":0.01888602988988578,"score_gpt":0.2952838839229059,"score_spread":0.2763978540330201,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3121057262","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95312345,0.008416455,0.00359782,0.0025036428,0.0007849182,0.0042943754,0.014881486,0.00031932528,0.012078531],"genre_scores_gemma":[0.97122484,0.0015086001,0.003046038,0.0024430365,0.00029702985,0.004292173,0.012041404,0.000112007205,0.0050350158],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99803823,0.0011697967,0.00008094083,0.00015030899,0.00014147477,0.00041929542],"domain_scores_gemma":[0.99735105,0.0009904595,0.00054904225,0.00030525718,0.00014421996,0.0006599538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0067709857,0.0014145365,0.0024819567,0.00039146515,0.0005128598,0.0019510179,0.0006701825,0.0012811964,0.0057681412],"category_scores_gemma":[0.0043636123,0.00046651953,0.0032194636,0.0004474118,0.00054348516,0.0012885303,0.0004941855,0.0034605267,0.0010735134],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.876623,0.004881133,0.013487095,0.0007787299,0.0041692033,0.00033626315,0.00016095722,0.006291519,0.009681497,0.00057475554,0.013125488,0.069890454],"study_design_scores_gemma":[0.4758509,0.3787997,0.098575026,0.0002629787,0.006730678,0.0009240982,0.00023892701,0.0075008706,0.0087709,0.0031692816,0.019042004,0.0001347197],"about_ca_topic_score_codex":0.00041433214,"about_ca_topic_score_gemma":0.0014679807,"teacher_disagreement_score":0.0067709857,"about_ca_system_score_codex":0.00095498457,"about_ca_system_score_gemma":0.001364566,"threshold_uncertainty_score":0.0358088},"labels":[],"label_agreement":null},{"id":"W3135451264","doi":"10.25251/skin.5.supp.32","title":"Evolution of Patient Perceptions of Psoriatic Disease: Results From the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Mental Health and Psychiatry","field":"Arts and Humanities","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Disease; Perception; Medicine; Psoriasis; Dermatology; Psychology; Pathology; Neuroscience","score_opus":0.05909140626378356,"score_gpt":0.2805296217580594,"score_spread":0.22143821549427584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135451264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984347,0.000056750956,0.000041962343,0.00031539993,0.0000052288137,0.000022773902,0.00020294286,0.0000024289914,0.0009177389],"genre_scores_gemma":[0.9993123,0.0000604617,0.00011167679,0.00014604429,0.000005813333,0.000020216297,0.00016221966,0.0000018668806,0.0001793852],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979188,0.0009497252,0.00023306534,0.00014875481,0.0004540347,0.00029560132],"domain_scores_gemma":[0.99241674,0.0020593249,0.003035335,0.00032728034,0.0009422316,0.0012191023],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034767403,0.000112864625,0.0003222736,0.0006046696,0.00076843094,0.0010724165,0.00026676562,0.0006251822,0.0019153794],"category_scores_gemma":[0.010938148,0.00015839514,0.0006335667,0.0006269756,0.00056412705,0.00092717813,0.0014602691,0.0013213243,0.00026386778],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020920804,0.00027860494,0.98238903,0.00004005169,0.00008099072,0.00006153967,0.005568516,0.00007268939,0.0001990031,0.00006953522,0.0007923848,0.010238578],"study_design_scores_gemma":[0.0000130467815,0.00027728072,0.9905201,0.00001912436,0.000023176963,0.00008984363,0.008000047,0.00016242194,0.00006686705,0.000049595736,0.00076579594,0.000012632778],"about_ca_topic_score_codex":0.0073609604,"about_ca_topic_score_gemma":0.008061706,"teacher_disagreement_score":0.0073609604,"about_ca_system_score_codex":0.00087058265,"about_ca_system_score_gemma":0.0009482956,"threshold_uncertainty_score":0.01838696},"labels":[],"label_agreement":null},{"id":"W3200049481","doi":"10.25251/skin.5.supp.58","title":"COVID-19 in tralokinumab-treated patients with moderate-to- severe atopic dermatitis: case series from the ECZTEND long- term extension trial","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"LEO Pharma","keywords":"Atopic dermatitis; Medicine; Coronavirus disease 2019 (COVID-19); Dermatology; Term (time); Series (stratigraphy); Extension (predicate logic); 2019-20 coronavirus outbreak; Pediatrics; Internal medicine; Virology; Disease; Computer science","score_opus":0.014492670223765958,"score_gpt":0.27155961202400886,"score_spread":0.2570669418002429,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3200049481","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878896,0.0075048306,0.00028297608,0.0002998487,0.00007486544,0.00012303231,0.00035896266,0.0000098882765,0.0034560068],"genre_scores_gemma":[0.9973572,0.0013789883,0.00012498282,0.00030526225,0.0000661577,0.00002849687,0.00045508196,0.000004218533,0.00027962177],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994912,0.00018216089,0.00006987507,0.00007016173,0.000098104,0.000088614026],"domain_scores_gemma":[0.9994355,0.00024293702,0.00013099983,0.000052560663,0.00003537989,0.00010252792],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008409366,0.0002570498,0.0006345777,0.0001332945,0.00031333853,0.000669711,0.00024822392,0.00041828677,0.0012662116],"category_scores_gemma":[0.0012695459,0.00012231027,0.0008394711,0.00030095075,0.0002840786,0.00034499724,0.00018554232,0.00059862656,0.0002018879],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.085875966,0.0034324743,0.6626432,0.0017972791,0.0029763824,0.04190216,0.0004970254,0.0011502762,0.023512056,0.0009827993,0.012298771,0.16293162],"study_design_scores_gemma":[0.019224964,0.02842268,0.82326496,0.0005698416,0.0040941355,0.09218779,0.00076640875,0.0026865737,0.004078578,0.00071050075,0.023885176,0.00010836431],"about_ca_topic_score_codex":0.00049356546,"about_ca_topic_score_gemma":0.0012661676,"teacher_disagreement_score":0.0012662116,"about_ca_system_score_codex":0.00040592617,"about_ca_system_score_gemma":0.00036554172,"threshold_uncertainty_score":0.004447341},"labels":[],"label_agreement":null},{"id":"W3211411127","doi":"10.25251/skin.5.supp.39","title":"Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Versus Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Onset of Action in the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Bristol-Myers Squibb","keywords":"Apremilast; Medicine; Placebo; Psoriasis; Plaque psoriasis; Pharmacology; Internal medicine; Dermatology; Pathology; Psoriatic arthritis","score_opus":0.050049962194994205,"score_gpt":0.33098603349030825,"score_spread":0.28093607129531406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211411127","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95206517,0.032862812,0.0007731768,0.0014486866,0.0007143556,0.00091475365,0.0016448741,0.0002874151,0.009288905],"genre_scores_gemma":[0.9849642,0.0075898473,0.00058810704,0.0007271031,0.0002710549,0.0004152053,0.0009551571,0.000024091698,0.0044653513],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9996525,0.00016372773,0.000025446792,0.000051097333,0.000037427522,0.00006969493],"domain_scores_gemma":[0.99957246,0.00012998654,0.00008498491,0.000019293322,0.00002462477,0.00016868177],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001108083,0.00057650264,0.0017725831,0.00022022368,0.00026537955,0.00080878154,0.0003850741,0.00073328416,0.0061089555],"category_scores_gemma":[0.0008843767,0.00025706133,0.0011825243,0.00020867707,0.00037976305,0.0007891132,0.00017382966,0.0017153609,0.0006532783],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.85342926,0.0030569057,0.0007214236,0.0011914325,0.0010840783,0.000067325724,0.000053175394,0.00063200545,0.011136044,0.0002597774,0.0046412507,0.12372735],"study_design_scores_gemma":[0.77269024,0.19755505,0.014452806,0.0002098247,0.0014238536,0.00034937434,0.000085355925,0.0014341454,0.0037775186,0.00057217147,0.007396142,0.000053498075],"about_ca_topic_score_codex":0.00074363337,"about_ca_topic_score_gemma":0.002637198,"teacher_disagreement_score":0.0061089555,"about_ca_system_score_codex":0.0005492446,"about_ca_system_score_gemma":0.0005904816,"threshold_uncertainty_score":0.020436525},"labels":[],"label_agreement":null},{"id":"W3211412243","doi":"10.25251/skin.5.supp.34","title":"Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Efficacy by Baseline Disease Characteristics and Demographics in Two Pivotal Phase 3 Trials","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Phytochemistry Medicinal Plant Applications","field":"Agricultural and Biological Sciences","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Allergan; Genentech; Astellas Pharma; Glenmark Pharmaceuticals; Pfizer; Biogen; Incyte; Sun Pharma; Dermira; Coherus Biosciences; Valeant Pharmaceuticals International; Ablynx; Celgene; Novartis; GlaxoSmithKline; Astellas Pharma US; Amgen; Galderma; LEO Pharma; Ortho Dermatologics; Eli Lilly and Company; Bristol-Myers Squibb; Bausch Health; Bayer HealthCare; Sanofi; Regeneron Pharmaceuticals; Abbott Laboratories","keywords":"Demographics; Plaque psoriasis; Medicine; Baseline (sea); Psoriasis; Disease; Internal medicine; Clinical trial; Dermatology; Demography","score_opus":0.03108208345977064,"score_gpt":0.32647029681699785,"score_spread":0.2953882133572272,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211412243","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9623444,0.020492222,0.0014987459,0.0014802788,0.00048268464,0.004432742,0.0032091576,0.0002959698,0.005763901],"genre_scores_gemma":[0.97413445,0.011764257,0.0019835765,0.0018430054,0.00041135543,0.0034023284,0.0024236054,0.000060828923,0.003976593],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99938345,0.00026159894,0.00003967118,0.00010266974,0.000083037354,0.0001295625],"domain_scores_gemma":[0.99936515,0.00018520177,0.00014801539,0.000053423322,0.000051833813,0.00019641922],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022001613,0.0014677681,0.002649596,0.00050077913,0.0004674314,0.0010722766,0.0008712113,0.0012861927,0.007812676],"category_scores_gemma":[0.0012625307,0.0006728708,0.0023499606,0.00052558107,0.00075617945,0.0009747628,0.00031728458,0.002815013,0.0011220216],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8562308,0.016107049,0.0019730432,0.0017480028,0.0021823107,0.000094047326,0.000135016,0.0007414268,0.016230855,0.00023413704,0.0042248126,0.10009852],"study_design_scores_gemma":[0.8525223,0.13215788,0.009926877,0.00012037587,0.0012504148,0.000105072126,0.000041252257,0.0004205856,0.0009126297,0.00022799471,0.002280147,0.00003449537],"about_ca_topic_score_codex":0.0010223059,"about_ca_topic_score_gemma":0.0033792404,"teacher_disagreement_score":0.007812676,"about_ca_system_score_codex":0.00063825515,"about_ca_system_score_gemma":0.0009236936,"threshold_uncertainty_score":0.02613604},"labels":[],"label_agreement":null},{"id":"W3211628515","doi":"10.25251/skin.5.supp.42","title":"Once-Daily Roflumilast Cream 0.3%, a Potent Phosphodiesterase-4 Inhibitor, Provided Safe and Effective Treatment of Psoriasis in the DERMIS-1 and DERMIS-2 Phase 3 Trials","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Phosphodiesterase function and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Roflumilast; Dermis; Psoriasis; Medicine; Pharmacology; Phosphodiesterase inhibitor; Dermatology; Internal medicine; Pathology","score_opus":0.01646162550159773,"score_gpt":0.301729772481566,"score_spread":0.2852681469799683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211628515","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87333035,0.033126585,0.005999329,0.0048195207,0.00172751,0.006752136,0.007105618,0.0013457732,0.06579323],"genre_scores_gemma":[0.95877993,0.009309347,0.0026467696,0.0017684029,0.00034506805,0.0016518893,0.0030144723,0.00007600603,0.022408074],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9997665,0.00009895596,0.000012182957,0.000032241827,0.00003810089,0.000052042342],"domain_scores_gemma":[0.99980885,0.000043327298,0.00003475502,0.000020438767,0.000025122281,0.00006751541],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077287585,0.00048404094,0.0008454609,0.0002574135,0.000331063,0.00038837307,0.00032043146,0.0006836193,0.009687566],"category_scores_gemma":[0.00044407442,0.00018566161,0.00068000326,0.00016434709,0.0002455942,0.00037105172,0.00013531509,0.0013071109,0.001547021],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29782015,0.01789833,0.0017156295,0.0021257054,0.0012214828,0.00030435168,0.000089497575,0.00085103366,0.14622983,0.0010590861,0.034051858,0.49663305],"study_design_scores_gemma":[0.50227374,0.36110702,0.019938529,0.0003790321,0.0011493393,0.001133212,0.00007911962,0.0017248854,0.03661013,0.0011403247,0.07440832,0.000056423745],"about_ca_topic_score_codex":0.00084018736,"about_ca_topic_score_gemma":0.0028317797,"teacher_disagreement_score":0.009687566,"about_ca_system_score_codex":0.00034109256,"about_ca_system_score_gemma":0.0005380248,"threshold_uncertainty_score":0.032408178},"labels":[],"label_agreement":null},{"id":"W3211829948","doi":"10.25251/skin.5.supp.48","title":"Long-term Safety and Efficacy of Fixed-Combination Halobetasol Propionate and Tazarotene Lotion in Patients With Clinically Meaningful Improvement in Plaque Psoriasis","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Bausch Health; Ortho Dermatologics","keywords":"Tazarotene; Lotion; Medicine; Psoriasis; Plaque psoriasis; Dermatology; Adverse effect; Fixed-dose combination; Pharmacology","score_opus":0.006887610117860704,"score_gpt":0.23037279793076346,"score_spread":0.22348518781290275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211829948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947497,0.0039635235,0.00012563725,0.000114823226,0.000042492255,0.000056001798,0.00016907678,0.000015717473,0.0007630662],"genre_scores_gemma":[0.9985985,0.00054693606,0.000077492245,0.00010883467,0.00007074851,0.000031507392,0.0001961342,0.000002211415,0.00036758263],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9995103,0.00017312793,0.000048683665,0.00007061721,0.00011667094,0.00008061846],"domain_scores_gemma":[0.99925524,0.00021981065,0.00019367997,0.00007268377,0.00008024118,0.00017821447],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009714932,0.000376542,0.0013495699,0.000258354,0.00039456415,0.00041030193,0.00032715517,0.0006334043,0.0014208583],"category_scores_gemma":[0.0013911116,0.0001655713,0.00096922496,0.0002714094,0.00033120284,0.00048978196,0.00016037308,0.00109116,0.00036439218],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.572899,0.013607451,0.10844181,0.0007681013,0.0026859322,0.0011833858,0.00029284248,0.0014496574,0.062277492,0.00014990503,0.0012570358,0.23498741],"study_design_scores_gemma":[0.04782657,0.29503432,0.6377773,0.0000983299,0.0028895931,0.0017237591,0.00022131002,0.002200197,0.009178248,0.00018783055,0.00277231,0.000090135225],"about_ca_topic_score_codex":0.00079198496,"about_ca_topic_score_gemma":0.0011667818,"teacher_disagreement_score":0.0014208583,"about_ca_system_score_codex":0.00042938444,"about_ca_system_score_gemma":0.0003579202,"threshold_uncertainty_score":0.005137801},"labels":[],"label_agreement":null},{"id":"W3211979812","doi":"10.25251/skin.5.supp.94","title":"A Randomized, Double-blind, Vehicle-Controlled Phase 2a Study Evaluating Once Daily Roflumilast Foam 0.3% in Patients With Moderate to Severe Seborrheic Dermatitis","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Nail Diseases and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Lynde Centre for Dermatology","funders":"","keywords":"Roflumilast; Double blind; Seborrheic dermatitis; Medicine; Randomized controlled trial; Dermatology; Surgery; Internal medicine; Placebo; Alternative medicine","score_opus":0.023237423125617,"score_gpt":0.3309825190124378,"score_spread":0.3077450958868208,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211979812","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850594,0.0044272663,0.001053384,0.00051147817,0.00066303747,0.004776666,0.0008157484,0.00020719972,0.002485989],"genre_scores_gemma":[0.98541844,0.0033378883,0.0016145469,0.0012278608,0.00053063215,0.003936343,0.0007184542,0.000029667328,0.003186158],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9993906,0.0002850234,0.000045338435,0.00010401514,0.00004810398,0.0001268699],"domain_scores_gemma":[0.999206,0.00025175884,0.000108591514,0.000078700694,0.00006786792,0.00028699494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001586644,0.0014437236,0.0040371995,0.00069041084,0.00060788385,0.0008552032,0.0010967432,0.0017488786,0.007682179],"category_scores_gemma":[0.00126933,0.0008916605,0.0016488,0.00048247984,0.0014540408,0.0011931822,0.0003323691,0.0022252093,0.0012062248],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9526129,0.020185793,0.0004170397,0.00069918385,0.00058756163,0.000066311506,0.000055938384,0.00020132931,0.008584543,0.00009963977,0.00066584285,0.015823964],"study_design_scores_gemma":[0.89800155,0.09971225,0.0011894334,0.000014583863,0.00019977997,0.00002400811,0.000018726481,0.00016991251,0.00030321165,0.000055673536,0.0002990305,0.000011865374],"about_ca_topic_score_codex":0.0014244004,"about_ca_topic_score_gemma":0.0029492935,"teacher_disagreement_score":0.007682179,"about_ca_system_score_codex":0.00058448775,"about_ca_system_score_gemma":0.001227266,"threshold_uncertainty_score":0.025699437},"labels":[],"label_agreement":null},{"id":"W3212033307","doi":"10.25251/skin.5.supp.57","title":"Assessing long-term maintenance of efficacy with tralokinumab monotherapy in patients with moderate-to-severe atopic dermatitis: combined results from two phase 3, randomized, double-blind, placebo-controlled trials (ECZTRA 1 and 2)","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"LEO Pharma","keywords":"Atopic dermatitis; Medicine; Placebo; Double blind; Term (time); Randomized controlled trial; Placebo-controlled study; Dermatology; Pediatrics; Internal medicine; Alternative medicine; Pathology","score_opus":0.023699825724071356,"score_gpt":0.32221820947727425,"score_spread":0.2985183837532029,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212033307","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9666585,0.027408956,0.00075689476,0.00061072514,0.00043768086,0.0016052615,0.0010927693,0.00012229219,0.0013069641],"genre_scores_gemma":[0.98593265,0.007454629,0.0013827459,0.00083311397,0.00047261297,0.0015783518,0.001342294,0.00002419348,0.000979373],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99830437,0.00085247745,0.0001984498,0.00027032933,0.00015960768,0.00021471069],"domain_scores_gemma":[0.99761343,0.0008257512,0.0006523091,0.00022500372,0.00019729773,0.0004861828],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005365945,0.0019242284,0.00559538,0.0006194796,0.0006535355,0.001517171,0.00115455,0.0023880054,0.0032408393],"category_scores_gemma":[0.0027229167,0.000744991,0.0052750297,0.00063724077,0.0010870742,0.0019298989,0.00050792843,0.0032323876,0.00061478565],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96062183,0.0036589273,0.0015739431,0.0012216266,0.005216147,0.000039424507,0.00007898452,0.00027592666,0.004309471,0.00003281931,0.00041970715,0.022551307],"study_design_scores_gemma":[0.8881598,0.09764438,0.008926261,0.00007817035,0.003570375,0.00007080431,0.000038324648,0.00023737916,0.0006525061,0.000067626286,0.00052195205,0.00003239343],"about_ca_topic_score_codex":0.0010350246,"about_ca_topic_score_gemma":0.0027776856,"teacher_disagreement_score":0.00559538,"about_ca_system_score_codex":0.00090451306,"about_ca_system_score_gemma":0.0011282123,"threshold_uncertainty_score":0.028378129},"labels":[],"label_agreement":null},{"id":"W3212061951","doi":"10.25251/skin.5.supp.63","title":"Long-Term Safety and Disease Control With Ruxolitinib Cream in Atopic Dermatitis: Results From Two Phase 3 Studies","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Incyte","keywords":"Ruxolitinib; Atopic dermatitis; Medicine; Dermatology; Term (time); Disease; Disease control; Internal medicine; Environmental health; Myelofibrosis; Physics","score_opus":0.014321010066676652,"score_gpt":0.3113860671939269,"score_spread":0.2970650571272503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212061951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97754544,0.016286923,0.0009217877,0.00042086063,0.0001347278,0.0012864714,0.0011287943,0.00008269469,0.002192205],"genre_scores_gemma":[0.98812985,0.0060182875,0.0008863853,0.0007186024,0.00019346473,0.00083418225,0.0014509889,0.00002776541,0.0017405833],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9989637,0.0004898728,0.00009151683,0.00014651108,0.00015008179,0.00015839978],"domain_scores_gemma":[0.998514,0.00056888966,0.00036253675,0.00018502392,0.00014321174,0.0002263288],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032575997,0.0008957552,0.0023784032,0.00032030712,0.00051884574,0.0011670237,0.0007003937,0.0013653752,0.0029887569],"category_scores_gemma":[0.001744516,0.00032636794,0.0032493595,0.00031120746,0.0007227782,0.0008539497,0.00023763641,0.0021648123,0.0006279611],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7438122,0.026292022,0.006588632,0.0022672603,0.0063497117,0.00034096037,0.000282835,0.0013420678,0.04170515,0.00016913196,0.0027118158,0.16813813],"study_design_scores_gemma":[0.5360184,0.38758513,0.051233485,0.00028818354,0.0060119834,0.000736514,0.00014137778,0.0010090877,0.010925709,0.00035910745,0.0056049763,0.000086055275],"about_ca_topic_score_codex":0.00085105293,"about_ca_topic_score_gemma":0.0016375257,"teacher_disagreement_score":0.0032575997,"about_ca_system_score_codex":0.0007546019,"about_ca_system_score_gemma":0.0006897078,"threshold_uncertainty_score":0.017228067},"labels":[],"label_agreement":null},{"id":"W3212333063","doi":"10.25251/skin.5.supp.52","title":"Bimekizumab response maintenance through two years of treatment in patients with moderate to severe plaque psoriasis who responded after 16 weeks: Interim results from the BE BRIGHT open-label extension trial","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Plaque psoriasis; Interim; Open label; Medicine; Psoriasis; Extension (predicate logic); Internal medicine; Dermatology; Interim analysis; Clinical trial; Surgery; History","score_opus":0.02578579340508559,"score_gpt":0.280982458042791,"score_spread":0.2551966646377054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212333063","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98622626,0.0055226833,0.000529405,0.0013434744,0.000474748,0.00084162765,0.0014790365,0.00013434961,0.0034484759],"genre_scores_gemma":[0.9889052,0.0016160267,0.00075854704,0.0017751764,0.00043298723,0.0012157187,0.0017076238,0.000035559216,0.0035530673],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99897254,0.000391524,0.000050062143,0.00016428165,0.00008023723,0.00034140472],"domain_scores_gemma":[0.99868006,0.00030960192,0.00028976327,0.0001626136,0.000075519376,0.0004824644],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029193594,0.0010321607,0.0034487727,0.00028182627,0.0006130607,0.0017941043,0.0008325945,0.0018373032,0.0052657],"category_scores_gemma":[0.0018250645,0.00053835136,0.0028047855,0.00033029314,0.0010064557,0.0017258427,0.0005028553,0.004389449,0.0015823842],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9535348,0.0055105994,0.0018730898,0.0004401732,0.001086263,0.00006977845,0.00010201077,0.00040755497,0.0030822244,0.00013999191,0.0027349843,0.031018566],"study_design_scores_gemma":[0.87885743,0.10237973,0.014307586,0.00009410247,0.0011225922,0.0001028965,0.000067161694,0.0004642484,0.00056498975,0.0003415174,0.0016654956,0.000032196887],"about_ca_topic_score_codex":0.0010273713,"about_ca_topic_score_gemma":0.0016966253,"teacher_disagreement_score":0.0052657,"about_ca_system_score_codex":0.0007746539,"about_ca_system_score_gemma":0.0009090434,"threshold_uncertainty_score":0.017615557},"labels":[],"label_agreement":null},{"id":"W3212399069","doi":"10.25251/skin.5.supp.49","title":"Long-term Outcomes of Fixed-Combination Halobetasol Propionate and Tazarotene Lotion Stratified by Baseline Signs and Symptoms of Psoriasis","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bausch Health; Ortho Dermatologics","keywords":"Tazarotene; Lotion; Psoriasis; Medicine; Dermatology; Internal medicine; Pharmacology","score_opus":0.011908172349742327,"score_gpt":0.24588944887510455,"score_spread":0.23398127652536221,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212399069","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954418,0.0027202172,0.000079945254,0.00008475463,0.000062772255,0.000025119118,0.0006982768,0.000006096644,0.000880978],"genre_scores_gemma":[0.9980599,0.0003997843,0.000021468482,0.00008641878,0.000070071685,0.000020350117,0.0008057798,0.0000017167081,0.0005344172],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99932885,0.000113430295,0.000055424727,0.00016514999,0.00009139971,0.0002458239],"domain_scores_gemma":[0.99870455,0.00024489936,0.0004141706,0.000114021896,0.00014590759,0.00037641067],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009275264,0.00039893118,0.0012754344,0.0002585043,0.00037131997,0.0008312181,0.0004121187,0.0008824701,0.0021259603],"category_scores_gemma":[0.001423054,0.00019792604,0.0023558438,0.0004308946,0.0003225189,0.00091845955,0.00041801113,0.0013207858,0.00039336947],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38779494,0.0032707695,0.55549556,0.00042954786,0.0064116535,0.0005751747,0.0001826916,0.00087059423,0.0055039725,0.0001731143,0.0016867649,0.037605293],"study_design_scores_gemma":[0.002729306,0.021564424,0.97003514,0.00007452199,0.0030387386,0.00022649173,0.00022316069,0.0004960442,0.0004879594,0.00016350127,0.00091051555,0.000050149443],"about_ca_topic_score_codex":0.0026445703,"about_ca_topic_score_gemma":0.0035009156,"teacher_disagreement_score":0.0026445703,"about_ca_system_score_codex":0.0005679121,"about_ca_system_score_gemma":0.0005032672,"threshold_uncertainty_score":0.007112026},"labels":[],"label_agreement":null},{"id":"W3212504077","doi":"10.25251/skin.5.supp.51","title":"Efficacy of Brodalumab vs Ustekinumab by Prior TNFα Inhibitor Exposure: Post hoc Analysis of Two Phase 3 Psoriasis Studies","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Biotech; Allergan; LEO Pharma; Eli Lilly and Company; Ortho Dermatologics; Galderma; Incyte; Dermira; Tulane University; Celgene; Regeneron Pharmaceuticals; Bausch Health; Novartis; Amgen; Pfizer","keywords":"Ustekinumab; Post-hoc analysis; Medicine; Psoriasis; Post hoc; Dermatology; Pharmacology; Internal medicine; Tumor necrosis factor alpha; Adalimumab","score_opus":0.016614763979763615,"score_gpt":0.2994205924946756,"score_spread":0.282805828514912,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212504077","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99139786,0.0026493226,0.0010540162,0.00023046289,0.00047597458,0.0011571615,0.0012673308,0.00009613153,0.0016716607],"genre_scores_gemma":[0.9929006,0.00078433135,0.0009225417,0.00035705796,0.00025883561,0.0013301594,0.0007832154,0.0000626684,0.0026005176],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99338573,0.0038489592,0.00041951562,0.0008918516,0.00041895008,0.0010349829],"domain_scores_gemma":[0.992082,0.0047027743,0.0010102114,0.0009288225,0.00051004987,0.00076613354],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008189215,0.0023264075,0.008739149,0.0005759828,0.00068516016,0.0022520316,0.0014661526,0.00203558,0.006730591],"category_scores_gemma":[0.006153803,0.0010065885,0.008025558,0.00060278573,0.0013471928,0.0018627297,0.0008050025,0.005197436,0.00086529105],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98659074,0.0022804346,0.00074267713,0.00017252682,0.0032310318,0.000029442792,0.000031345455,0.00044323155,0.0026672326,0.000030154119,0.0002915982,0.0034896175],"study_design_scores_gemma":[0.48296148,0.4481561,0.034664437,0.00009650512,0.020166606,0.0001314658,0.00019850016,0.0036645427,0.0068624816,0.0005153185,0.0024368283,0.00014575146],"about_ca_topic_score_codex":0.0011482101,"about_ca_topic_score_gemma":0.002122642,"teacher_disagreement_score":0.008739149,"about_ca_system_score_codex":0.0010680076,"about_ca_system_score_gemma":0.0015128194,"threshold_uncertainty_score":0.04330921},"labels":[],"label_agreement":null},{"id":"W3212595479","doi":"10.25251/skin.5.supp.50","title":"Retreatment With Brodalumab Results in Skin Clearance and Improvements in Quality of Life in Patients With Psoriasis After Treatment Interruption","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bausch Health; Ortho Dermatologics","keywords":"Psoriasis; Medicine; Dermatology; Quality of life (healthcare); Intensive care medicine; Nursing","score_opus":0.01449934001659458,"score_gpt":0.2550851118258947,"score_spread":0.24058577180930013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212595479","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9766261,0.015767528,0.00020150673,0.0006908431,0.000273901,0.00006144301,0.00014363728,0.000048538484,0.006186347],"genre_scores_gemma":[0.9967174,0.0015594306,0.00016877246,0.00042719534,0.00009963807,0.00001766917,0.00013380611,0.0000050332073,0.00087097037],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9997254,0.00007403553,0.000024097051,0.000041354615,0.000062363084,0.00007283227],"domain_scores_gemma":[0.99956614,0.00013980654,0.000106146515,0.00002816261,0.00005189687,0.00010773636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051655335,0.00013760792,0.00068803836,0.00011458735,0.00024100335,0.00044791854,0.00017654993,0.00030452618,0.0023946238],"category_scores_gemma":[0.001010451,0.00008193956,0.0006580856,0.00012908933,0.00010691275,0.00018469703,0.0000814021,0.0005458952,0.00032885346],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10488066,0.006050475,0.116997845,0.0009033567,0.0021988794,0.0010313889,0.00018755073,0.00059992686,0.026079843,0.0001599126,0.011768737,0.7291414],"study_design_scores_gemma":[0.010240236,0.03405217,0.93337625,0.00026332896,0.0016274984,0.0029639287,0.00020018457,0.0012649569,0.0036189004,0.0001840534,0.012169423,0.00003911401],"about_ca_topic_score_codex":0.0010053632,"about_ca_topic_score_gemma":0.0020432353,"teacher_disagreement_score":0.0023946238,"about_ca_system_score_codex":0.00024998456,"about_ca_system_score_gemma":0.00018737066,"threshold_uncertainty_score":0.008010805},"labels":[],"label_agreement":null},{"id":"W3212964692","doi":"10.25251/skin.5.supp.64","title":"Itch-Free State in Patients With Atopic Dermatitis Treated With Ruxolitinib Cream","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Incyte","keywords":"Ruxolitinib; Atopic dermatitis; Dermatology; Medicine; Internal medicine; Myelofibrosis","score_opus":0.005396938450692176,"score_gpt":0.2249584020200947,"score_spread":0.21956146356940254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212964692","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99340916,0.0012952198,0.00008848244,0.00015693305,0.00003331898,0.000019589163,0.00009420021,0.0000076945325,0.00489543],"genre_scores_gemma":[0.9993525,0.00024212379,0.000026056488,0.000077988705,0.000026660056,0.000003910086,0.000056726793,8.910727e-7,0.00021315023],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99989605,0.000021482188,0.000012308779,0.000019936904,0.000017634991,0.000032577947],"domain_scores_gemma":[0.99984634,0.000058404778,0.000038248505,0.000008779949,0.000011605272,0.00003663343],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013660413,0.00017360174,0.00036334788,0.00025509155,0.00036093706,0.00028111783,0.00012333634,0.00028756054,0.0020635398],"category_scores_gemma":[0.00063413545,0.00007893206,0.0002870445,0.00025274855,0.00015141022,0.00022595494,0.00010822259,0.00023239329,0.0002201296],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005607518,0.0006661973,0.8674789,0.0001761497,0.0002668875,0.08214303,0.00030221223,0.00024281803,0.0066510667,0.0003649259,0.002074224,0.034026064],"study_design_scores_gemma":[0.00035339856,0.001398039,0.9128476,0.0000696458,0.00035882107,0.080413364,0.00046279322,0.0010069531,0.00073504844,0.00033978556,0.0019920564,0.00002248242],"about_ca_topic_score_codex":0.000803012,"about_ca_topic_score_gemma":0.0010289464,"teacher_disagreement_score":0.0020635398,"about_ca_system_score_codex":0.00016696054,"about_ca_system_score_gemma":0.0001195995,"threshold_uncertainty_score":0.006903231},"labels":[],"label_agreement":null},{"id":"W3212995571","doi":"10.25251/skin.5.supp.35","title":"Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Long-Term Extension Trial of a Novel Therapeutic Aryl Hydrocarbon Receptor Modulating Agent","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"","keywords":"Term (time); Extension (predicate logic); Aryl hydrocarbon receptor; Aryl; Psoriasis; Hydrocarbon; Medicine; Combinatorial chemistry; Pharmacology; Chemistry; Computer science; Dermatology; Organic chemistry; Physics; Biochemistry","score_opus":0.034237871899152575,"score_gpt":0.2839932816325126,"score_spread":0.24975540973336002,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212995571","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98845834,0.0052623563,0.0005563225,0.0005260118,0.00043601298,0.0010544821,0.00083100336,0.00014013656,0.0027352904],"genre_scores_gemma":[0.9875553,0.003948976,0.00081124716,0.0008503646,0.0004387483,0.00093128794,0.0012252365,0.000026381646,0.0042123566],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9994623,0.00015071708,0.000025124951,0.00010869833,0.00005696338,0.00019615228],"domain_scores_gemma":[0.9994221,0.00011731779,0.00006885125,0.00006559828,0.000047025966,0.0002790953],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012937746,0.001370973,0.0031467522,0.0004860223,0.0005543008,0.0010267519,0.0010126632,0.0017317969,0.0047185775],"category_scores_gemma":[0.000777029,0.0005399215,0.001915055,0.0004342083,0.0010434069,0.0011927583,0.0003137277,0.0038617088,0.0011262193],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8934517,0.03420894,0.00088446814,0.0005986043,0.00086422334,0.00016079888,0.00008106855,0.00058670616,0.013940444,0.00013946368,0.0011983898,0.053885195],"study_design_scores_gemma":[0.62453854,0.36163965,0.008518744,0.00007477626,0.00080752134,0.00017154911,0.00006069593,0.0008732403,0.0016793985,0.00018624621,0.0014095824,0.000040131068],"about_ca_topic_score_codex":0.0019736493,"about_ca_topic_score_gemma":0.0034793648,"teacher_disagreement_score":0.0047185775,"about_ca_system_score_codex":0.0006976534,"about_ca_system_score_gemma":0.00097294705,"threshold_uncertainty_score":0.015785217},"labels":[],"label_agreement":null},{"id":"W3213252676","doi":"10.25251/skin.5.supp.37","title":"Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Compared With Placebo and Apremilast in Moderate to Severe Psoriasis: Integrated Laboratory Parameter Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Inflammatory mediators and NSAID effects","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Bristol-Myers Squibb","keywords":"Apremilast; Placebo; Psoriasis; Medicine; Internal medicine; Pharmacology; Dermatology; Psoriatic arthritis; Alternative medicine; Pathology","score_opus":0.024652951725289696,"score_gpt":0.29938542965671344,"score_spread":0.27473247793142375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213252676","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9539288,0.03643141,0.00063523866,0.0009495211,0.0004541773,0.00065615034,0.0020095995,0.00019620347,0.0047388417],"genre_scores_gemma":[0.9859189,0.008703038,0.00061144383,0.0005615081,0.00028048546,0.00032891546,0.0014508481,0.000020934323,0.0021240287],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99951375,0.0002494511,0.000045340475,0.00006724677,0.000058415975,0.00006574678],"domain_scores_gemma":[0.9994041,0.00020151158,0.0001584675,0.00003269563,0.00003996889,0.00016337995],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001268722,0.0007089485,0.0023061638,0.0002664954,0.00019953499,0.00077192776,0.00043322038,0.00068004866,0.0041231653],"category_scores_gemma":[0.0011047701,0.00024186727,0.0015134087,0.00029216727,0.00037071444,0.00075958914,0.0001911783,0.0015487124,0.00053117593],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89295673,0.0026136215,0.0013034097,0.0012987233,0.0024434738,0.00003545759,0.000033129443,0.00050592277,0.00921832,0.00008604662,0.002183272,0.08732185],"study_design_scores_gemma":[0.74617285,0.21103998,0.026799478,0.00021070558,0.0048112185,0.00028556486,0.000081897284,0.001462341,0.004387115,0.00030987224,0.0043873177,0.000051572522],"about_ca_topic_score_codex":0.00077664666,"about_ca_topic_score_gemma":0.002405837,"teacher_disagreement_score":0.0041231653,"about_ca_system_score_codex":0.0004932257,"about_ca_system_score_gemma":0.00051515887,"threshold_uncertainty_score":0.01379329},"labels":[],"label_agreement":null},{"id":"W3213483770","doi":"10.25251/skin.5.supp.67","title":"Effects of Ruxolitinib Cream in Patients With Atopic Dermatitis With Head and/or Neck Involvement","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"Incyte","keywords":"Ruxolitinib; Atopic dermatitis; Medicine; Dermatology; Head and neck; Internal medicine; Surgery","score_opus":0.005928745990522907,"score_gpt":0.23804003275672872,"score_spread":0.23211128676620582,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213483770","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9836494,0.01209363,0.000056426237,0.00027915507,0.00013127466,0.000052887575,0.00012537478,0.000013502384,0.0035984202],"genre_scores_gemma":[0.99665546,0.0023287754,0.00008071468,0.00020942444,0.00007544732,0.000018555986,0.00011693581,0.0000016613478,0.0005129498],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9998503,0.000061483945,0.000015267098,0.0000199991,0.000021233596,0.00003178249],"domain_scores_gemma":[0.9998118,0.0000959024,0.0000326126,0.000007934828,0.000013381771,0.000038342798],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029845684,0.00021603056,0.00085866783,0.00012315267,0.00020574515,0.00023835938,0.00013587804,0.0002760726,0.0022466134],"category_scores_gemma":[0.000663427,0.00008708595,0.0005039638,0.00010569814,0.00008692897,0.0001710084,0.00009090237,0.00043778177,0.00026352107],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3566345,0.008748434,0.14970289,0.0027031074,0.002936093,0.0064888247,0.00027021472,0.0010634575,0.04066341,0.00022940163,0.0073342854,0.42322546],"study_design_scores_gemma":[0.043713413,0.10504151,0.81037617,0.0005272375,0.0051604006,0.0101161655,0.0006199072,0.0025353152,0.008887195,0.00028089114,0.012668153,0.00007369577],"about_ca_topic_score_codex":0.0010373455,"about_ca_topic_score_gemma":0.0022412988,"teacher_disagreement_score":0.0022466134,"about_ca_system_score_codex":0.00021414548,"about_ca_system_score_gemma":0.00020041416,"threshold_uncertainty_score":0.007515669},"labels":[],"label_agreement":null},{"id":"W3213530550","doi":"10.25251/skin.5.supp.53","title":"Bimekizumab versus secukinumab efficacy across subgroups of patients with moderate to severe plaque psoriasis: Results from the multicenter, randomized, double-blinded phase 3b BE RADIANT trial","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"UCB Pharma","keywords":"Secukinumab; Medicine; Plaque psoriasis; Double blinded; Psoriasis; Dermatology; Randomized controlled trial; Multicenter study; Internal medicine; Psoriatic arthritis; Alternative medicine; Placebo; Pathology","score_opus":0.028914308113880276,"score_gpt":0.2928783056741451,"score_spread":0.2639639975602648,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213530550","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98786163,0.006893416,0.0005357749,0.00078571594,0.00047022282,0.0010912945,0.0008584732,0.000066726505,0.0014366858],"genre_scores_gemma":[0.9922937,0.0020481558,0.00074620446,0.0010801832,0.00046183908,0.0011446406,0.0009290061,0.000024767174,0.0012715027],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99859494,0.0007773331,0.00010409005,0.00024328844,0.00010180087,0.00017856933],"domain_scores_gemma":[0.9987232,0.00038833052,0.00035801614,0.00014730597,0.00009269664,0.00029041123],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002909387,0.0020681354,0.0042468486,0.00033324413,0.0006193249,0.0016532257,0.0008650462,0.0018245425,0.004213507],"category_scores_gemma":[0.0025700943,0.0007552314,0.003802028,0.0004248615,0.0011533211,0.0013245732,0.0005343663,0.003080189,0.00078505604],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9869071,0.0015191212,0.0009869926,0.0003051113,0.0016120373,0.000019324365,0.00003404491,0.00013750083,0.0013419157,0.000047736623,0.0004751403,0.0066140313],"study_design_scores_gemma":[0.95984626,0.031233545,0.0056450795,0.0000435526,0.0018232849,0.000039819,0.00003821891,0.00029038597,0.000286237,0.0002420398,0.0004894472,0.000022072416],"about_ca_topic_score_codex":0.0006998552,"about_ca_topic_score_gemma":0.0015682583,"teacher_disagreement_score":0.0042468486,"about_ca_system_score_codex":0.000719133,"about_ca_system_score_gemma":0.00084319775,"threshold_uncertainty_score":0.015386522},"labels":[],"label_agreement":null},{"id":"W3213541100","doi":"10.25251/skin.5.supp.43","title":"Once-Daily Roflumilast Foam 0.3% Improves Severity and Burden of Itch in Patients With Scalp and Body Psoriasis in a Randomized, Double-blind, Vehicle-Controlled Phase 2b Study","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Probity Medical Research","funders":"","keywords":"Scalp; Double blind; Medicine; Randomized controlled trial; Roflumilast; Psoriasis; Dermatology; Surgery; Internal medicine; Pathology; Alternative medicine","score_opus":0.06720391279295425,"score_gpt":0.3627389373596417,"score_spread":0.29553502456668745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213541100","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99093515,0.0032784056,0.0004465825,0.0004839796,0.00029611797,0.0021300311,0.000815722,0.00011796949,0.0014960304],"genre_scores_gemma":[0.98919594,0.0028843298,0.00091460004,0.0008240484,0.00044495155,0.0025369253,0.0008577295,0.0000266177,0.0023148784],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99947375,0.00023575612,0.00003635047,0.00009380342,0.00004993811,0.000110392386],"domain_scores_gemma":[0.9993297,0.00021449669,0.00013378705,0.00007415006,0.000050761486,0.00019719434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014397611,0.0016462394,0.0038796288,0.0005936012,0.00046296464,0.0010419595,0.0010147735,0.0017208084,0.0078523],"category_scores_gemma":[0.0013212884,0.0008178385,0.0019848174,0.00048696785,0.0011679734,0.001264027,0.00033770036,0.0024693697,0.001339403],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.962782,0.01432833,0.00046024556,0.0006148115,0.00072795217,0.000046894726,0.000032903186,0.00018709688,0.0037782844,0.00006579504,0.00064712315,0.016328424],"study_design_scores_gemma":[0.9422482,0.055157565,0.0016363312,0.000018660701,0.00027808012,0.000022173048,0.000014532012,0.00018489042,0.0002115649,0.00004685009,0.00016934912,0.000011699038],"about_ca_topic_score_codex":0.0013391069,"about_ca_topic_score_gemma":0.001950656,"teacher_disagreement_score":0.0078523,"about_ca_system_score_codex":0.000559227,"about_ca_system_score_gemma":0.0007293111,"threshold_uncertainty_score":0.026268542},"labels":[],"label_agreement":null},{"id":"W3213641793","doi":"10.25251/skin.5.supp.62","title":"Tapinarof Cream 1% Once Daily for the Treatment of Moderate to Severe Atopic Dermatitis in Children and Adults: The Pivotal Phase 3 ADORING Clinical Program","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"LEO Pharma; EMD Serono; Bausch Health; Glenmark Pharmaceuticals; Sanofi Genzyme; Incyte; Dermira; Regeneron Pharmaceuticals; Kiniksa Pharmaceuticals; Celgene; Sanofi; Amgen; Pfizer; Galderma; Ortho Dermatologics; Eli Lilly and Company; Bristol-Myers Squibb; GlaxoSmithKline","keywords":"Atopic dermatitis; Medicine; Dermatology","score_opus":0.017686213655082696,"score_gpt":0.34434660661192623,"score_spread":0.3266603929568435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213641793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9275148,0.037119333,0.0022849804,0.0032368964,0.0009863897,0.010694795,0.0038603256,0.0002528711,0.014049735],"genre_scores_gemma":[0.93551713,0.03268513,0.0070391484,0.004670638,0.00074753584,0.0060805334,0.0037585252,0.000080377555,0.009420967],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9997503,0.00011439063,0.0000134045895,0.000030924653,0.000033401604,0.000057676483],"domain_scores_gemma":[0.9996247,0.00008089418,0.000058962996,0.000022928498,0.000051836298,0.00016065742],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013054593,0.00076897047,0.0013147416,0.0002788837,0.00042738428,0.00073771185,0.0007098997,0.0010067875,0.00482251],"category_scores_gemma":[0.0006784455,0.0002949023,0.0010466874,0.00024929765,0.00045756862,0.00049148477,0.00024619882,0.0019605723,0.00073000265],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.41629583,0.056851685,0.007359664,0.004153615,0.0018029158,0.00041016235,0.000384031,0.001405995,0.04169409,0.0012777464,0.03721482,0.43114942],"study_design_scores_gemma":[0.6812907,0.26048556,0.022062834,0.0005720567,0.00078939,0.00071644085,0.00014900208,0.00096993626,0.0035142265,0.0004677842,0.02893758,0.000044601962],"about_ca_topic_score_codex":0.0015017512,"about_ca_topic_score_gemma":0.0048339614,"teacher_disagreement_score":0.00482251,"about_ca_system_score_codex":0.0005119157,"about_ca_system_score_gemma":0.0012773393,"threshold_uncertainty_score":0.01613295},"labels":[],"label_agreement":null},{"id":"W3213872593","doi":"10.25251/skin.5.supp.59","title":"Long-Term Improvements Observed in Tralokinumab-Treated Patients with Moderate-to-Severe Atopic Dermatitis: an ECZTEND Interim Analysis","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Atopic dermatitis; Interim; Term (time); Interim analysis; Medicine; Dermatology; Pediatrics; Psychology; Internal medicine; Political science; Clinical trial; Physics","score_opus":0.014937053087534355,"score_gpt":0.26885961384074514,"score_spread":0.2539225607532108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213872593","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99042517,0.0029013094,0.00041764154,0.00013684064,0.000067922476,0.00018636555,0.0038287991,0.000024070632,0.002011854],"genre_scores_gemma":[0.99213386,0.0006592485,0.00026664833,0.0002803149,0.00006896634,0.00018678734,0.0051489403,0.000010191899,0.0012449907],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9982663,0.00051749597,0.00019678849,0.00024559695,0.00037132716,0.00040257527],"domain_scores_gemma":[0.99777716,0.00074036425,0.00067353644,0.00027409956,0.00026243983,0.00027235426],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035787465,0.00051001454,0.0016216333,0.0003640809,0.00040631564,0.0013528862,0.00047259804,0.0006373713,0.0016712354],"category_scores_gemma":[0.0023437154,0.00022075934,0.0035788484,0.00049257634,0.0003441807,0.00090425037,0.00041156766,0.0016050991,0.0003907223],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.52215403,0.003893855,0.36170465,0.0012228201,0.015109007,0.0005055373,0.00023177569,0.002978978,0.009601526,0.0003076699,0.0033516777,0.07893846],"study_design_scores_gemma":[0.017344438,0.06795405,0.8880781,0.00016386647,0.015208822,0.00056955026,0.0002058551,0.0012994931,0.0033387356,0.00022581137,0.0055284025,0.000082964165],"about_ca_topic_score_codex":0.0009164932,"about_ca_topic_score_gemma":0.0017675884,"teacher_disagreement_score":0.0035787465,"about_ca_system_score_codex":0.0006732348,"about_ca_system_score_gemma":0.0008211225,"threshold_uncertainty_score":0.018926501},"labels":[],"label_agreement":null},{"id":"W3213919372","doi":"10.25251/skin.5.supp.44","title":"Long-term Safety and Efficacy of Roflumilast Cream 0.3% in Adult Patients With Chronic Plaque Psoriasis: Results From a 52-Week, Phase 2b Open-Label Study","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Probity Medical Research; University of British Columbia; Queen's University","funders":"","keywords":"Roflumilast; Open label; Plaque psoriasis; Medicine; Psoriasis; Dermatology; Adverse effect; Term (time); Pharmacology; Internal medicine; COPD","score_opus":0.016306808373359905,"score_gpt":0.2737719592662977,"score_spread":0.2574651508929378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213919372","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931138,0.0041807657,0.00039313146,0.000207451,0.00006869447,0.0005397192,0.0005596009,0.000070978276,0.0008657462],"genre_scores_gemma":[0.99235356,0.0027624848,0.0006889641,0.00066660985,0.0002550156,0.00067792996,0.0010400404,0.000024892968,0.0015304306],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9993529,0.0002807888,0.00005330846,0.00010847767,0.000088418514,0.00011624844],"domain_scores_gemma":[0.99917585,0.00022035082,0.00021499857,0.00009885092,0.00007088183,0.0002190194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00179226,0.0011764169,0.0025266537,0.00033572855,0.0004091741,0.0007925338,0.0006418383,0.0015346323,0.00277466],"category_scores_gemma":[0.0011120547,0.00055492483,0.0013984478,0.00033039672,0.00088805624,0.0010130878,0.00023878133,0.002250398,0.0009656193],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.79446936,0.037641875,0.0065475837,0.0011770918,0.0015537168,0.0002931896,0.00024593313,0.000859551,0.055373274,0.00009599647,0.0018633715,0.099879086],"study_design_scores_gemma":[0.48222396,0.46666592,0.04281377,0.000076795994,0.0010960277,0.0004000429,0.00009845587,0.0007610109,0.0037166113,0.00012297493,0.0019625016,0.00006189161],"about_ca_topic_score_codex":0.00063727476,"about_ca_topic_score_gemma":0.0011253565,"teacher_disagreement_score":0.00277466,"about_ca_system_score_codex":0.00041983396,"about_ca_system_score_gemma":0.0005653395,"threshold_uncertainty_score":0.009478509},"labels":[],"label_agreement":null},{"id":"W3214388010","doi":"10.25251/skin.5.supp.41","title":"Roflumilast Cream 0.3% Improved the Severity and Impact of Itch in Patients With Chronic Plaque Psoriasis in the Phase 3 DERMIS-1 and DERMIS-2 Studies","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Autoimmune Bullous Skin Diseases","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Dermis; Plaque psoriasis; Medicine; Roflumilast; Psoriasis; Dermatology; Pathology; Internal medicine","score_opus":0.010570115979971097,"score_gpt":0.30207330137651917,"score_spread":0.29150318539654807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214388010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893995,0.0066919746,0.00023375892,0.00042261597,0.00010651961,0.00037735037,0.00021535292,0.000053045565,0.002499831],"genre_scores_gemma":[0.9960757,0.0022569173,0.00032394278,0.00025467062,0.000102204984,0.00009822342,0.00015826286,0.0000067709616,0.0007232047],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9996369,0.00020231093,0.000030943385,0.000032531105,0.000032659984,0.00006464926],"domain_scores_gemma":[0.999627,0.00014743644,0.00006839595,0.000034847457,0.000030478173,0.000091839014],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012293801,0.00047868452,0.0012518276,0.00020851436,0.00025989933,0.00037695828,0.00025851687,0.00043444993,0.0029364608],"category_scores_gemma":[0.0007544028,0.00020119092,0.0010308479,0.0001772572,0.00026707558,0.00047140708,0.00015489462,0.0010593665,0.00029359976],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5724951,0.019742236,0.011631133,0.0021351648,0.0019848293,0.0005905274,0.00023997022,0.000702296,0.09008956,0.00018023177,0.0033952347,0.29681373],"study_design_scores_gemma":[0.26396725,0.6191858,0.09289241,0.00027516123,0.002260803,0.0010363715,0.00020260538,0.0010435147,0.0134622995,0.00023489236,0.0053857234,0.000053135183],"about_ca_topic_score_codex":0.00062860246,"about_ca_topic_score_gemma":0.002036643,"teacher_disagreement_score":0.0029364608,"about_ca_system_score_codex":0.00024626948,"about_ca_system_score_gemma":0.0003517644,"threshold_uncertainty_score":0.0098234415},"labels":[],"label_agreement":null},{"id":"W3214413975","doi":"10.25251/skin.5.6.4","title":"Light and Laser-based Treatments for Hidradenitis Suppurativa: A Systematic Review","year":2021,"lang":"en","type":"review","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Hidradenitis Suppurativa and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health; Vancouver General Hospital; University of Toronto; University of British Columbia","funders":"","keywords":"Hidradenitis suppurativa; Medicine; Randomized controlled trial; Dermatology; Surgery; Internal medicine","score_opus":0.03419813216321437,"score_gpt":0.3506739263673362,"score_spread":0.3164757942041218,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214413975","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009241301,0.9983329,0.000066854824,0.00009487633,0.00005414693,0.00024205074,0.00012815643,0.000005122841,0.00015183349],"genre_scores_gemma":[0.013690435,0.9847259,0.00044033927,0.0003618044,0.00006179475,0.00049460295,0.0001227298,0.0000031800735,0.00009924291],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99597186,0.0014407623,0.0013905767,0.00027997125,0.0007689116,0.00014790172],"domain_scores_gemma":[0.9881071,0.0075619123,0.0028250876,0.00013373663,0.0011997493,0.00017244808],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046344693,0.0012895622,0.008557084,0.006226808,0.00059693324,0.0019892058,0.0015726628,0.001789177,0.0045490386],"category_scores_gemma":[0.01607392,0.000866745,0.007476001,0.007240122,0.00069857814,0.0015475132,0.001003621,0.0009353332,0.00027910926],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025154537,0.000022924412,0.0003694964,0.970873,0.0078059454,0.00007128709,0.00007067434,0.000060592036,0.000120512224,0.000067287736,0.0006927748,0.019593965],"study_design_scores_gemma":[0.00077422184,0.00056025723,0.004794874,0.8496441,0.12846608,0.0005705382,0.00026817626,0.00014548849,0.00024064738,0.00020339974,0.014288269,0.000043816493],"about_ca_topic_score_codex":0.006321507,"about_ca_topic_score_gemma":0.018729383,"teacher_disagreement_score":0.008557084,"about_ca_system_score_codex":0.0026282845,"about_ca_system_score_gemma":0.0074512432,"threshold_uncertainty_score":0.024509728},"labels":[],"label_agreement":null},{"id":"W3214549902","doi":"10.25251/skin.5.supp.38","title":"Deucravacitinib Improves Psoriasis Symptoms and Signs Diary Domain Scores in Patients With Moderate to Severe Plaque Psoriasis: Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Studies","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Bristol-Myers Squibb","keywords":"Psoriasis; Plaque psoriasis; Medicine; Domain (mathematical analysis); Dermatology; Mathematics; Mathematical analysis","score_opus":0.012569610244830129,"score_gpt":0.24920588041576186,"score_spread":0.23663627017093172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214549902","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97587466,0.018262004,0.00033335062,0.00063583447,0.00016091997,0.0002813432,0.0008183565,0.00015230745,0.0034812773],"genre_scores_gemma":[0.99195683,0.0050596255,0.00036495214,0.00041585916,0.00009035245,0.000086344175,0.000844555,0.0000139764215,0.0011675984],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.999765,0.00008926418,0.000021985725,0.00002994547,0.000046342513,0.000047522597],"domain_scores_gemma":[0.9996928,0.000084548636,0.00008587918,0.000020659927,0.000035587767,0.00008051162],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007031973,0.00042058242,0.0012229349,0.00014202797,0.00019557956,0.0004469736,0.00027052764,0.00038531038,0.0025004335],"category_scores_gemma":[0.0005600466,0.00015420362,0.0009887188,0.0001480978,0.0001925375,0.0003731112,0.00011164339,0.001017611,0.00038308723],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3308753,0.012098261,0.0137313185,0.0026627805,0.004387165,0.00019779697,0.00013107313,0.0018427643,0.055999015,0.00017107555,0.0140874,0.5638161],"study_design_scores_gemma":[0.34218112,0.3558112,0.24470532,0.00033523433,0.0045900834,0.001832983,0.00019973697,0.004015206,0.021420246,0.00045989384,0.024313947,0.00013505944],"about_ca_topic_score_codex":0.0007656074,"about_ca_topic_score_gemma":0.0029647101,"teacher_disagreement_score":0.0025004335,"about_ca_system_score_codex":0.00035867834,"about_ca_system_score_gemma":0.00034467783,"threshold_uncertainty_score":0.008364797},"labels":[],"label_agreement":null},{"id":"W4221049281","doi":"10.25251/skin.6.supp.20","title":"Tirbanibulin Ointment Eradicates HPV-57 (+) Periungual Squamous Cell Carcinoma","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Guenther Dermatology Research Centre","funders":"","keywords":"Basal cell; Dermatology; Medicine; Internal medicine","score_opus":0.017191107007565896,"score_gpt":0.28836527338770396,"score_spread":0.2711741663801381,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221049281","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95859474,0.011160598,0.001037039,0.0010053302,0.00030324966,0.00014326152,0.00022198599,0.00028292538,0.027250752],"genre_scores_gemma":[0.99259514,0.002551228,0.00051512953,0.00032731978,0.000054939337,0.000022019276,0.00015482341,0.000019254263,0.0037601683],"study_design_codex":"design_other","study_design_gemma":"case_report","domain_scores_codex":[0.99994063,0.000009698333,0.00000383913,0.0000070572955,0.000016340915,0.000022446913],"domain_scores_gemma":[0.99995494,0.000009805946,0.0000076169054,0.000008164782,0.0000068303943,0.000012621333],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014922529,0.00016072686,0.00035824653,0.00015887857,0.00021659175,0.0002140532,0.00012984869,0.0001853572,0.0040304023],"category_scores_gemma":[0.00021734228,0.00007382568,0.00023617317,0.00007052895,0.00010489678,0.00014420842,0.000094067465,0.00030940052,0.0007264259],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010489206,0.0017548933,0.016830476,0.0008060997,0.00025028558,0.0063182334,0.00008072424,0.0007427498,0.41731527,0.00046571362,0.014452164,0.5304943],"study_design_scores_gemma":[0.004602894,0.05205183,0.29042047,0.00079091016,0.0014429379,0.073258296,0.0007199547,0.010344672,0.35812426,0.0010288258,0.20713751,0.000077481374],"about_ca_topic_score_codex":0.00074970507,"about_ca_topic_score_gemma":0.0017128265,"teacher_disagreement_score":0.0040304023,"about_ca_system_score_codex":0.00016758642,"about_ca_system_score_gemma":0.0001981449,"threshold_uncertainty_score":0.0134830475},"labels":[],"label_agreement":null},{"id":"W4228999540","doi":"10.25251/skin.6.supp.2","title":"Guselkumab (GUS) in Psoriasis Patients With a History of Malignancy: 5-Year Safety From VOYAGE (VOY)1&2","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Probity Medical Research","funders":"","keywords":"Psoriasis; Malignancy; Medicine; Dermatology; Internal medicine","score_opus":0.009601773036925079,"score_gpt":0.19994825235826888,"score_spread":0.1903464793213438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4228999540","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9838155,0.013250582,0.00020006082,0.0005020878,0.00011855393,0.00003735741,0.00014290313,0.000012019971,0.0019208813],"genre_scores_gemma":[0.9969976,0.002040631,0.00008316787,0.0002544611,0.00006943986,0.000008491815,0.00021192762,0.0000020058167,0.00033231184],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996642,0.00009652093,0.000038600512,0.00004034107,0.000091928916,0.00006844528],"domain_scores_gemma":[0.9994598,0.00011786905,0.00017206692,0.000026285798,0.00005516651,0.00016882802],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008233583,0.00018906569,0.0005944859,0.00023635857,0.00038253577,0.00048458503,0.00019801006,0.000606193,0.00072462065],"category_scores_gemma":[0.0010447875,0.00009721993,0.000633464,0.00028375266,0.00019193282,0.0004387345,0.00024529392,0.0009280483,0.00023199391],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.047476586,0.00417144,0.66275233,0.00040654012,0.0009540242,0.0032608882,0.0003134472,0.00078980136,0.009137951,0.00029317892,0.0031522682,0.26729164],"study_design_scores_gemma":[0.0017213485,0.029034825,0.9532596,0.00014178404,0.00055238965,0.005472631,0.00032695546,0.0012117774,0.001616678,0.00022578814,0.006397928,0.00003841879],"about_ca_topic_score_codex":0.0013158991,"about_ca_topic_score_gemma":0.0013672372,"teacher_disagreement_score":0.0013158991,"about_ca_system_score_codex":0.0003819475,"about_ca_system_score_gemma":0.00038755202,"threshold_uncertainty_score":0.0043544173},"labels":[],"label_agreement":null},{"id":"W4229010470","doi":"10.25251/skin.6.supp.1","title":"Low Risk of Serious Infections and Infections of Interest in Psoriasis Patients Treated with Guselkumab (GUS) for up to 5 Years in VOYAGE (VOY) 1&2 Phase 3 Trials","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Dalhousie University","funders":"","keywords":"Psoriasis; Medicine; Internal medicine; Dermatology","score_opus":0.03227119884599514,"score_gpt":0.29356994865446284,"score_spread":0.2612987498084677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229010470","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8898751,0.08301152,0.0028182124,0.003911227,0.00088280387,0.0011810584,0.0030196165,0.0001825741,0.015117872],"genre_scores_gemma":[0.98338807,0.009465442,0.0012539666,0.001969089,0.00043912666,0.00048283095,0.0012083628,0.000018021696,0.0017750826],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9990395,0.0005507113,0.00006554447,0.00013514125,0.00010914274,0.00010001555],"domain_scores_gemma":[0.9984731,0.0005545477,0.00047392078,0.00008215572,0.00009326026,0.00032291035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020669065,0.00043101085,0.0015923057,0.00029540545,0.00031362753,0.0006457585,0.00037427398,0.0011841361,0.0056164665],"category_scores_gemma":[0.0022563387,0.00022493649,0.0024560823,0.00034523263,0.00040829685,0.000582453,0.00027771623,0.0019223345,0.00050427945],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5882319,0.0043744226,0.03419117,0.0051579163,0.009673999,0.00025272707,0.00012689689,0.0008038592,0.011179805,0.0008491888,0.011068554,0.3340896],"study_design_scores_gemma":[0.4842835,0.22304855,0.2419532,0.0016794571,0.011928685,0.001289652,0.00018343648,0.0016179733,0.003534344,0.0027750817,0.027608842,0.00009725835],"about_ca_topic_score_codex":0.0005417425,"about_ca_topic_score_gemma":0.0016050562,"teacher_disagreement_score":0.0056164665,"about_ca_system_score_codex":0.0004025545,"about_ca_system_score_gemma":0.00054572715,"threshold_uncertainty_score":0.018788934},"labels":[],"label_agreement":null},{"id":"W4229015785","doi":"10.25251/skin.6.supp.s29","title":"Efficacy and safety of tralokinumab in adolescents with moderate-to- severe atopic dermatitis: results of the phase 3 ECZTRA 6 trial","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"LEO Pharma","keywords":"Atopic dermatitis; Medicine; Dermatology; Phase (matter); Pediatrics; Physics","score_opus":0.01069320491428947,"score_gpt":0.26975126163442137,"score_spread":0.2590580567201319,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229015785","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98943734,0.007960714,0.0001415226,0.00039204772,0.00011738858,0.00020874833,0.00051637256,0.000026704345,0.001199157],"genre_scores_gemma":[0.9949033,0.0026773498,0.00028261854,0.0005451414,0.000099770885,0.00019632842,0.00051329326,0.000009412598,0.000772792],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9995999,0.00018955542,0.000026760203,0.0000632387,0.000056439316,0.000064003725],"domain_scores_gemma":[0.9993382,0.00020840828,0.00018724942,0.00003993711,0.00004531851,0.00018085529],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012584679,0.00048507075,0.0011154589,0.0001261418,0.00026145068,0.0007108322,0.00036800647,0.00071534526,0.0019156474],"category_scores_gemma":[0.0010179863,0.00021348902,0.0019390658,0.00013427756,0.0003838487,0.0004679648,0.00014632284,0.0023770526,0.00031611667],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8115718,0.009623481,0.022789827,0.002347542,0.0056349146,0.00035684573,0.00025186827,0.001440897,0.016799774,0.0003411083,0.005168128,0.12367378],"study_design_scores_gemma":[0.6745984,0.19537652,0.110662445,0.00047672162,0.0056312336,0.0010817923,0.00021524547,0.0015717769,0.0037043544,0.00044740606,0.0061735357,0.000060624654],"about_ca_topic_score_codex":0.00063300686,"about_ca_topic_score_gemma":0.0021798355,"teacher_disagreement_score":0.0019156474,"about_ca_system_score_codex":0.00053913135,"about_ca_system_score_gemma":0.00061889185,"threshold_uncertainty_score":0.0066554546},"labels":[],"label_agreement":null},{"id":"W4229015799","doi":"10.25251/skin.6.supp.7","title":"Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Efficacy by Baseline Disease Characteristics and Demographics in Two Pivotal Phase 3 Trials","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Phytochemistry Medicinal Plant Applications","field":"Agricultural and Biological Sciences","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Allergan; Genentech; Astellas Pharma; Glenmark Pharmaceuticals; Pfizer; Biogen; Incyte; Sun Pharma; Dermira; Coherus Biosciences; Valeant Pharmaceuticals International; Ablynx; Celgene; Novartis; GlaxoSmithKline; Astellas Pharma US; Amgen; Galderma; LEO Pharma; Ortho Dermatologics; Eli Lilly and Company; Bristol-Myers Squibb; Bausch Health; Bayer HealthCare; Sanofi; Regeneron Pharmaceuticals; Abbott Laboratories","keywords":"Demographics; Plaque psoriasis; Medicine; Baseline (sea); Psoriasis; Internal medicine; Disease; Dermatology; Demography; Biology","score_opus":0.029593604166776147,"score_gpt":0.31888867373731816,"score_spread":0.289295069570542,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229015799","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96257806,0.020361416,0.0014940529,0.001469237,0.000479867,0.004402489,0.0031798808,0.00029601174,0.0057389745],"genre_scores_gemma":[0.974319,0.011650965,0.0019824468,0.0018385965,0.0004110843,0.0033702655,0.0024030139,0.00006082687,0.003963769],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99938357,0.00026194198,0.00003943073,0.00010261141,0.00008317202,0.00012921134],"domain_scores_gemma":[0.99936885,0.00018324878,0.0001474964,0.000053035692,0.000051788007,0.00019557023],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022045663,0.0014728003,0.0026459328,0.00050197676,0.0004663446,0.0010760408,0.0008699367,0.0012851403,0.007748176],"category_scores_gemma":[0.0012580366,0.0006748642,0.002351372,0.00052756135,0.00075514684,0.00097536814,0.0003172162,0.0028171716,0.0011183417],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8565896,0.016211223,0.0019817883,0.0017430078,0.0021866446,0.00009421909,0.00013578695,0.0007438634,0.01641089,0.00023352342,0.004227444,0.09944198],"study_design_scores_gemma":[0.8521642,0.13254355,0.00990568,0.000119520846,0.0012488858,0.00010516832,0.000041389605,0.00042180455,0.00091732503,0.00022628244,0.0022716888,0.000034491077],"about_ca_topic_score_codex":0.0010221408,"about_ca_topic_score_gemma":0.0033945758,"teacher_disagreement_score":0.007748176,"about_ca_system_score_codex":0.0006359463,"about_ca_system_score_gemma":0.0009228037,"threshold_uncertainty_score":0.025920272},"labels":[],"label_agreement":null},{"id":"W4229034592","doi":"10.25251/skin.6.supp.4","title":"Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Bristol-Myers Squibb","keywords":"Plaque psoriasis; Medicine; Psoriasis; Internal medicine; Pharmacology; Dermatology","score_opus":0.04009431060346913,"score_gpt":0.302258072534325,"score_spread":0.2621637619308559,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229034592","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9650593,0.024272444,0.00093544985,0.0010112941,0.00023326663,0.0005817387,0.0015565574,0.0002891305,0.0060608103],"genre_scores_gemma":[0.98243207,0.009287119,0.000764743,0.00081382296,0.00016485559,0.0002832977,0.0022962156,0.000044596134,0.003913285],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99973816,0.00008963106,0.000017758657,0.000040483766,0.000047817997,0.00006618485],"domain_scores_gemma":[0.9996556,0.00008345292,0.00006864963,0.000027152144,0.000028915381,0.00013620697],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011347212,0.00063600665,0.0015753224,0.00019429559,0.00028935392,0.00071113347,0.00035070628,0.00058411766,0.002648554],"category_scores_gemma":[0.0004661895,0.00021746747,0.0010290723,0.00018690548,0.00034238337,0.0005109568,0.0001687298,0.0017101438,0.0006275869],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.37704614,0.013722661,0.0051819733,0.0022217655,0.0024015934,0.0002933722,0.00018193646,0.0028083602,0.07549442,0.0003418987,0.018950045,0.5013559],"study_design_scores_gemma":[0.5100907,0.35811102,0.07497375,0.00029549314,0.0024791353,0.0017795501,0.00017169584,0.0040174634,0.02298894,0.0007276112,0.024226941,0.00013768113],"about_ca_topic_score_codex":0.0008880469,"about_ca_topic_score_gemma":0.003341989,"teacher_disagreement_score":0.002648554,"about_ca_system_score_codex":0.0004665398,"about_ca_system_score_gemma":0.00045354827,"threshold_uncertainty_score":0.00886035},"labels":[],"label_agreement":null},{"id":"W4229036839","doi":"10.25251/skin.6.supp.28","title":"Long-Term Safety and Disease Control of Ruxolitinib Cream Among Adolescents With Atopic Dermatitis: Results From Two Phase 3 Studies","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Incyte","keywords":"Atopic dermatitis; Ruxolitinib; Medicine; Term (time); Dermatology; Disease; Phase (matter); Pediatrics; Internal medicine; Physics; Myelofibrosis","score_opus":0.01165511170678087,"score_gpt":0.29115345297157696,"score_spread":0.2794983412647961,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229036839","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99269295,0.005399993,0.0002724346,0.00012844193,0.000038681363,0.00040385284,0.00038248417,0.000019511204,0.00066167844],"genre_scores_gemma":[0.9953466,0.0024479756,0.00038099382,0.00030861355,0.00007270244,0.00032859136,0.00058055774,0.000009046398,0.00052486476],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99901915,0.0004731778,0.00008489333,0.00014891956,0.00014686896,0.00012703784],"domain_scores_gemma":[0.99871945,0.0004612351,0.00036416494,0.00012392193,0.00013002593,0.00020126966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026184716,0.0005556303,0.0018523064,0.00024625493,0.0003814566,0.0009318721,0.00046874257,0.000987274,0.0015180085],"category_scores_gemma":[0.0016469957,0.0002820389,0.002410998,0.0002557844,0.0005322828,0.0006498533,0.00021239163,0.0017427913,0.0003105652],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7362636,0.02656313,0.03267836,0.0017873585,0.008188483,0.0003515452,0.00039186372,0.0011559627,0.0334348,0.00015102132,0.0015896079,0.15744436],"study_design_scores_gemma":[0.41089734,0.40778148,0.15676913,0.00028376823,0.009516082,0.00068215956,0.00022956794,0.0010042872,0.008683323,0.00022526877,0.00385399,0.000073667754],"about_ca_topic_score_codex":0.00089305366,"about_ca_topic_score_gemma":0.0018541666,"teacher_disagreement_score":0.0026184716,"about_ca_system_score_codex":0.0006682841,"about_ca_system_score_gemma":0.00063955464,"threshold_uncertainty_score":0.013848007},"labels":[],"label_agreement":null},{"id":"W4229043584","doi":"10.25251/skin.6.supp.5","title":"Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Long-Term Extension Trial of a Novel Therapeutic Aryl Hydrocarbon Receptor Modulating Agent","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"","keywords":"Term (time); Aryl hydrocarbon receptor; Psoriasis; Extension (predicate logic); Medicine; Aryl; Pharmacology; Dermatology; Chemistry; Computer science; Physics; Organic chemistry; Biochemistry","score_opus":0.0328903932308255,"score_gpt":0.27828189498316785,"score_spread":0.24539150175234237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229043584","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884,0.0052746665,0.00056050246,0.0005265866,0.0004394658,0.0010594283,0.0008338721,0.00014159415,0.0027638606],"genre_scores_gemma":[0.9875715,0.0039151856,0.0008100289,0.0008569288,0.00044309453,0.0009335983,0.0012215642,0.00002653997,0.004221533],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99946016,0.00015180573,0.000024995865,0.00010903178,0.000057353613,0.0001966803],"domain_scores_gemma":[0.9994242,0.000115978335,0.00006861143,0.00006530934,0.000047144928,0.00027873358],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012987308,0.001379285,0.0031514047,0.00048816254,0.0005552182,0.0010378858,0.0010145444,0.001736626,0.0047067883],"category_scores_gemma":[0.00077564566,0.0005446214,0.0019237082,0.00043692582,0.0010480828,0.0011992919,0.00031563424,0.003881393,0.001127232],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89421725,0.034202445,0.00088168954,0.00059509807,0.00087031873,0.00016120779,0.00008120157,0.00058841525,0.013966102,0.00013976352,0.0012060321,0.053090584],"study_design_scores_gemma":[0.62626743,0.36003095,0.008413235,0.0000738974,0.0008060538,0.00017069669,0.000060865637,0.0008718845,0.0016705049,0.00018531017,0.0014092246,0.00003994663],"about_ca_topic_score_codex":0.001974837,"about_ca_topic_score_gemma":0.0034946864,"teacher_disagreement_score":0.0047067883,"about_ca_system_score_codex":0.00069823005,"about_ca_system_score_gemma":0.0009747173,"threshold_uncertainty_score":0.015745819},"labels":[],"label_agreement":null},{"id":"W4236619224","doi":"10.25251/skin.5.supp.8","title":"Efficacy and Safety of Ruxolitinib Cream for the Treatment of Atopic Dermatitis: Pooled Analysis of Two Phase 3, Randomized, Double-Blind Studies","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Incyte","keywords":"Atopic dermatitis; Ruxolitinib; Medicine; Double blind; Dermatology; Randomized controlled trial; Internal medicine; Alternative medicine; Myelofibrosis; Pathology; Placebo","score_opus":0.035284372762504644,"score_gpt":0.3721015180146055,"score_spread":0.3368171452521009,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4236619224","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.72276723,0.25660136,0.0057205143,0.0008622554,0.0014428993,0.0058308416,0.0032007634,0.0002951267,0.0032789959],"genre_scores_gemma":[0.9674654,0.025172925,0.002411998,0.0006840811,0.0005342461,0.0018984776,0.001096575,0.000038820384,0.000697502],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99552804,0.0027320525,0.0006762491,0.0004748066,0.00041685332,0.00017201032],"domain_scores_gemma":[0.99363387,0.0033817308,0.0017889169,0.00051211455,0.000402234,0.00028109638],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00977477,0.0016991444,0.00782109,0.0008961922,0.0004027161,0.0018768662,0.0009277022,0.0017721563,0.0027880669],"category_scores_gemma":[0.009644086,0.00085461105,0.009681333,0.00080676784,0.0009601416,0.0013674677,0.0005568389,0.0020112453,0.00035860293],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.85942423,0.00097190344,0.0016119613,0.013298904,0.08922544,0.00005475287,0.00005859846,0.0007897873,0.0035048719,0.0001063829,0.00063690427,0.030316265],"study_design_scores_gemma":[0.8038976,0.040515643,0.012515318,0.00096328557,0.13691731,0.00016192734,0.00006305268,0.0011648971,0.001683921,0.00041792906,0.0016077129,0.00009139268],"about_ca_topic_score_codex":0.00056259194,"about_ca_topic_score_gemma":0.0012578969,"teacher_disagreement_score":0.00977477,"about_ca_system_score_codex":0.00073760183,"about_ca_system_score_gemma":0.00085906795,"threshold_uncertainty_score":0.051694572},"labels":[],"label_agreement":null},{"id":"W4241580772","doi":"10.25251/skin.4.supp.30","title":"Tapinarof Cream for the Treatment of Plaque Psoriasis: Efficacy and Safety by Baseline Disease Characteristics and Skin Type in a Phase 2b Randomized Study","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of British Columbia","funders":"","keywords":"Plaque psoriasis; Medicine; Dermatology; Psoriasis; Baseline (sea); Phase (matter); Randomized controlled trial; Internal medicine; Biology; Physics","score_opus":0.01703836544243391,"score_gpt":0.27875486484144557,"score_spread":0.26171649939901165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4241580772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98858005,0.0043631042,0.00061803096,0.0003994662,0.000251483,0.0030368534,0.0012645944,0.00009847191,0.0013878472],"genre_scores_gemma":[0.9845599,0.0042918846,0.0016685018,0.0008771955,0.00056685763,0.0037434003,0.0015223441,0.000053909713,0.0027159327],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9990891,0.00043999255,0.000041815616,0.0001591532,0.000103616905,0.00016628084],"domain_scores_gemma":[0.9985043,0.000475627,0.00027100692,0.00015716796,0.00011496405,0.00047695605],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023104863,0.002194904,0.004005601,0.00052455807,0.0004978307,0.0014034442,0.0011738619,0.0018760338,0.008197984],"category_scores_gemma":[0.0019553814,0.0010595421,0.0019252854,0.00064184505,0.0014743747,0.0016031761,0.00048056463,0.003677997,0.0011005081],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9733729,0.0105588,0.0005203502,0.00037460122,0.00064806786,0.000029552299,0.00003967582,0.00021202382,0.003128002,0.000068220405,0.00044969466,0.01059818],"study_design_scores_gemma":[0.9161348,0.08006077,0.002343355,0.000024031951,0.00040726314,0.00003162709,0.00001760121,0.00026464093,0.00026981317,0.00010692307,0.00032368687,0.000015542495],"about_ca_topic_score_codex":0.0010371766,"about_ca_topic_score_gemma":0.001818922,"teacher_disagreement_score":0.008197984,"about_ca_system_score_codex":0.00077328656,"about_ca_system_score_gemma":0.0012721888,"threshold_uncertainty_score":0.027424991},"labels":[],"label_agreement":null},{"id":"W4309313095","doi":"10.25251/skin.6.supp.104","title":"A Phase 2 Study of Oral Difelikefalin for Moderate-to-Severe Pruritus in Subjects With Notalgia Paresthetica (KOMFORT)","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"","keywords":"Phase (matter); Medicine; Dermatology; Psychology; Chemistry; Organic chemistry","score_opus":0.016322774058655832,"score_gpt":0.3044332328889435,"score_spread":0.28811045883028763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309313095","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99100775,0.0020060958,0.000681936,0.0004147022,0.0002361423,0.0030367791,0.0009070537,0.000097741846,0.0016118886],"genre_scores_gemma":[0.9876226,0.0019478939,0.0014997121,0.0009894368,0.00032796562,0.00284424,0.001484102,0.000030082772,0.003253811],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99944705,0.00024662205,0.000025276047,0.00008720897,0.00004454615,0.00014924585],"domain_scores_gemma":[0.9994136,0.0001341009,0.00007512608,0.00006090316,0.000041579267,0.00027466405],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015823744,0.0017128111,0.0026402725,0.0005373512,0.0006270129,0.00082700513,0.001076912,0.0015689858,0.005630591],"category_scores_gemma":[0.0008908941,0.00076870195,0.0019510866,0.00040934555,0.0010401683,0.0008976985,0.0003019903,0.0027021386,0.00090039906],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.85287124,0.070551,0.0019441815,0.00073903555,0.000832963,0.00023578234,0.00019165239,0.00047957464,0.030661955,0.00016020931,0.0015567408,0.039775547],"study_design_scores_gemma":[0.6460692,0.34482974,0.0063416,0.000017761904,0.00025397286,0.000124979,0.00004339083,0.00024922666,0.0010616763,0.00006798193,0.00092384766,0.0000166171],"about_ca_topic_score_codex":0.0017662824,"about_ca_topic_score_gemma":0.0048438944,"teacher_disagreement_score":0.005630591,"about_ca_system_score_codex":0.00067346456,"about_ca_system_score_gemma":0.0013001635,"threshold_uncertainty_score":0.0188362},"labels":[],"label_agreement":null},{"id":"W4309313322","doi":"10.25251/skin.6.supp.47","title":"Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy by prior treatment in the phase 3 POETYK PSO-1 trial","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Bristol-Myers Squibb","keywords":"Plaque psoriasis; Medicine; Psoriasis; Internal medicine; Gastroenterology; Dermatology; Pharmacology","score_opus":0.023743141155382914,"score_gpt":0.29033300301102205,"score_spread":0.26658986185563915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309313322","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9649587,0.017918926,0.0007773602,0.0013693105,0.0005373185,0.0011094911,0.0021010714,0.0004276438,0.010800131],"genre_scores_gemma":[0.9817644,0.0061311275,0.000646119,0.0014173097,0.00022910142,0.0006749912,0.0022467375,0.00004432211,0.0068458887],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9997451,0.00008637379,0.000013621766,0.000044315122,0.00003414728,0.00007649865],"domain_scores_gemma":[0.9997209,0.00005732203,0.00004260474,0.000023154475,0.000020290963,0.00013586257],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009000397,0.00076287886,0.0017423474,0.00018857383,0.00037723602,0.000906942,0.0004580011,0.0009186915,0.0057125175],"category_scores_gemma":[0.00050894375,0.00029059162,0.0013006317,0.00018417928,0.00039864398,0.00060347863,0.00018918814,0.0022627013,0.0011503071],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6750221,0.009377876,0.0027014029,0.0019806055,0.0022239366,0.00022132,0.0001282272,0.0017024045,0.023225691,0.00047441063,0.01953187,0.26341015],"study_design_scores_gemma":[0.7883276,0.16963089,0.02215766,0.0002159973,0.0010551714,0.00059863046,0.00006939683,0.0019989451,0.0040136357,0.0005783662,0.011286353,0.000067321074],"about_ca_topic_score_codex":0.0009004535,"about_ca_topic_score_gemma":0.0034609674,"teacher_disagreement_score":0.0057125175,"about_ca_system_score_codex":0.00059754035,"about_ca_system_score_gemma":0.0005588647,"threshold_uncertainty_score":0.019110262},"labels":[],"label_agreement":null},{"id":"W4309313508","doi":"10.25251/skin.6.supp.72","title":"Bimekizumab infection rates in patients with moderate to severe plaque psoriasis: Analysis of pooled data from 2 years of treatment in phase 3 and 3b clinical trials","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"UCB Pharma","keywords":"Plaque psoriasis; Medicine; Psoriasis; Clinical trial; Pooled analysis; Internal medicine; Dermatology; Meta-analysis","score_opus":0.05224517280317597,"score_gpt":0.3519867857175708,"score_spread":0.29974161291439483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309313508","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9238855,0.068840586,0.0015857028,0.00019916473,0.00018216226,0.0003196491,0.0034213832,0.000063555206,0.0015022112],"genre_scores_gemma":[0.9932962,0.0037135882,0.0004034754,0.00020107963,0.0001264487,0.00015412239,0.0018757454,0.000021416527,0.00020778277],"study_design_codex":"observational","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98542386,0.0086719105,0.001872971,0.002040039,0.0014425986,0.0005486372],"domain_scores_gemma":[0.98359066,0.008185456,0.0053428947,0.0015588612,0.00080162106,0.0005204731],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.016535781,0.0011510229,0.005061425,0.0013936581,0.00035541592,0.0019134122,0.0007789391,0.0016826991,0.0011136767],"category_scores_gemma":[0.010992856,0.0010279294,0.01102765,0.0019491137,0.00057407306,0.001455137,0.0009705501,0.0014986906,0.00017872437],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26229018,0.0005134836,0.48880863,0.004877122,0.18983167,0.00033612995,0.00032817945,0.0030180027,0.003986259,0.00019653162,0.0022598354,0.043553997],"study_design_scores_gemma":[0.014969264,0.013402631,0.883391,0.00046331107,0.08138627,0.00069263094,0.0002551607,0.0020625643,0.0009075855,0.0002983882,0.0020136884,0.0001575498],"about_ca_topic_score_codex":0.0009315729,"about_ca_topic_score_gemma":0.0016420042,"teacher_disagreement_score":0.016535781,"about_ca_system_score_codex":0.00057913543,"about_ca_system_score_gemma":0.0006297685,"threshold_uncertainty_score":0.087450564},"labels":[],"label_agreement":null},{"id":"W4309315772","doi":"10.25251/skin.6.6.5","title":"A Prospective, Multi-Center Clinical Utility Study Demonstrates That the 40-Gene Expression Profile (40-GEP) Test Impacts Clinical Management for Medicare-Eligible Patients with High-Risk Cutaneous Squamous Cell Carcinoma (cSCC)","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Nonmelanoma Skin Cancer Studies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"","keywords":"Medicine; Internal medicine; Oncology; Risk assessment; Prospective cohort study; Population; Incidence (geometry); Personalized medicine; Intensive care medicine; Bioinformatics; Environmental health","score_opus":0.027628696026849586,"score_gpt":0.31933419288452153,"score_spread":0.29170549685767194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309315772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9994659,0.00005069733,0.00007214386,0.00003657733,0.0000015539946,0.000010434146,0.00012333506,0.0000023535415,0.00023694121],"genre_scores_gemma":[0.9996164,0.000026731846,0.00008902734,0.000052031202,0.0000052591768,0.000007802392,0.00012577804,0.0000010922128,0.000075755364],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986419,0.0006039047,0.00011078081,0.0002450718,0.00023801134,0.00016033025],"domain_scores_gemma":[0.9942668,0.0017640158,0.0022721223,0.0004377603,0.00041551937,0.00084376073],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024955655,0.0002049807,0.00018231514,0.00056088343,0.00043376506,0.0007942701,0.00023703245,0.00030289832,0.0012718587],"category_scores_gemma":[0.0071301595,0.00017952335,0.00030397854,0.00065718504,0.00045110376,0.0006142234,0.00076710706,0.0005054799,0.00024102772],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037166942,0.00014492261,0.99663264,0.0000035778087,0.000036935166,0.000042749012,0.00007617311,0.000042189004,0.00017327012,0.000015501135,0.00010995835,0.002350296],"study_design_scores_gemma":[0.00003384138,0.00064841745,0.99834764,0.0000026227701,0.00002769,0.00015713206,0.00013636725,0.00028938102,0.00014478707,0.000019253132,0.00018908519,0.0000036997785],"about_ca_topic_score_codex":0.0032709686,"about_ca_topic_score_gemma":0.0038812251,"teacher_disagreement_score":0.0032709686,"about_ca_system_score_codex":0.00048117954,"about_ca_system_score_gemma":0.00053019053,"threshold_uncertainty_score":0.013198018},"labels":[],"label_agreement":null},{"id":"W4309316023","doi":"10.25251/skin.6.supp.67","title":"Bimekizumab efficacy and safety through two years in patients with moderate psoriasis: Analysis of pooled data from five phase 3/3b clinical trials","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"","keywords":"Pooled analysis; Psoriasis; Clinical trial; Medicine; Dermatology; Internal medicine; Meta-analysis","score_opus":0.05999239470806655,"score_gpt":0.3657157579674115,"score_spread":0.30572336325934496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309316023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84981036,0.1401066,0.002431372,0.00040255074,0.00026125618,0.0007726837,0.0038180496,0.00012773961,0.002269319],"genre_scores_gemma":[0.98783475,0.007995748,0.0006407734,0.00041672165,0.00016198454,0.00031126442,0.0022631271,0.000027546943,0.0003479868],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9935922,0.0034344762,0.0009005169,0.0009728482,0.0007299615,0.00036992083],"domain_scores_gemma":[0.99213564,0.0038193732,0.0024171602,0.0007203907,0.00046849545,0.00043904196],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015264174,0.0012214007,0.0062655425,0.0010254948,0.00046253786,0.0020733825,0.0007194819,0.0013737411,0.0013082792],"category_scores_gemma":[0.008332437,0.0006532142,0.011234148,0.0015602509,0.0006491341,0.0013417598,0.0008053922,0.0017282811,0.000192597],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5833141,0.0009873854,0.0850201,0.007397834,0.24290787,0.00021058907,0.00020043744,0.0035103937,0.0061523193,0.00017893054,0.002431849,0.06768827],"study_design_scores_gemma":[0.16702683,0.06950435,0.41445038,0.0010585273,0.3345358,0.0008871763,0.00028069396,0.0025659576,0.0025500034,0.00094551366,0.005949746,0.0002450299],"about_ca_topic_score_codex":0.00081620633,"about_ca_topic_score_gemma":0.0016016465,"teacher_disagreement_score":0.015264174,"about_ca_system_score_codex":0.00072522374,"about_ca_system_score_gemma":0.00087631185,"threshold_uncertainty_score":0.08072561},"labels":[],"label_agreement":null},{"id":"W4309316727","doi":"10.25251/skin.6.supp.52","title":"Treat-to-Target Outcomes and Measures of Treatment Success in Three Phase 3 Trials of Tapinarof Cream 1% Once Daily for Mild to Severe Plaque Psoriasis","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Phytochemistry Medicinal Plant Applications","field":"Agricultural and Biological Sciences","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Innovaderm (Canada)","funders":"","keywords":"Plaque psoriasis; Medicine; Psoriasis; Phase (matter); Dermatology; Surgery","score_opus":0.0751774596558274,"score_gpt":0.3329815334567032,"score_spread":0.25780407380087583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309316727","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98962337,0.0031103666,0.0008647516,0.00026825556,0.00015746352,0.0024487278,0.0014653446,0.000073630974,0.0019880903],"genre_scores_gemma":[0.99441105,0.00070379284,0.0006869665,0.00032387517,0.00009445452,0.0018593505,0.0009030943,0.000023435476,0.0009939757],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99390256,0.0036640123,0.00054156175,0.0005342048,0.00075238605,0.00060524733],"domain_scores_gemma":[0.99506605,0.001924813,0.0012951614,0.0005025693,0.00047813632,0.00073331443],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010819678,0.0014732841,0.0030025083,0.0007835056,0.0008543761,0.0011298008,0.0009818096,0.0017043394,0.0038609202],"category_scores_gemma":[0.0066638947,0.0006856116,0.004358755,0.00061897055,0.0012965513,0.0016536154,0.0007397527,0.0037857795,0.0005964553],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9447388,0.012877715,0.0036619636,0.00037955324,0.0030513436,0.000030995743,0.00015692224,0.0011163657,0.0037017867,0.00009572926,0.00095418486,0.029234692],"study_design_scores_gemma":[0.503374,0.42920116,0.05679622,0.00009493952,0.0040013497,0.000087177665,0.00015544775,0.0018106559,0.002577815,0.0004763429,0.0013308622,0.00009394142],"about_ca_topic_score_codex":0.002311985,"about_ca_topic_score_gemma":0.0049240594,"teacher_disagreement_score":0.010819678,"about_ca_system_score_codex":0.0013890046,"about_ca_system_score_gemma":0.0014761714,"threshold_uncertainty_score":0.05722058},"labels":[],"label_agreement":null},{"id":"W4309317324","doi":"10.25251/skin.6.supp.74","title":"Efficacy and safety of up to two years of tralokinumab treatment in adults of different racial subgroups with moderate-to-severe atopic dermatitis","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"LEO Pharma","keywords":"Atopic dermatitis; Medicine; Dermatology","score_opus":0.007148115195066833,"score_gpt":0.25207674052890033,"score_spread":0.2449286253338335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309317324","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957867,0.0028768622,0.000056288827,0.000080841295,0.000031417054,0.000037001075,0.0002651814,0.0000072300927,0.0008584147],"genre_scores_gemma":[0.9986947,0.00047878307,0.000043889137,0.0001355282,0.000037476053,0.000029415012,0.0002883866,0.0000013254332,0.00029046863],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996432,0.00008647824,0.000039927054,0.0000882936,0.000050059884,0.00009206236],"domain_scores_gemma":[0.9994086,0.0001521337,0.00017684123,0.000044475415,0.0000559021,0.00016208422],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00082576525,0.00030638734,0.00095736556,0.00021942094,0.0003859705,0.00048287964,0.00018837488,0.00051712384,0.0015195552],"category_scores_gemma":[0.001210668,0.00011929447,0.0014431545,0.0001970294,0.00018959987,0.0005930538,0.00020236644,0.00076409866,0.00021815948],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5238439,0.0076102866,0.28275552,0.0007416525,0.0033404995,0.000439851,0.00041307884,0.0014590563,0.01286669,0.00021541388,0.0016635032,0.16465051],"study_design_scores_gemma":[0.0143714165,0.05922706,0.9191498,0.00012408206,0.0026839443,0.00042997114,0.00025044242,0.000815154,0.0011372612,0.0001408384,0.0016239915,0.00004599556],"about_ca_topic_score_codex":0.0017900706,"about_ca_topic_score_gemma":0.0025717963,"teacher_disagreement_score":0.0017900706,"about_ca_system_score_codex":0.0004240753,"about_ca_system_score_gemma":0.00040201048,"threshold_uncertainty_score":0.0050834417},"labels":[],"label_agreement":null},{"id":"W4309317622","doi":"10.25251/skin.6.supp.66","title":"Bimekizumab safety in patients with moderate to severe plaque psoriasis: Analysis of pooled data from up to three years of treatment in phase 2 and 3 clinical trials","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Plaque psoriasis; Clinical trial; Pooled analysis; Psoriasis; Internal medicine; Dermatology; Meta-analysis","score_opus":0.0520842969948615,"score_gpt":0.34155571863602985,"score_spread":0.28947142164116835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309317622","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8437825,0.1477759,0.0018252946,0.00048510957,0.00035239267,0.000565752,0.0029635185,0.000102662394,0.0021469253],"genre_scores_gemma":[0.9863377,0.009973371,0.0004651091,0.0005145174,0.00029523842,0.00026407497,0.0018061735,0.00002526904,0.0003185607],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9928676,0.0042254734,0.0007788102,0.0009798633,0.00069664186,0.0004516885],"domain_scores_gemma":[0.98948413,0.005390259,0.003148089,0.0009353458,0.00054373447,0.0004983475],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014242014,0.0012783727,0.00638029,0.0009636061,0.00045370267,0.0021128755,0.00071308995,0.0017349636,0.0014917025],"category_scores_gemma":[0.010083525,0.00070114265,0.01194646,0.0014910365,0.00072092906,0.0015794324,0.0008763762,0.0019943786,0.00022390792],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.63857865,0.00080431195,0.08328857,0.007039299,0.18778883,0.00030130247,0.00021520274,0.003401299,0.0045631668,0.00019818617,0.0025051837,0.071316026],"study_design_scores_gemma":[0.2104206,0.07661101,0.44445717,0.0012396167,0.2521616,0.0010770751,0.00028770964,0.003046361,0.0021624207,0.0012688548,0.0069858935,0.00028167944],"about_ca_topic_score_codex":0.00061307295,"about_ca_topic_score_gemma":0.0012786393,"teacher_disagreement_score":0.014242014,"about_ca_system_score_codex":0.0007264931,"about_ca_system_score_gemma":0.00095688127,"threshold_uncertainty_score":0.07531983},"labels":[],"label_agreement":null},{"id":"W4309317789","doi":"10.25251/skin.6.supp.70","title":"Bimekizumab versus secukinumab continuous maintenance of response at every visit through one year in patients with moderate to severe plaque psoriasis: Post-hoc results from the BE RADIANT phase 3b trial","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Secukinumab; Plaque psoriasis; Post-hoc analysis; Medicine; Post hoc; Psoriasis; Dermatology; Physical therapy; Internal medicine","score_opus":0.015508266964146407,"score_gpt":0.2422494022651389,"score_spread":0.22674113530099252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309317789","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985862,0.006630391,0.00055507454,0.0009848821,0.0006094273,0.00083131535,0.0014795765,0.00013315132,0.0029140715],"genre_scores_gemma":[0.99002516,0.0023682122,0.0006195167,0.0009872864,0.0004700018,0.0008623079,0.0014135416,0.00004584258,0.0032082272],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99868387,0.00069438905,0.00005952174,0.00020706492,0.00008882629,0.0002663352],"domain_scores_gemma":[0.9988041,0.00041683263,0.00025884723,0.00016155605,0.00007577369,0.0002829619],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029801656,0.0019813597,0.0049152914,0.00037368358,0.00052413455,0.0017957499,0.0010914463,0.0013187199,0.005417789],"category_scores_gemma":[0.0020689927,0.00075982296,0.0047482834,0.00045503254,0.001105832,0.0015688131,0.00051324104,0.004951417,0.0012705965],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98459816,0.0016489016,0.0005404797,0.00027127686,0.0018287873,0.000021088665,0.000029800796,0.00045007517,0.0009975961,0.000051571016,0.0008249887,0.008737392],"study_design_scores_gemma":[0.9137617,0.07480934,0.006466656,0.000054505563,0.0025422613,0.00004930041,0.000049206188,0.0007502682,0.0004110721,0.00026786036,0.0008104555,0.00002727942],"about_ca_topic_score_codex":0.0015802055,"about_ca_topic_score_gemma":0.0030038687,"teacher_disagreement_score":0.005417789,"about_ca_system_score_codex":0.0009677873,"about_ca_system_score_gemma":0.0010056453,"threshold_uncertainty_score":0.018124342},"labels":[],"label_agreement":null},{"id":"W4309317883","doi":"10.25251/skin.6.supp.57","title":"Efficacy and Tolerability of Roflumilast Cream 0.3% in Patients With Chronic Plaque Psoriasis Involvement on the Face, Intertriginous, or Genital Areas: Pooled Results From Phase 3 Trials (DERMIS-1 and DERMIS-2)","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Autoimmune Bullous Skin Diseases","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; SKiN Health","funders":"","keywords":"Intertriginous; Dermis; Tolerability; Psoriasis; Dermatology; Roflumilast; Medicine; Plaque psoriasis; Discontinuation; Sex organ; Surgery; Internal medicine; Pathology; Adverse effect; Biology; COPD","score_opus":0.023313140750098885,"score_gpt":0.284818307337959,"score_spread":0.2615051665878601,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309317883","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.919799,0.07295195,0.0006698513,0.0005363742,0.00030194034,0.00054725405,0.0013395565,0.00013323422,0.0037208304],"genre_scores_gemma":[0.9878593,0.00939949,0.00037280007,0.0004618737,0.00022735444,0.00023056021,0.0007609551,0.000016064987,0.00067143864],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99928904,0.00040308418,0.000075112555,0.00009173383,0.00006266751,0.00007823353],"domain_scores_gemma":[0.9991596,0.00038808526,0.00022627696,0.000056484223,0.00004959248,0.00011995848],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023669312,0.00088263326,0.0027537763,0.00043996455,0.00020388543,0.0008387799,0.00047948986,0.0007990519,0.0021387485],"category_scores_gemma":[0.0016577637,0.00040819915,0.0028951713,0.0004738236,0.00043268202,0.00077912654,0.00021433544,0.0012737778,0.00043493864],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.77737474,0.0029615406,0.009688733,0.006242018,0.020805314,0.00024108656,0.00017076515,0.0020645007,0.020063698,0.00014797885,0.0032952733,0.1569444],"study_design_scores_gemma":[0.7199031,0.16243139,0.0845155,0.00062656286,0.02201053,0.00071321963,0.00018848447,0.001821503,0.0031862454,0.000409074,0.00407344,0.00012089345],"about_ca_topic_score_codex":0.00088904845,"about_ca_topic_score_gemma":0.0025006367,"teacher_disagreement_score":0.0027537763,"about_ca_system_score_codex":0.0004348854,"about_ca_system_score_gemma":0.00041083328,"threshold_uncertainty_score":0.012517691},"labels":[],"label_agreement":null},{"id":"W4309317888","doi":"10.25251/skin.6.supp.45","title":"Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, versus placebo and apremilast in moderate to severe plaque psoriasis: analysis of body surface area involvement in the phase 3 POETYK PSO-1 and PSO-2 trials","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre de Recherche Dermatologique du Québec Métropolitain; Hôtel-Dieu de Québec","funders":"XBiotech; Bristol-Myers Squibb","keywords":"Apremilast; Plaque psoriasis; Placebo; Medicine; Psoriasis; Tyrosine-kinase inhibitor; Body surface area; Internal medicine; Pharmacology; Dermatology; Pathology; Psoriatic arthritis; Alternative medicine","score_opus":0.03984404570829199,"score_gpt":0.3064452367381327,"score_spread":0.2666011910298407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309317888","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9651318,0.029018352,0.00046723112,0.00071394176,0.0002798054,0.00048162404,0.001160953,0.0000993323,0.0026469359],"genre_scores_gemma":[0.99057615,0.0061978376,0.00039031624,0.0003946585,0.00019718111,0.00022370796,0.00087822834,0.000015990912,0.0011257731],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9990613,0.0005708627,0.00006524505,0.000120817014,0.00009307195,0.00008879377],"domain_scores_gemma":[0.99902916,0.00040371253,0.00021532299,0.00005806365,0.000049277933,0.00024443053],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002540235,0.00075578544,0.002870008,0.00037277094,0.00021636204,0.001033951,0.00049108017,0.0007786115,0.0024309685],"category_scores_gemma":[0.0017046445,0.0003289607,0.0022198828,0.0004007377,0.00056042144,0.000942102,0.0002392022,0.0017646754,0.000348692],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90379983,0.0020346006,0.0034222268,0.0011625432,0.004311491,0.00005076582,0.00005061716,0.0011093457,0.0065515097,0.00017009195,0.0016624719,0.075674534],"study_design_scores_gemma":[0.7369306,0.1975454,0.045309253,0.00019984659,0.0083766505,0.00049812614,0.00012205395,0.002589761,0.0023956022,0.00069778995,0.005253339,0.00008152239],"about_ca_topic_score_codex":0.00059673504,"about_ca_topic_score_gemma":0.0021891156,"teacher_disagreement_score":0.002870008,"about_ca_system_score_codex":0.0006855439,"about_ca_system_score_gemma":0.0005844727,"threshold_uncertainty_score":0.013434172},"labels":[],"label_agreement":null},{"id":"W4309317896","doi":"10.25251/skin.6.supp.50","title":"Exposure–Response Analysis Demonstrates Response to Tapinarof is Driven by Local Effects at Sites of Application","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Insect and Pesticide Research","field":"Agricultural and Biological Sciences","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of British Columbia","funders":"","keywords":"Response analysis; Psychology; Biology","score_opus":0.008707033818594471,"score_gpt":0.25483260660608825,"score_spread":0.24612557278749378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309317896","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99176884,0.00014292203,0.004604835,0.0000991258,0.000027419606,0.000105416875,0.0007814051,0.00005138167,0.0024186024],"genre_scores_gemma":[0.9927107,0.00011576745,0.0021138345,0.00014486977,0.00000915138,0.000102652055,0.00051834114,0.000031878128,0.0042529106],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9993538,0.00008585554,0.000029778717,0.00021168061,0.00017208692,0.00014667136],"domain_scores_gemma":[0.99955374,0.00015014109,0.00006385939,0.000067437184,0.00010750287,0.000057312936],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026792387,0.0003141659,0.00038787507,0.00018118888,0.00026949123,0.00042380497,0.00022346983,0.0006604349,0.00650549],"category_scores_gemma":[0.00053317804,0.00020627749,0.0005183843,0.00019770555,0.00027309632,0.0003571039,0.0003371824,0.00086302793,0.00080311805],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00061987864,0.000115502124,0.0014956446,0.00002295191,0.000007787353,0.000024151039,0.000017737755,0.00006824139,0.9957135,0.0000142830995,0.000049448165,0.001850952],"study_design_scores_gemma":[0.000026095178,0.0036942798,0.18848981,0.0000111104055,0.00004888164,0.0003013411,0.00029955586,0.002757005,0.80214953,0.00015405974,0.002045674,0.000022669723],"about_ca_topic_score_codex":0.002207145,"about_ca_topic_score_gemma":0.0035249994,"teacher_disagreement_score":0.00650549,"about_ca_system_score_codex":0.00029799965,"about_ca_system_score_gemma":0.0002513569,"threshold_uncertainty_score":0.021763027},"labels":[],"label_agreement":null},{"id":"W4309318166","doi":"10.25251/skin.6.supp.63","title":"Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: correlations between patient-reported outcomes and clinical responses in the phase 3 clinical trials POETYK PSO-1 and POETYK PSO-2","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Cytokine Signaling Pathways and Interactions","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Bristol-Myers Squibb","keywords":"Plaque psoriasis; Medicine; Clinical trial; Psoriasis; Internal medicine; Allosteric regulation; Dermatology; Oncology","score_opus":0.12771938908151773,"score_gpt":0.443138186868686,"score_spread":0.3154187977871683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309318166","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936568,0.0046919743,0.00020618478,0.00013317421,0.000031431227,0.000042127707,0.00026137204,0.000027031761,0.00094992045],"genre_scores_gemma":[0.99855846,0.0006090223,0.00014634275,0.000078372126,0.000029977238,0.000020143872,0.0003133325,0.0000027144274,0.00024157035],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99942386,0.0002617113,0.000049911432,0.000075161464,0.00012363581,0.00006566368],"domain_scores_gemma":[0.9987803,0.000499292,0.00038134214,0.000053316347,0.00008095112,0.00020476036],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016018448,0.00030781556,0.0006863219,0.0002217912,0.0001406097,0.00055598153,0.00017945182,0.00034211893,0.0008618888],"category_scores_gemma":[0.0015787197,0.00012548221,0.00042754586,0.00024401168,0.00019928855,0.0003892239,0.00015147246,0.0007790141,0.00016990415],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26164496,0.005899857,0.29012924,0.00088138744,0.003320072,0.00031544906,0.00017486149,0.003773446,0.06893938,0.00021094234,0.004392395,0.36031795],"study_design_scores_gemma":[0.019178407,0.08868637,0.86420107,0.00007847797,0.0015815514,0.0015024953,0.00014721582,0.007064541,0.012492318,0.00032434482,0.004649145,0.00009415076],"about_ca_topic_score_codex":0.00038181423,"about_ca_topic_score_gemma":0.0010406362,"teacher_disagreement_score":0.0016018448,"about_ca_system_score_codex":0.00030811122,"about_ca_system_score_gemma":0.00026008824,"threshold_uncertainty_score":0.008471489},"labels":[],"label_agreement":null},{"id":"W4309319190","doi":"10.25251/skin.6.supp.65","title":"Bimekizumab maintenance of response through three years in patients with moderate to severe plaque psoriasis who responded at Week 16: Results from the BE BRIGHT open-label extension trial","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Plaque psoriasis; Open label; Psoriasis; Medicine; Extension (predicate logic); Internal medicine; Dermatology; Randomized controlled trial; Computer science","score_opus":0.02902341705181288,"score_gpt":0.2578144856618625,"score_spread":0.2287910686100496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309319190","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99183977,0.004134703,0.00024986238,0.0006161982,0.00021214403,0.00045046504,0.0007307249,0.000060781153,0.0017054569],"genre_scores_gemma":[0.99371004,0.001426367,0.0003895239,0.0008174499,0.0002602687,0.00059287774,0.0008301335,0.000019793993,0.0019534845],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9991602,0.00035008197,0.00004127884,0.0001297982,0.000067293084,0.00025132514],"domain_scores_gemma":[0.9988979,0.00025195815,0.00024956025,0.00012031782,0.000059422528,0.00042072395],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024165486,0.0009781539,0.0028390533,0.00027672984,0.0005143633,0.001432557,0.0007069427,0.0014499942,0.0034744511],"category_scores_gemma":[0.0014955748,0.0004543848,0.0022107784,0.00033122022,0.0009628559,0.001322564,0.00041850272,0.0036522734,0.0009660219],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95362693,0.00564028,0.0024734712,0.0004375206,0.00095348543,0.000069861904,0.000107096195,0.00041499533,0.0038091778,0.00010706546,0.0017402263,0.030619875],"study_design_scores_gemma":[0.8473875,0.12960905,0.018969921,0.000079051955,0.0010062292,0.00012048926,0.00007321116,0.0005126723,0.0006239325,0.00025398395,0.0013293244,0.000034605462],"about_ca_topic_score_codex":0.0009907259,"about_ca_topic_score_gemma":0.0015311132,"teacher_disagreement_score":0.0034744511,"about_ca_system_score_codex":0.00073915056,"about_ca_system_score_gemma":0.0007841285,"threshold_uncertainty_score":0.01278007},"labels":[],"label_agreement":null},{"id":"W4309319238","doi":"10.25251/skin.6.supp.51","title":"Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Pooled Efficacy from Three Phase 3 Trials","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Phytochemistry Medicinal Plant Applications","field":"Agricultural and Biological Sciences","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"LEO Pharma; EMD Serono; Bausch Health; Sanofi Genzyme; Incyte; Castle Biosciences; Dermira; UCB Pharma; Sun Pharma; Regeneron Pharmaceuticals; Helsinn; Kiniksa Pharmaceuticals; Celgene; Sanofi; Amgen; Helsinn Therapeutics; Meiji Seika Pharma; Pfizer; Galderma; Ortho Dermatologics; Eli Lilly and Company; Bristol-Myers Squibb; GlaxoSmithKline","keywords":"Plaque psoriasis; Medicine; Psoriasis; Dermatology; Internal medicine","score_opus":0.0526612199441704,"score_gpt":0.3150997554401381,"score_spread":0.2624385354959677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309319238","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8115428,0.13398214,0.0076315436,0.0021772124,0.0021174678,0.015497052,0.011001449,0.00086209836,0.015188378],"genre_scores_gemma":[0.93568814,0.04489586,0.0030928985,0.0019748467,0.0009602814,0.0048892493,0.003881534,0.00010554218,0.00451173],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9983374,0.00088649394,0.00016188054,0.00022622685,0.00019434262,0.0001936468],"domain_scores_gemma":[0.9985587,0.0006182262,0.00035852156,0.00013376291,0.00012833843,0.00020242661],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042212866,0.0018799307,0.0052598566,0.0008988356,0.00052355556,0.0014568703,0.001018946,0.001690116,0.009802488],"category_scores_gemma":[0.0025121085,0.000911421,0.0064209406,0.0008793108,0.00089549745,0.0011199259,0.0005075601,0.0025120296,0.0011371574],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9036005,0.0039164666,0.0007568647,0.0060076346,0.0147245955,0.000095495205,0.00008422618,0.0007440321,0.009562043,0.0001511737,0.0029240516,0.057432815],"study_design_scores_gemma":[0.889944,0.08028122,0.0075739324,0.0005358027,0.01597295,0.00012604099,0.0000552614,0.00044033932,0.0011712967,0.00028876917,0.0035593018,0.000050966944],"about_ca_topic_score_codex":0.0015659969,"about_ca_topic_score_gemma":0.0052499413,"teacher_disagreement_score":0.009802488,"about_ca_system_score_codex":0.0008231551,"about_ca_system_score_gemma":0.0010773963,"threshold_uncertainty_score":0.03279257},"labels":[],"label_agreement":null},{"id":"W4309681771","doi":"10.25251/skin.6.supp.68","title":"Bimekizumab efficacy and safety through three years in patients with moderate to severe plaque psoriasis: Long-term results from the BE SURE randomized controlled trial and the BE BRIGHT open-label extension","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dermatrials Research","funders":"","keywords":"Open label; Plaque psoriasis; Medicine; Term (time); Randomized controlled trial; Psoriasis; Extension (predicate logic); Internal medicine; Dermatology; Computer science; Physics","score_opus":0.01666533154652453,"score_gpt":0.24956503916923573,"score_spread":0.2328997076227112,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309681771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98096424,0.012757455,0.0005526599,0.0010183738,0.0005015904,0.0007202204,0.0013899171,0.00009998426,0.0019955866],"genre_scores_gemma":[0.9900411,0.0033555876,0.0006193645,0.0012031252,0.00053061347,0.0008443966,0.0012572879,0.000026901309,0.0021217375],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99836737,0.0008073062,0.00011336558,0.0002853685,0.00015754407,0.00026898133],"domain_scores_gemma":[0.99772984,0.00065862905,0.0006500489,0.0002714408,0.0001657491,0.0005243487],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003737916,0.0010524386,0.003925539,0.00035963085,0.0007290262,0.0018351777,0.00083946553,0.0024012383,0.005168329],"category_scores_gemma":[0.0034682802,0.0006831689,0.0038766004,0.00050669536,0.001464928,0.0019134469,0.00067586184,0.003778322,0.00089579524],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9814372,0.0027096344,0.0013201459,0.00043197192,0.0015002101,0.000025952275,0.00003785242,0.00014468902,0.0011125667,0.00006851077,0.0007564238,0.010454819],"study_design_scores_gemma":[0.9128851,0.067042254,0.014389224,0.000089552785,0.0033609516,0.00005500958,0.000060417242,0.00030504432,0.0005004688,0.00024913024,0.0010200627,0.000042782056],"about_ca_topic_score_codex":0.0010052042,"about_ca_topic_score_gemma":0.0014145034,"teacher_disagreement_score":0.005168329,"about_ca_system_score_codex":0.0007842698,"about_ca_system_score_gemma":0.0009394779,"threshold_uncertainty_score":0.019768178},"labels":[],"label_agreement":null},{"id":"W4324057396","doi":"10.25251/skin.7.2.5","title":"Efficacy and Safety of Tralokinumab in US Adults with Moderate-to-Severe Atopic Dermatitis: A Post-hoc Analysis of ECZTRA3","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"LEO Pharma; Galderma; Ortho Dermatologics; Valeant Pharmaceuticals International; Celgene; GlaxoSmithKline; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Post-hoc analysis; Placebo; Eczema Area and Severity Index; Medicine; Atopic dermatitis; Population; Randomized controlled trial; Adverse effect; Internal medicine; Dermatology; Alternative medicine","score_opus":0.006425292969851087,"score_gpt":0.2508883681065757,"score_spread":0.24446307513672463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324057396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99625045,0.0007995402,0.00035206537,0.000103998886,0.00005982694,0.0005161888,0.0010807451,0.00002547062,0.0008115954],"genre_scores_gemma":[0.99689204,0.00018871446,0.0004177345,0.00019191235,0.00006135654,0.00046295623,0.0010760068,0.000012947964,0.0006963733],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99709153,0.0017156748,0.0001983772,0.00037265138,0.00030637684,0.00031526442],"domain_scores_gemma":[0.99629825,0.0016281384,0.0007204337,0.0005051037,0.0004743603,0.0003737299],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0060707256,0.0010212585,0.0018423015,0.00029144812,0.0003882195,0.000730219,0.00061679847,0.00065173855,0.0042348434],"category_scores_gemma":[0.0043689148,0.00027435916,0.0043078386,0.0003206637,0.00048820442,0.00065222295,0.0004846825,0.0014147244,0.00053645123],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9252101,0.004996618,0.031368695,0.00057443895,0.009358701,0.00015462849,0.00017301127,0.0012964584,0.007447498,0.000092836344,0.002070506,0.017256461],"study_design_scores_gemma":[0.15561156,0.4196416,0.36672544,0.00012122112,0.0269142,0.0006091194,0.00034789424,0.009259015,0.014524259,0.00034013987,0.0057880026,0.000117609576],"about_ca_topic_score_codex":0.0011820974,"about_ca_topic_score_gemma":0.0022200656,"teacher_disagreement_score":0.0060707256,"about_ca_system_score_codex":0.0007560703,"about_ca_system_score_gemma":0.0012678752,"threshold_uncertainty_score":0.032105386},"labels":[],"label_agreement":null},{"id":"W4324057425","doi":"10.25251/skin.7.supp.154","title":"Short-Term Efficacy and Safety of Abrocitinib by Baseline Disease Severity in Patients With Moderate-to-Severe Atopic Dermatitis","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"","keywords":"Atopic dermatitis; Medicine; Baseline (sea); Term (time); Internal medicine; Dermatology; Pediatrics","score_opus":0.007331924977722276,"score_gpt":0.25178102304082506,"score_spread":0.24444909806310278,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324057425","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98124576,0.014922266,0.00024079929,0.00016117375,0.00006092773,0.00033577098,0.0009384176,0.000021904865,0.002072952],"genre_scores_gemma":[0.99691343,0.0012844318,0.00015965229,0.0002237978,0.00007513608,0.00018164361,0.00078713294,0.0000024979904,0.00037215796],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9992508,0.00026598645,0.000087951914,0.00012686315,0.00015174542,0.000116574935],"domain_scores_gemma":[0.9988004,0.0003294358,0.00040216773,0.00006610082,0.000121260295,0.00028060653],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018209517,0.00048774574,0.0013125244,0.0003262373,0.00026997342,0.00058869825,0.00025361852,0.0003916309,0.0021530453],"category_scores_gemma":[0.001485946,0.00019872955,0.0014867351,0.00031381444,0.00020795625,0.0006344618,0.00031012256,0.0010567926,0.000373511],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4075634,0.0069042966,0.2875562,0.00195815,0.0049891626,0.00033595192,0.0003164632,0.00182012,0.023829676,0.00018843432,0.003818369,0.2607198],"study_design_scores_gemma":[0.042508714,0.122099765,0.8213823,0.00021465492,0.0032240967,0.00081326213,0.00018886231,0.0021178422,0.0034253432,0.00027644163,0.0036779859,0.00007073508],"about_ca_topic_score_codex":0.000628536,"about_ca_topic_score_gemma":0.0015410101,"teacher_disagreement_score":0.0021530453,"about_ca_system_score_codex":0.00051576394,"about_ca_system_score_gemma":0.0004214363,"threshold_uncertainty_score":0.009630203},"labels":[],"label_agreement":null},{"id":"W4324057437","doi":"10.25251/skin.7.supp.117","title":"Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy by prior treatment in the phase 3 POETYK PSO-1 trial","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Bristol-Myers Squibb","keywords":"Medicine; Placebo; Apremilast; Psoriasis; Internal medicine; Plaque psoriasis; Tolerability; Randomized controlled trial; Clinical trial; Gastroenterology; Dermatology; Adverse effect; Psoriatic arthritis; Pathology","score_opus":0.030488021619105438,"score_gpt":0.3025046343398302,"score_spread":0.27201661272072475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324057437","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909093,0.00311647,0.00041814707,0.00028640358,0.00008773778,0.0018538589,0.000944465,0.000076985074,0.0023065875],"genre_scores_gemma":[0.99324167,0.00094470393,0.00056716026,0.00053228135,0.00013259261,0.0017145897,0.0013737314,0.000016407103,0.0014769033],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9993149,0.0003370925,0.000051225892,0.00012505082,0.00007362317,0.000098089884],"domain_scores_gemma":[0.99943775,0.00011427723,0.00012831391,0.00006332482,0.000039533214,0.0002167191],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002460575,0.0007567977,0.0017002361,0.0001816996,0.00040434924,0.0007412328,0.00043493966,0.0007854204,0.0038516056],"category_scores_gemma":[0.0008991623,0.00033027297,0.0014108334,0.00021586707,0.0004177544,0.0005728271,0.00027463265,0.0020784936,0.0005717926],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9235694,0.01085695,0.0046947645,0.00066357764,0.0012894982,0.00008109424,0.00010528416,0.0005838334,0.015072986,0.00013223085,0.0027521744,0.040198322],"study_design_scores_gemma":[0.79564524,0.17151166,0.025501002,0.00006487304,0.00097453286,0.00023297114,0.000029391347,0.0007903653,0.0025989092,0.0002484754,0.002376462,0.00002600968],"about_ca_topic_score_codex":0.00036831197,"about_ca_topic_score_gemma":0.0010785105,"teacher_disagreement_score":0.0038516056,"about_ca_system_score_codex":0.00042945278,"about_ca_system_score_gemma":0.00073510996,"threshold_uncertainty_score":0.013012886},"labels":[],"label_agreement":null},{"id":"W4324057454","doi":"10.25251/skin.7.supp.172","title":"Intralesional Treatment of Basal Cell Carcinoma in a Genetically Inducible Mouse Model","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Hedgehog Signaling Pathway Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada); Feldan (Canada)","funders":"University of Toronto","keywords":"GLI1; PTCH1; Basal cell carcinoma; Vismodegib; Medicine; Cancer research; Gene knockdown; Pathology; Nevoid basal-cell carcinoma syndrome; Hedgehog signaling pathway; Biology; Basal cell; Cell culture; Gene","score_opus":0.02518759387727277,"score_gpt":0.27093723948518805,"score_spread":0.2457496456079153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324057454","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96930707,0.0031089503,0.016223365,0.00035667804,0.00026234408,0.0006217453,0.002713612,0.0010642632,0.006342131],"genre_scores_gemma":[0.95980674,0.0031732272,0.016376026,0.0001889017,0.000053460215,0.0009040076,0.0027775944,0.00016695942,0.016553026],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99956554,0.000045410507,0.00003855932,0.000117252865,0.00017056985,0.00006260461],"domain_scores_gemma":[0.9997408,0.000024899327,0.00008998905,0.000049221133,0.000024870373,0.000070207505],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036840417,0.0009352499,0.00045296174,0.00094533165,0.00028563937,0.00037026923,0.0005653234,0.00082005904,0.0026850456],"category_scores_gemma":[0.00009954009,0.00026614298,0.00062117435,0.00026025143,0.00044949452,0.00037996366,0.00022226098,0.001336413,0.0009695519],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016235225,0.00033444434,0.0002175341,0.000079824335,0.000010447872,0.00010737084,0.00001943531,0.00009983012,0.99715,0.00016898426,0.00014306196,0.0015067043],"study_design_scores_gemma":[0.000071861126,0.0014984244,0.0019343871,0.000027669204,0.000050522824,0.0006570183,0.000028096705,0.0008703605,0.99072987,0.00006186621,0.004060934,0.000008959544],"about_ca_topic_score_codex":0.0006160335,"about_ca_topic_score_gemma":0.0009053602,"teacher_disagreement_score":0.0026850456,"about_ca_system_score_codex":0.00036518837,"about_ca_system_score_gemma":0.00033831454,"threshold_uncertainty_score":0.00898236},"labels":[],"label_agreement":null},{"id":"W4324057472","doi":"10.25251/skin.7.supp.132","title":"Brodalumab: 4-Year US Pharmacovigilance Report","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bausch Health; Ortho Dermatologics","keywords":"Pharmacovigilance; Medicine; Pharmacology; Drug","score_opus":0.22720433651924277,"score_gpt":0.44317975554895983,"score_spread":0.21597541902971706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324057472","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8057603,0.031859137,0.0027482237,0.0081581855,0.00050883694,0.00044344485,0.12419635,0.000852126,0.02547342],"genre_scores_gemma":[0.9251599,0.0049138777,0.0009767418,0.002704734,0.00031631076,0.00015084297,0.06259935,0.00008702052,0.0030912329],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978515,0.00023357985,0.00048685147,0.00027132584,0.000910466,0.00024623776],"domain_scores_gemma":[0.9953531,0.00097160414,0.0022312342,0.00019447887,0.00103136,0.00021830508],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017090882,0.00051960687,0.00072706654,0.0023928005,0.00036344142,0.0015576191,0.00049792515,0.0010806477,0.0029062557],"category_scores_gemma":[0.006190273,0.00032678575,0.0015192233,0.003015295,0.00016854632,0.0009792495,0.0006609846,0.0014475031,0.00087412616],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023166453,0.0003496936,0.89457226,0.00054452545,0.001991757,0.0026493003,0.0001431821,0.0020794715,0.00076104864,0.0005653786,0.052064747,0.041961964],"study_design_scores_gemma":[0.00024724525,0.00027260365,0.9482777,0.00042704996,0.0019842251,0.0051216097,0.00020778166,0.003549979,0.00096729654,0.00052390416,0.038337406,0.00008320232],"about_ca_topic_score_codex":0.01586312,"about_ca_topic_score_gemma":0.011383851,"teacher_disagreement_score":0.01586312,"about_ca_system_score_codex":0.0014814911,"about_ca_system_score_gemma":0.0016380918,"threshold_uncertainty_score":0.031541586},"labels":[],"label_agreement":null},{"id":"W4324057475","doi":"10.25251/skin.7.supp.109","title":"Efficacy and Safety Results of Apremilast in Pediatric Patients With Moderate to Severe Plaque Psoriasis: 16-Week Results From SPROUT, a Phase 3, Randomized, Controlled Study","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stollery Children's Hospital; University of Alberta","funders":"Galderma; Celgene; Les Laboratories Pierre Fabre; Regeneron Pharmaceuticals; Pfizer; Amgen","keywords":"Apremilast; Plaque psoriasis; Medicine; Randomized controlled trial; Psoriasis; Dermatology; Physical therapy; Internal medicine; Psoriatic arthritis","score_opus":0.010800901179962612,"score_gpt":0.24335464792855624,"score_spread":0.23255374674859364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324057475","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919709,0.0049889814,0.00066529994,0.00022596006,0.00006502395,0.0007437148,0.0005467418,0.0001211889,0.0006721205],"genre_scores_gemma":[0.9897288,0.003944825,0.0026562957,0.00059859967,0.00014810759,0.0011303308,0.00075596094,0.00004200778,0.0009950366],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99931896,0.00037937658,0.00005391229,0.00008938046,0.00009818705,0.00006016611],"domain_scores_gemma":[0.9990095,0.00029713335,0.00033591458,0.00006225106,0.000061918836,0.00023319328],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020827933,0.0009490457,0.0018537238,0.00029989213,0.0002280794,0.0005831109,0.0004908789,0.00096468173,0.0017671494],"category_scores_gemma":[0.0013761603,0.00040740645,0.0015380761,0.00023877448,0.0006854616,0.00070345873,0.00021278,0.0021545803,0.00031844704],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7594786,0.03151219,0.0076314905,0.0032541542,0.0025062924,0.0005889554,0.0003589901,0.0028012248,0.049548134,0.0003319864,0.0028916148,0.13909626],"study_design_scores_gemma":[0.5781283,0.38415226,0.026096111,0.00016313395,0.0009575971,0.00074504485,0.00008444194,0.0015792202,0.005857007,0.00016455492,0.002025828,0.00004658016],"about_ca_topic_score_codex":0.00039660904,"about_ca_topic_score_gemma":0.0009770208,"teacher_disagreement_score":0.0020827933,"about_ca_system_score_codex":0.00041123392,"about_ca_system_score_gemma":0.00083099556,"threshold_uncertainty_score":0.011014998},"labels":[],"label_agreement":null},{"id":"W4324057524","doi":"10.25251/skin.7.supp.142","title":"3 years of tralokinumab treatment provides long term disease control as demonstrated by clinically meaningful outcomes in modera te to severe atopic dermatitis","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Dalhousie University","funders":"Manchester Biomedical Research Centre; LEO Pharma; European Academy of Dermatology and Venereology; National Institute for Health and Care Research","keywords":"Atopic dermatitis; Medicine; Term (time); Dermatology; Disease; Pediatrics; Internal medicine","score_opus":0.012560566447797432,"score_gpt":0.30044894912074316,"score_spread":0.28788838267294575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324057524","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98343116,0.001865104,0.00079224445,0.0005292586,0.00015458591,0.000059894064,0.0072156666,0.00012843225,0.0058236634],"genre_scores_gemma":[0.9956339,0.00014760865,0.00024409959,0.00014064794,0.000045234305,0.000017874885,0.0029597452,0.00000981331,0.00080107],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988102,0.00050443644,0.00010647618,0.0001805454,0.00014876861,0.00024975117],"domain_scores_gemma":[0.9958287,0.001323403,0.0013727952,0.0006219742,0.0003247216,0.00052840833],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028081082,0.00023557429,0.00054643396,0.00026901017,0.00032040945,0.0007795807,0.00017821691,0.00034990913,0.0047085136],"category_scores_gemma":[0.005045632,0.00009342935,0.0011304284,0.00041005167,0.00018278841,0.0005569309,0.00039295494,0.0010424192,0.00049549836],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0647845,0.0021971338,0.7323721,0.00051107205,0.00300658,0.00055507466,0.00024868787,0.0024790335,0.010223694,0.0006448018,0.0182265,0.16475086],"study_design_scores_gemma":[0.00045106927,0.0044532823,0.98620045,0.000052765346,0.00075774966,0.00046448855,0.000088041474,0.00090979744,0.0012672793,0.0002234461,0.005117682,0.00001390482],"about_ca_topic_score_codex":0.0020686158,"about_ca_topic_score_gemma":0.004606342,"teacher_disagreement_score":0.0047085136,"about_ca_system_score_codex":0.0003531831,"about_ca_system_score_gemma":0.00057428126,"threshold_uncertainty_score":0.015751481},"labels":[],"label_agreement":null},{"id":"W4324057567","doi":"10.25251/skin.7.supp.188","title":"Sustained hair regrowth with ritlecitinib to Week 48 in patients with alopecia areata: post hoc analysis of the ALLEGRO phase 2b/3 study","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Hair Growth and Disorders","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Concert Pharmaceuticals; Pfizer; Eli Lilly and Company","keywords":"Alopecia areata; Post-hoc analysis; Post hoc; Medicine; Hair growth; Dermatology; Hair loss; Dentistry; Internal medicine; Physiology","score_opus":0.008155090515938535,"score_gpt":0.26552122042382226,"score_spread":0.2573661299078837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324057567","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948153,0.0011050508,0.00052716484,0.000121114426,0.00008565486,0.0013240555,0.0008614479,0.000072647694,0.0010876375],"genre_scores_gemma":[0.99628985,0.00027707327,0.0005267875,0.00018136854,0.00009903283,0.0010565089,0.000680409,0.000021143884,0.0008677722],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9982462,0.00097535044,0.000121392884,0.00024331159,0.00017371622,0.00024005667],"domain_scores_gemma":[0.99758565,0.000994129,0.00063055236,0.00028154926,0.00021928313,0.0002888724],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044869976,0.00096295495,0.002538568,0.0003490063,0.00032883277,0.00087342056,0.00047893965,0.0006261924,0.0031702556],"category_scores_gemma":[0.0026525068,0.0002709869,0.0034538207,0.00030984034,0.0004816417,0.00075445924,0.00032978092,0.0018717225,0.0004358592],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9100329,0.0068550673,0.017259575,0.0008602749,0.006694734,0.0002045107,0.00014680665,0.0020953722,0.0152883725,0.00008823082,0.002152302,0.038321786],"study_design_scores_gemma":[0.3034254,0.5351515,0.13675244,0.00007122947,0.007163897,0.0003727224,0.00015603458,0.004150915,0.008128751,0.00029827573,0.0042396607,0.000089159366],"about_ca_topic_score_codex":0.00047448688,"about_ca_topic_score_gemma":0.0013764919,"teacher_disagreement_score":0.0044869976,"about_ca_system_score_codex":0.00051325053,"about_ca_system_score_gemma":0.0010092994,"threshold_uncertainty_score":0.023729742},"labels":[],"label_agreement":null},{"id":"W4324057575","doi":"10.25251/skin.7.supp.143","title":"Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate to severe atopic dermatitis: including adverse events of special interest","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Dalhousie University","funders":"Manchester Biomedical Research Centre; LEO Pharma; European Academy of Dermatology and Venereology; National Institute for Health and Care Research","keywords":"Atopic dermatitis; Adverse effect; Medicine; Dermatology; Safety profile; Internal medicine","score_opus":0.027101992236513023,"score_gpt":0.2916953761349444,"score_spread":0.26459338389843134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324057575","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9497535,0.016089141,0.010731973,0.00068223366,0.00028346828,0.00089696737,0.0033518518,0.0010345893,0.017176216],"genre_scores_gemma":[0.9909565,0.0013916147,0.0019357617,0.00036075208,0.00009840288,0.00015294839,0.0008264505,0.0000717681,0.0042057764],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9994023,0.00019016246,0.00006684516,0.00009555606,0.00015752578,0.00008771159],"domain_scores_gemma":[0.9981103,0.00071204477,0.0003695701,0.00024043777,0.00043703764,0.0001306628],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011441523,0.0005318814,0.0007729944,0.00020358548,0.0002960909,0.00047073243,0.00030904028,0.00036271746,0.0037489594],"category_scores_gemma":[0.0018398698,0.00011834533,0.0010302392,0.00022379843,0.00016499872,0.00038563728,0.0001749052,0.0014657059,0.00095345406],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028080793,0.0035958749,0.032696903,0.0037911197,0.001993857,0.0013295758,0.00033795505,0.0027885332,0.32934278,0.00036004643,0.007115064,0.5885675],"study_design_scores_gemma":[0.0053117094,0.11761581,0.6114913,0.0005503332,0.0041433237,0.0132987825,0.0003330696,0.006049487,0.15395148,0.00080902065,0.08626551,0.00018015318],"about_ca_topic_score_codex":0.00048949424,"about_ca_topic_score_gemma":0.0016626558,"teacher_disagreement_score":0.0037489594,"about_ca_system_score_codex":0.00030271066,"about_ca_system_score_gemma":0.00042964015,"threshold_uncertainty_score":0.012541473},"labels":[],"label_agreement":null},{"id":"W4324057607","doi":"10.25251/skin.7.supp.110","title":"Efficacy and Safety of Apremilast in Patients With Genital Psoriasis: Results From the Phase 3, Randomized, Placebo-Controlled, Double-blind DISCREET Study","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lynde Centre for Dermatology; Probity Medical Research; Guenther Dermatology Research Centre","funders":"","keywords":"Apremilast; Psoriasis; Placebo; Double blind; Medicine; Randomized controlled trial; Dermatology; Internal medicine; Alternative medicine; Psoriatic arthritis; Pathology","score_opus":0.015637138701321746,"score_gpt":0.2629802931701529,"score_spread":0.24734315446883118,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324057607","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9799993,0.013700712,0.0008490824,0.0006897845,0.00031392436,0.0013771923,0.0010732998,0.0002644557,0.0017322379],"genre_scores_gemma":[0.9893538,0.0041797133,0.001541503,0.0013531356,0.00035114755,0.000937577,0.0008749536,0.000045406887,0.0013627538],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9994086,0.00033826934,0.000041841555,0.00008238159,0.000060308805,0.00006866299],"domain_scores_gemma":[0.9989882,0.00038744614,0.00023574206,0.00008053563,0.000048471633,0.00025953847],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019398329,0.0011122645,0.0028815072,0.0003743455,0.00034596885,0.00095859583,0.0006995155,0.0015161696,0.0038657042],"category_scores_gemma":[0.0016590838,0.000600377,0.0017741851,0.0003660488,0.0009886152,0.0010566129,0.0002494417,0.0027218782,0.0006803948],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93706745,0.0071752677,0.0012050228,0.0012032859,0.001196825,0.00009869654,0.000077042685,0.00055203435,0.010605121,0.00010248047,0.0010999852,0.039616797],"study_design_scores_gemma":[0.8934892,0.097721115,0.006085328,0.00004477535,0.00044228806,0.00013331547,0.000028516173,0.00044289062,0.0007749364,0.00014261284,0.0006670266,0.000027997577],"about_ca_topic_score_codex":0.00034695741,"about_ca_topic_score_gemma":0.0007455879,"teacher_disagreement_score":0.0038657042,"about_ca_system_score_codex":0.0003706107,"about_ca_system_score_gemma":0.00064095866,"threshold_uncertainty_score":0.012932122},"labels":[],"label_agreement":null},{"id":"W4324057615","doi":"10.25251/skin.7.supp.144","title":"Efficacy and safety of up to two years of tralokinumab treatment in adults of different racial subgroups with moderate-to-severe atopic dermatitis","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"LEO Pharma","keywords":"Atopic dermatitis; Medicine; Dermatology; Pediatrics; Demography","score_opus":0.008880852189369267,"score_gpt":0.26553392449584384,"score_spread":0.25665307230647455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324057615","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99678826,0.002271279,0.00004196496,0.0000677972,0.000022834523,0.000025696496,0.00018312455,0.00000655479,0.0005926257],"genre_scores_gemma":[0.998953,0.00038221347,0.0000355903,0.000099544544,0.00002988231,0.000021449736,0.00021561314,0.0000011477465,0.0002615915],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99963963,0.000082745864,0.000038802336,0.000088211644,0.000044991666,0.00010552639],"domain_scores_gemma":[0.9993642,0.00016549499,0.00018604776,0.00004676645,0.000059806698,0.00017764319],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008166167,0.0003431305,0.0009791002,0.00024882462,0.00041375548,0.00053962617,0.00020796497,0.00053329114,0.0013187861],"category_scores_gemma":[0.0012706612,0.0001226216,0.0014216921,0.00022420741,0.00019705213,0.0006520731,0.0002264089,0.00089770963,0.00019599643],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4380362,0.009317313,0.3393541,0.00081129285,0.003150035,0.00054034847,0.00065593474,0.0018002082,0.015822431,0.0002602102,0.0013506952,0.18890125],"study_design_scores_gemma":[0.008343108,0.049391977,0.93566215,0.000095982476,0.0022337197,0.0004140419,0.0002970455,0.0008226326,0.0011365166,0.00013123052,0.0014285018,0.000043162345],"about_ca_topic_score_codex":0.0016933518,"about_ca_topic_score_gemma":0.0025477635,"teacher_disagreement_score":0.0016933518,"about_ca_system_score_codex":0.0004464545,"about_ca_system_score_gemma":0.000400154,"threshold_uncertainty_score":0.004411757},"labels":[],"label_agreement":null},{"id":"W4324057622","doi":"10.25251/skin.7.supp.141","title":"Efficacy and safety of tralokinumab treatment in adults of different racial subgroups with moderate-to-severe atopic dermatitis in three randomized, placebo-controlled phase 3 trials","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"LEO Pharma; Galderma; Glenmark Pharmaceuticals; Kiniksa Pharmaceuticals; Eli Lilly and Company","keywords":"Atopic dermatitis; Placebo; Medicine; Randomized controlled trial; Internal medicine; Dermatology; Alternative medicine","score_opus":0.014477368623124837,"score_gpt":0.2926574619221865,"score_spread":0.2781800932990617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324057622","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874735,0.007944785,0.000489701,0.0003719694,0.00022034442,0.001839361,0.00058158254,0.000059477312,0.0010192043],"genre_scores_gemma":[0.9924119,0.0025249678,0.000855909,0.0007725962,0.00015397416,0.0019055076,0.00064261444,0.000013771145,0.0007186135],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9987835,0.00057959126,0.00013157763,0.00023363266,0.000094413685,0.0001772233],"domain_scores_gemma":[0.99847096,0.00056794414,0.000413027,0.00012461605,0.00012520907,0.00029818414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003100229,0.0017372809,0.0029691234,0.00043395444,0.0010971141,0.0013588591,0.0007742812,0.0017288744,0.0032961315],"category_scores_gemma":[0.0028032267,0.00064606074,0.0046838783,0.00051089085,0.0012026821,0.0011162631,0.00038653,0.0027411024,0.0003857937],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9776977,0.003078591,0.0022819682,0.0006460211,0.0026592165,0.00003366308,0.00012066827,0.00018468048,0.0025609545,0.000058417627,0.0003344661,0.010343625],"study_design_scores_gemma":[0.9343858,0.051784832,0.0096131675,0.00006623107,0.0026339763,0.000059882226,0.00007498303,0.00023933688,0.0005164695,0.00012427036,0.00047381475,0.000027165008],"about_ca_topic_score_codex":0.0012973512,"about_ca_topic_score_gemma":0.0039204373,"teacher_disagreement_score":0.0032961315,"about_ca_system_score_codex":0.00092602347,"about_ca_system_score_gemma":0.0010362121,"threshold_uncertainty_score":0.016395807},"labels":[],"label_agreement":null},{"id":"W4324057639","doi":"10.25251/skin.7.supp.139","title":"The impact of tralokinumab on quality of life and school in patients aged 12-17 with atopic dermatitis: results from the phase 3 ECZTRA 6 trial","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of British Columbia","funders":"LEO Pharma","keywords":"Atopic dermatitis; Medicine; Quality of life (healthcare); Pediatrics; Dermatology; Nursing","score_opus":0.025225339208978622,"score_gpt":0.32953247423253335,"score_spread":0.3043071350235547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324057639","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97937346,0.017344467,0.000081483704,0.00059145526,0.0001671234,0.00028878648,0.000841773,0.000015519745,0.0012959111],"genre_scores_gemma":[0.98909944,0.0071491725,0.00034242636,0.0009388009,0.0002446849,0.00038287113,0.0008396118,0.00000873048,0.0009942303],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99971324,0.00012544569,0.000024849394,0.00003958467,0.00003987547,0.000056931844],"domain_scores_gemma":[0.9994628,0.0001178358,0.00016607087,0.000020509762,0.000041101266,0.00019168656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010915643,0.00055288954,0.0009775129,0.00016105117,0.00027378168,0.00054815755,0.0003733389,0.0006888805,0.0019400045],"category_scores_gemma":[0.000990506,0.00017210045,0.0020690372,0.00027222233,0.00024140283,0.00033260617,0.00020724189,0.0020553048,0.00023813063],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.74937,0.0121145565,0.06981126,0.0027212868,0.008388636,0.0004692843,0.00032334967,0.001002204,0.00787924,0.00014203829,0.0063943327,0.14138383],"study_design_scores_gemma":[0.41982523,0.1421719,0.42033285,0.0006426441,0.008863388,0.00073762436,0.0002640864,0.00077527395,0.0014151983,0.0001824904,0.004724365,0.000065067405],"about_ca_topic_score_codex":0.0022093146,"about_ca_topic_score_gemma":0.0061317016,"teacher_disagreement_score":0.0022093146,"about_ca_system_score_codex":0.0005288064,"about_ca_system_score_gemma":0.00054738065,"threshold_uncertainty_score":0.006489992},"labels":[],"label_agreement":null},{"id":"W4324057674","doi":"10.25251/skin.7.supp.177","title":"Primary analysis of Phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma who progressed on or were intolerant to hedgehog inhibitors","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Hedgehog Signaling Pathway Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Regeneron Pharmaceuticals; Sanofi","keywords":"Basal cell carcinoma; Primary (astronomy); Oncology; Hedgehog signaling pathway; Medicine; Hedgehog; Basal (medicine); Carcinoma; Internal medicine; Cancer research; Basal cell; Biology; Physics; Cell biology","score_opus":0.015741400842797987,"score_gpt":0.2847594909094331,"score_spread":0.26901809006663513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324057674","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99426645,0.0010610924,0.0003930536,0.00013540268,0.00004226546,0.0005626011,0.0018131437,0.000036106223,0.0016898763],"genre_scores_gemma":[0.9951532,0.00020632638,0.00043918134,0.0002586874,0.0000542754,0.00043202747,0.002605802,0.000021740772,0.00082862226],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9986601,0.0006359169,0.000062748106,0.00021122606,0.00012739477,0.0003026193],"domain_scores_gemma":[0.99857354,0.0005112468,0.0002571689,0.000151307,0.00010980285,0.0003969814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030195967,0.0008575668,0.0020178566,0.0005302545,0.00047098374,0.0013451979,0.00039148718,0.00055560435,0.003150211],"category_scores_gemma":[0.0022128758,0.0003905929,0.0015845689,0.0005013869,0.0004942983,0.0008479285,0.00037219498,0.0013438482,0.0004557154],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.69852585,0.009312779,0.16681018,0.0006197942,0.0027931011,0.00054580654,0.00024622318,0.0035744465,0.049124535,0.00029380267,0.0036264968,0.06452706],"study_design_scores_gemma":[0.100217916,0.29769224,0.55854654,0.000091379065,0.0037680177,0.0014336304,0.00025602587,0.0049576582,0.021970289,0.00067834376,0.010298837,0.00008919997],"about_ca_topic_score_codex":0.00056080456,"about_ca_topic_score_gemma":0.0015666246,"teacher_disagreement_score":0.003150211,"about_ca_system_score_codex":0.0012916741,"about_ca_system_score_gemma":0.0012385471,"threshold_uncertainty_score":0.015969396},"labels":[],"label_agreement":null},{"id":"W4324057737","doi":"10.25251/skin.7.supp.140","title":"Safety of tralokinumab in pediatric patients aged 12-17 years with moderate to severe atopic dermatitis: results from the phase 3 ECZTRA 6 trial","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Sanofi Genzyme; Genentech; LEO Pharma; Astellas Pharma; Galderma; Eli Lilly and Company; AstraZeneca; Aimmune Therapeutics; Dermira; UCB Pharma; Regeneron Pharmaceuticals; National Institute for Health and Care Research; Teva Pharmaceutical Industries; European Commission; Sanofi; Amgen; Pfizer; Celgene; GlaxoSmithKline","keywords":"Atopic dermatitis; Medicine; Pediatrics; Dermatology","score_opus":0.013811928063855046,"score_gpt":0.2680551295444405,"score_spread":0.25424320148058543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324057737","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98526627,0.009257378,0.00035765144,0.0005889841,0.00012111492,0.0011103897,0.0019466556,0.00006438115,0.0012873247],"genre_scores_gemma":[0.9836157,0.007290559,0.0015135099,0.0013785975,0.00022328636,0.0019750528,0.0024069287,0.000032512846,0.001563834],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9995635,0.0002197271,0.000030738796,0.00006140784,0.000054340802,0.00007023751],"domain_scores_gemma":[0.9992003,0.00016082554,0.00027558688,0.000043604803,0.00005451593,0.0002651398],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015969785,0.0007683061,0.0014527162,0.00015184093,0.000295037,0.0006537193,0.0004638362,0.0008913861,0.0024813535],"category_scores_gemma":[0.0009937283,0.00025895005,0.0016823475,0.00024030857,0.00042538144,0.00047301242,0.0002184692,0.002129291,0.00044599827],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7833569,0.018370856,0.039771926,0.0034324958,0.0034935623,0.0009102094,0.00038243993,0.0015218423,0.018134613,0.0004001338,0.008400709,0.12182431],"study_design_scores_gemma":[0.71574235,0.18337175,0.084937364,0.0003758312,0.002588588,0.0013777865,0.00015261114,0.00075212395,0.002836899,0.0001989508,0.007624084,0.000041513835],"about_ca_topic_score_codex":0.0006876388,"about_ca_topic_score_gemma":0.0022821745,"teacher_disagreement_score":0.0024813535,"about_ca_system_score_codex":0.00055369484,"about_ca_system_score_gemma":0.0013313219,"threshold_uncertainty_score":0.00844568},"labels":[],"label_agreement":null},{"id":"W4324057742","doi":"10.25251/skin.7.supp.196","title":"Efficacy and Safety of Roflumilast Foam 0.3% in Patients With Seborrheic Dermatitis in a Phase 3 Trial","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Nail Diseases and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"","keywords":"Tolerability; Roflumilast; Medicine; Erythema; Scalp; Clinical endpoint; Randomized controlled trial; Adverse effect; Discontinuation; Seborrheic dermatitis; Internal medicine; Clinical trial; Dermatology","score_opus":0.008512607443391216,"score_gpt":0.27847646736367015,"score_spread":0.26996385992027894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324057742","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9796705,0.0058743013,0.00081636274,0.00094515766,0.00037089724,0.00706102,0.0019267668,0.00021672035,0.0031181893],"genre_scores_gemma":[0.98093593,0.002875723,0.0018682169,0.0015638852,0.00025583836,0.008399064,0.0016995447,0.00003584425,0.002365927],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99934345,0.0003139298,0.000044027773,0.00010407335,0.00005922946,0.00013519307],"domain_scores_gemma":[0.99896646,0.00028432888,0.0002585673,0.00007088042,0.000117733485,0.00030203504],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002444418,0.0013649708,0.002239051,0.00038347617,0.00052275194,0.0010673999,0.00088713015,0.0017241276,0.006715015],"category_scores_gemma":[0.0015871866,0.0005784519,0.0025132045,0.00037308576,0.0007585526,0.0009505792,0.0003533941,0.0028054125,0.0010855839],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92155576,0.01922454,0.0018912699,0.0016625187,0.0014109014,0.0001850954,0.0002272023,0.0006445418,0.014292001,0.00018523243,0.003147351,0.035573635],"study_design_scores_gemma":[0.8520431,0.14142454,0.0033409453,0.00007715867,0.00047051904,0.00012361215,0.000042580436,0.00040917489,0.0006643341,0.00016392651,0.0012189638,0.000021088415],"about_ca_topic_score_codex":0.0006250234,"about_ca_topic_score_gemma":0.0017736702,"teacher_disagreement_score":0.006715015,"about_ca_system_score_codex":0.00071087596,"about_ca_system_score_gemma":0.0014246772,"threshold_uncertainty_score":0.022464037},"labels":[],"label_agreement":null},{"id":"W4324057774","doi":"10.25251/skin.7.supp.111","title":"Durability of Efficacy and Safety of Roflumilast Cream 0.3% in Adults With Chronic Plaque Psoriasis From a 52-Week, Phase 2 Open-Label Safety Trial","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Pharmaceutical studies and practices","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Probity Medical Research; University of British Columbia; Queen's University","funders":"","keywords":"Medicine; Tolerability; Adverse effect; Cohort; Roflumilast; Internal medicine; Psoriasis; Randomized controlled trial; Open label; Surgery; Dermatology; COPD","score_opus":0.05145775588564373,"score_gpt":0.3755849522784312,"score_spread":0.3241271963927875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324057774","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99223435,0.0027179518,0.00036722803,0.00026557184,0.0000726364,0.0014852177,0.0015648169,0.00005989164,0.0012324137],"genre_scores_gemma":[0.99190825,0.0012731743,0.0008321758,0.0005174852,0.00024416196,0.0015582441,0.002659232,0.000019915862,0.000987398],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99897134,0.00040891112,0.000096386444,0.00021289484,0.00016857678,0.00014195453],"domain_scores_gemma":[0.99830234,0.00037050946,0.0004833211,0.00016856096,0.00016595083,0.0005093859],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039952924,0.0011318944,0.0016921164,0.0003098758,0.000499052,0.00091131375,0.0005397242,0.001144535,0.004006931],"category_scores_gemma":[0.0020782908,0.0004099708,0.0012582379,0.0002979011,0.00045932474,0.0008852278,0.00034638107,0.0027350527,0.0009768682],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8173406,0.044964835,0.017288303,0.00083125866,0.0015224969,0.00019662853,0.0003154022,0.00059072726,0.03329216,0.000097814256,0.0035270639,0.080032766],"study_design_scores_gemma":[0.5055598,0.4385423,0.047946975,0.00007603122,0.00092205504,0.00034808615,0.000050749197,0.00052101846,0.0034734716,0.00011409687,0.0024126612,0.000032782893],"about_ca_topic_score_codex":0.00040982637,"about_ca_topic_score_gemma":0.0009945248,"teacher_disagreement_score":0.004006931,"about_ca_system_score_codex":0.0005563306,"about_ca_system_score_gemma":0.001015034,"threshold_uncertainty_score":0.02112943},"labels":[],"label_agreement":null},{"id":"W4377157506","doi":"10.25251/skin.7.3.19","title":"Disseminated Varicella-zoster Virus Infection in an Immunocompetent Host","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Herpesvirus Infections and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health; University of British Columbia; University of Toronto","funders":"","keywords":"Virology; Host (biology); Virus; Varicella zoster virus; Medicine; Biology; Genetics","score_opus":0.017746574329109352,"score_gpt":0.31183783940429555,"score_spread":0.2940912650751862,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4377157506","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93954426,0.012439248,0.0026411717,0.0040852837,0.0005025006,0.00017547404,0.00011540223,0.00017441661,0.040322166],"genre_scores_gemma":[0.99439776,0.002455716,0.00056158495,0.00067503186,0.00041372425,0.0000114710965,0.000018788169,0.0000060846355,0.001459858],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9998455,0.000043965953,0.000010543459,0.000023792047,0.00002222072,0.000054029966],"domain_scores_gemma":[0.9997031,0.0000884889,0.0000803444,0.000023259898,0.000012759249,0.00009200442],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017467987,0.0007143009,0.00041478482,0.00054697826,0.00075062586,0.0009915367,0.00028552665,0.0012245651,0.0022694794],"category_scores_gemma":[0.00106645,0.0003121426,0.00020448644,0.00034995753,0.00078108796,0.000931842,0.00074660184,0.0015169226,0.00055220857],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005825975,0.000050380826,0.007315614,0.00007233939,0.000005772547,0.9829578,0.00022593033,0.00010142974,0.0034790612,0.00044359022,0.00078756193,0.00450221],"study_design_scores_gemma":[0.0000129706705,0.00013012504,0.007869554,0.000041031115,0.000008107864,0.98863935,0.00025811367,0.00019802024,0.000594638,0.00025728816,0.0019821483,0.000008732547],"about_ca_topic_score_codex":0.0005415159,"about_ca_topic_score_gemma":0.0010950603,"teacher_disagreement_score":0.0022694794,"about_ca_system_score_codex":0.0004979921,"about_ca_system_score_gemma":0.00030943946,"threshold_uncertainty_score":0.0075921416},"labels":[],"label_agreement":null},{"id":"W4384465773","doi":"10.25251/skin.7.supp.220","title":"Efficacy and Safety of Roflumilast Cream 0.15% in Adults and Children Aged ≥6 Years With Mild to Moderate Atopic Dermatitis in Two Phase 3 Trials (INTEGUMENT-1 and INTEGUMENT-2)","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Probity Medical Research; Queen's University","funders":"","keywords":"Integument; Atopic dermatitis; Roflumilast; Dermatology; Medicine; Internal medicine; Anatomy","score_opus":0.012838536675441098,"score_gpt":0.30837476925559376,"score_spread":0.29553623258015266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384465773","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898671,0.007283965,0.00014672751,0.00028083764,0.000090501264,0.0005740439,0.0008183223,0.00004105943,0.00089748605],"genre_scores_gemma":[0.9926442,0.003550939,0.000491962,0.0004903152,0.00012749108,0.00071643776,0.0011621133,0.000014991415,0.00080153474],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9992999,0.00033263516,0.00006160153,0.00012172726,0.000060548307,0.00012368853],"domain_scores_gemma":[0.99910897,0.00030493963,0.00021474382,0.000051620467,0.00005776445,0.00026195342],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017498703,0.0010096456,0.002264666,0.00027963237,0.00029097308,0.00069871696,0.00066392607,0.0012461678,0.0028927675],"category_scores_gemma":[0.0015254834,0.00048748823,0.0021282346,0.00028401843,0.00064298144,0.0008286893,0.00032379653,0.0024628127,0.0005189738],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8907246,0.01161388,0.009731451,0.0015477156,0.001898942,0.00027310336,0.00040495157,0.00048633548,0.015235151,0.0001219933,0.0017202459,0.066241555],"study_design_scores_gemma":[0.7051896,0.22821824,0.059812095,0.00014286114,0.0014522716,0.0004808314,0.00016176714,0.00040562084,0.0019758176,0.00010761236,0.0020032167,0.00005002126],"about_ca_topic_score_codex":0.0015351841,"about_ca_topic_score_gemma":0.0041050413,"teacher_disagreement_score":0.0028927675,"about_ca_system_score_codex":0.0006661437,"about_ca_system_score_gemma":0.00080466195,"threshold_uncertainty_score":0.009677231},"labels":[],"label_agreement":null},{"id":"W4384469487","doi":"10.25251/skin.7.supp.219","title":"Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Efficacy by Baseline Demographic and Disease Characteristics in the Phase 3 POETYK PSO-1 and PSO-2 Trials","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"Bristol-Myers Squibb","keywords":"Medicine; Psoriasis Area and Severity Index; Placebo; Plaque psoriasis; Internal medicine; Psoriasis; Population; Gastroenterology; Dermatology; Pathology","score_opus":0.02762875616616525,"score_gpt":0.29977164924700356,"score_spread":0.27214289308083833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384469487","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9843317,0.01141904,0.00034255974,0.0001949062,0.00003606083,0.0006308634,0.0011351178,0.00002819845,0.0018815541],"genre_scores_gemma":[0.9945209,0.001968154,0.0003878498,0.00021839835,0.00006262836,0.0004962913,0.0017993149,0.000006045898,0.0005404911],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9988129,0.0005815168,0.00011504698,0.00021078023,0.00018704892,0.0000927874],"domain_scores_gemma":[0.9992481,0.00023133386,0.00024163669,0.000042015752,0.00006539118,0.00017143041],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029640957,0.0004959719,0.0013729563,0.0002442733,0.0002883677,0.00071811944,0.00030661555,0.0004562317,0.0015586488],"category_scores_gemma":[0.0013087615,0.00021474558,0.0015383117,0.00036852006,0.00027112514,0.00047159966,0.00024286879,0.0008809373,0.0001818294],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.762424,0.0064102313,0.077403896,0.0024855388,0.011133036,0.00016565717,0.00020954412,0.0019071726,0.019042742,0.00023223569,0.00475677,0.11382916],"study_design_scores_gemma":[0.33445433,0.17264818,0.45927715,0.0003639289,0.010095386,0.001352632,0.00016183428,0.003174682,0.0063406536,0.00079878006,0.011225668,0.00010671141],"about_ca_topic_score_codex":0.0005286452,"about_ca_topic_score_gemma":0.0021913813,"teacher_disagreement_score":0.0029640957,"about_ca_system_score_codex":0.00036979935,"about_ca_system_score_gemma":0.00068225805,"threshold_uncertainty_score":0.015675843},"labels":[],"label_agreement":null},{"id":"W4384469537","doi":"10.25251/skin.7.4.8","title":"Beware of the “Blue Nevus”: A Case Report","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Dermatology; Medicine; Seborrheic keratosis; Melanoma; Blue nevus; Melanosis; Nevus; Cryotherapy; Lentigo; Melanocytic nevus; Biopsy; Pathology; Radiology","score_opus":0.01680851786479874,"score_gpt":0.2784894628973337,"score_spread":0.2616809450325349,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384469537","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9218051,0.034127716,0.009290622,0.0064703925,0.0016102641,0.00037715072,0.00025574965,0.00036645614,0.025696462],"genre_scores_gemma":[0.9815524,0.007531778,0.004168332,0.0016578037,0.0023986944,0.00006932094,0.000089125024,0.000038334536,0.002494181],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9992194,0.00011371637,0.00009391989,0.00019151106,0.0001426471,0.00023878508],"domain_scores_gemma":[0.99872154,0.00038378706,0.00036979045,0.00015011268,0.00007874809,0.00029603383],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004452303,0.002381776,0.0011985697,0.0030441352,0.0032837477,0.00253901,0.0011367222,0.0065383883,0.0024023536],"category_scores_gemma":[0.0025664358,0.0013644535,0.0009716951,0.0014942973,0.0020503805,0.0030833946,0.0022672315,0.0039993795,0.0013159948],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008264714,0.000023332748,0.0020053294,0.000031808708,0.000005083635,0.9957411,0.00015171281,0.000026859365,0.0005699388,0.00014569679,0.00022805065,0.0010628755],"study_design_scores_gemma":[0.0000015709096,0.000011977692,0.00047883592,0.000007724261,0.0000043161904,0.9987626,0.00007113002,0.000043020107,0.000108311804,0.00006221621,0.00044499728,0.0000033135666],"about_ca_topic_score_codex":0.001095823,"about_ca_topic_score_gemma":0.0016986406,"teacher_disagreement_score":0.0065383883,"about_ca_system_score_codex":0.0008441741,"about_ca_system_score_gemma":0.00064401666,"threshold_uncertainty_score":0.008036733},"labels":[],"label_agreement":null},{"id":"W4384469580","doi":"10.25251/skin.7.supp.218","title":"Durability of Efficacy and Safety of Roflumilast Cream 0.3% in Adults With Chronic Plaque Psoriasis From a 52-Week, Phase 2 Open-Label Safety Trial","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Pharmaceutical studies and practices","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Probity Medical Research; University of British Columbia; Queen's University","funders":"","keywords":"Open label; Roflumilast; Medicine; Plaque psoriasis; Psoriasis; Safety profile; Dermatology; Adverse effect; Internal medicine","score_opus":0.05145775588564373,"score_gpt":0.3755849522784312,"score_spread":0.3241271963927875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384469580","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98916095,0.0063116816,0.00046282067,0.0004451215,0.00013009032,0.0008734297,0.0008467573,0.00009324903,0.0016759929],"genre_scores_gemma":[0.9936547,0.0020508135,0.0005291161,0.0007267427,0.00025566109,0.0006143842,0.00091045623,0.000021612375,0.0012365227],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9991671,0.00034112553,0.000083637,0.00015392898,0.00010260454,0.0001517641],"domain_scores_gemma":[0.9987796,0.0003902498,0.00028397603,0.00013659224,0.0001068065,0.00030280216],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026101016,0.00104948,0.0021905464,0.00030497767,0.00039377148,0.0009395602,0.0005130681,0.0015041226,0.004144238],"category_scores_gemma":[0.0021039525,0.00046371462,0.0014299204,0.0002874783,0.00069522084,0.0012932891,0.00028857426,0.0028688007,0.001115451],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.81662977,0.017573318,0.005727216,0.0012793243,0.0019813427,0.00023712493,0.00030754582,0.0008609535,0.036055468,0.00016829323,0.0024893652,0.116690256],"study_design_scores_gemma":[0.5930072,0.3650663,0.031869482,0.00010119727,0.001281419,0.00042716795,0.000102372185,0.00079858,0.004262873,0.00023349417,0.0027864105,0.00006352161],"about_ca_topic_score_codex":0.00038338936,"about_ca_topic_score_gemma":0.0007385957,"teacher_disagreement_score":0.004144238,"about_ca_system_score_codex":0.00042939794,"about_ca_system_score_gemma":0.0005329179,"threshold_uncertainty_score":0.013863921},"labels":[],"label_agreement":null},{"id":"W4384469618","doi":"10.25251/skin.7.supp.226","title":"Efficacy and Safety of Roflumilast Foam 0.3% in Patients With Seborrheic Dermatitis in a Phase 3 Trial: Assessment of Pruritus","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Nail Diseases and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"","keywords":"Roflumilast; Seborrheic dermatitis; Medicine; Dermatology; Phase (matter); Internal medicine; Chemistry","score_opus":0.009433614513604138,"score_gpt":0.3102727549736702,"score_spread":0.30083914046006605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384469618","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910019,0.0048102876,0.00035976127,0.00046017938,0.00014221609,0.0010491734,0.00047318416,0.00011997103,0.0015833074],"genre_scores_gemma":[0.9937615,0.00218462,0.0006546184,0.00053339015,0.0001381136,0.0009062233,0.00058261224,0.00002604191,0.0012128834],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9994512,0.00028152514,0.000035189183,0.000076913326,0.000048775404,0.00010645942],"domain_scores_gemma":[0.99936444,0.00021312268,0.00011397348,0.00005450004,0.000050223258,0.00020369538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015903966,0.0011909709,0.002086831,0.0004384364,0.00036311173,0.0009414447,0.0007935366,0.0015028127,0.0040869806],"category_scores_gemma":[0.0011973063,0.0005199408,0.0017840933,0.00035667265,0.00085921865,0.0010656253,0.00024221807,0.0026887946,0.00086194096],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.85332185,0.02100808,0.0022732934,0.0014197967,0.0014722234,0.00023812431,0.00024632318,0.0011444822,0.03007127,0.00019923333,0.0019054477,0.0866997],"study_design_scores_gemma":[0.7177242,0.26846543,0.008691268,0.00007383669,0.0005011303,0.00025907843,0.00008823309,0.00088489725,0.0019010097,0.0001513133,0.001219829,0.000039793136],"about_ca_topic_score_codex":0.000763576,"about_ca_topic_score_gemma":0.0014928309,"teacher_disagreement_score":0.0040869806,"about_ca_system_score_codex":0.0005456996,"about_ca_system_score_gemma":0.0006813535,"threshold_uncertainty_score":0.013672292},"labels":[],"label_agreement":null},{"id":"W4388625555","doi":"10.25251/skin.7.supp.290","title":"A Systematic Literature Review and Network Meta-Analysis of Comparative Efficacy of Topical Fixed-Dose Combination Treatments for Moderate to Severe Acne Vulgaris","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Acne and Rosacea Treatments and Effects","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Acne; Meta-analysis; Randomized controlled trial; MEDLINE; Systematic review; Internal medicine; Dermatology","score_opus":0.048590313473708714,"score_gpt":0.3539348043226664,"score_spread":0.30534449084895765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388625555","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0049660923,0.99149334,0.0008377144,0.00027945885,0.000193007,0.0008107878,0.0008647648,0.000029430263,0.00052540796],"genre_scores_gemma":[0.21328008,0.77450854,0.005044766,0.001273163,0.00035303365,0.0033553087,0.001694489,0.00004309411,0.00044757765],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.975444,0.0140935285,0.005495795,0.0021561917,0.0023559725,0.00045437386],"domain_scores_gemma":[0.9645073,0.027017735,0.0048915823,0.0008918544,0.002326447,0.00036503465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.023927739,0.0029299313,0.02140075,0.01241327,0.0008612256,0.0037675377,0.0026458825,0.0025350428,0.005506046],"category_scores_gemma":[0.053173754,0.0013753984,0.03791757,0.010992509,0.00097037444,0.0026263515,0.0017981534,0.0020376542,0.0004650499],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021482862,0.000037403726,0.0022211948,0.43475717,0.5474673,0.00010791897,0.00007088685,0.0006225485,0.00015159464,0.000196766,0.0005879308,0.011631013],"study_design_scores_gemma":[0.00094110786,0.00023543726,0.0022731004,0.034637526,0.95981395,0.00007532515,0.000035246794,0.00024662763,0.00006678054,0.00027937486,0.0013750592,0.000020503918],"about_ca_topic_score_codex":0.008750967,"about_ca_topic_score_gemma":0.01755811,"teacher_disagreement_score":0.023927739,"about_ca_system_score_codex":0.0044080555,"about_ca_system_score_gemma":0.0069570555,"threshold_uncertainty_score":0.12654346},"labels":[],"label_agreement":null},{"id":"W4388625669","doi":"10.25251/skin.7.supp.240","title":"Deucravacitinib in Plaque Psoriasis: 3-Year Safety and Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"National Institute for Health and Care Research; Manchester Biomedical Research Centre; Bristol-Myers Squibb","keywords":"Medicine; Psoriasis Area and Severity Index; Psoriasis; Placebo; Plaque psoriasis; Adverse effect; Apremilast; Internal medicine; Randomized controlled trial; Dosing; Dermatology; Psoriatic arthritis","score_opus":0.03578117792347708,"score_gpt":0.304577256432096,"score_spread":0.2687960785086189,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388625669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94700944,0.037699115,0.0010717929,0.0010838268,0.0002094394,0.0018079074,0.0037538982,0.00017995517,0.0071846102],"genre_scores_gemma":[0.98142356,0.009083324,0.00076170097,0.0011264244,0.00027911237,0.0010127901,0.004801059,0.00003312318,0.0014788931],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9986646,0.0005765114,0.00010045408,0.00020601698,0.00025634997,0.0001960363],"domain_scores_gemma":[0.99790156,0.00044241484,0.0007267261,0.00019247603,0.0002706391,0.00046620955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043261237,0.0009914052,0.0016016656,0.00035587026,0.00049184094,0.0014174154,0.0006095027,0.0012344933,0.002223755],"category_scores_gemma":[0.0024371627,0.00032145952,0.0027187956,0.0004252418,0.00044786496,0.0011416434,0.00039627228,0.0028710002,0.0005787676],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6111447,0.020896666,0.024675809,0.0035752885,0.009907288,0.0003696008,0.00045535003,0.0054252986,0.021085335,0.0005079855,0.017996378,0.28396022],"study_design_scores_gemma":[0.5543901,0.25630432,0.14806107,0.00066137244,0.008983059,0.0016508377,0.0002312514,0.0041286773,0.00747743,0.0014859474,0.01644901,0.0001769224],"about_ca_topic_score_codex":0.00079369615,"about_ca_topic_score_gemma":0.0020222168,"teacher_disagreement_score":0.0043261237,"about_ca_system_score_codex":0.00076553226,"about_ca_system_score_gemma":0.0009848764,"threshold_uncertainty_score":0.022879004},"labels":[],"label_agreement":null},{"id":"W4388625689","doi":"10.25251/skin.7.supp.272","title":"Lebrikizumab-Treated Patients With Atopic Dermatitis Had No Increase in Treatment-Emergent Adverse Events of Facial, Head, and Neck Erythema Compared to Placebo","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Dermatology; Atopic dermatitis; Adverse effect; Placebo; Head and neck; Erythema; Surgery; Internal medicine; Pathology; Alternative medicine","score_opus":0.011247788586143774,"score_gpt":0.26379962457932654,"score_spread":0.25255183599318276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388625689","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902021,0.004711668,0.00040309277,0.00024177851,0.00020678401,0.00014917634,0.0003614048,0.00006083649,0.0036630486],"genre_scores_gemma":[0.998288,0.00046842988,0.00019564341,0.00014617214,0.000042861484,0.000023054507,0.00013421444,0.0000037590178,0.000697825],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99967384,0.00013245798,0.000042857875,0.000043772077,0.000049791735,0.00005721617],"domain_scores_gemma":[0.99948394,0.00020685524,0.0001290119,0.00003580171,0.000057816338,0.00008652781],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057319226,0.00020111134,0.0008706735,0.00010663946,0.00018369575,0.0003198744,0.0001411461,0.00034638337,0.0035422882],"category_scores_gemma":[0.0012019234,0.00011033087,0.0008781261,0.00010799383,0.00012205989,0.0002897589,0.00010063442,0.0007280657,0.00026168386],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38218936,0.0049233437,0.101039216,0.0023258335,0.0040702196,0.0015301451,0.00029710072,0.00070194784,0.101688825,0.0002456893,0.0034511136,0.39753726],"study_design_scores_gemma":[0.085059196,0.2632683,0.60304874,0.00031504253,0.0059163566,0.004496336,0.000426512,0.0021403544,0.022302926,0.00033461812,0.012619683,0.00007202062],"about_ca_topic_score_codex":0.00055692747,"about_ca_topic_score_gemma":0.0013328317,"teacher_disagreement_score":0.0035422882,"about_ca_system_score_codex":0.00028051116,"about_ca_system_score_gemma":0.0002610763,"threshold_uncertainty_score":0.011850059},"labels":[],"label_agreement":null},{"id":"W4388625690","doi":"10.25251/skin.7.supp.239","title":"Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Absolute PASI Outcomes Over 52 Weeks in the Phase 3 POETYK PSO-1 Trial","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"National Institute for Health and Care Research; Manchester Biomedical Research Centre; Bristol-Myers Squibb","keywords":"Apremilast; Medicine; Psoriasis; Placebo; Psoriasis Area and Severity Index; Internal medicine; Gastroenterology; Randomization; Randomized controlled trial; Plaque psoriasis; Pharmacology; Dermatology; Psoriatic arthritis; Pathology","score_opus":0.02818460525731643,"score_gpt":0.30724518295219083,"score_spread":0.2790605776948744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388625690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9845894,0.008450186,0.00043155582,0.00065833936,0.00023551723,0.0012644998,0.0009793235,0.000106386804,0.0032846665],"genre_scores_gemma":[0.9934115,0.0021130464,0.00045409804,0.00051667047,0.0001731369,0.0008722225,0.0009347222,0.000012856769,0.0015116931],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9995222,0.00022923382,0.000031727668,0.00008433773,0.000054494507,0.000078026584],"domain_scores_gemma":[0.99946004,0.00012274622,0.00014297922,0.000035795016,0.000042900145,0.00019556569],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001693667,0.00094252126,0.0016041243,0.00019686735,0.00029089127,0.0008670011,0.0004890698,0.0009076025,0.0029410196],"category_scores_gemma":[0.0009271155,0.00031071831,0.001866648,0.00021077291,0.00048243869,0.0007912853,0.00025306924,0.0025502597,0.00041617046],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.91769904,0.006597225,0.002723234,0.0012357493,0.0021734873,0.00009039004,0.00011421459,0.0011130159,0.009373777,0.00023299443,0.0035357457,0.05511108],"study_design_scores_gemma":[0.83317304,0.14535156,0.014414421,0.000115113566,0.0012413204,0.00026067498,0.000048882972,0.0012272904,0.0015678947,0.0003623631,0.0022032536,0.000034191093],"about_ca_topic_score_codex":0.00051726826,"about_ca_topic_score_gemma":0.0014150923,"teacher_disagreement_score":0.0029410196,"about_ca_system_score_codex":0.0005924759,"about_ca_system_score_gemma":0.000676486,"threshold_uncertainty_score":0.009838641},"labels":[],"label_agreement":null},{"id":"W4388625692","doi":"10.25251/skin.7.supp.297","title":"Baricitinib Treatment Increases Eyebrow and Eyelash Regrowth Up to 52 Weeks","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Retinal and Optic Conditions","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lynde Centre for Dermatology","funders":"Incyte; Eli Lilly and Company","keywords":"Eyelash; Eyebrow; Medicine; Dermatology; Computer science; Surgery; Biology","score_opus":0.019071533120826826,"score_gpt":0.29880478806053223,"score_spread":0.2797332549397054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388625692","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95825297,0.011737882,0.0010476682,0.0010913117,0.0007024919,0.00028215104,0.002836526,0.0007265014,0.023322495],"genre_scores_gemma":[0.9739171,0.0022303464,0.00082196156,0.0005031522,0.00006410072,0.00013974258,0.002410108,0.00006156632,0.0198519],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9998267,0.000014734508,0.0000085033325,0.00003284061,0.00004272037,0.00007460498],"domain_scores_gemma":[0.9998716,0.000024685214,0.00002110945,0.00001824844,0.000027073527,0.00003723306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013372085,0.00035463358,0.0005195428,0.00023041047,0.00025445293,0.00032579002,0.00020874769,0.0004462311,0.013638747],"category_scores_gemma":[0.00034589414,0.00012425629,0.00054884347,0.0001297806,0.00014084521,0.00028852612,0.00020544582,0.0012080945,0.0023807054],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035070013,0.0044831266,0.00609382,0.0008625702,0.00027337967,0.0015802194,0.00012950039,0.00069721584,0.64350533,0.00021437515,0.022939505,0.2841509],"study_design_scores_gemma":[0.0065159607,0.06886223,0.32717305,0.00059237215,0.0010480544,0.01063334,0.00061051024,0.0026900829,0.4359866,0.000657616,0.14502297,0.00020719926],"about_ca_topic_score_codex":0.0016431522,"about_ca_topic_score_gemma":0.00345848,"teacher_disagreement_score":0.013638747,"about_ca_system_score_codex":0.00033813348,"about_ca_system_score_gemma":0.00030123923,"threshold_uncertainty_score":0.045626104},"labels":[],"label_agreement":null},{"id":"W4388625695","doi":"10.25251/skin.7.6.24","title":"Beyond Acne Vulgaris: Role of Cutibacterium Acnes in Atopic Dermatitis and Psoriasis","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Acne; Atopic dermatitis; Dermatology; Psoriasis; Medicine","score_opus":0.007171880382064845,"score_gpt":0.2555385961651061,"score_spread":0.24836671578304126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388625695","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13980664,0.8323289,0.0006983287,0.00986103,0.0011928786,0.000023564211,0.00009990403,0.00002620785,0.015962552],"genre_scores_gemma":[0.7904701,0.19719467,0.0007201822,0.0017513977,0.0042203153,0.00001859916,0.00008144911,0.000009936007,0.0055333814],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997271,0.000094298506,0.000029128245,0.000037855785,0.000059422753,0.000052243126],"domain_scores_gemma":[0.9993573,0.00034994158,0.0000990155,0.00003138487,0.000078646575,0.000083786814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043713016,0.00035823765,0.0006481434,0.0009828841,0.00029552853,0.0017546279,0.00035494255,0.0011600147,0.0034453573],"category_scores_gemma":[0.00091722124,0.00014313588,0.0003724287,0.00064080354,0.0008997794,0.0018422533,0.0006095626,0.0010935939,0.00041810854],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004786256,0.0012876277,0.12626399,0.00545496,0.0005482735,0.02994047,0.0019227746,0.0010118886,0.039172843,0.04401451,0.01841647,0.72718],"study_design_scores_gemma":[0.00065500493,0.0028082305,0.45511872,0.004210323,0.0012419157,0.09149054,0.006650629,0.0034721212,0.0065857056,0.07361136,0.35395876,0.00019669723],"about_ca_topic_score_codex":0.0011338402,"about_ca_topic_score_gemma":0.001893306,"teacher_disagreement_score":0.0034453573,"about_ca_system_score_codex":0.00035738334,"about_ca_system_score_gemma":0.0005120038,"threshold_uncertainty_score":0.011525869},"labels":[],"label_agreement":null},{"id":"W4388625848","doi":"10.25251/skin.7.supp.294","title":"Integrated Safety Analysis of Ritlecitinib in Adolescent Patients with Alopecia Areata from the Randomized, Placebo-Controlled ALLEGRO Phase 2b/3 and Ongoing Open-Label Phase 3 ALLEGRO-LT Studies","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Hair Growth and Disorders","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Pfizer","keywords":"Alopecia areata; Placebo; Phase (matter); Medicine; Open label; Dermatology; Randomized controlled trial; Psychology; Internal medicine; Alternative medicine; Physics; Pathology","score_opus":0.0338854993569062,"score_gpt":0.3409284818206344,"score_spread":0.3070429824637282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388625848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9746249,0.015646745,0.0013836445,0.0007553575,0.00015693976,0.0014703614,0.0027609903,0.00014845173,0.0030526668],"genre_scores_gemma":[0.98915917,0.003988043,0.0013551188,0.00088569813,0.00016792495,0.0008094389,0.0025042458,0.00003095851,0.0010993885],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9989453,0.0005914554,0.00006162579,0.00013155276,0.00015487244,0.00011512029],"domain_scores_gemma":[0.9985594,0.00046534603,0.00045920844,0.00012750056,0.00015350417,0.00023493674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029544595,0.00050189183,0.0014873226,0.00035044726,0.00024885355,0.00090142916,0.00050772825,0.0007401772,0.0037077973],"category_scores_gemma":[0.0022115854,0.00023832188,0.00224341,0.00033202293,0.00042504948,0.00071731716,0.00024124845,0.0019600946,0.0004234827],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.67324156,0.006176311,0.013775199,0.002335144,0.0075414637,0.00015141015,0.00020390305,0.0028624604,0.015416727,0.00055340154,0.004841545,0.27290082],"study_design_scores_gemma":[0.6456182,0.23840733,0.081198335,0.00037491278,0.009023777,0.00067646866,0.00013282441,0.002621526,0.005428689,0.00067693886,0.015745636,0.000095331394],"about_ca_topic_score_codex":0.0005264452,"about_ca_topic_score_gemma":0.0018384438,"teacher_disagreement_score":0.0037077973,"about_ca_system_score_codex":0.00082584127,"about_ca_system_score_gemma":0.0012301432,"threshold_uncertainty_score":0.015624821},"labels":[],"label_agreement":null},{"id":"W4388625988","doi":"10.25251/skin.7.supp.254","title":"Apremilast in Pediatric Patients With Moderate to Severe Plaque Psoriasis: 16-Week Efficacy and Safety Results From the Phase 3, Randomized, Double-Blind, Placebo-Controlled SPROUT Study","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stollery Children's Hospital; University of Alberta","funders":"Amgen","keywords":"Apremilast; Medicine; Double blind; Placebo; Psoriasis; Plaque psoriasis; Dermatology; Randomized controlled trial; Placebo-controlled study; Double blind study; Internal medicine; Alternative medicine; Pathology; Psoriatic arthritis","score_opus":0.017666931991307977,"score_gpt":0.2602192344788104,"score_spread":0.24255230248750242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388625988","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893198,0.005646268,0.0010168991,0.0004017887,0.00011128694,0.0016690838,0.0008328281,0.00015051523,0.00085146975],"genre_scores_gemma":[0.9847847,0.0061760563,0.0036055055,0.0008886289,0.00030142625,0.0017853185,0.0010267936,0.000053113796,0.0013783181],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9993506,0.00035938516,0.00005477221,0.0000815755,0.000085959895,0.0000676682],"domain_scores_gemma":[0.998784,0.00031887525,0.0003791388,0.00009826279,0.00008421534,0.00033557593],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023624338,0.0010743036,0.0021014153,0.00024822654,0.00030302283,0.00057456596,0.00061250734,0.0010900191,0.0023040825],"category_scores_gemma":[0.0014122764,0.00044412247,0.0015370366,0.00031200543,0.0006632895,0.00076849246,0.0002545245,0.002549018,0.00043233755],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7738047,0.03403673,0.005518473,0.002501072,0.002150423,0.0004973854,0.00030196938,0.0013112748,0.048929874,0.00019272204,0.0030558428,0.12769952],"study_design_scores_gemma":[0.62663335,0.3460801,0.019524585,0.00008851038,0.00068371237,0.0005513634,0.000062537656,0.0005184776,0.0039961357,0.000115101706,0.001716764,0.00002942185],"about_ca_topic_score_codex":0.000441965,"about_ca_topic_score_gemma":0.0012635895,"teacher_disagreement_score":0.0023624338,"about_ca_system_score_codex":0.00035907433,"about_ca_system_score_gemma":0.0010148687,"threshold_uncertainty_score":0.012493849},"labels":[],"label_agreement":null},{"id":"W4388625991","doi":"10.25251/skin.7.supp.253","title":"How Labeling Warnings and Precautions May Impact the Proportion of Psoriasis Patients Initiating New Treatments","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Mental Health and Psychiatry","field":"Arts and Humanities","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Psoriasis; Medicine; Dermatology","score_opus":0.03492004508033811,"score_gpt":0.29667873088430535,"score_spread":0.2617586858039672,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388625991","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.37789926,0.006705334,0.012150352,0.45637017,0.00441685,0.0003386256,0.0024318958,0.00040046574,0.13928704],"genre_scores_gemma":[0.96588504,0.0021400305,0.004053809,0.022799324,0.0014336976,0.00007122667,0.0003223269,0.000046493245,0.003248105],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9823355,0.010637797,0.0010942029,0.001197717,0.0033990717,0.0013356645],"domain_scores_gemma":[0.8835903,0.078897074,0.018538887,0.003405816,0.011209119,0.004358843],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.017780507,0.00026350474,0.00037254376,0.0013984852,0.001456045,0.005927536,0.0011396724,0.0037747603,0.014571922],"category_scores_gemma":[0.16830814,0.00037446973,0.0012122777,0.0009980391,0.00121401,0.0046318085,0.0013889234,0.0043443516,0.0012932904],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020042511,0.0021816455,0.4503646,0.0006888106,0.00060729816,0.0004715121,0.002389873,0.0074389344,0.0012195356,0.037143003,0.09148102,0.4040096],"study_design_scores_gemma":[0.0010301601,0.0029451835,0.5483909,0.0046136877,0.0022969225,0.0014994403,0.010988175,0.040491894,0.005557625,0.18232262,0.1993299,0.0005334277],"about_ca_topic_score_codex":0.01901813,"about_ca_topic_score_gemma":0.01883694,"teacher_disagreement_score":0.01901813,"about_ca_system_score_codex":0.00293402,"about_ca_system_score_gemma":0.005986924,"threshold_uncertainty_score":0.09403348},"labels":[],"label_agreement":null},{"id":"W4388626014","doi":"10.25251/skin.7.supp.236","title":"Time to Onset of a Minimal Clinically Important Difference in DLQI with Guselkumab Treatment in VOYAGE 1","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Toronto; Dalhousie University; Probity Medical Research","funders":"Janssen Scientific Affairs","keywords":"Dermatology Life Quality Index; Minimal clinically important difference; Medicine; Quality of life (healthcare); Adalimumab; Psoriasis; Psoriasis Area and Severity Index; Randomized controlled trial; Internal medicine; Placebo; Randomization; Physical therapy; Surgery; Dermatology; Disease; Pathology","score_opus":0.015940636727592213,"score_gpt":0.26762430941817744,"score_spread":0.2516836726905852,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388626014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922282,0.004555032,0.00047728888,0.00023105353,0.00010021888,0.00033320798,0.0008236429,0.000030161698,0.0012212344],"genre_scores_gemma":[0.9976767,0.00039761333,0.00031976288,0.00016582373,0.000038723738,0.00026037727,0.00068860094,0.00000586711,0.0004465953],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9987245,0.0006498603,0.00008238317,0.00022842851,0.00011521345,0.00019951955],"domain_scores_gemma":[0.9974356,0.001140995,0.0007101009,0.000108963155,0.000088742265,0.00051558367],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033183456,0.00038851477,0.0024612537,0.00027895867,0.00023728954,0.0008891734,0.00037427575,0.0006440704,0.0025621185],"category_scores_gemma":[0.003816194,0.00022453963,0.0017537168,0.0002618291,0.0003340005,0.0005767343,0.00044054163,0.0018120705,0.00021047768],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8309134,0.0052175727,0.05028872,0.0009707493,0.0021609147,0.00015770955,0.00015822296,0.0030608082,0.010414511,0.00040207192,0.0020286376,0.09422661],"study_design_scores_gemma":[0.16324158,0.4433591,0.3700756,0.00034290415,0.0023680837,0.00070816855,0.00017472456,0.006424761,0.0051025935,0.0011315751,0.0069616428,0.00010929303],"about_ca_topic_score_codex":0.00042008515,"about_ca_topic_score_gemma":0.0006768719,"teacher_disagreement_score":0.0033183456,"about_ca_system_score_codex":0.0006310065,"about_ca_system_score_gemma":0.00073135283,"threshold_uncertainty_score":0.017549276},"labels":[],"label_agreement":null},{"id":"W4388626033","doi":"10.25251/skin.7.supp.286","title":"Spesolimab for Hidradenitis Suppurativa: A Proof-of-Concept Study","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Hidradenitis Suppurativa and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"","keywords":"Hidradenitis suppurativa; Medicine; Placebo; Internal medicine; Dosing; Intertriginous; Adverse effect; Gastroenterology; Adalimumab; Surgery; Pathology; Tumor necrosis factor alpha","score_opus":0.03057522950790823,"score_gpt":0.3238723228457288,"score_spread":0.29329709333782056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388626033","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.852337,0.09258215,0.014511138,0.0047181384,0.0019304237,0.016861068,0.006091322,0.00054028013,0.01042844],"genre_scores_gemma":[0.9240038,0.037793472,0.0131533835,0.0043757744,0.0011241841,0.008413979,0.0048527187,0.000056957764,0.0062257275],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9992254,0.00037177623,0.000047741316,0.00008726525,0.00015113814,0.00011659376],"domain_scores_gemma":[0.9990496,0.00023729853,0.00023332723,0.00006712976,0.00013564479,0.00027704437],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004226682,0.0015487412,0.0013622644,0.00039041383,0.00025152182,0.0012215507,0.000874746,0.0014694835,0.0058124354],"category_scores_gemma":[0.0012535381,0.00036419093,0.0019376304,0.00028356552,0.0005831784,0.0007455194,0.00040104132,0.0024381378,0.0013147527],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1868001,0.07053368,0.0030945467,0.022974096,0.004346145,0.001909856,0.00059406343,0.0034503993,0.33260417,0.0019624322,0.025653053,0.3460774],"study_design_scores_gemma":[0.30173674,0.5812956,0.007961035,0.0011499049,0.0024688805,0.0030178116,0.00014323638,0.0017493342,0.036703706,0.0007418978,0.06295233,0.00007946201],"about_ca_topic_score_codex":0.00015686415,"about_ca_topic_score_gemma":0.00042520894,"teacher_disagreement_score":0.0058124354,"about_ca_system_score_codex":0.00051804987,"about_ca_system_score_gemma":0.0016459541,"threshold_uncertainty_score":0.022353113},"labels":[],"label_agreement":null},{"id":"W4388626054","doi":"10.25251/skin.7.supp.291","title":"Integrated Safety Analysis of Ritlecitinib for the Treatment of Alopecia Areata (AA) From the Phase 2 and Phase 3 ALLEGRO Clinical Trial Program","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Hair Growth and Disorders","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Pfizer","keywords":"Alopecia areata; Phase (matter); Dermatology; Medicine; Chemistry; Organic chemistry","score_opus":0.08132641213904793,"score_gpt":0.4348392751947991,"score_spread":0.35351286305575114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388626054","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80610526,0.04982499,0.007046453,0.0035661324,0.00045153132,0.045942646,0.06447299,0.00068061904,0.021909306],"genre_scores_gemma":[0.88070613,0.01644962,0.0094283745,0.0049927593,0.0006158321,0.030783122,0.048320152,0.00020653597,0.008497413],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99575883,0.002477063,0.00028472955,0.0004088829,0.00076140487,0.0003090265],"domain_scores_gemma":[0.9968631,0.0008776273,0.0010764487,0.00023468689,0.00052624673,0.00042202006],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009266319,0.0012139,0.0022674429,0.0012171796,0.0006100045,0.002065133,0.0008272818,0.0014782732,0.010035017],"category_scores_gemma":[0.005173154,0.00053922256,0.0047925734,0.00097584823,0.00041472493,0.0010591157,0.0010006907,0.0019105033,0.001015913],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.66662604,0.0072443695,0.0211509,0.011271048,0.033703756,0.00049534143,0.00041083753,0.003745575,0.023321144,0.0011462475,0.027592346,0.20329241],"study_design_scores_gemma":[0.5799936,0.16619083,0.11015398,0.0023335195,0.04501339,0.0013045616,0.00025173713,0.002852448,0.0086003505,0.0018622263,0.08123219,0.00021115626],"about_ca_topic_score_codex":0.0006332808,"about_ca_topic_score_gemma":0.002472422,"teacher_disagreement_score":0.010035017,"about_ca_system_score_codex":0.0010827545,"about_ca_system_score_gemma":0.002934998,"threshold_uncertainty_score":0.049005568},"labels":[],"label_agreement":null},{"id":"W4388626055","doi":"10.25251/skin.7.supp.258","title":"Maintenance of Clinical Response With Continued Risankizumab Treatment for Moderate-to-Severe Psoriasis Through 304 Weeks: Interim Analysis of the LIMMitless Open-Label Extension Study","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Pharmaceutical studies and practices","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Medicine; Psoriasis Area and Severity Index; Psoriasis; Internal medicine; Adverse effect; Maintenance therapy; Interim analysis; Clinical trial; Randomized controlled trial; Gastroenterology; Surgery; Chemotherapy; Immunology","score_opus":0.20484667369043627,"score_gpt":0.48630819427542,"score_spread":0.28146152058498375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388626055","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985227,0.001818579,0.0021648342,0.00037364458,0.00020519266,0.0025461002,0.0043253456,0.00027240394,0.0030668674],"genre_scores_gemma":[0.9860335,0.00034817343,0.0026025088,0.00065578544,0.00016996653,0.002867257,0.0052370583,0.000048789567,0.0020368842],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9967955,0.001786784,0.00018370694,0.0003531901,0.00038015915,0.00050074974],"domain_scores_gemma":[0.99536467,0.001281071,0.0012717982,0.0010495478,0.000396841,0.0006361047],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010820087,0.0014040606,0.0031104407,0.0004893468,0.0005121866,0.0016811714,0.0010563346,0.0014683371,0.0035666872],"category_scores_gemma":[0.005187013,0.0005171854,0.0037692918,0.0004637723,0.00088070944,0.0014217091,0.0006128983,0.003163055,0.0009193544],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9447541,0.00790994,0.008535588,0.0003019406,0.0024088973,0.00009910251,0.00010808564,0.0015223827,0.006574919,0.00016827321,0.0024679506,0.025148753],"study_design_scores_gemma":[0.42069983,0.48175195,0.071237914,0.00011238666,0.0058850697,0.00040833943,0.000105281484,0.0054917405,0.0073950137,0.0010406253,0.005745563,0.00012634623],"about_ca_topic_score_codex":0.0002871871,"about_ca_topic_score_gemma":0.00048294038,"teacher_disagreement_score":0.010820087,"about_ca_system_score_codex":0.0007568655,"about_ca_system_score_gemma":0.0014134861,"threshold_uncertainty_score":0.057222784},"labels":[],"label_agreement":null},{"id":"W4388626067","doi":"10.25251/skin.7.supp.257","title":"Efficacy and Safety of Risankizumab Compared with Apremilast in Patients with Moderate Plaque Psoriasis: Mean PASI and BSA Results From the Phase 4 IMMpulse Trial","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"Janssen Biotech; Glenmark Pharmaceuticals; LEO Pharma; Incyte; Dermira; Regeneron Pharmaceuticals; Celgene; Sanofi; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Psoriasis Area and Severity Index; Apremilast; Psoriasis; Randomized controlled trial; Body surface area; Plaque psoriasis; Internal medicine; Gastroenterology; Dermatology","score_opus":0.013720690003934744,"score_gpt":0.2400699069863114,"score_spread":0.22634921698237664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388626067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98545593,0.00909304,0.00042224422,0.00055169145,0.00016922876,0.0011204621,0.0009528197,0.000102149585,0.0021324286],"genre_scores_gemma":[0.9929777,0.0021203114,0.0009151075,0.00072956714,0.00031359834,0.0010706314,0.0009163096,0.000014224498,0.00094262575],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99907637,0.00052807346,0.00007698265,0.00011889717,0.00012476667,0.000074900745],"domain_scores_gemma":[0.9991462,0.00025152758,0.0002657877,0.000054058848,0.000056601344,0.00022585267],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026135573,0.0008621912,0.0018112409,0.00024177921,0.00023464445,0.00086238014,0.00050568284,0.0008231567,0.002866995],"category_scores_gemma":[0.0015928586,0.0003636908,0.0014158323,0.00025434283,0.00055920327,0.0006114723,0.0002857396,0.0017819419,0.00045416458],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9110917,0.008476712,0.0037724732,0.0014127804,0.0019389805,0.0000729586,0.000087021064,0.0006628161,0.013653952,0.00015088092,0.0017572128,0.05692243],"study_design_scores_gemma":[0.70915014,0.2693804,0.015402903,0.00009286835,0.001219093,0.0001896208,0.00003349564,0.0007232474,0.0019432851,0.00024928513,0.0015841146,0.00003153762],"about_ca_topic_score_codex":0.0002273527,"about_ca_topic_score_gemma":0.00057547115,"teacher_disagreement_score":0.002866995,"about_ca_system_score_codex":0.00041280655,"about_ca_system_score_gemma":0.0007743738,"threshold_uncertainty_score":0.0138219595},"labels":[],"label_agreement":null},{"id":"W4388626087","doi":"10.25251/skin.7.supp.256","title":"A Phase 3b Study Evaluating Safety and Efficacy of Risankizumab in Adult Patients with Moderate-to-Severe Plaque Psoriasis with Palmoplantar (Non-Pustular) Involvement","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Pharmaceutical studies and practices","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"","keywords":"Medicine; Psoriasis Area and Severity Index; Randomized controlled trial; Placebo; Clinical endpoint; Internal medicine; Gastroenterology; Psoriasis; Dermatology","score_opus":0.03396525115363107,"score_gpt":0.3609531808656619,"score_spread":0.32698792971203083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388626087","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987716,0.0030041796,0.00070526794,0.0004885753,0.00010173933,0.0041070157,0.0017519725,0.000080865415,0.0020443718],"genre_scores_gemma":[0.98919106,0.0013260837,0.0018253042,0.0008903809,0.00017289429,0.0033138914,0.0018122459,0.000018696086,0.0014496363],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9994771,0.00029541928,0.000030258898,0.00006618625,0.00006363819,0.000067397305],"domain_scores_gemma":[0.9993206,0.00013442889,0.00016389064,0.00005410078,0.000059368806,0.0002675718],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021712675,0.000770317,0.0013299318,0.00018672504,0.00030304908,0.0005097638,0.0005248772,0.00074154197,0.0050875526],"category_scores_gemma":[0.0009731834,0.00039955578,0.0011476272,0.0002446481,0.00047144727,0.00045947623,0.00024611762,0.002057314,0.00094458123],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8781276,0.031855896,0.008915035,0.00074966234,0.0011476704,0.00014159497,0.00016342914,0.00067786186,0.022786312,0.00013982368,0.0029850737,0.052309934],"study_design_scores_gemma":[0.73402053,0.24261446,0.018704936,0.000036806014,0.00044669287,0.00018671503,0.000026028727,0.00042402002,0.0016281096,0.00010541898,0.001790386,0.00001590898],"about_ca_topic_score_codex":0.00052352564,"about_ca_topic_score_gemma":0.0014173054,"teacher_disagreement_score":0.0050875526,"about_ca_system_score_codex":0.00048023334,"about_ca_system_score_gemma":0.001279255,"threshold_uncertainty_score":0.01701957},"labels":[],"label_agreement":null},{"id":"W4388626089","doi":"10.25251/skin.7.supp.293","title":"Sustained Scalp, Eyebrow, and Eyelash Hair Regrowth with Ritlecitinib Through Week 48 in Patients with Alopecia Areata: Post-Hoc Analysis of the ALLEGRO Phase 2b/3 Study","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Hair Growth and Disorders","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Concert Pharmaceuticals; Pfizer; Eli Lilly and Company","keywords":"Alopecia areata; Eyebrow; Scalp; Eyelash; Dermatology; Post-hoc analysis; Medicine; Post hoc; Hair loss; Hair growth; Surgery; Orthodontics; Internal medicine; Biology; Physiology","score_opus":0.00823029362534534,"score_gpt":0.2649879771580626,"score_spread":0.2567576835327173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388626089","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99624,0.0013064309,0.0002520572,0.00010960844,0.000073512434,0.0005876336,0.00075481675,0.000052759744,0.0006231403],"genre_scores_gemma":[0.9967344,0.00040501778,0.0004031872,0.00017707857,0.00008615163,0.0006359697,0.0006883857,0.000016673675,0.0008530867],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9984817,0.00079464127,0.00009247434,0.00023689895,0.00014791133,0.00024640665],"domain_scores_gemma":[0.9985019,0.00050246646,0.0003836891,0.00016536277,0.00012246646,0.00032419772],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003810629,0.0011375411,0.0037251967,0.00033682483,0.0003372475,0.0010419651,0.000641285,0.0007859572,0.003705744],"category_scores_gemma":[0.0016616787,0.00033881725,0.0043311957,0.0003360406,0.0005035345,0.00093034527,0.0004035983,0.002315884,0.00058411155],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96179426,0.0047170566,0.004900976,0.00041748636,0.0034892792,0.00006258806,0.00007090411,0.00086549,0.006057488,0.00003410625,0.0006627354,0.01692769],"study_design_scores_gemma":[0.41449878,0.4933,0.075345896,0.000066471715,0.007080023,0.00019656717,0.00013964112,0.002593654,0.0043217735,0.00017105126,0.0022154336,0.00007061675],"about_ca_topic_score_codex":0.0007287744,"about_ca_topic_score_gemma":0.00220895,"teacher_disagreement_score":0.003810629,"about_ca_system_score_codex":0.000709962,"about_ca_system_score_gemma":0.0012563769,"threshold_uncertainty_score":0.020152748},"labels":[],"label_agreement":null},{"id":"W4388626102","doi":"10.25251/skin.7.supp.246","title":"Flare Frequency and Duration in Patients with Generalized Pustular Psoriasis (GPP)","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Flare; Psoriasis; Erythema; Generalized pustular psoriasis; Sepsis; Pediatrics; Dermatology; Internal medicine","score_opus":0.008628953416183355,"score_gpt":0.21938818921263625,"score_spread":0.2107592357964529,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388626102","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984785,0.0007639473,0.00002978696,0.000052794443,0.0000033596887,0.000005924762,0.00023447923,0.000003734741,0.0004275312],"genre_scores_gemma":[0.9995479,0.00013821898,0.000042086078,0.000030878586,0.000008528895,0.000004160832,0.00016666764,6.2793765e-7,0.00006083761],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997037,0.00006315287,0.0000421232,0.000067497625,0.000057144585,0.000066338784],"domain_scores_gemma":[0.998684,0.0002101495,0.00084840856,0.000026575937,0.00008538131,0.00014560393],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038101597,0.0001483686,0.00021561714,0.0008345867,0.00033921897,0.00045179963,0.00018176284,0.00034553904,0.0020188084],"category_scores_gemma":[0.0018485016,0.000116039664,0.00025328578,0.0008391033,0.00011822307,0.00042467058,0.000221027,0.00028994985,0.00016662736],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000060072947,0.000012721865,0.99778974,0.000009221793,0.000017018623,0.000162897,0.00004071734,0.000022402515,0.000078393845,0.000005907692,0.000074543204,0.0017263523],"study_design_scores_gemma":[0.000004601894,0.0000625402,0.99810684,0.000009568113,0.000014055043,0.0014348488,0.000112261034,0.000063175205,0.000020406678,0.000008409818,0.00016105606,0.0000021399],"about_ca_topic_score_codex":0.0036621594,"about_ca_topic_score_gemma":0.004292237,"teacher_disagreement_score":0.0036621594,"about_ca_system_score_codex":0.00040208985,"about_ca_system_score_gemma":0.00020898289,"threshold_uncertainty_score":0.0072817206},"labels":[],"label_agreement":null},{"id":"W4388627102","doi":"10.25251/skin.7.supp.255","title":"Efficacy of Apremilast in Patients with Moderate-to-Severe Genital Psoriasis: Body Surface Area Subgroup Results from the Phase 3 DISCREET Trial","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lynde Centre for Dermatology; Probity Medical Research; Guenther Dermatology Research Centre","funders":"Amgen","keywords":"Apremilast; Psoriasis; Body surface area; Medicine; Dermatology; Internal medicine; Psoriatic arthritis","score_opus":0.016358601469401518,"score_gpt":0.24945393813424263,"score_spread":0.2330953366648411,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388627102","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9532038,0.030831175,0.0013606637,0.0029522171,0.0009827574,0.002176443,0.0030689435,0.0003058562,0.0051181065],"genre_scores_gemma":[0.98273844,0.0059332475,0.0012555654,0.002608588,0.0006993457,0.0012639933,0.0018923917,0.00005848738,0.0035499113],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9993623,0.00036540575,0.000040717234,0.00008300741,0.000056065335,0.00009240526],"domain_scores_gemma":[0.999154,0.0002842681,0.00020957737,0.0000860249,0.000057446105,0.0002087412],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002347047,0.0012611197,0.0031778852,0.00026890065,0.00036455496,0.0013349424,0.00070128933,0.0012578034,0.00521968],"category_scores_gemma":[0.0017108603,0.00044026432,0.003907057,0.00034226454,0.0005511971,0.0010075859,0.0003571943,0.0031733885,0.00068640104],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9457951,0.0020810368,0.0021413087,0.0016401366,0.0062866355,0.00010380593,0.00008343491,0.00065390556,0.0043854252,0.00016854219,0.0027600694,0.03390046],"study_design_scores_gemma":[0.94331735,0.040321875,0.009771446,0.00013558348,0.0030594782,0.0001228833,0.00006959831,0.00047663157,0.00040543737,0.0005381401,0.0017402706,0.00004132697],"about_ca_topic_score_codex":0.00065528747,"about_ca_topic_score_gemma":0.0022724625,"teacher_disagreement_score":0.00521968,"about_ca_system_score_codex":0.00049158593,"about_ca_system_score_gemma":0.00067359034,"threshold_uncertainty_score":0.017461538},"labels":[],"label_agreement":null},{"id":"W4388627217","doi":"10.25251/skin.7.supp.237","title":"PASI Improvement in the First 12 weeks from the Phase 3 VOYAGE 1, VOYAGE 2, ORION and ECLIPSE Guselkumab Clinical Trials","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; McMaster University; Dalhousie University; Probity Medical Research","funders":"Amgen","keywords":"Medicine; Placebo; Clinical trial; Interquartile range; Internal medicine","score_opus":0.06724673980502993,"score_gpt":0.35733990167381413,"score_spread":0.2900931618687842,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388627217","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9493557,0.027757859,0.002826113,0.000517164,0.00030788587,0.004424756,0.0051297555,0.0002596831,0.009421055],"genre_scores_gemma":[0.9795801,0.0040996023,0.002054839,0.00057594304,0.00022262234,0.0055130753,0.0037663863,0.000048057016,0.0041393046],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9961249,0.002195403,0.0004264873,0.00041442804,0.000457685,0.00038105767],"domain_scores_gemma":[0.9950283,0.0020087368,0.0017243471,0.00025672896,0.00048995035,0.0004919102],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010388986,0.0010048293,0.0024377343,0.0006771426,0.00047760113,0.0010847216,0.00042720343,0.00086684834,0.0028702656],"category_scores_gemma":[0.006101355,0.00034856604,0.0020731152,0.00065366755,0.00036918395,0.0007314766,0.0005508103,0.002209977,0.0006299774],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.77128404,0.005061427,0.038495596,0.0029838847,0.0038802365,0.00010478571,0.00021420528,0.0018303446,0.013288575,0.00036814815,0.0064537064,0.15603505],"study_design_scores_gemma":[0.167647,0.4286735,0.35880533,0.00078368216,0.005602984,0.00054214883,0.0001393171,0.0031860818,0.012439305,0.0010611647,0.02099659,0.00012291946],"about_ca_topic_score_codex":0.00028366962,"about_ca_topic_score_gemma":0.0008152335,"teacher_disagreement_score":0.010388986,"about_ca_system_score_codex":0.000494877,"about_ca_system_score_gemma":0.0009029756,"threshold_uncertainty_score":0.054942846},"labels":[],"label_agreement":null},{"id":"W4388627467","doi":"10.25251/skin.7.supp.251","title":"Investigator- and Patient-Rated Local Tolerability in Phase 3 Trials of Topical Roflumilast in Patients With Psoriasis, Seborrheic Dermatitis, and Atopic Dermatitis","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dermatrials Research; Probity Medical Research; Queen's University","funders":"","keywords":"Roflumilast; Tolerability; Dermatology; Seborrheic dermatitis; Medicine; Atopic dermatitis; Psoriasis; Apremilast; Internal medicine; Adverse effect","score_opus":0.014233596826854404,"score_gpt":0.2521682519196282,"score_spread":0.2379346550927738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388627467","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9492018,0.0340718,0.0017372217,0.00077432365,0.0002502526,0.0056441356,0.002419571,0.00018068752,0.0057201916],"genre_scores_gemma":[0.98447186,0.006933778,0.0018560424,0.00072970014,0.00016454078,0.0032157814,0.0012542129,0.00003132237,0.0013427706],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9966403,0.0021740748,0.00039131014,0.0002112017,0.00034290607,0.00024013953],"domain_scores_gemma":[0.99753016,0.0010201865,0.00078609353,0.00010967474,0.00028942633,0.00026445262],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007987315,0.0009343134,0.002122636,0.000511216,0.00048087625,0.0009471555,0.0004612797,0.0009999798,0.0030998397],"category_scores_gemma":[0.005219472,0.0004166442,0.0032529891,0.000689466,0.00041024073,0.00088720286,0.00029546657,0.0018866684,0.00032862564],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7043692,0.01270663,0.016228229,0.006772511,0.010245851,0.0002875754,0.0007193394,0.002235728,0.030857272,0.00034423984,0.006009667,0.20922378],"study_design_scores_gemma":[0.5275262,0.3495313,0.10078902,0.0006757964,0.0042781886,0.000770031,0.00033205436,0.0015087249,0.0050693993,0.0004554189,0.008923483,0.0001403563],"about_ca_topic_score_codex":0.00061408704,"about_ca_topic_score_gemma":0.0019828924,"teacher_disagreement_score":0.007987315,"about_ca_system_score_codex":0.0005425264,"about_ca_system_score_gemma":0.0007726755,"threshold_uncertainty_score":0.042241514},"labels":[],"label_agreement":null},{"id":"W4388627499","doi":"10.25251/skin.7.supp.241","title":"Deucravacitinib in Plaque Psoriasis: Maintenance of Response Over 3 Years in the Phase 3 POETYK PSO-1 and PSO-2 Trials","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"Bristol-Myers Squibb","keywords":"Medicine; Psoriasis Area and Severity Index; Plaque psoriasis; Psoriasis; Placebo; Clinical endpoint; Apremilast; Clinical trial; Internal medicine; Randomized controlled trial; Tolerability; Adverse effect; Gastroenterology; Dermatology; Psoriatic arthritis","score_opus":0.03370635970462376,"score_gpt":0.3210922749445532,"score_spread":0.28738591523992946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388627499","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9727342,0.01943066,0.0006033939,0.0007696229,0.00014848018,0.0013442023,0.00089692615,0.00012195792,0.00395061],"genre_scores_gemma":[0.9914819,0.0037871387,0.0007161771,0.00064002845,0.00016377977,0.001076077,0.0012161572,0.000020477248,0.00089829246],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99873847,0.00068303203,0.000089164365,0.00016584103,0.00015707113,0.0001664917],"domain_scores_gemma":[0.9987153,0.00029010087,0.0003937305,0.000115457115,0.00012990853,0.00035554852],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043970766,0.00076357566,0.0017215082,0.00025029102,0.00058374123,0.0012114893,0.0005601296,0.001112353,0.0015091843],"category_scores_gemma":[0.0018627021,0.00028162618,0.0018105616,0.00035539002,0.0004099661,0.0010395824,0.0003340814,0.002671143,0.00036895243],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6706421,0.014921088,0.013608073,0.0023092332,0.004432453,0.00038044906,0.00045689405,0.0023966574,0.025610281,0.00045685575,0.008238106,0.25654778],"study_design_scores_gemma":[0.55079824,0.33684683,0.083169095,0.0003698612,0.0032054917,0.0014689855,0.00016592073,0.0026935036,0.0071704118,0.0009837011,0.013017073,0.00011091954],"about_ca_topic_score_codex":0.000603025,"about_ca_topic_score_gemma":0.002115932,"teacher_disagreement_score":0.0043970766,"about_ca_system_score_codex":0.00073683326,"about_ca_system_score_gemma":0.0009790433,"threshold_uncertainty_score":0.023254275},"labels":[],"label_agreement":null},{"id":"W4388627518","doi":"10.25251/skin.7.supp.274","title":"Lebrikizumab Demonstrates Consistent Efficacy at 16 Weeks in Patients With Moderate-to-Severe Atopic Dermatitis Regardless of Baseline Disease Severity","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"Dermira; Eli Lilly and Company","keywords":"Atopic dermatitis; Baseline (sea); Medicine; Disease; Dermatology; Internal medicine; Biology","score_opus":0.009731015848385895,"score_gpt":0.24444169373603114,"score_spread":0.23471067788764524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388627518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95415974,0.032975256,0.0018292419,0.0010986966,0.00023890425,0.0018952318,0.0020862187,0.00017986757,0.0055368436],"genre_scores_gemma":[0.9924971,0.0035855435,0.0009636794,0.0006824816,0.0001267179,0.00044255838,0.00065733213,0.00001284839,0.0010316477],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99911684,0.00045453996,0.00012228925,0.000107703134,0.00013173117,0.00006688562],"domain_scores_gemma":[0.99864846,0.0005366986,0.00044580418,0.00009177283,0.00014554987,0.0001315956],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031319195,0.00034466534,0.0014206283,0.0002360829,0.00021286198,0.0004760723,0.00026126677,0.0004226666,0.003218197],"category_scores_gemma":[0.0027464046,0.00018895863,0.0018077029,0.00026485478,0.00021912236,0.0005192232,0.00025223914,0.0010754629,0.0004710504],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.49518013,0.008733677,0.053031474,0.007529651,0.0065975194,0.00035063145,0.0003340115,0.0011933503,0.04287088,0.00026113412,0.0073879166,0.3765297],"study_design_scores_gemma":[0.29685763,0.35948944,0.29986194,0.0013351862,0.0053216997,0.0015194733,0.00030626307,0.0021788045,0.015832776,0.00072551466,0.016469222,0.00010194575],"about_ca_topic_score_codex":0.0005022871,"about_ca_topic_score_gemma":0.001826907,"teacher_disagreement_score":0.003218197,"about_ca_system_score_codex":0.0003564393,"about_ca_system_score_gemma":0.0006766591,"threshold_uncertainty_score":0.016563416},"labels":[],"label_agreement":null},{"id":"W4388627525","doi":"10.25251/skin.7.supp.283","title":"Tapinarof Cream 1% Once Daily: Significant Efficacy in the Treatment of Atopic Dermatitis in Two Pivotal Phase 3 Trials in Adults and Children Down to 2 Years of Age","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto; Innovaderm (Canada)","funders":"Sanofi Genzyme; Allergan; Genentech; Merz Pharmaceuticals; Galderma; Astellas Pharma; Coherus Biosciences; Glenmark Pharmaceuticals; Castle Biosciences; Pfizer; Biogen; Incyte; Boston Pharmaceuticals; Sun Pharma; Dermira; Les Laboratories Pierre Fabre; DUSA Pharmaceuticals; Meiji Seika Pharma; Kiniksa Pharmaceuticals; Baxalta; Novartis; Celgene; Ablynx; LEO Pharma; Ortho Dermatologics; Gilead Sciences; GlaxoSmithKline; Astellas Pharma US; Amgen; Eli Lilly and Company; Bristol-Myers Squibb; UCB Pharma; Valeant Pharmaceuticals International; Bausch Health; Bayer HealthCare; L'Oreal USA; Sanofi; Regeneron Pharmaceuticals; Abbott Laboratories","keywords":"Atopic dermatitis; Medicine; Pediatrics; Dermatology","score_opus":0.021127848193232216,"score_gpt":0.3429666336027493,"score_spread":0.3218387854095171,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388627525","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9627924,0.029128974,0.0008089748,0.0010963115,0.00042080678,0.0014716301,0.0014371977,0.0001665186,0.0026773845],"genre_scores_gemma":[0.9735997,0.018085102,0.0017841589,0.0012867352,0.00031776662,0.0008084265,0.0016531465,0.000054452186,0.0024105036],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9996244,0.00014982099,0.000023215318,0.000065197826,0.000042072646,0.00009532205],"domain_scores_gemma":[0.9992949,0.0002722719,0.000113614384,0.000033667628,0.000059324037,0.000226157],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019364642,0.0012299663,0.0023654655,0.0003848198,0.0003566495,0.0011493837,0.00065407885,0.0013387889,0.00373613],"category_scores_gemma":[0.0011560633,0.00042344976,0.0019769394,0.00036316155,0.0007097252,0.00085231324,0.0002562631,0.0029997688,0.0004885058],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.73171705,0.01984855,0.0046548746,0.0046096067,0.0029705656,0.0005988699,0.00068249094,0.0012077129,0.042315606,0.00059634773,0.0067369235,0.18406136],"study_design_scores_gemma":[0.7340138,0.23496598,0.018376673,0.00030554342,0.0013153603,0.00064515974,0.00018584993,0.00064444396,0.0035271635,0.00031869477,0.0056381146,0.000063149935],"about_ca_topic_score_codex":0.0012549184,"about_ca_topic_score_gemma":0.004415287,"teacher_disagreement_score":0.00373613,"about_ca_system_score_codex":0.00058074616,"about_ca_system_score_gemma":0.0008191742,"threshold_uncertainty_score":0.012498617},"labels":[],"label_agreement":null},{"id":"W4388627625","doi":"10.25251/skin.7.supp.275","title":"Patient-Level, Visit-by-Visit Data Highlight the Extent of Skin and Itch Improvement in Atopic Dermatitis With Lebrikizumab","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"Eli Lilly and Company","keywords":"Atopic dermatitis; Dermatology; Medicine","score_opus":0.014415897230552317,"score_gpt":0.26140892340517063,"score_spread":0.24699302617461832,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388627625","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98723817,0.0014686246,0.001244326,0.00016739023,0.000014936255,0.0002744544,0.003687152,0.00008062229,0.0058243517],"genre_scores_gemma":[0.9973029,0.00021224274,0.00065037946,0.00010525542,0.000015922547,0.000072530616,0.0011287628,0.000008229513,0.000503749],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979892,0.0008994896,0.00018349035,0.00028625806,0.00053155184,0.00011010403],"domain_scores_gemma":[0.9956151,0.001738568,0.001656743,0.00035597992,0.0003844202,0.00024918886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026562233,0.00023455387,0.0007653597,0.00040791498,0.00027561001,0.0004304352,0.00017952474,0.00031031275,0.0025887499],"category_scores_gemma":[0.0036730184,0.00011731815,0.000915667,0.00073070213,0.00015472146,0.0004516149,0.00033800618,0.0007057203,0.00036833147],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024961308,0.0016208158,0.85811925,0.00067201094,0.0017759042,0.00027085078,0.00029467,0.00087219494,0.009136695,0.00010818857,0.0026386632,0.099529445],"study_design_scores_gemma":[0.00043037144,0.00604842,0.9894769,0.000025104311,0.0004112261,0.00059316,0.000076353426,0.00048278322,0.0012239533,0.00006673161,0.0011506461,0.000014420895],"about_ca_topic_score_codex":0.00060658075,"about_ca_topic_score_gemma":0.002157814,"teacher_disagreement_score":0.0026562233,"about_ca_system_score_codex":0.00025385342,"about_ca_system_score_gemma":0.00023494623,"threshold_uncertainty_score":0.014047623},"labels":[],"label_agreement":null},{"id":"W4388627693","doi":"10.25251/skin.7.supp.281","title":"Rapid and Early Onset of Itch Relief with Tapinarof Cream 1% Once Daily in Two Pivotal Phase 3 Trials in Adults and Children Down to Two Years of Age with Atopic Dermatitis","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"","keywords":"Atopic dermatitis; Medicine; Pediatrics; Dermatology; Age of onset; Internal medicine; Disease","score_opus":0.01153428356414079,"score_gpt":0.30186421601574276,"score_spread":0.290329932451602,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388627693","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9801027,0.012854346,0.0006638732,0.00079870335,0.00030244008,0.0020739858,0.001162051,0.000094657655,0.0019471574],"genre_scores_gemma":[0.98564065,0.0068582348,0.0015816999,0.0009876,0.00018403618,0.0017536673,0.0012706905,0.000032776705,0.0016906827],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.999511,0.00020121665,0.00003026183,0.00007666936,0.0000410824,0.00013972618],"domain_scores_gemma":[0.99925095,0.0002738489,0.000103096936,0.00004637053,0.00005291274,0.00027288092],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002086833,0.0012616807,0.0028041292,0.0003287657,0.0003522537,0.0010301694,0.00062899676,0.001172378,0.004561101],"category_scores_gemma":[0.001434303,0.00047084907,0.0022532663,0.00032344882,0.0007459,0.00079396815,0.00030191577,0.003028811,0.00059668295],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8030179,0.020652963,0.0045557464,0.00349117,0.002261696,0.0005879765,0.0007570763,0.0011532372,0.030818302,0.0005306429,0.005038915,0.12713438],"study_design_scores_gemma":[0.7453317,0.23410723,0.013177715,0.00017970397,0.00076180405,0.00042093504,0.0001500056,0.00032617737,0.001675511,0.00022597157,0.0036044633,0.000038739858],"about_ca_topic_score_codex":0.0010388279,"about_ca_topic_score_gemma":0.004177808,"teacher_disagreement_score":0.004561101,"about_ca_system_score_codex":0.00058885844,"about_ca_system_score_gemma":0.0009046484,"threshold_uncertainty_score":0.015258372},"labels":[],"label_agreement":null},{"id":"W4388627694","doi":"10.25251/skin.7.supp.271","title":"Efficacy and Safety of Lebrikizumab Is Maintained to Two Years in Patients With Moderate-to-Severe Atopic Dermatitis","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"Dermira; Eli Lilly and Company","keywords":"Atopic dermatitis; Dermatology; Medicine","score_opus":0.006471958431611242,"score_gpt":0.2525797674709807,"score_spread":0.24610780903936946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388627694","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99204284,0.0051319627,0.000215235,0.00020268843,0.000039965384,0.00018431475,0.00037999297,0.000026204265,0.0017768332],"genre_scores_gemma":[0.998231,0.0007138121,0.0001557322,0.00024221443,0.000035286535,0.000049341415,0.0002936942,0.0000023700984,0.00027650443],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99925035,0.00028270012,0.000092842194,0.000116970325,0.00015994614,0.000097234435],"domain_scores_gemma":[0.99856913,0.0005025726,0.0004591512,0.00008807105,0.00018421591,0.0001967564],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020499942,0.00022214487,0.0008641927,0.00023084915,0.00032632967,0.0005560658,0.00019478175,0.0003559174,0.001181624],"category_scores_gemma":[0.0020597128,0.00013452042,0.0013966651,0.00029569142,0.00020726935,0.00043816565,0.00024676093,0.0008589791,0.0002695218],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0910978,0.0053111897,0.59020156,0.0016684032,0.0022961951,0.00113494,0.00057110394,0.00052770396,0.013713506,0.00017042737,0.0035615417,0.28974563],"study_design_scores_gemma":[0.00991312,0.061093863,0.9145286,0.0002652304,0.0016144079,0.0024035943,0.00044560697,0.0008686731,0.0033335818,0.00019318736,0.00530009,0.000040023642],"about_ca_topic_score_codex":0.0007787328,"about_ca_topic_score_gemma":0.0017313847,"teacher_disagreement_score":0.0020499942,"about_ca_system_score_codex":0.0004227202,"about_ca_system_score_gemma":0.00047796228,"threshold_uncertainty_score":0.010841548},"labels":[],"label_agreement":null},{"id":"W4390904660","doi":"10.25251/skin.8.supp.323","title":"Laboratory Parameters in Adolescent Patients Aged 12–17 with Moderate-to-Severe Atopic Dermatitis Treated with Tralokinumab Up to Week 52: Results from the Phase 3 ECZTRA 6 Trial","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"LEO Pharma","keywords":"Medicine; Placebo; Internal medicine; Population; Atopic dermatitis; Adverse effect; Randomized controlled trial; Urinalysis; Immunology; Urine; Pathology; Alternative medicine","score_opus":0.017325709700609523,"score_gpt":0.2691248105297688,"score_spread":0.25179910082915924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390904660","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996207,0.0026407517,0.00005600602,0.00008569758,0.00002700027,0.00017571413,0.00029732223,0.0000056970425,0.00050483184],"genre_scores_gemma":[0.9977902,0.0009004409,0.00016086776,0.00016435831,0.000051661344,0.0001567503,0.00055327703,0.000002134929,0.00022034175],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99954873,0.00021165186,0.000040765168,0.00007612668,0.00007124225,0.00005147409],"domain_scores_gemma":[0.999141,0.000186922,0.00033722608,0.000045842695,0.00008758185,0.0002015425],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014112553,0.00039068895,0.0010419505,0.00014662606,0.0002515427,0.00066317886,0.00030426212,0.0005145423,0.0014002763],"category_scores_gemma":[0.0011513222,0.00021447263,0.0009515075,0.00023313162,0.00023914062,0.00037244023,0.00017406701,0.0012542021,0.00021607567],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5469546,0.009888735,0.3610415,0.0012439464,0.0045302943,0.0003658964,0.00029301096,0.0006120154,0.007925962,0.000109240296,0.0028275016,0.06420737],"study_design_scores_gemma":[0.17712408,0.091845706,0.71915585,0.0003054452,0.003765231,0.00118457,0.00021807337,0.0010614571,0.0018319462,0.0001450406,0.0033224674,0.000040051596],"about_ca_topic_score_codex":0.0006333919,"about_ca_topic_score_gemma":0.0015604843,"teacher_disagreement_score":0.0014112553,"about_ca_system_score_codex":0.00040281398,"about_ca_system_score_gemma":0.0004294178,"threshold_uncertainty_score":0.007463515},"labels":[],"label_agreement":null},{"id":"W4390904669","doi":"10.25251/skin.8.supp.313","title":"Efficacy Comparison of Targeted Systemic Monotherapies Including Lebrikizumab for Moderate-to-Severe Atopic Dermatitis: a Network Meta-Analysis","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Eli Lilly and Company","keywords":"Medicine; Atopic dermatitis; Eczema Area and Severity Index; Internal medicine; Psoriasis Area and Severity Index; SCORAD; Placebo; Randomized controlled trial; Dermatology Life Quality Index; Confidence interval; Clinical trial; Meta-analysis; Dermatology; Disease; Psoriasis","score_opus":0.06190123348030831,"score_gpt":0.3494641162330036,"score_spread":0.2875628827526953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390904669","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.029087465,0.96166867,0.0035286124,0.0005372672,0.00050713425,0.0010234228,0.0024858566,0.00014646363,0.0010151002],"genre_scores_gemma":[0.7233047,0.25936446,0.0069257976,0.0016708794,0.00046327952,0.0033800271,0.0036246318,0.00013976406,0.0011264409],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9844297,0.010028596,0.0023293693,0.0018266113,0.0010475835,0.00033816442],"domain_scores_gemma":[0.9807786,0.0148272095,0.0023010168,0.0007756728,0.0009934483,0.00032404895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.019648274,0.003509285,0.018216938,0.005157196,0.0005410559,0.0035300343,0.0025363609,0.002261113,0.004405121],"category_scores_gemma":[0.030612655,0.001430045,0.05713399,0.00465595,0.00062963914,0.002005511,0.0019525404,0.0024407685,0.00045336265],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005028868,0.000022313403,0.002113586,0.05261969,0.93554217,0.00004584871,0.000027659633,0.0008889742,0.00012435735,0.00007714458,0.00025488893,0.0032545386],"study_design_scores_gemma":[0.0015827237,0.00019793709,0.0016967164,0.0022581522,0.99303013,0.000029037557,0.00001547673,0.00046504667,0.000050192546,0.00018667548,0.0004734739,0.0000145447],"about_ca_topic_score_codex":0.005893767,"about_ca_topic_score_gemma":0.008050206,"teacher_disagreement_score":0.019648274,"about_ca_system_score_codex":0.00235253,"about_ca_system_score_gemma":0.0019317286,"threshold_uncertainty_score":0.10391122},"labels":[],"label_agreement":null},{"id":"W4390904672","doi":"10.25251/skin.8.supp.344","title":"Overview of the Safety Profile From Efgartigimod Clinical Trials in Participants With Diverse IgG-Mediated Autoimmune Diseases","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Autoimmune Bullous Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Adverse effect; Placebo; Discontinuation; Medicine; Pemphigus; Dosing; Myasthenia gravis; Clinical trial; Incidence (geometry); Antibody; Immunology; Internal medicine; Pemphigus vulgaris; Pharmacology","score_opus":0.09975937179068395,"score_gpt":0.40087419878286107,"score_spread":0.3011148269921771,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390904672","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10046238,0.8147366,0.019209376,0.010832577,0.0008021437,0.008052257,0.012781998,0.0007401897,0.032382444],"genre_scores_gemma":[0.39699116,0.5293185,0.026560862,0.012529684,0.0025878777,0.010316805,0.01554048,0.0002695265,0.005885162],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99221826,0.0038375712,0.0018645208,0.00060397404,0.0012283449,0.0002473705],"domain_scores_gemma":[0.98468125,0.0075074867,0.004029597,0.00052630913,0.0026356636,0.0006195508],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.018399093,0.00093784614,0.0025083537,0.002016913,0.00054126926,0.002185958,0.0010928015,0.0013640767,0.0038296704],"category_scores_gemma":[0.012709263,0.0004805372,0.0032977753,0.0022817813,0.0005436083,0.0010056128,0.0006894548,0.0016559819,0.0009023847],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028489197,0.00055357884,0.0127766365,0.026074855,0.0059569166,0.00043185885,0.0002996218,0.0026826686,0.015148798,0.0019277937,0.018504152,0.8871541],"study_design_scores_gemma":[0.053898353,0.117000096,0.168009,0.031098465,0.031777292,0.009770717,0.0006987372,0.004042531,0.019400198,0.010795391,0.55309314,0.00041602593],"about_ca_topic_score_codex":0.0005993916,"about_ca_topic_score_gemma":0.0015847017,"teacher_disagreement_score":0.018399093,"about_ca_system_score_codex":0.0013599978,"about_ca_system_score_gemma":0.001838507,"threshold_uncertainty_score":0.09730482},"labels":[],"label_agreement":null},{"id":"W4390904689","doi":"10.25251/skin.8.supp.349","title":"Bimekizumab Efficacy by Prior Biologic Treatment in Patients with Moderate to Severe Hidradenitis Suppurativa: 48-Week Pooled Data from the Randomized, Double-Blind, Placebo-Controlled, Multicenter BE HEARD I and II Phase 3 Trials","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Hidradenitis Suppurativa and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto","funders":"Cilag; Genentech; LEO Pharma; Sanofi Genzyme; Incyte; National Eczema Association; Dermira; UCB Pharma; Sun Pharma; Regeneron Pharmaceuticals; Kiniksa Pharmaceuticals; Celgene; Biogen; Amgen; Pfizer; Galderma; Eli Lilly and Company; Sanofi","keywords":"Hidradenitis suppurativa; Medicine; Double blind; Placebo; Multicenter study; Pooled analysis; Internal medicine; Multicenter trial; Dermatology; Randomized controlled trial; Pathology; Alternative medicine; Meta-analysis; Disease","score_opus":0.05229412364784481,"score_gpt":0.3412784765418269,"score_spread":0.2889843528939821,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390904689","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6789225,0.29995856,0.0023882918,0.0011425882,0.0010407482,0.0051143607,0.005725748,0.00022267993,0.005484577],"genre_scores_gemma":[0.9636315,0.02733359,0.0014649836,0.0010899892,0.0007931224,0.0023059233,0.002579698,0.00002989786,0.0007713095],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9947885,0.003042694,0.00080738426,0.0005380945,0.0005650374,0.000258286],"domain_scores_gemma":[0.99357575,0.0029811303,0.0020611163,0.00048190195,0.00039286556,0.00050716905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00966309,0.0013502571,0.0054115765,0.0008913357,0.0004591575,0.0018557522,0.0007323341,0.0017941761,0.0029650806],"category_scores_gemma":[0.009349682,0.0007022976,0.0082154805,0.0010105695,0.0007436628,0.0014057176,0.0006377955,0.0019976327,0.00032029004],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8762293,0.0017266797,0.010006332,0.01027555,0.056058493,0.00007056024,0.00010390445,0.0007423008,0.0026498693,0.00014205955,0.0016487741,0.040346142],"study_design_scores_gemma":[0.7693917,0.083611526,0.06612289,0.0015186513,0.07015625,0.00032038116,0.000113194124,0.001068361,0.0014778702,0.0005215025,0.0055771866,0.00012047636],"about_ca_topic_score_codex":0.0005894939,"about_ca_topic_score_gemma":0.0016687679,"teacher_disagreement_score":0.00966309,"about_ca_system_score_codex":0.0005414601,"about_ca_system_score_gemma":0.0007543517,"threshold_uncertainty_score":0.05110389},"labels":[],"label_agreement":null},{"id":"W4390904736","doi":"10.25251/skin.8.supp.317","title":"Cost-per-Responder Analysis of Tralokinumab versus Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis in the US and Canada","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; University of Winnipeg; Guenther Dermatology Research Centre","funders":"","keywords":"Dupilumab; Medicine; Atopic dermatitis; Eczema Area and Severity Index; Dermatology","score_opus":0.009187213847154527,"score_gpt":0.25410663789559734,"score_spread":0.2449194240484428,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390904736","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9799641,0.005970876,0.0005268068,0.0007815371,0.000036908452,0.0008080533,0.007362838,0.000023485667,0.0045253537],"genre_scores_gemma":[0.9955557,0.0008076179,0.0006357879,0.00013847911,0.0000114136365,0.00012915257,0.0017715998,0.0000063761286,0.0009438989],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976774,0.000910075,0.000153465,0.00021042055,0.000548035,0.0005007308],"domain_scores_gemma":[0.99664587,0.0012447882,0.00070345355,0.00009983141,0.0008840488,0.00042197033],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028856806,0.0007949731,0.0014808049,0.0016061179,0.0006781733,0.0014101255,0.0013589257,0.0005347538,0.0036438084],"category_scores_gemma":[0.007518063,0.0003904073,0.004637017,0.0026117694,0.0005379249,0.00035404816,0.00086964126,0.001132549,0.00013822521],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15055248,0.0022657742,0.49162745,0.0057800002,0.033305805,0.0009825452,0.0007234074,0.1803246,0.002374477,0.008277558,0.0108530205,0.11293285],"study_design_scores_gemma":[0.019081892,0.013091536,0.73080033,0.0011627817,0.028435687,0.0009862232,0.0020028204,0.1900386,0.0018909475,0.0020524669,0.010130352,0.0003262447],"about_ca_topic_score_codex":0.8669472,"about_ca_topic_score_gemma":0.88398516,"teacher_disagreement_score":0.13305283,"about_ca_system_score_codex":0.046979763,"about_ca_system_score_gemma":0.02336026,"threshold_uncertainty_score":0.34086365},"labels":[],"label_agreement":null},{"id":"W4390905440","doi":"10.25251/skin.8.supp.305","title":"Bimekizumab 3-year Safety and Tolerability in Moderate to Severe Plaque Psoriasis: Long-term Pooled Analysis from Five Phase 3/3b Trials","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cilag; Manchester Biomedical Research Centre; Galderma; Meiji Seika Pharma; Astellas Pharma; Celltrion; Eisai; UCB Pharma; Valeant Pharmaceuticals International; Argenx; Pfizer; Biogen; Incyte; Genentech; Torii Pharmaceutical; Dalhousie University; Castle Biosciences; Sun Pharma; Dermira; Universität zu Lübeck; Regeneron Pharmaceuticals; National Institute for Health and Care Research; Teva Pharmaceutical Industries; Celgene; Yale University; Sanofi; Amgen; LEO Pharma; Ortho Dermatologics; AstraZeneca; Eli Lilly and Company; Samsung; Bristol-Myers Squibb","keywords":"Tolerability; Plaque psoriasis; Medicine; Term (time); Pooled analysis; Psoriasis; Internal medicine; Dermatology; Adverse effect; Meta-analysis; Physics","score_opus":0.01961196471794321,"score_gpt":0.29877832102755414,"score_spread":0.27916635630961095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390905440","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7484044,0.23956634,0.0031997743,0.00061169424,0.0005261979,0.00090738165,0.003856752,0.00022875346,0.0026986785],"genre_scores_gemma":[0.9741088,0.01971397,0.0009768273,0.00074082956,0.00032926153,0.0005860075,0.0026638687,0.00005752192,0.00082295126],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9962231,0.002033426,0.0004065607,0.0005890852,0.00041029646,0.00033751753],"domain_scores_gemma":[0.99530303,0.0020197406,0.001356154,0.00057845516,0.00038643973,0.0003562162],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011917279,0.0019120787,0.007286994,0.0007790375,0.0005294073,0.00248843,0.0009966566,0.0015750088,0.0020415657],"category_scores_gemma":[0.006416902,0.00082238286,0.01391406,0.0011882257,0.000720563,0.0015108421,0.00085349043,0.0028980111,0.00037657865],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.64737093,0.0010103151,0.019886173,0.009931461,0.24312499,0.0001908455,0.00017988165,0.0046659796,0.0051462525,0.00019078671,0.0029570123,0.065345295],"study_design_scores_gemma":[0.3584816,0.074718036,0.15653561,0.0014470067,0.39287165,0.0008362928,0.0003148467,0.0034164374,0.0026701041,0.0012644088,0.007165277,0.0002787265],"about_ca_topic_score_codex":0.0010692944,"about_ca_topic_score_gemma":0.0021716044,"teacher_disagreement_score":0.011917279,"about_ca_system_score_codex":0.0010024928,"about_ca_system_score_gemma":0.0009391695,"threshold_uncertainty_score":0.063025355},"labels":[],"label_agreement":null},{"id":"W4390933271","doi":"10.25251/skin.8.supp.309","title":"Investigator- and Patient-Rated Local Tolerability in Phase 3 Trials of Topical Roflumilast in Patients With Psoriasis, Seborrheic Dermatitis, and Atopic Dermatitis","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dermatrials Research; Probity Medical Research; Queen's University","funders":"","keywords":"Tolerability; Dermatology; Medicine; Atopic dermatitis; Roflumilast; Dermis; Seborrheic dermatitis; Psoriasis; Erythema; Transepidermal water loss; Stratum corneum; Adverse effect; Pharmacology; Pathology; Internal medicine","score_opus":0.011008101040012647,"score_gpt":0.27515729889299273,"score_spread":0.2641491978529801,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390933271","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98472136,0.0076561407,0.0004980271,0.00041298097,0.00012273813,0.0037566286,0.0009312707,0.00004990681,0.0018508214],"genre_scores_gemma":[0.99072623,0.0022037895,0.0008505499,0.0006148587,0.00016668839,0.0038736186,0.00077230006,0.000015458549,0.00077650853],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99680436,0.0021269375,0.00027228575,0.00022958122,0.0003166653,0.00025022638],"domain_scores_gemma":[0.9957415,0.0016369846,0.0013848481,0.00019044195,0.0003661526,0.00068001606],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006864948,0.0012150945,0.0020465564,0.00047415184,0.0007032037,0.0010255567,0.0006818349,0.0011065381,0.0034327805],"category_scores_gemma":[0.005265301,0.00072274794,0.0026753142,0.0005664085,0.000656558,0.0011024416,0.00040219928,0.0027597712,0.00056269893],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.87603545,0.020841578,0.018449044,0.0012256885,0.0032669709,0.00019138896,0.00039639548,0.0010214631,0.011679802,0.00009184817,0.00245251,0.064347856],"study_design_scores_gemma":[0.5738901,0.3708878,0.048499327,0.000084052095,0.0013485469,0.00027175774,0.00013498646,0.0009279864,0.00175394,0.00013202749,0.0020118237,0.000057635152],"about_ca_topic_score_codex":0.00070681336,"about_ca_topic_score_gemma":0.0026170136,"teacher_disagreement_score":0.006864948,"about_ca_system_score_codex":0.00078846654,"about_ca_system_score_gemma":0.0011769785,"threshold_uncertainty_score":0.036305785},"labels":[],"label_agreement":null},{"id":"W4390933743","doi":"10.25251/skin.8.supp.307","title":"Bimekizumab Efficacy Through 3 Years in Patients with Moderate to Severe Plaque Psoriasis: Long-term Pooled Analysis from BE BRIGHT","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"UCB Pharma","keywords":"Medicine; Dermatology Life Quality Index; Plaque psoriasis; Psoriasis Area and Severity Index; Discontinuation; Psoriasis; Adverse effect; Internal medicine; Clinical trial; Dosing; Dermatology","score_opus":0.009459164200808652,"score_gpt":0.24160882969120187,"score_spread":0.23214966549039323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390933743","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.78976595,0.17434007,0.00943446,0.00076154224,0.00044544836,0.0015278475,0.019535724,0.00041261286,0.0037763107],"genre_scores_gemma":[0.9785104,0.0072781816,0.0021458867,0.00048191735,0.00025567054,0.00088490266,0.009139547,0.00007992692,0.0012235998],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9883066,0.0073169493,0.0012528794,0.0015520856,0.001156065,0.00041534498],"domain_scores_gemma":[0.9857196,0.0060286517,0.0035776142,0.0029160606,0.0013191812,0.00043896676],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02786875,0.0013179523,0.005753917,0.0014202232,0.00041521562,0.001627959,0.0008530323,0.0012190929,0.0025575175],"category_scores_gemma":[0.017718704,0.0010171967,0.01520357,0.0016770646,0.0003917879,0.0009921588,0.0013600767,0.0011396984,0.00041435304],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21468455,0.00041364942,0.10357886,0.009901041,0.6216491,0.00028985183,0.00028334337,0.0028932504,0.003528092,0.0002871396,0.0070374575,0.035453696],"study_design_scores_gemma":[0.030068163,0.016419861,0.35910267,0.0012619549,0.57756925,0.00064703217,0.00020215649,0.0032644765,0.0015633611,0.00082564715,0.008879041,0.00019636385],"about_ca_topic_score_codex":0.0019559602,"about_ca_topic_score_gemma":0.0031200915,"teacher_disagreement_score":0.02786875,"about_ca_system_score_codex":0.0005876869,"about_ca_system_score_gemma":0.0011776373,"threshold_uncertainty_score":0.14738578},"labels":[],"label_agreement":null},{"id":"W4391033331","doi":"10.25251/skin.8.supp.356","title":"Apremilast for the Treatment of Psoriasis in Special Areas in Pediatric Patients in the SPROUT Study","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stollery Children's Hospital; University of Alberta","funders":"Amgen","keywords":"Apremilast; Psoriasis; Medicine; Dermatology; Intensive care medicine; Psoriatic arthritis","score_opus":0.016159876219574692,"score_gpt":0.26458304217604783,"score_spread":0.24842316595647315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391033331","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9810651,0.011450249,0.00038059248,0.00062268967,0.00016450942,0.0018376425,0.0021935052,0.000041030788,0.0022446832],"genre_scores_gemma":[0.98115736,0.00915578,0.0018478046,0.0010757283,0.00036867033,0.0026240854,0.0022660892,0.00001528873,0.0014891729],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9995011,0.00028916993,0.00004081068,0.00006375392,0.00005881257,0.00004619977],"domain_scores_gemma":[0.9992124,0.0001326214,0.00029495236,0.000044949586,0.00005323107,0.0002618172],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014766334,0.00060317595,0.0014633121,0.0001428298,0.00024948287,0.00043275376,0.00030878786,0.00048463925,0.0028198657],"category_scores_gemma":[0.0008796268,0.0002746649,0.001765788,0.0002541455,0.00029787296,0.0003718201,0.00026058863,0.0013258555,0.00028709925],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.81765246,0.012165157,0.033827297,0.0034388043,0.0056913965,0.0005442203,0.00029455137,0.0010106827,0.013338569,0.00042314737,0.01004643,0.101567365],"study_design_scores_gemma":[0.71908325,0.17830594,0.08442951,0.00034993546,0.0041845045,0.001054962,0.00011003255,0.00061074924,0.002035485,0.0001979978,0.009607088,0.000030569106],"about_ca_topic_score_codex":0.0005648381,"about_ca_topic_score_gemma":0.0019667072,"teacher_disagreement_score":0.0028198657,"about_ca_system_score_codex":0.00033450112,"about_ca_system_score_gemma":0.0011282933,"threshold_uncertainty_score":0.009433389},"labels":[],"label_agreement":null},{"id":"W4391033341","doi":"10.25251/skin.8.supp.355","title":"Roflumilast Cream 0.3% in Patients With Chronic Plaque Psoriasis: Individual Patient PASI and PASI-HD Responses: Pooled DERMIS-1 and DERMIS-2 Phase 3 Trials","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Probity Medical Research; Queen's University; University of British Columbia","funders":"","keywords":"Dermis; Medicine; Psoriasis; Plaque psoriasis; Dermatology; Pathology","score_opus":0.01578545855335113,"score_gpt":0.2696607524575266,"score_spread":0.25387529390417546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391033341","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9682255,0.022998728,0.0009840004,0.0004813892,0.00012948702,0.0025968126,0.001484472,0.00015893899,0.0029405807],"genre_scores_gemma":[0.9863537,0.0063537485,0.0015695374,0.00070379634,0.00032984288,0.0023672823,0.0014762816,0.000025107975,0.00082066696],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.998928,0.00059249374,0.000097059405,0.00014226523,0.000119683544,0.00012051484],"domain_scores_gemma":[0.99833506,0.00051140296,0.0005434749,0.00013511065,0.00014466698,0.0003302012],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0052921693,0.0011502907,0.0026526747,0.00046859283,0.0003620599,0.0009938736,0.00053824845,0.0011207392,0.0021872781],"category_scores_gemma":[0.0018949133,0.00043411684,0.0028905484,0.00067286403,0.0004148394,0.0007548792,0.00032396574,0.0019860438,0.00052987883],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7221942,0.018632768,0.019152606,0.0031319428,0.009478344,0.00024802657,0.00034911782,0.0017090583,0.03340947,0.00017050153,0.0036183663,0.18790561],"study_design_scores_gemma":[0.5593984,0.36194056,0.06384602,0.00027036614,0.004778141,0.0006583181,0.00008714746,0.0008854073,0.0027217318,0.00031262505,0.0050320006,0.000069259186],"about_ca_topic_score_codex":0.000431975,"about_ca_topic_score_gemma":0.0015525438,"teacher_disagreement_score":0.0052921693,"about_ca_system_score_codex":0.0007046853,"about_ca_system_score_gemma":0.0010147246,"threshold_uncertainty_score":0.027987957},"labels":[],"label_agreement":null},{"id":"W4392906163","doi":"10.25251/skin.8.supp.372","title":"Roflumilast Cream 0.15% in Patients with Atopic Dermatitis: Individual Patient Response from the Pooled INTEGUMENT-1 and INTEGUMENT-2 Phase 3 Trials","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Probity Medical Research; University of British Columbia; Queen's University","funders":"","keywords":"Integument; Roflumilast; Atopic dermatitis; Dermatology; Medicine; Internal medicine; Anatomy","score_opus":0.012671455455694428,"score_gpt":0.2855433712234824,"score_spread":0.27287191576778796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392906163","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9355529,0.054587148,0.0009826774,0.00048324256,0.00014283226,0.003073898,0.0023680774,0.00014456404,0.0026646575],"genre_scores_gemma":[0.985502,0.008262896,0.0011091147,0.0006744774,0.00025105503,0.0017565227,0.0016868601,0.000018035787,0.00073909573],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99775237,0.001384518,0.00029738952,0.00024322949,0.00017766206,0.0001447844],"domain_scores_gemma":[0.99823123,0.00067094836,0.00059764483,0.00013865133,0.00014869132,0.00021283209],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0065046945,0.0012703121,0.0036388624,0.00066966214,0.0003443576,0.0009403985,0.00052710046,0.00097508373,0.0025921133],"category_scores_gemma":[0.0028593796,0.00049178937,0.0037411351,0.0007067598,0.000339246,0.00070800254,0.00044017428,0.001200668,0.0003569099],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7720887,0.004262868,0.021251703,0.005303573,0.026215808,0.0003066373,0.00028361287,0.0012665826,0.016864114,0.00010179932,0.0030121224,0.1490424],"study_design_scores_gemma":[0.6609868,0.20164771,0.0941508,0.0004444206,0.029843664,0.0009922798,0.00013936381,0.0009457138,0.0037774763,0.00026808257,0.006693748,0.00010993245],"about_ca_topic_score_codex":0.00032062945,"about_ca_topic_score_gemma":0.0012950408,"teacher_disagreement_score":0.0065046945,"about_ca_system_score_codex":0.00061921746,"about_ca_system_score_gemma":0.00079010415,"threshold_uncertainty_score":0.034400523},"labels":[],"label_agreement":null},{"id":"W4392906202","doi":"10.25251/skin.8.supp.375","title":"Safety of Tralokinumab for the Treatment of Atopic Dermatitis in Patients with Up to 4.5 Years of Treatment: An Updated Integrated Analysis of Eight Clinical Trials","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"LEO Pharma; European Academy of Dermatology and Venereology","keywords":"Atopic dermatitis; Clinical trial; Medicine; Dermatology; Internal medicine","score_opus":0.03268452212128633,"score_gpt":0.36459071650208064,"score_spread":0.33190619438079433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392906202","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.59202784,0.2512555,0.009604075,0.0033314936,0.0003108044,0.0035925151,0.13122249,0.00063278846,0.0080224285],"genre_scores_gemma":[0.8829176,0.027118696,0.007516749,0.0016504219,0.0003570464,0.0025849387,0.076638676,0.00015663978,0.0010593953],"study_design_codex":"observational","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98243904,0.007644364,0.0027381433,0.0029112184,0.003739842,0.0005272991],"domain_scores_gemma":[0.9520419,0.018922364,0.02063325,0.0035073813,0.00402092,0.00087422517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.028837768,0.0007216037,0.0034066588,0.0018133897,0.00033465485,0.002595491,0.0011645722,0.0007303447,0.0022062904],"category_scores_gemma":[0.024632946,0.00050447177,0.0070325197,0.003093585,0.0003646243,0.0014446321,0.0012814306,0.0015066628,0.00033359093],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09127876,0.0005813,0.34870055,0.03575085,0.20316583,0.0002441755,0.00040118396,0.0073987953,0.006242561,0.0010340092,0.020420952,0.28478107],"study_design_scores_gemma":[0.020108996,0.010401837,0.6961258,0.0052144513,0.20039007,0.0012753331,0.00014225389,0.0053328094,0.0030089223,0.0019369964,0.05587015,0.00019241279],"about_ca_topic_score_codex":0.0011977365,"about_ca_topic_score_gemma":0.0031344213,"teacher_disagreement_score":0.028837768,"about_ca_system_score_codex":0.0014094375,"about_ca_system_score_gemma":0.0020929251,"threshold_uncertainty_score":0.15251052},"labels":[],"label_agreement":null},{"id":"W4392906211","doi":"10.25251/skin.8.supp.376","title":"Continuous Tralokinumab Treatment over 4 Years in Adults with Moderate-to-Severe Atopic Dermatitis Provides Long-Term Disease Control","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"LEO Pharma; European Academy of Dermatology and Venereology","keywords":"Atopic dermatitis; Medicine; Term (time); Disease; Dermatology; Pediatrics; Disease control; Internal medicine; Environmental health; Physics","score_opus":0.005724724808118464,"score_gpt":0.24956516057734138,"score_spread":0.2438404357692229,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392906211","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922449,0.0048525776,0.00040528545,0.00009758008,0.000039212668,0.00016490235,0.001037457,0.000029504692,0.0011285453],"genre_scores_gemma":[0.9980921,0.00056378776,0.00022765252,0.0000886192,0.000038122675,0.000064040614,0.00070417847,0.0000037582122,0.00021768337],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9984432,0.0007314221,0.00013025828,0.00028354215,0.00020760103,0.00020404728],"domain_scores_gemma":[0.9980134,0.00092222996,0.0005773213,0.00020991827,0.0000996098,0.00017754795],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004060596,0.00044452105,0.0010603378,0.00021858359,0.00026753586,0.0006562099,0.00039837026,0.00035725458,0.0031135592],"category_scores_gemma":[0.0036212516,0.00021102768,0.0035105075,0.00033973844,0.00014832603,0.0004588134,0.0003556515,0.00073920697,0.00026457515],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.51987094,0.004260463,0.24919759,0.0021521698,0.020462506,0.00042827587,0.0001959799,0.0056824763,0.014235661,0.00020497837,0.0032049888,0.18010397],"study_design_scores_gemma":[0.034111723,0.102501124,0.8309365,0.0002654337,0.016457507,0.0009253209,0.00012812017,0.0063300123,0.0033246884,0.00026826048,0.0046908655,0.000060523085],"about_ca_topic_score_codex":0.0013044259,"about_ca_topic_score_gemma":0.0038189993,"teacher_disagreement_score":0.004060596,"about_ca_system_score_codex":0.00044436514,"about_ca_system_score_gemma":0.0006520182,"threshold_uncertainty_score":0.021474719},"labels":[],"label_agreement":null},{"id":"W4392906239","doi":"10.25251/skin.8.supp.391","title":"Maintenance Acne Treatment With Topical Tazarotene after Oral Isotretinoin: Overview and Case Reports","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Acne and Rosacea Treatments and Effects","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bausch Health; Ortho Dermatologics","keywords":"Tazarotene; Acne; Isotretinoin; Medicine; Dermatology; Lotion; Adapalene; Retinoid; Hyperpigmentation; Benzoyl peroxide; Pharmacology","score_opus":0.012655390998048929,"score_gpt":0.2815169935818741,"score_spread":0.2688616025838252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392906239","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.22667748,0.72978836,0.009931539,0.0064011784,0.0014625451,0.0003067625,0.000493697,0.0004255784,0.024512792],"genre_scores_gemma":[0.78766584,0.1966898,0.0036737293,0.003073259,0.003698354,0.0000705995,0.00054063165,0.00006389664,0.0045239385],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9994987,0.00006341504,0.00011847692,0.00012702224,0.000095354444,0.000097047916],"domain_scores_gemma":[0.99954814,0.000115906245,0.00016498928,0.00003219693,0.00004809331,0.00009054386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024586267,0.0013544081,0.0009875073,0.0024919608,0.0012008579,0.0011761743,0.0010116411,0.0024901268,0.002165117],"category_scores_gemma":[0.000853717,0.00046085735,0.000911359,0.0022598354,0.0009621415,0.0018360434,0.00085030316,0.0027341142,0.00079454185],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000087103974,0.00011924542,0.0112368455,0.0009923936,0.000094964984,0.93470156,0.0004610954,0.00025563565,0.0035888972,0.00071635057,0.0042199395,0.04352604],"study_design_scores_gemma":[0.0000053044496,0.000027001077,0.0019195987,0.00010660187,0.000036862264,0.9915563,0.000099236204,0.00008431888,0.00030940285,0.00016384675,0.00568023,0.000011259094],"about_ca_topic_score_codex":0.0013908313,"about_ca_topic_score_gemma":0.001989866,"teacher_disagreement_score":0.0024919608,"about_ca_system_score_codex":0.00069676136,"about_ca_system_score_gemma":0.00058153213,"threshold_uncertainty_score":0.007243037},"labels":[],"label_agreement":null},{"id":"W4392912933","doi":"10.25251/skin.8.supp.400","title":"Concealing Meets Healing in the Treatment of Toenail Onychomycosis: A Review of Concurrent Nail Polish Use With Topical Efinaconazole 10% Solution","year":2024,"lang":"en","type":"review","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Nail Diseases and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bausch Health; Ortho Dermatologics","keywords":"Dermatology; Medicine; Nail (fastener); Nail matrix; Clinical efficacy; Clinical study; Nail plate; Cure rate; Dentistry; Surgery","score_opus":0.06807302359266415,"score_gpt":0.3842191934297035,"score_spread":0.31614616983703936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392912933","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00027807415,0.9994673,0.000027961503,0.000055758956,0.00003628325,0.000007744691,0.000010870744,0.0000015504795,0.000114402974],"genre_scores_gemma":[0.0031040122,0.9965076,0.00013771749,0.00012599293,0.000045499164,0.0000131974675,0.000022862363,0.0000013687363,0.0000417441],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99856573,0.00038556167,0.00054963864,0.00015642979,0.00030047193,0.00004220095],"domain_scores_gemma":[0.99462944,0.0038598492,0.0008845884,0.0000616553,0.00046593402,0.000098414086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002212784,0.0006316849,0.0025257813,0.0033656706,0.00029412957,0.0010719034,0.0011929935,0.0011401012,0.0020446184],"category_scores_gemma":[0.00464861,0.00045140294,0.002159695,0.0032017678,0.00062893174,0.0013664166,0.00054103066,0.0007862617,0.00025358202],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004207706,0.000101512676,0.0005804654,0.43144143,0.0013343139,0.0002392456,0.00020938927,0.00015321876,0.00084403314,0.00049078005,0.0052547115,0.5589301],"study_design_scores_gemma":[0.00062390586,0.0024294574,0.012879788,0.5743508,0.020812193,0.0073377495,0.00084243395,0.0004948722,0.0015662309,0.00093026046,0.3776255,0.00010671348],"about_ca_topic_score_codex":0.0026599271,"about_ca_topic_score_gemma":0.0052620578,"teacher_disagreement_score":0.0033656706,"about_ca_system_score_codex":0.0006482148,"about_ca_system_score_gemma":0.0020792068,"threshold_uncertainty_score":0.011702418},"labels":[],"label_agreement":null},{"id":"W4392926895","doi":"10.25251/skin.8.supp.366","title":"Deucravacitinib in Plaque Psoriasis: 3-year Safety and Efficacy Results from the Phase 3 POETYK PSO-1 and PSO-2 Trials","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"National Institute for Health and Care Research; Manchester Biomedical Research Centre; Dermira; Bristol-Myers Squibb","keywords":"Plaque psoriasis; Psoriasis; Medicine; Particle swarm optimization; Phase (matter); Dermatology; Mathematics; Physics; Mathematical optimization","score_opus":0.02849553644203048,"score_gpt":0.301655482586512,"score_spread":0.2731599461444815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392926895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9629658,0.022620643,0.0013046312,0.00089461636,0.00014202774,0.0013826619,0.0051497133,0.00016269994,0.0053771515],"genre_scores_gemma":[0.98301655,0.0056166914,0.00084211444,0.0008831737,0.00019913269,0.0009591227,0.0071867113,0.00004020303,0.0012563711],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99792176,0.0010005169,0.00015798156,0.00033781215,0.00035665274,0.0002252633],"domain_scores_gemma":[0.99661213,0.0007991969,0.0012047217,0.00038804446,0.00041765106,0.0005782833],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006719319,0.00095207966,0.0015833541,0.00033522226,0.00051892037,0.0014455636,0.0006715482,0.001141084,0.002145008],"category_scores_gemma":[0.0039090193,0.0003413489,0.0030963684,0.00051008817,0.00042107987,0.0011652107,0.00047502224,0.0027580867,0.0005928128],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6385076,0.013423661,0.049267333,0.0028236245,0.014835773,0.0002986647,0.0005067062,0.0069434405,0.01416166,0.00052447285,0.01747338,0.24123366],"study_design_scores_gemma":[0.4559577,0.19718507,0.29280657,0.00071851985,0.0166272,0.001739903,0.00028416992,0.0071150837,0.0072236126,0.0022965306,0.017815879,0.00022969721],"about_ca_topic_score_codex":0.0008335873,"about_ca_topic_score_gemma":0.0019491062,"teacher_disagreement_score":0.006719319,"about_ca_system_score_codex":0.000739788,"about_ca_system_score_gemma":0.0010399291,"threshold_uncertainty_score":0.035535574},"labels":[],"label_agreement":null},{"id":"W4392927062","doi":"10.25251/skin.8.supp.364","title":"Deucravacitinib in Moderate Plaque Psoriasis: Efficacy in the Phase 3 POETYK PSO-1 and PSO-2 Trials","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"Bristol-Myers Squibb","keywords":"Plaque psoriasis; Psoriasis; Medicine; Dermatology","score_opus":0.03951776206723881,"score_gpt":0.32725086810167403,"score_spread":0.28773310603443525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392927062","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9360648,0.04072197,0.0012074794,0.0017432316,0.00028644476,0.004090415,0.0031891305,0.000302242,0.012394268],"genre_scores_gemma":[0.980891,0.008351725,0.0014094249,0.0014075349,0.0002903704,0.0024904187,0.003182091,0.00003899114,0.0019385102],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99924445,0.00039122402,0.0000579261,0.00012010112,0.00009707958,0.00008929576],"domain_scores_gemma":[0.999283,0.00016022555,0.00020456061,0.00005300009,0.000082103965,0.00021717232],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024577978,0.00072308717,0.0014692491,0.00022327987,0.0004223911,0.0010684986,0.00047926276,0.0008764718,0.0031108872],"category_scores_gemma":[0.0012422825,0.00023338028,0.0017009047,0.00030978158,0.00035787324,0.0006208254,0.00033712422,0.0019434458,0.00044079995],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6796125,0.011898042,0.0085619595,0.006675212,0.0056640524,0.0004126559,0.00036736275,0.0017503046,0.043020748,0.00084121607,0.015773002,0.22542287],"study_design_scores_gemma":[0.759581,0.16120592,0.042737063,0.00074236037,0.0033863024,0.0013833181,0.00009838588,0.0013923864,0.00706642,0.0011764972,0.02114806,0.00008218222],"about_ca_topic_score_codex":0.0005892649,"about_ca_topic_score_gemma":0.002316339,"teacher_disagreement_score":0.0031108872,"about_ca_system_score_codex":0.00061772764,"about_ca_system_score_gemma":0.00097040355,"threshold_uncertainty_score":0.012998223},"labels":[],"label_agreement":null},{"id":"W4392928122","doi":"10.25251/skin.8.supp.373","title":"Association Between Early Clinical Responses and Long-Term Outcomes With Ruxolitinib Cream Treatment in Mild to Moderate Atopic Dermatitis","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health; University of British Columbia; Lynde Centre for Dermatology; Probity Medical Research; University of Calgary","funders":"Incyte","keywords":"Ruxolitinib; Atopic dermatitis; Medicine; Dermatology; Term (time); Dupilumab; Internal medicine; Myelofibrosis","score_opus":0.034762432166310454,"score_gpt":0.3578718123601323,"score_spread":0.32310938019382185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392928122","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99713,0.002164702,0.00007252551,0.0000310573,0.000010485754,0.0000346899,0.00013244008,0.000002899698,0.00042122736],"genre_scores_gemma":[0.9991986,0.00023663828,0.000047833233,0.000032825832,0.00001976935,0.00003079825,0.0001821211,8.478332e-7,0.00025053453],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99899894,0.00053136755,0.00010147345,0.00011275425,0.00012100942,0.0001344292],"domain_scores_gemma":[0.9969572,0.0012097218,0.0011649735,0.00015520037,0.00015972341,0.00035327266],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003074757,0.00024357726,0.00060393644,0.000217113,0.00018301183,0.00040441594,0.00025358467,0.00044025132,0.0011121713],"category_scores_gemma":[0.0023310427,0.00012524003,0.0010917245,0.00018928539,0.00017083011,0.00042044398,0.00022206311,0.00071837817,0.00012190729],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29640004,0.0046999096,0.59628934,0.00093355466,0.0047706417,0.00042546954,0.00021400522,0.0014923717,0.012190487,0.00013613056,0.00069818593,0.08174973],"study_design_scores_gemma":[0.0038707952,0.03779206,0.95388806,0.000061027742,0.0010723147,0.00025698688,0.000058660036,0.0006715793,0.0015298527,0.00009235669,0.0006826768,0.00002353453],"about_ca_topic_score_codex":0.00025870968,"about_ca_topic_score_gemma":0.0007252939,"teacher_disagreement_score":0.003074757,"about_ca_system_score_codex":0.000244085,"about_ca_system_score_gemma":0.00018083607,"threshold_uncertainty_score":0.016261041},"labels":[],"label_agreement":null},{"id":"W4392928286","doi":"10.25251/skin.8.supp.382","title":"Early Oligoarticular Psoriatic Arthritis Responds to Treatment With Apremilast: Week 16 Results From FOREMOST - a Phase 4 Randomized Controlled Trial","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Toronto Western Hospital","funders":"Pfizer; Amgen","keywords":"Apremilast; Psoriatic arthritis; Medicine; Randomized controlled trial; Dermatology; Internal medicine; Arthritis","score_opus":0.012300118375394525,"score_gpt":0.28083346937827974,"score_spread":0.2685333510028852,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392928286","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9415735,0.03372084,0.0013432853,0.0026676396,0.0010680342,0.010078187,0.0034214433,0.0003123132,0.005814795],"genre_scores_gemma":[0.9535117,0.011784873,0.0058891135,0.003682757,0.001410622,0.013327414,0.002323953,0.00007300229,0.007996616],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9984316,0.0009004078,0.00013993075,0.0001960717,0.0001516595,0.00018025578],"domain_scores_gemma":[0.9965655,0.0011721643,0.001041307,0.000298527,0.00033011264,0.0005924467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004214055,0.00137383,0.0035976223,0.0005544836,0.00050956046,0.0018076263,0.0011175568,0.002407638,0.009065038],"category_scores_gemma":[0.0036176338,0.0005804847,0.0041494365,0.00043926286,0.0010017696,0.0014549411,0.0005985013,0.0028058218,0.0009979326],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.944674,0.0081778215,0.0010909577,0.0048585576,0.003567801,0.000079214595,0.00009862864,0.00033515782,0.0039859265,0.00013230875,0.00248066,0.030518934],"study_design_scores_gemma":[0.935227,0.057432327,0.002644394,0.0002740364,0.0018307727,0.00008467017,0.000029457473,0.00028055775,0.00052103447,0.00017269386,0.001468224,0.00003498048],"about_ca_topic_score_codex":0.00033778488,"about_ca_topic_score_gemma":0.0010670562,"teacher_disagreement_score":0.009065038,"about_ca_system_score_codex":0.0005997773,"about_ca_system_score_gemma":0.0011299644,"threshold_uncertainty_score":0.030325532},"labels":[],"label_agreement":null},{"id":"W4392928302","doi":"10.25251/skin.8.supp.361","title":"Measuring GPPGA, Pain, Symptom, and Quality of Life Index Scores in Untreated Generalized Pustular Psoriasis: Results from the Placebo Group of the Effisayil-2 Trial","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"Pfizer Pharmaceuticals; Sanofi Genzyme; Regeneron Pharmaceuticals; Meiji Seika Pharma; Eli Lilly and Company; Bristol-Myers Squibb; LEO Pharma; Incyte; Amgen","keywords":"Placebo; Psoriasis; Dermatology Life Quality Index; Medicine; Generalized pustular psoriasis; Quality of life (healthcare); Placebo group; Index (typography); Physical therapy; Dermatology; Alternative medicine; Pathology","score_opus":0.03282687181193359,"score_gpt":0.25589317684163365,"score_spread":0.22306630502970007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392928302","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883486,0.0071594734,0.0002447845,0.00042402762,0.0001456914,0.0008893906,0.0009290569,0.00003118405,0.0018277831],"genre_scores_gemma":[0.9932105,0.0020895102,0.00050770934,0.0004998308,0.0003073325,0.0013878234,0.001145733,0.000009150365,0.0008424127],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99850154,0.0009634236,0.00008821901,0.00018707586,0.00013494836,0.0001248523],"domain_scores_gemma":[0.99864894,0.00037838824,0.00043039545,0.00014575511,0.00008386911,0.00031276047],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034573805,0.0011697849,0.0022999144,0.00025947965,0.00032565524,0.0010581445,0.0006693827,0.0014946361,0.0035081445],"category_scores_gemma":[0.0022642296,0.00047503805,0.0021992181,0.00033303103,0.00084939576,0.0009523297,0.0004302658,0.0023724798,0.0004549454],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95758724,0.004469832,0.0057433965,0.0007562047,0.002181706,0.00006736824,0.00010044684,0.00028214545,0.003129813,0.000099047094,0.00085101963,0.024731738],"study_design_scores_gemma":[0.867788,0.108464025,0.020510457,0.00009061026,0.0013051137,0.00012955291,0.000048384263,0.00028072626,0.00041165433,0.00019734312,0.0007526185,0.000021546364],"about_ca_topic_score_codex":0.00034730192,"about_ca_topic_score_gemma":0.00057644554,"teacher_disagreement_score":0.0035081445,"about_ca_system_score_codex":0.00040932742,"about_ca_system_score_gemma":0.00059852016,"threshold_uncertainty_score":0.018284619},"labels":[],"label_agreement":null},{"id":"W4392928363","doi":"10.25251/skin.8.supp.396","title":"Bimekizumab Response Maintenance to 48 Weeks in Patients with Moderate to Severe Hidradenitis Suppurativa: Pooled Responder Analysis from the Phase 3, Double-Blind, Placebo-Controlled, Randomized Clinical Trials BE HEARD I and II","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Hidradenitis Suppurativa and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; UCB Pharma; Bausch Health; Swedish Orphan Biovitrum; National and Kapodistrian University of Athens; Insmed; Eisai; Celltrion; XBiotech; Celgene; Amgen; Pfizer; Eli Lilly and Company; Galderma; Incyte","keywords":"Hidradenitis suppurativa; Medicine; Placebo; Double blind; Randomized controlled trial; Clinical trial; Single blind; Internal medicine; Pooled analysis; Meta-analysis; Alternative medicine; Disease; Pathology","score_opus":0.041108410531418754,"score_gpt":0.3781181349803364,"score_spread":0.33700972444891764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392928363","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8068239,0.17069323,0.0035567398,0.0024617098,0.0026742015,0.0050353464,0.0035071853,0.00041508386,0.00483264],"genre_scores_gemma":[0.971751,0.016825726,0.0018666139,0.0025340933,0.0011233347,0.0023061943,0.0013356237,0.00005183862,0.0022056494],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9968706,0.0021315604,0.00029340782,0.0003266437,0.00016055987,0.00021726068],"domain_scores_gemma":[0.99752766,0.0011238726,0.00072528457,0.00021842343,0.00013082847,0.00027404225],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006430838,0.0014537735,0.005844774,0.00064901775,0.00039533994,0.0015307706,0.00075798784,0.0019424398,0.0046495567],"category_scores_gemma":[0.00501173,0.0008125327,0.0077208607,0.0006016716,0.0008347724,0.001277048,0.0005043254,0.0026892577,0.0006298741],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9576045,0.00075738435,0.0011434319,0.004182656,0.013119974,0.00004163261,0.000047202342,0.0003353811,0.0015751764,0.000072509814,0.0012023754,0.019917622],"study_design_scores_gemma":[0.96078247,0.021566683,0.0062510977,0.00028570934,0.009364878,0.000047349822,0.000042192194,0.00030644273,0.00029188537,0.00017552692,0.00085720693,0.000028590463],"about_ca_topic_score_codex":0.0007802983,"about_ca_topic_score_gemma":0.0017186718,"teacher_disagreement_score":0.006430838,"about_ca_system_score_codex":0.0006226748,"about_ca_system_score_gemma":0.00075779104,"threshold_uncertainty_score":0.034009933},"labels":[],"label_agreement":null},{"id":"W4400930425","doi":"10.25251/skin.8.4.7","title":"Pain Management of Refractory Hidradenitis Suppurativa: Case Report","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Hidradenitis Suppurativa and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Hidradenitis suppurativa; Refractory (planetary science); Medicine; Dermatology; Pain management; Physical therapy; Internal medicine; Materials science; Disease","score_opus":0.014687235114499134,"score_gpt":0.2967603647936037,"score_spread":0.28207312967910453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400930425","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.898081,0.054656282,0.00717123,0.0075193625,0.0010382892,0.00055889203,0.00041914306,0.00030188865,0.030253895],"genre_scores_gemma":[0.98464775,0.0067474805,0.0020608564,0.0021872534,0.0019238298,0.0000676237,0.00012587302,0.000034700617,0.0022046247],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99891615,0.00018458898,0.00013031698,0.0002078004,0.0001794003,0.0003817772],"domain_scores_gemma":[0.9982857,0.00045256838,0.00056155084,0.0001256988,0.00010835676,0.00046596932],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049562356,0.0018708736,0.0013166192,0.0017931149,0.0028289761,0.002005361,0.0011450796,0.004145606,0.0032760329],"category_scores_gemma":[0.0031813052,0.0008342961,0.0010905416,0.0016473462,0.0015682224,0.0021758967,0.001726584,0.0030137429,0.000956257],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018657696,0.000037289938,0.0032129663,0.00007171459,0.000008978813,0.9944687,0.00014339697,0.000048424663,0.0002770964,0.00010976816,0.00041366322,0.0011893907],"study_design_scores_gemma":[0.000008695812,0.000025522775,0.0010217818,0.000024250705,0.000007955925,0.9978764,0.000114855604,0.000084681305,0.00010226514,0.00007105587,0.00065818545,0.0000043665405],"about_ca_topic_score_codex":0.0013748542,"about_ca_topic_score_gemma":0.0017856685,"teacher_disagreement_score":0.004145606,"about_ca_system_score_codex":0.0009216996,"about_ca_system_score_gemma":0.000840058,"threshold_uncertainty_score":0.010959387},"labels":[],"label_agreement":null},{"id":"W4400930442","doi":"10.25251/skin.8.supp.407","title":"Deucravacitinib in Plaque Psoriasis: Maintenance of Response Over 4 Years in the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; SKiN Health; Queen's University","funders":"","keywords":"Medicine; Psoriasis Area and Severity Index; Plaque psoriasis; Psoriasis; Placebo; Internal medicine; Clinical endpoint; Randomized controlled trial; Dermatology","score_opus":0.026229748451744,"score_gpt":0.3182034868212671,"score_spread":0.2919737383695231,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400930442","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989926,0.007085099,0.0003211562,0.00024812625,0.000035430643,0.00034840885,0.00047302037,0.00004479383,0.0015179353],"genre_scores_gemma":[0.9959436,0.0015369081,0.00039525056,0.00022701564,0.0000504759,0.00028368,0.0010293564,0.000008366741,0.00052540645],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9989955,0.00048343468,0.00008050098,0.00014874373,0.00015502682,0.00013677806],"domain_scores_gemma":[0.998939,0.00024302784,0.00033138803,0.000111794565,0.000107860134,0.00026693425],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040511545,0.0004980042,0.0012755522,0.00019472808,0.00044391464,0.00088946195,0.00041418284,0.0006696318,0.0009988882],"category_scores_gemma":[0.001771802,0.0001981689,0.0012043162,0.0003107444,0.00028926207,0.00071901997,0.00029180347,0.0017523167,0.0002505164],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5018314,0.013340886,0.05665424,0.0015317316,0.0059122965,0.000386707,0.0006946982,0.0041393978,0.02856989,0.00040754947,0.0070015145,0.37952965],"study_design_scores_gemma":[0.2749471,0.34527913,0.33964956,0.00031999062,0.0055257822,0.001867559,0.00026728827,0.0051806164,0.01264175,0.0010036614,0.013183594,0.00013406441],"about_ca_topic_score_codex":0.0007352722,"about_ca_topic_score_gemma":0.0024039345,"teacher_disagreement_score":0.0040511545,"about_ca_system_score_codex":0.00073706993,"about_ca_system_score_gemma":0.0007904789,"threshold_uncertainty_score":0.02142477},"labels":[],"label_agreement":null},{"id":"W4400930553","doi":"10.25251/skin.8.supp.412","title":"Stability of Long-Term Therapeutic Responses to Tralokinumab in Adults with Moderate-to-Severe Atopic Dermatitis","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health; University of British Columbia","funders":"","keywords":"Medicine; Atopic dermatitis; Eczema Area and Severity Index; Post-hoc analysis; Clinical trial; Quality of life (healthcare); Dupilumab; Clinical endpoint; Pediatrics; Internal medicine; Dermatology","score_opus":0.014108445610969777,"score_gpt":0.2828125700735875,"score_spread":0.2687041244626177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400930553","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987863,0.0004908823,0.00008296431,0.000017023976,0.000003155077,0.00003248263,0.0003287131,0.0000024267663,0.00025605937],"genre_scores_gemma":[0.9993036,0.000083871455,0.00006689289,0.00002871195,0.000015105004,0.00002845663,0.00040976945,9.4662136e-7,0.000062679894],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987073,0.00037903377,0.00022789495,0.00030401256,0.00023909987,0.00014269791],"domain_scores_gemma":[0.9973047,0.000956746,0.0011336491,0.00015693273,0.0001904423,0.00025760036],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018917801,0.0002493685,0.00062928547,0.0005903935,0.00041853805,0.0005647261,0.00032778174,0.0004203297,0.0022370014],"category_scores_gemma":[0.0035464363,0.00017366333,0.00071266637,0.00054233434,0.0002763033,0.0004327866,0.00040909354,0.00052830915,0.0002487672],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007011644,0.00017500171,0.984444,0.00007473878,0.00028790455,0.00010108646,0.00009617722,0.000096545446,0.00052822207,0.000022337414,0.00018417773,0.0069780704],"study_design_scores_gemma":[0.00026052532,0.0019495342,0.99608433,0.000014895002,0.00016881138,0.0005498775,0.00008636922,0.00031823874,0.00017467522,0.000027537473,0.00035954142,0.0000057001284],"about_ca_topic_score_codex":0.0005906245,"about_ca_topic_score_gemma":0.0009449405,"teacher_disagreement_score":0.0022370014,"about_ca_system_score_codex":0.0002850819,"about_ca_system_score_gemma":0.00027649195,"threshold_uncertainty_score":0.010004818},"labels":[],"label_agreement":null},{"id":"W4400930587","doi":"10.25251/skin.8.supp.404","title":"Bimekizumab Safety and Tolerability in Moderate to Severe Plaque Psoriasis: Pooled Analysis from Up to 4 Years of Treatment in 5 Phase 3/3b Clinical Trials","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"UCB Pharma; Eisai; Torii Pharmaceutical; Amgen","keywords":"Tolerability; Plaque psoriasis; Medicine; Pooled analysis; Clinical trial; Psoriasis; Internal medicine; Dermatology; Adverse effect; Meta-analysis","score_opus":0.04438970228239314,"score_gpt":0.36332345056434967,"score_spread":0.31893374828195653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400930587","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.50004065,0.46979982,0.0064069103,0.000808954,0.0005493623,0.0036277943,0.013222428,0.0004478175,0.005096242],"genre_scores_gemma":[0.9420878,0.042705175,0.0024560269,0.0009000173,0.0005151928,0.003377282,0.0069640363,0.000107202126,0.0008873593],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9839839,0.009702211,0.0021452494,0.0018565949,0.0017535819,0.0005583937],"domain_scores_gemma":[0.98220426,0.00839549,0.006404351,0.0014110388,0.0009913318,0.00059340155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.029552406,0.0019479564,0.00833553,0.0017329976,0.000550631,0.0023563663,0.0009895118,0.001647278,0.0032483276],"category_scores_gemma":[0.020637516,0.001080711,0.019515412,0.0026346557,0.00071861676,0.0015061249,0.0012448154,0.001637299,0.00038466687],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36873505,0.0006438054,0.05173836,0.026285188,0.47843677,0.00022573146,0.0001919098,0.0044425875,0.0037688578,0.00019267452,0.0041269474,0.061212085],"study_design_scores_gemma":[0.14966767,0.03870286,0.22710519,0.0033112979,0.56554335,0.00089528965,0.00015167608,0.0023724705,0.0014646759,0.0011997255,0.00937254,0.00021331514],"about_ca_topic_score_codex":0.00093621947,"about_ca_topic_score_gemma":0.0019191715,"teacher_disagreement_score":0.029552406,"about_ca_system_score_codex":0.0008087939,"about_ca_system_score_gemma":0.0014790988,"threshold_uncertainty_score":0.15628988},"labels":[],"label_agreement":null},{"id":"W4400930719","doi":"10.25251/skin.8.supp.409","title":"Spesolimab Rapidly Improves Quality of Life in Patients with Generalized Pustular Psoriasis, as per Dermatology Life Quality Index Scores: Data from the Effisayil 2 Trial","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Dermatology Life Quality Index; Placebo; Medicine; Psoriasis Area and Severity Index; Psoriasis; Clinical endpoint; Internal medicine; Quality of life (healthcare); Randomized controlled trial; Dermatology; Pathology","score_opus":0.030731104938953067,"score_gpt":0.2982840636318148,"score_spread":0.2675529586928617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400930719","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9490088,0.039194126,0.00048476795,0.0011999585,0.0002863892,0.001192513,0.0043728314,0.00008052073,0.004180087],"genre_scores_gemma":[0.9838778,0.0075034285,0.0006595732,0.0010469203,0.00029688975,0.0011554991,0.004128413,0.0000133047615,0.0013181982],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99886227,0.00068830774,0.00009754396,0.00011395989,0.00012479503,0.00011316302],"domain_scores_gemma":[0.9989115,0.0003347442,0.00037561465,0.00008784209,0.00008104805,0.00020919507],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003215576,0.001073196,0.0019101677,0.00031885473,0.0002338166,0.0008846405,0.0004814163,0.0009099325,0.0035034835],"category_scores_gemma":[0.0016438994,0.00026587516,0.0025226837,0.00048831984,0.0005137824,0.00061430567,0.00036692258,0.0017960911,0.00046061733],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8579201,0.0041265707,0.014675707,0.0044704666,0.009086342,0.00022170857,0.00014084566,0.0017078371,0.008147943,0.00022702859,0.00695307,0.09232241],"study_design_scores_gemma":[0.8487677,0.09096892,0.049804434,0.00032595376,0.0036868888,0.00043581089,0.000068677495,0.000803094,0.0009683505,0.00035303683,0.0037733684,0.00004381607],"about_ca_topic_score_codex":0.0002864294,"about_ca_topic_score_gemma":0.0009488355,"teacher_disagreement_score":0.0035034835,"about_ca_system_score_codex":0.00033263693,"about_ca_system_score_gemma":0.0005106737,"threshold_uncertainty_score":0.017005801},"labels":[],"label_agreement":null},{"id":"W4400930743","doi":"10.25251/skin.8.supp.406","title":"Deucravacitinib in Plaque Psoriasis: 4-Year Safety and Efficacy Results From the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"National Institute for Health and Care Research; Manchester Biomedical Research Centre; Dermira; Bristol-Myers Squibb","keywords":"Plaque psoriasis; Psoriasis; Medicine; Computer science; Dermatology","score_opus":0.02818014222467983,"score_gpt":0.30170471001867927,"score_spread":0.2735245677939994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400930743","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9683244,0.023307268,0.00075154804,0.0005350903,0.00009140846,0.00070336385,0.0024690407,0.00010870013,0.0037091158],"genre_scores_gemma":[0.9863175,0.006004895,0.0005965408,0.00059560256,0.00015324226,0.00053749303,0.0046451096,0.00002265853,0.0011270012],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99842656,0.00070137985,0.00014381425,0.00022413,0.0002953467,0.00020893365],"domain_scores_gemma":[0.99725205,0.0006340016,0.0009617033,0.0002936528,0.00035239678,0.0005061474],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00545247,0.00092784857,0.0014434955,0.00039003624,0.0004831209,0.0013796568,0.00057562115,0.0011168614,0.0014797505],"category_scores_gemma":[0.0031758167,0.0002958076,0.0025006104,0.00041416526,0.0003997899,0.0010636795,0.00045877622,0.0022244577,0.00044073336],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.56311756,0.016824221,0.057127103,0.002806015,0.01326908,0.00040917553,0.0005931089,0.008189062,0.025771184,0.00044002157,0.013688063,0.2977654],"study_design_scores_gemma":[0.3183641,0.30785564,0.32347095,0.0005636845,0.01365673,0.0018994431,0.00029581424,0.0053847046,0.01032321,0.0011566922,0.016803995,0.00022495842],"about_ca_topic_score_codex":0.0008510817,"about_ca_topic_score_gemma":0.0018154614,"teacher_disagreement_score":0.00545247,"about_ca_system_score_codex":0.0007940336,"about_ca_system_score_gemma":0.00090594526,"threshold_uncertainty_score":0.028835773},"labels":[],"label_agreement":null},{"id":"W4404455102","doi":"10.25251/skin.8.supp.485","title":"Safety and Efficacy of Photodynamic Therapy with ALA 10% Topical Gel Activated by Red Light versus ALA 20% Topical Solution Activated by Blue Light for the Treatment of Actinic Keratosis on the Upper Extremities: A Blinded Randomized Study","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Nonmelanoma Skin Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Covenant Health","funders":"","keywords":"Actinic keratosis; Photodynamic therapy; Dermatology; Medicine; Red light; Blue light; Keratosis; Chemistry; Internal medicine; Materials science; Organic chemistry; Biology","score_opus":0.018438164768994725,"score_gpt":0.2954829230626983,"score_spread":0.27704475829370356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404455102","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99038005,0.0016244629,0.00078218954,0.00018314882,0.00038908052,0.005354063,0.0003829711,0.00005739252,0.00084662775],"genre_scores_gemma":[0.98705626,0.0013250231,0.0020886573,0.00043003852,0.00081921846,0.0063824807,0.00042000218,0.000023639379,0.0014546913],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9960278,0.0024521023,0.0003474403,0.0005304969,0.00033710574,0.00030505983],"domain_scores_gemma":[0.99386156,0.0023983167,0.0017177003,0.0005068816,0.0005347567,0.0009807573],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0062480294,0.0021006844,0.004904889,0.0007925202,0.000612995,0.0014852845,0.0013875504,0.0027813602,0.0051231263],"category_scores_gemma":[0.005421634,0.0010811759,0.0024210599,0.0005784839,0.0023707377,0.0014960022,0.0005456403,0.0026714785,0.0009903348],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.982941,0.0105996905,0.00027661826,0.00021035198,0.00026051613,0.000010615457,0.000020234282,0.00008841031,0.0018557169,0.00002480471,0.000067274035,0.0036447945],"study_design_scores_gemma":[0.71782136,0.27919808,0.0011348156,0.00002242945,0.00042053225,0.000015588552,0.00001679765,0.00029958977,0.00082567113,0.00006561824,0.0001649378,0.000014700325],"about_ca_topic_score_codex":0.0004543096,"about_ca_topic_score_gemma":0.00066246535,"teacher_disagreement_score":0.0062480294,"about_ca_system_score_codex":0.000835688,"about_ca_system_score_gemma":0.0016207048,"threshold_uncertainty_score":0.033043146},"labels":[],"label_agreement":null},{"id":"W4404455104","doi":"10.25251/skin.8.supp.423","title":"Deucravacitinib in Plaque Psoriasis: 4-year Safety and Efficacy Results from the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"National Institute for Health and Care Research; Manchester Biomedical Research Centre; Bristol-Myers Squibb","keywords":"Plaque psoriasis; Psoriasis; Medicine; Phase (matter); Dermatology; Computer science; Physics","score_opus":0.02818014222467983,"score_gpt":0.30170471001867927,"score_spread":0.2735245677939994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404455104","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9731636,0.018852897,0.0006910216,0.00046452807,0.000082618724,0.00066184456,0.0022318973,0.00009951892,0.0037521261],"genre_scores_gemma":[0.98849165,0.004685326,0.000561974,0.00049752346,0.00013124265,0.00044847673,0.004009324,0.00001843271,0.0011560522],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99871016,0.0005775205,0.000116266994,0.00018393892,0.00024105492,0.00017093027],"domain_scores_gemma":[0.9979138,0.00046302343,0.0007197068,0.0002315031,0.00027409082,0.0003978778],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004569717,0.00086405105,0.0012230707,0.00034871293,0.00043553114,0.0012255424,0.0004962653,0.0009638875,0.0015589909],"category_scores_gemma":[0.002585,0.00026616175,0.0021836783,0.00035320618,0.00034260572,0.0009164551,0.00038238193,0.002004867,0.00041433686],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.570882,0.01652075,0.058491293,0.0025386591,0.012380908,0.00037623273,0.0004971157,0.0069312956,0.027715331,0.00040773518,0.012336832,0.29092178],"study_design_scores_gemma":[0.31543583,0.29828277,0.33363566,0.0005099335,0.012842934,0.0018682841,0.0002752848,0.005317513,0.012272803,0.0010882078,0.018266814,0.00020401087],"about_ca_topic_score_codex":0.00081378134,"about_ca_topic_score_gemma":0.0018263054,"teacher_disagreement_score":0.004569717,"about_ca_system_score_codex":0.00070767704,"about_ca_system_score_gemma":0.0008340374,"threshold_uncertainty_score":0.0241673},"labels":[],"label_agreement":null},{"id":"W4404455106","doi":"10.25251/skin.8.supp.445","title":"Long-Term Efficacy and Safety of Risankizumab for csDMARD-IR Patients With Active Psoriatic Arthritis: 196-Week Results From the KEEPsAKE 1 Trial","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"","keywords":"Psoriatic arthritis; Medicine; Term (time); Dermatology; Internal medicine; Psoriasis; Physics","score_opus":0.012776850158861274,"score_gpt":0.2643596050151742,"score_spread":0.25158275485631293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404455106","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933286,0.0035797835,0.0002382396,0.00024142035,0.00007896863,0.00042918173,0.0009565759,0.000027801345,0.0011195142],"genre_scores_gemma":[0.9927603,0.0015546043,0.00052761356,0.00038864237,0.00023926808,0.0006004967,0.0023379042,0.000016150725,0.0015749364],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9987424,0.00059045246,0.00013908755,0.00016258672,0.00022917821,0.00013629242],"domain_scores_gemma":[0.997498,0.00050231273,0.001090596,0.00031001444,0.00016619929,0.00043283857],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003671251,0.0009097557,0.0017805116,0.00022226266,0.00043697478,0.0010143144,0.0005833569,0.0009522657,0.002954749],"category_scores_gemma":[0.0021239908,0.00039044098,0.0020104425,0.00029769383,0.0005745082,0.0008989765,0.00054412585,0.0025371232,0.00061615213],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9189912,0.009319171,0.015522171,0.0010109731,0.0026774278,0.00011109489,0.00017960055,0.001006018,0.011712762,0.0000732861,0.0018041347,0.03759212],"study_design_scores_gemma":[0.5782937,0.3056384,0.10200244,0.00015385349,0.0034434178,0.00036781564,0.00011179605,0.0007451744,0.00505994,0.0001770593,0.003909223,0.000097224336],"about_ca_topic_score_codex":0.0003070555,"about_ca_topic_score_gemma":0.00088771863,"teacher_disagreement_score":0.003671251,"about_ca_system_score_codex":0.00047131747,"about_ca_system_score_gemma":0.0006205465,"threshold_uncertainty_score":0.019415617},"labels":[],"label_agreement":null},{"id":"W4404455125","doi":"10.25251/skin.8.supp.483","title":"Evaluating the safety and efficacy of aminolevulinic acid 20% topical solution activated by blue light in the treatment of facial cutaneous squamous cell carcinoma in situ","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"bioluminescence and chemiluminescence research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"In situ; Basal cell; Dermatology; Medicine; Cancer research; Oncology; Internal medicine; Chemistry","score_opus":0.020685035602132352,"score_gpt":0.3196906771358646,"score_spread":0.2990056415337322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404455125","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986345,0.00085268373,0.00016263011,0.000022957245,0.000009810273,0.00007781771,0.000017349723,0.000003934089,0.00021837238],"genre_scores_gemma":[0.9989052,0.00046505325,0.00027054053,0.000041216073,0.000023686418,0.000059656668,0.00005267329,0.0000021847177,0.00017981644],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99967265,0.00016492803,0.000026319065,0.00003689132,0.00006689974,0.000032333544],"domain_scores_gemma":[0.99948657,0.0001952256,0.00015272881,0.000038023765,0.00006598117,0.000061431456],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000935082,0.00022307369,0.00048571665,0.00012915839,0.0001636492,0.0002560047,0.00019972476,0.0002683109,0.0009172301],"category_scores_gemma":[0.00063764595,0.000099793375,0.0003939538,0.00010211204,0.00021098644,0.00018241548,0.00009989783,0.00050789985,0.00017466003],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20482518,0.032614075,0.046265475,0.0014812012,0.0007915305,0.00086625415,0.00068277476,0.0024996775,0.4688244,0.00021828579,0.00073546014,0.24019565],"study_design_scores_gemma":[0.008767012,0.8354488,0.056114957,0.000053406333,0.000684739,0.001179885,0.00023047884,0.0024922013,0.09217712,0.00008271971,0.0027446349,0.000023993322],"about_ca_topic_score_codex":0.00019119983,"about_ca_topic_score_gemma":0.00025832493,"teacher_disagreement_score":0.000935082,"about_ca_system_score_codex":0.000206658,"about_ca_system_score_gemma":0.00028105325,"threshold_uncertainty_score":0.0049452186},"labels":[],"label_agreement":null},{"id":"W4404455128","doi":"10.25251/skin.8.supp.432","title":"Bimekizumab 4-year Efficacy in High-impact Areas in Moderate to Severe Plaque Psoriasis: Pooled Results from BE BRIGHT","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"","keywords":"Plaque psoriasis; Medicine; Psoriasis; Dermatology; Internal medicine","score_opus":0.013005384212936908,"score_gpt":0.25876436658693264,"score_spread":0.24575898237399574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404455128","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5124368,0.46293834,0.0021841612,0.00090525445,0.0012342354,0.0010168885,0.01123905,0.00020909439,0.007836343],"genre_scores_gemma":[0.9155234,0.06691235,0.0011964857,0.0012487932,0.0013774342,0.00080109,0.009819958,0.00007602762,0.0030442956],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978235,0.0010310009,0.00029649402,0.00032827535,0.0002867786,0.00023390746],"domain_scores_gemma":[0.99784005,0.00071362674,0.0006573677,0.00029880987,0.0002806454,0.00020958361],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0053114523,0.0012836887,0.004782654,0.0010096292,0.00029361233,0.0016335376,0.00068423693,0.0012040931,0.0030869232],"category_scores_gemma":[0.0036623613,0.0005719199,0.0094963955,0.001414339,0.00034833484,0.0008153466,0.000647713,0.0014937859,0.00056450977],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.60030085,0.0009123765,0.024158392,0.019580472,0.21305153,0.0002306914,0.00012121204,0.003474589,0.004136091,0.0003664562,0.011434191,0.12223301],"study_design_scores_gemma":[0.28977725,0.038461715,0.27968243,0.0034374625,0.36211613,0.0006842136,0.0002171172,0.0023323405,0.0022069379,0.0012013866,0.019646004,0.00023700512],"about_ca_topic_score_codex":0.0017865356,"about_ca_topic_score_gemma":0.0033753691,"teacher_disagreement_score":0.0053114523,"about_ca_system_score_codex":0.00066396745,"about_ca_system_score_gemma":0.0006086575,"threshold_uncertainty_score":0.02809},"labels":[],"label_agreement":null},{"id":"W4404455143","doi":"10.25251/skin.8.supp.446","title":"Long-Term Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 196-Week Results From the KEEPsAKE 2 Trial","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"","keywords":"Psoriatic arthritis; Medicine; Term (time); Internal medicine; Arthritis; Physical therapy; Physics","score_opus":0.01979361521127971,"score_gpt":0.29436113465455854,"score_spread":0.27456751944327884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404455143","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99235946,0.0034831965,0.00028758057,0.00030532148,0.00009317136,0.00048672565,0.0015820576,0.00003057852,0.0013719322],"genre_scores_gemma":[0.98924863,0.0018124239,0.00070365943,0.0004519852,0.00031382893,0.0010225012,0.0037268908,0.000021815165,0.00269834],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.998754,0.0006730234,0.00011681182,0.00014492145,0.00019137551,0.000119893666],"domain_scores_gemma":[0.998005,0.000430539,0.00083742925,0.00023976648,0.00013791933,0.00034945452],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032795288,0.0009077127,0.0018011172,0.0001680628,0.00035052546,0.000921676,0.0004974773,0.000805525,0.0032429257],"category_scores_gemma":[0.0020059997,0.00041174525,0.002089464,0.00022776799,0.00058007264,0.0007441569,0.0005207401,0.0020663608,0.00058862194],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95312506,0.003918091,0.008760223,0.0008503405,0.0026407242,0.00008560051,0.000117357275,0.0007207616,0.008059628,0.0000681421,0.0015189964,0.020135105],"study_design_scores_gemma":[0.7390894,0.17403354,0.07425935,0.0001582916,0.0040393104,0.00027166662,0.00009034653,0.0006132682,0.0033421845,0.00019733721,0.0038201758,0.00008503848],"about_ca_topic_score_codex":0.00036221262,"about_ca_topic_score_gemma":0.0011048638,"teacher_disagreement_score":0.0032795288,"about_ca_system_score_codex":0.0004102243,"about_ca_system_score_gemma":0.0005807154,"threshold_uncertainty_score":0.017343998},"labels":[],"label_agreement":null},{"id":"W4404455153","doi":"10.25251/skin.8.supp.469","title":"Race and Ethnicity Sub-Groups of Alopecia Areata Patients have Differing Clinical Characteristics: TARGET-DERM AA","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Hair Growth and Disorders","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Castle Biosciences; Pfizer; Eli Lilly and Company; Galderma; Incyte; National Alopecia Areata Foundation","keywords":"Alopecia areata; Race (biology); Ethnic group; Dermatology; Medicine; Gender studies; Sociology; Anthropology","score_opus":0.01588515999310801,"score_gpt":0.29884443098644325,"score_spread":0.28295927099333523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404455153","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948726,0.00032415718,0.00017172928,0.00012668864,0.000013830408,0.000056546818,0.0008979364,0.000008655971,0.0035278003],"genre_scores_gemma":[0.9986847,0.00006673433,0.000104995146,0.000091655886,0.0000137058305,0.000045738634,0.0005816155,0.00000381486,0.00040699565],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99961156,0.000051547722,0.000039616596,0.00009002428,0.00009414727,0.000113190894],"domain_scores_gemma":[0.99960965,0.00004938704,0.00015791437,0.00002245935,0.00006342959,0.00009726634],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003058136,0.00015326981,0.0002783885,0.00056962605,0.000661201,0.0005503446,0.00020285576,0.0002454308,0.005940219],"category_scores_gemma":[0.0008594188,0.000087398425,0.00034099357,0.00063205947,0.00020183671,0.00042815908,0.00046251275,0.0003039084,0.0006890581],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031286513,0.000079530415,0.9913139,0.000019342671,0.000042346295,0.0002005999,0.00028063456,0.00002418528,0.0009572755,0.00009110923,0.0006146933,0.0060634646],"study_design_scores_gemma":[0.000014695694,0.000077317294,0.99729854,0.000012619704,0.000017095215,0.0009652265,0.000646347,0.000105819694,0.00012518089,0.00010199375,0.000630333,0.0000048007832],"about_ca_topic_score_codex":0.0053964118,"about_ca_topic_score_gemma":0.010886831,"teacher_disagreement_score":0.005940219,"about_ca_system_score_codex":0.00036491518,"about_ca_system_score_gemma":0.00037775224,"threshold_uncertainty_score":0.01987207},"labels":[],"label_agreement":null},{"id":"W4404455182","doi":"10.25251/skin.8.supp.450","title":"Real-World Effectiveness of Upadacitinib in Moderate‑to‑Severe Atopic Dermatitis (AD): Results From Longitudinal Analyses of the CorEvitas AD Registry","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Probity Medical Research; Queen's University","funders":"LEO Pharma; Eli Lilly and Company; Bristol-Myers Squibb; Janssen Pharmaceuticals; Genentech; Chugai Pharmaceutical; Amgen","keywords":"Atopic dermatitis; Medicine; Longitudinal data; Dermatology; Data mining; Computer science","score_opus":0.028431092919943782,"score_gpt":0.3357071688554863,"score_spread":0.3072760759355425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404455182","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98888856,0.0020955421,0.00040081466,0.00023303182,0.00003001306,0.0000779015,0.007370416,0.000018473766,0.00088519877],"genre_scores_gemma":[0.99175936,0.00048205702,0.00032018285,0.0001191626,0.000039152575,0.000086113614,0.0070007304,0.00000873198,0.00018442118],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.993439,0.0031569358,0.0008832551,0.0010821398,0.0010623008,0.0003763977],"domain_scores_gemma":[0.9707636,0.005222677,0.015597237,0.0035667364,0.003794784,0.0010548914],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01166046,0.00030162546,0.00055176823,0.00087032636,0.00058665883,0.0014402769,0.0006948864,0.00044271955,0.00110099],"category_scores_gemma":[0.020286538,0.000240928,0.0013540534,0.0018468545,0.00034019887,0.001030927,0.0010552568,0.00089185266,0.00027629643],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013495024,0.00010923137,0.9929691,0.00006395041,0.00084003614,0.00003016054,0.0000710692,0.00013814251,0.00007040398,0.00006143527,0.0006723658,0.0036246637],"study_design_scores_gemma":[0.00017267816,0.00065319723,0.9953471,0.000060749593,0.000777633,0.00022364657,0.00012948534,0.00056636,0.00018980239,0.00008845658,0.0017699207,0.000020916359],"about_ca_topic_score_codex":0.006509969,"about_ca_topic_score_gemma":0.0075381747,"teacher_disagreement_score":0.01166046,"about_ca_system_score_codex":0.00087630894,"about_ca_system_score_gemma":0.0010905208,"threshold_uncertainty_score":0.061667144},"labels":[],"label_agreement":null},{"id":"W4404455186","doi":"10.25251/skin.8.6.3","title":"Tissue-Engineered Skin Substitutes for Use in Clinical Dermatological Practice","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Biomedical Ethics and Regulation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Dermatology; Medicine; Dermatological diseases","score_opus":0.053981853303566064,"score_gpt":0.39659422435907066,"score_spread":0.34261237105550457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404455186","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0051940074,0.9660453,0.0048885522,0.0060339603,0.0011268697,0.0004149786,0.00022268199,0.00003391189,0.016039832],"genre_scores_gemma":[0.07495805,0.90042937,0.01664704,0.0036317904,0.00090589083,0.0007726671,0.00030662437,0.00002987348,0.0023186812],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99274546,0.0036104973,0.0011374649,0.00022540789,0.0021608358,0.00012032305],"domain_scores_gemma":[0.98580265,0.010106712,0.0019434015,0.00035811003,0.0016018826,0.00018729057],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008834372,0.0003068308,0.0007640597,0.0020071962,0.00045806548,0.002857383,0.00054455624,0.0014921317,0.0062169484],"category_scores_gemma":[0.021609524,0.00015136822,0.00081303227,0.001725129,0.0010563472,0.0016295213,0.0013171171,0.0011999838,0.0011631591],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021009283,0.00021113527,0.0010974742,0.065269485,0.00021390273,0.00080092024,0.0013342809,0.00032792724,0.005632255,0.015921611,0.015904015,0.89307684],"study_design_scores_gemma":[0.00008832967,0.00067943527,0.0038955025,0.103338316,0.0005449145,0.0031872534,0.0022864763,0.00018589506,0.005446791,0.013552932,0.8667296,0.000064561944],"about_ca_topic_score_codex":0.000383497,"about_ca_topic_score_gemma":0.00095669896,"teacher_disagreement_score":0.008834372,"about_ca_system_score_codex":0.00064415415,"about_ca_system_score_gemma":0.0025719479,"threshold_uncertainty_score":0.04672122},"labels":[],"label_agreement":null},{"id":"W4404455203","doi":"10.25251/skin.8.supp.434","title":"Bimekizumab Clinical Efficacy in Important Body Regions and Health-related Quality of Life in Patients with Plaque Psoriasis: Data from Four Phase 3/3b Comparator-controlled Trial Periods","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dermatrials Research","funders":"LEO Pharma; Case Western Reserve University; Amgen; Pfizer; Bristol-Myers Squibb; Eli Lilly and Company; Sun Pharma; Biogen","keywords":"Plaque psoriasis; Psoriasis; Quality of life (healthcare); Medicine; Clinical trial; Phase (matter); Physical therapy; Physical medicine and rehabilitation; Internal medicine; Dermatology; Nursing; Physics","score_opus":0.08402653805773325,"score_gpt":0.3715673497894008,"score_spread":0.28754081173166757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404455203","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9651985,0.02340151,0.000762696,0.0005935867,0.00019760324,0.002770335,0.004004776,0.000098329045,0.002972744],"genre_scores_gemma":[0.9878229,0.0045636334,0.0008959509,0.00059742766,0.0002467656,0.0022935423,0.0028145511,0.000023239174,0.00074192765],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.996552,0.001963981,0.0004135121,0.00033052647,0.0004510697,0.0002888319],"domain_scores_gemma":[0.99623185,0.0012914315,0.0012593614,0.0002970165,0.00027330258,0.0006471509],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0075269775,0.0012848141,0.003330375,0.0006176226,0.0005720164,0.0015084924,0.00082993234,0.0013948831,0.0036543666],"category_scores_gemma":[0.005405759,0.00049566186,0.0043975986,0.00093788817,0.0008698521,0.0012015038,0.0005498973,0.0028389085,0.00045455116],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9530287,0.0040320666,0.0058323676,0.0013729632,0.0053366683,0.000054968332,0.000090645175,0.0006014377,0.0030031719,0.00008284596,0.0010286202,0.025535487],"study_design_scores_gemma":[0.8795031,0.079142526,0.032934725,0.00015033761,0.0045436234,0.00012370988,0.000050497412,0.0005381333,0.0012856233,0.00022021642,0.0014665402,0.00004095064],"about_ca_topic_score_codex":0.00094287016,"about_ca_topic_score_gemma":0.0018120843,"teacher_disagreement_score":0.0075269775,"about_ca_system_score_codex":0.00078097783,"about_ca_system_score_gemma":0.0011834516,"threshold_uncertainty_score":0.039806962},"labels":[],"label_agreement":null},{"id":"W4404455223","doi":"10.25251/skin.8.supp.471","title":"Generic vs. Disease-Specific Patient Reported Outcome (PRO) Instruments for Assessing HRQoL Burden Among Patients Diagnosed with Alopecia Areata: Evidence from TARGET-DERM AA","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Hair Growth and Disorders","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Alopecia areata; Medicine; Patient-reported outcome; Dermatology; Disease; Burden of disease; Quality of life (healthcare); Internal medicine","score_opus":0.03808850697775853,"score_gpt":0.2852042641100399,"score_spread":0.24711575713228137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404455223","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89472044,0.09428426,0.0008892544,0.0015160729,0.00020267381,0.00042482393,0.002009751,0.000015916008,0.0059368033],"genre_scores_gemma":[0.98795545,0.009344745,0.0007472406,0.00042670732,0.0001444293,0.0001930097,0.0010121395,0.0000039654497,0.00017233877],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9923315,0.0046793437,0.0006696036,0.00066629087,0.001386951,0.00026636873],"domain_scores_gemma":[0.9762329,0.015560252,0.004917606,0.0008743182,0.0017804801,0.0006345087],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.013462594,0.00047374074,0.0010396185,0.0011447519,0.00028425385,0.0013646777,0.0007382252,0.000728429,0.0018975448],"category_scores_gemma":[0.025061728,0.00020891517,0.0021543866,0.0016168253,0.0006393986,0.0009637107,0.0008597936,0.00084288645,0.00018698783],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008348501,0.00062989164,0.8868233,0.0026979288,0.006222012,0.000031684285,0.0003195492,0.00044241262,0.00014415907,0.00034939926,0.00070556224,0.09328554],"study_design_scores_gemma":[0.0016832785,0.0038930497,0.98465997,0.0016934739,0.0035952362,0.0001615998,0.0005580355,0.0010098987,0.00011931599,0.0003750903,0.002216183,0.000034877918],"about_ca_topic_score_codex":0.0031539865,"about_ca_topic_score_gemma":0.004934945,"teacher_disagreement_score":0.9865374,"about_ca_system_score_codex":0.0006547709,"about_ca_system_score_gemma":0.0008208784,"threshold_uncertainty_score":0.07119781},"labels":[],"label_agreement":null},{"id":"W4404455231","doi":"10.25251/skin.8.supp.437","title":"Bimekizumab 4-year Maintenance of Responses in Week 16 Responders with Moderate to Severe Plaque Psoriasis: Results from the BE BRIGHT Open-label Extension Phase 3 Trial","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"School of Medicine, Indiana University; Universidade de São Paulo; Manchester Biomedical Research Centre; Dalhousie University; National Institute for Health and Care Research","keywords":"Plaque psoriasis; Open label; Psoriasis; Medicine; Internal medicine; Dermatology; Clinical trial","score_opus":0.2612660508904314,"score_gpt":0.4255791209063332,"score_spread":0.16431307001590179,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404455231","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99386567,0.002038847,0.00022950726,0.00030283086,0.000085601096,0.0010266382,0.0009388239,0.000043435455,0.0014686852],"genre_scores_gemma":[0.9916156,0.0011479208,0.00077741727,0.00061841524,0.00024006354,0.0016376266,0.0018210323,0.000022238557,0.0021196476],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9987698,0.0006919704,0.00005289962,0.00011561537,0.00013032263,0.00023934893],"domain_scores_gemma":[0.99821764,0.0003343911,0.00045787648,0.000192519,0.0001135587,0.0006840144],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044232705,0.0008892709,0.0020983038,0.00030398462,0.0004994658,0.0010132544,0.0007692427,0.0012740308,0.003709649],"category_scores_gemma":[0.0018957432,0.00048330287,0.0018276541,0.00030053724,0.0007156153,0.00095752603,0.00047420245,0.0034528326,0.000985387],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93121994,0.025800385,0.004608472,0.00031283876,0.0006889929,0.000068042806,0.00012795655,0.000403347,0.007777955,0.00010390052,0.002027952,0.02686016],"study_design_scores_gemma":[0.63637584,0.33250284,0.026119815,0.00005524032,0.0006673671,0.00016252235,0.00004922504,0.0005446456,0.0013805886,0.00018225108,0.0019280526,0.00003163704],"about_ca_topic_score_codex":0.00063495093,"about_ca_topic_score_gemma":0.0010964067,"teacher_disagreement_score":0.0044232705,"about_ca_system_score_codex":0.00055510073,"about_ca_system_score_gemma":0.0013365428,"threshold_uncertainty_score":0.023392797},"labels":[],"label_agreement":null},{"id":"W4404455235","doi":"10.25251/skin.8.supp.473","title":"Bimekizumab Efficacy and Safety Through 2 years in Patients with Hidradenitis Suppurativa: Results from the Phase 3 BE HEARD I&II trials and Open-Label Extension BE HEARD EXT","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Hidradenitis Suppurativa and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Geotab (Canada)","funders":"LEO Pharma; InflaRx; Idorsia Pharmaceuticals; European Academy of Dermatology and Venereology; Eisai; Bundesministerium für Bildung und Forschung; Insmed; Incyte; Celgene; Biogen; L'Oreal USA; European Commission; Sanofi; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Hidradenitis suppurativa; Open label; Extension (predicate logic); Phase (matter); Medicine; Dermatology; Internal medicine; Clinical trial; Computer science; Chemistry; Programming language","score_opus":0.07663420508063443,"score_gpt":0.3691144696220155,"score_spread":0.2924802645413811,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404455235","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9467441,0.03793798,0.0006400607,0.0013166751,0.00032212984,0.0027037219,0.00548594,0.00009108307,0.0047584805],"genre_scores_gemma":[0.9766774,0.008728726,0.0012120763,0.0018604585,0.0008114947,0.0024509844,0.005870137,0.000029270795,0.0023593802],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9980692,0.0010479338,0.00015802374,0.00024878248,0.00024207013,0.00023390571],"domain_scores_gemma":[0.99682105,0.0007329338,0.0011493522,0.00023960107,0.0002560508,0.00080101506],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0054732207,0.00093622395,0.0022824307,0.00039525365,0.00055272254,0.001289682,0.0006972818,0.0014705202,0.0046241223],"category_scores_gemma":[0.0037087977,0.00051154185,0.0029239836,0.00059586775,0.0005576512,0.0017290085,0.00068261544,0.0027495448,0.0007426367],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.84962493,0.013989788,0.015897878,0.0027042585,0.005271784,0.0001626688,0.0002929097,0.00085965585,0.005035296,0.0001974416,0.005951341,0.10001205],"study_design_scores_gemma":[0.6300596,0.2775742,0.077118725,0.00039539023,0.0047582593,0.00039527038,0.00017240718,0.00072298775,0.0016063384,0.00033411905,0.006774579,0.00008814402],"about_ca_topic_score_codex":0.0009891113,"about_ca_topic_score_gemma":0.0024487355,"teacher_disagreement_score":0.0054732207,"about_ca_system_score_codex":0.00073996175,"about_ca_system_score_gemma":0.0010924314,"threshold_uncertainty_score":0.028945506},"labels":[],"label_agreement":null},{"id":"W4404455251","doi":"10.25251/skin.8.supp.431","title":"Bimekizumab Efficacy and Safety Over 48 Weeks in US and Canadian Patients with Psoriasis who had a Treatment Interruption After 3 Years of Treatment: Results from BE RADIANT","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dermatrials Research; Probity Medical Research; University of Toronto","funders":"","keywords":"Psoriasis; Medicine; Dermatology","score_opus":0.009632729964742385,"score_gpt":0.23137510540230313,"score_spread":0.22174237543756076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404455251","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896791,0.0054356297,0.000113683,0.00030399658,0.0000236208,0.0002094479,0.0010339097,0.000018334089,0.00318236],"genre_scores_gemma":[0.99623364,0.0014600832,0.00024151297,0.00024506744,0.00002802055,0.000055482964,0.0010041471,0.000004664443,0.0007273625],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99877626,0.00019580725,0.000054626154,0.000115785486,0.0005591206,0.00029837404],"domain_scores_gemma":[0.99875927,0.00013718526,0.00028380184,0.00006063901,0.00037207623,0.00038702093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017527972,0.0003310024,0.00077853363,0.00034057867,0.0012645273,0.00052687066,0.0004171185,0.00044707416,0.0016781323],"category_scores_gemma":[0.0018668744,0.00015185641,0.00099737,0.0009793339,0.0003638963,0.00027022554,0.00026889527,0.00094921974,0.00018061981],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17073241,0.006774042,0.48263764,0.0011632335,0.0025846642,0.00050199864,0.0016592455,0.0017300901,0.012042508,0.00037174535,0.009662441,0.31013995],"study_design_scores_gemma":[0.008860021,0.01864887,0.9600506,0.000106596555,0.0009184015,0.0004267497,0.0003822655,0.0010049519,0.0017721014,0.00005457717,0.0077069574,0.000067930356],"about_ca_topic_score_codex":0.5506391,"about_ca_topic_score_gemma":0.71955985,"teacher_disagreement_score":0.4493609,"about_ca_system_score_codex":0.007929212,"about_ca_system_score_gemma":0.0068103373,"threshold_uncertainty_score":0.9040146},"labels":[],"label_agreement":null},{"id":"W4404455265","doi":"10.25251/skin.8.supp.461","title":"Why Do Optimal Targets for Itch and Skin Clearance Matter in Atopic Dermatitis Treatment? Insights from TARGET-DERM AD Registry","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Galderma; Pfizer","keywords":"Atopic dermatitis; Dermatology; Medicine","score_opus":0.0079587013863197,"score_gpt":0.26058198014489276,"score_spread":0.25262327875857304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404455265","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86263996,0.032162867,0.0018634362,0.041167006,0.0003412949,0.00024792936,0.022173833,0.00008848738,0.039315134],"genre_scores_gemma":[0.9869801,0.004392396,0.0012146771,0.002763629,0.00015404775,0.000093464805,0.0037873164,0.000022996417,0.00059146236],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99365187,0.00241857,0.0007139008,0.00079468975,0.0018058488,0.0006150777],"domain_scores_gemma":[0.9748189,0.008233168,0.0070006587,0.00161858,0.0063263145,0.0020023612],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0091853235,0.00010871835,0.0005514289,0.0007631992,0.00065055484,0.0018790755,0.0009062513,0.00044843825,0.0033990294],"category_scores_gemma":[0.032313947,0.00014025673,0.0005236579,0.0028481325,0.00041678245,0.001172909,0.00088256306,0.00095891836,0.00047037358],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00069631875,0.00012663033,0.8889766,0.00046962174,0.00023263154,0.000039205883,0.00062362634,0.0002144564,0.00008241375,0.0013647022,0.020706333,0.08646752],"study_design_scores_gemma":[0.0001276034,0.00019717592,0.965938,0.001109011,0.00031240797,0.0002140547,0.002097448,0.00089932274,0.00018882191,0.0017705229,0.0271117,0.00003404444],"about_ca_topic_score_codex":0.07389286,"about_ca_topic_score_gemma":0.11806924,"teacher_disagreement_score":0.07389286,"about_ca_system_score_codex":0.0034837553,"about_ca_system_score_gemma":0.006063422,"threshold_uncertainty_score":0.14692551},"labels":[],"label_agreement":null},{"id":"W4404455267","doi":"10.25251/skin.8.supp.475","title":"Bimekizumab impact on draining tunnels: A dynamic assessment in patients with moderate to severe HS using pooled Week 48 results from BE HEARD I&II","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"Idorsia Pharmaceuticals; LEO Pharma; Incyte; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Pooled analysis; Medicine; Internal medicine; Meta-analysis","score_opus":0.016534721351604737,"score_gpt":0.3092758611476984,"score_spread":0.2927411397960937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404455267","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98540515,0.010652055,0.0005859933,0.00010245965,0.00006769193,0.0005125629,0.0016058711,0.000030542316,0.0010377517],"genre_scores_gemma":[0.9961584,0.0011943717,0.00049843616,0.000102604434,0.00008988492,0.00035942826,0.0013036412,0.000006493122,0.00028675885],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9966788,0.0018206205,0.00045075789,0.0004247593,0.00043266173,0.00019231097],"domain_scores_gemma":[0.9958248,0.0013482125,0.001621675,0.00048617413,0.0002948536,0.00042417887],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0069692982,0.0008677834,0.0028725525,0.0007623611,0.00026505714,0.0011053802,0.0004994705,0.0006372675,0.0020426929],"category_scores_gemma":[0.0060477685,0.00048753587,0.0042107888,0.00086329394,0.00028030557,0.0007568698,0.0009416595,0.000713182,0.00021535599],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5681273,0.0019887341,0.30700567,0.0028998675,0.045020744,0.00014322081,0.00022607709,0.001532712,0.0040855333,0.000107573724,0.0015163096,0.06734636],"study_design_scores_gemma":[0.084499255,0.116590895,0.74976605,0.0004384603,0.04015283,0.0004359841,0.00030966068,0.0022799033,0.0014380397,0.0003018164,0.0036394605,0.0001477149],"about_ca_topic_score_codex":0.00056581415,"about_ca_topic_score_gemma":0.0013098321,"teacher_disagreement_score":0.0069692982,"about_ca_system_score_codex":0.0004071902,"about_ca_system_score_gemma":0.00065613614,"threshold_uncertainty_score":0.036857665},"labels":[],"label_agreement":null},{"id":"W4404455270","doi":"10.25251/skin.8.supp.441","title":"Zasocitinib (TAK-279), a Selective, Oral TYK2 Inhibitor, Reduces Body Surface Area Involvement in a Phase 2b Trial in Moderate-to-Severe Plaque Psoriasis","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Plaque psoriasis; Medicine; Psoriasis; Body surface area; Dermatology; Internal medicine","score_opus":0.024201131398376464,"score_gpt":0.29140096923614606,"score_spread":0.26719983783776957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404455270","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98954797,0.004072405,0.0005605906,0.00049140526,0.00014675983,0.002501098,0.0008068247,0.00015147583,0.0017214238],"genre_scores_gemma":[0.9920053,0.002398386,0.0011102114,0.0004168209,0.0001587059,0.0015633446,0.001074283,0.000021540991,0.0012513538],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9996146,0.00017185151,0.000031974585,0.00006335324,0.00005121922,0.00006701398],"domain_scores_gemma":[0.9994468,0.00011615541,0.00013520422,0.000028943938,0.000052038653,0.00022084107],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018473943,0.0010981786,0.0016579247,0.00036282657,0.00036294057,0.0007011272,0.00059411884,0.0008330862,0.0035026562],"category_scores_gemma":[0.0009218028,0.00040326163,0.0013273509,0.00033393808,0.00058056327,0.0004767399,0.00020946427,0.001932397,0.00057020184],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8759946,0.016806146,0.003222519,0.0016260523,0.0017591882,0.00014041337,0.00014042047,0.0013922225,0.03591971,0.00015244998,0.0031296716,0.059716523],"study_design_scores_gemma":[0.8612062,0.12682007,0.007371531,0.000041734856,0.0005347123,0.0001812978,0.000024521252,0.0006103607,0.0019966795,0.00008672373,0.0011091536,0.000017030987],"about_ca_topic_score_codex":0.0008250767,"about_ca_topic_score_gemma":0.0024384093,"teacher_disagreement_score":0.0035026562,"about_ca_system_score_codex":0.0006122213,"about_ca_system_score_gemma":0.001191768,"threshold_uncertainty_score":0.0117176175},"labels":[],"label_agreement":null},{"id":"W4404455273","doi":"10.25251/skin.8.supp.433","title":"Bimekizumab Long-term Efficacy in Patients with Moderate to Severe Plaque Psoriasis After Switching From Adalimumab, Ustekinumab, or Secukinumab: Results from Up to 4 Years of Total Treatment from BE BRIGHT and BE RADIANT","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Ustekinumab; Secukinumab; Medicine; Plaque psoriasis; Adalimumab; Dermatology; Psoriasis; Internal medicine; Tumor necrosis factor alpha; Psoriatic arthritis","score_opus":0.011477805515059185,"score_gpt":0.2361622407124037,"score_spread":0.2246844351973445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404455273","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99700624,0.0019367551,0.000068246045,0.00006208596,0.00001947403,0.00011649735,0.00015912113,0.0000079738,0.0006235818],"genre_scores_gemma":[0.99820673,0.00053224555,0.00015893411,0.00018873226,0.000072348295,0.00010978157,0.00036176562,0.000003093171,0.00036634397],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991844,0.00026590689,0.0000643949,0.00010269472,0.0001710359,0.0002115047],"domain_scores_gemma":[0.99889696,0.0001760005,0.000393691,0.00006054976,0.00008213402,0.00039058927],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022774779,0.00047171523,0.0011071159,0.00035503798,0.000495979,0.0007572182,0.00038192963,0.0005452613,0.0014598415],"category_scores_gemma":[0.0010686691,0.00020981686,0.0014609569,0.00036730547,0.00037746786,0.0007752698,0.00036263277,0.0016696149,0.00037714522],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2589817,0.04959614,0.4286251,0.0010085136,0.00302046,0.0009815232,0.0009050662,0.0015694675,0.034838885,0.00020727693,0.0024402903,0.21782562],"study_design_scores_gemma":[0.010128498,0.24339686,0.7364214,0.00006465944,0.0013289956,0.000674337,0.00027817397,0.0010439157,0.004659024,0.00014153379,0.0017986642,0.00006381528],"about_ca_topic_score_codex":0.00082354114,"about_ca_topic_score_gemma":0.0015261141,"teacher_disagreement_score":0.0022774779,"about_ca_system_score_codex":0.00072553556,"about_ca_system_score_gemma":0.0004867142,"threshold_uncertainty_score":0.012044609},"labels":[],"label_agreement":null},{"id":"W4404455285","doi":"10.25251/skin.8.supp.463","title":"Impact of Therapeutic Inertia on Patient-Reported Outcomes in Moderate-to-Severe Atopic Dermatitis: A 12-Month Longitudinal Study from the TARGET-DERM AD Registry","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Atopic dermatitis; Medicine; Longitudinal study; Dermatology; Patient registry; Pediatrics; Pathology","score_opus":0.022400432095734304,"score_gpt":0.3143109992616946,"score_spread":0.2919105671659603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404455285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99852306,0.00027558848,0.00007898732,0.00006170364,0.0000055235223,0.000022481865,0.00072267425,0.0000032151231,0.000306901],"genre_scores_gemma":[0.9988423,0.00007046428,0.00006200278,0.000035416735,0.000008705258,0.000021723985,0.00089591654,0.0000018646755,0.000061658706],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974542,0.0009602513,0.00032937166,0.00041625043,0.000534523,0.000305453],"domain_scores_gemma":[0.98629224,0.0019252277,0.008269601,0.00088257535,0.0014759271,0.001154406],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0050738133,0.0002489625,0.00046740708,0.0007482369,0.0006398207,0.00095374975,0.0004639485,0.00043541033,0.00078633736],"category_scores_gemma":[0.009550663,0.00019652939,0.0009460241,0.0011498799,0.00027324137,0.0007442279,0.0008161939,0.0010192303,0.00017555967],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022717929,0.000059098686,0.9985435,0.0000070054007,0.000074710806,0.000018215302,0.0000641848,0.00002793563,0.000028792403,0.0000071110317,0.00008592431,0.0008563827],"study_design_scores_gemma":[0.000018432811,0.00021890998,0.999193,0.000008464248,0.000056826455,0.000075719814,0.00010289904,0.00014803435,0.000026000529,0.0000109524835,0.00013596423,0.0000048316306],"about_ca_topic_score_codex":0.008453249,"about_ca_topic_score_gemma":0.01040093,"teacher_disagreement_score":0.008453249,"about_ca_system_score_codex":0.0008145479,"about_ca_system_score_gemma":0.0008140346,"threshold_uncertainty_score":0.026833236},"labels":[],"label_agreement":null},{"id":"W4404455301","doi":"10.25251/skin.8.supp.442","title":"Evaluation of Changes in Laboratory Parameters from a Phase 2b Trial of Zasocitinib (TAK-279), an Oral, Selective TYK2 Inhibitor, in Patients with Moderate-to-Severe Plaque Psoriasis","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Lynde Centre for Dermatology; SKiN Health","funders":"","keywords":"Plaque psoriasis; Medicine; Internal medicine; Psoriasis; Dermatology; Pharmacology","score_opus":0.022981120971243156,"score_gpt":0.29019544373035705,"score_spread":0.2672143227591139,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404455301","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960473,0.0013581287,0.00037789086,0.00011352651,0.000028396764,0.0006883266,0.0006587643,0.000027927945,0.0006997382],"genre_scores_gemma":[0.99722254,0.00040098667,0.0004204367,0.00014803196,0.000062109495,0.00057142344,0.00089478964,0.000005315291,0.00027435587],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9988305,0.0006145572,0.00009170809,0.00019227157,0.00017631806,0.000094650364],"domain_scores_gemma":[0.99795675,0.000500417,0.0007611842,0.00012639147,0.00016756947,0.00048770307],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037091253,0.0011063564,0.0017394967,0.00035037062,0.00041311973,0.00072809315,0.00046518954,0.0007347678,0.0021838674],"category_scores_gemma":[0.0021067876,0.0004608303,0.001240379,0.00035226948,0.00050951843,0.0005363636,0.00026775684,0.0019226987,0.00035727007],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.86295867,0.01761925,0.03537435,0.0007651833,0.0024144487,0.00019749023,0.0001449349,0.0015693627,0.03065763,0.0000715194,0.001245873,0.04698132],"study_design_scores_gemma":[0.36457253,0.48484692,0.13437028,0.000050516486,0.0023817217,0.0005365462,0.00006364651,0.0017454237,0.0094303535,0.00013266312,0.0018169928,0.00005247436],"about_ca_topic_score_codex":0.0002804622,"about_ca_topic_score_gemma":0.00054457673,"teacher_disagreement_score":0.0037091253,"about_ca_system_score_codex":0.0005311587,"about_ca_system_score_gemma":0.00090010744,"threshold_uncertainty_score":0.019615948},"labels":[],"label_agreement":null},{"id":"W4404455317","doi":"10.25251/skin.8.supp.470","title":"Demographics and Disease Characteristics of Patients with Alopecia Areata with Comorbid Atopic Dermatitis, Vitiligo or Anxiety/Depression: TARGET-DERM AA","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Hair Growth and Disorders","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Castle Biosciences; Galderma; Incyte; Sanofi; Pfizer; Concert Pharmaceuticals; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Alopecia areata; Vitiligo; Atopic dermatitis; Dermatology; Demographics; Depression (economics); Medicine; Anxiety; Psychiatry","score_opus":0.005028587827783405,"score_gpt":0.22306850765820477,"score_spread":0.21803991983042137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404455317","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99856704,0.00010135909,0.000025804906,0.000039714414,0.0000036170986,0.000015022027,0.00061009126,0.0000018189511,0.000635523],"genre_scores_gemma":[0.99931717,0.00003319559,0.000023718207,0.00003508762,0.000008738682,0.000014804081,0.0004426562,4.898318e-7,0.0001241776],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997178,0.000030301071,0.000037945938,0.000067003384,0.000064679465,0.000082322564],"domain_scores_gemma":[0.99936646,0.00008610772,0.00027397537,0.000019425068,0.000068538146,0.00018553488],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024751024,0.00012822723,0.00023973899,0.00053521193,0.0004033033,0.00040665525,0.0001698554,0.00027785712,0.0027497527],"category_scores_gemma":[0.0009903277,0.00010657034,0.00026679615,0.0007082455,0.00018249691,0.0004017661,0.00029225225,0.00026279045,0.0002679024],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000636758,0.000036125217,0.9988801,0.000004059558,0.000010563417,0.000050267565,0.000041534728,0.000017531747,0.00008659297,0.000009221382,0.00012508358,0.0006752549],"study_design_scores_gemma":[0.000009818566,0.00010070899,0.99894696,0.000003868269,0.000008717868,0.0004212708,0.00024495294,0.00008787353,0.000018774666,0.000012423032,0.00014230714,0.000002429825],"about_ca_topic_score_codex":0.009534636,"about_ca_topic_score_gemma":0.013980042,"teacher_disagreement_score":0.009534636,"about_ca_system_score_codex":0.00044243457,"about_ca_system_score_gemma":0.00044542577,"threshold_uncertainty_score":0.01895827},"labels":[],"label_agreement":null},{"id":"W4404455334","doi":"10.25251/skin.8.supp.462","title":"Persistent Inadequate Disease Control and Therapeutic Inertia in Moderate-to-Severe Atopic Dermatitis: A 12-month Longitudinal Analysis of Real-world Outcomes from the TARGET-DERM AD registry","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Atopic dermatitis; Medicine; Disease; Longitudinal study; Pediatrics; Dermatology; Internal medicine; Pathology","score_opus":0.01728837496855759,"score_gpt":0.27741785221710435,"score_spread":0.26012947724854674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404455334","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99847895,0.00015958307,0.000077116434,0.000037977647,0.000004058923,0.000025677462,0.0010122797,0.0000031030984,0.0002012686],"genre_scores_gemma":[0.99819833,0.000070245274,0.000092730304,0.000027160646,0.000006383994,0.000026646743,0.0015138254,0.0000022512272,0.000062481246],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99815434,0.0005586414,0.00023175332,0.00037213878,0.0003871183,0.00029605543],"domain_scores_gemma":[0.99079543,0.0010268535,0.0046525723,0.00081947027,0.0015298927,0.0011757913],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003717365,0.00028822533,0.0005002393,0.0013278624,0.0009017487,0.0010452972,0.00067349663,0.0005431903,0.00071741076],"category_scores_gemma":[0.005304013,0.00027358966,0.0007453926,0.0019345548,0.00042555062,0.00084608915,0.0010826704,0.0009557897,0.00022132393],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012873468,0.00003334333,0.9992194,0.000004207267,0.000041659056,0.000017210226,0.00006418263,0.000015725718,0.000028958884,0.0000052845435,0.00006817164,0.0003730453],"study_design_scores_gemma":[0.000015387483,0.00015340208,0.99910283,0.00000676641,0.000041130414,0.000097310614,0.00022038684,0.00016607661,0.00002853243,0.0000088394245,0.0001534953,0.0000058757264],"about_ca_topic_score_codex":0.03908163,"about_ca_topic_score_gemma":0.042445857,"teacher_disagreement_score":0.03908163,"about_ca_system_score_codex":0.0014133702,"about_ca_system_score_gemma":0.0015390364,"threshold_uncertainty_score":0.077708304},"labels":[],"label_agreement":null},{"id":"W4406295719","doi":"10.25251/skin.9.supp.510","title":"Long-Term Efficacy and Safety of Lebrikizumab Is Maintained in Patients With Moderate-to-Severe Atopic Dermatitis: Results Up to 3 Years From ADjoin","year":2025,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"Dermira; Eli Lilly and Company","keywords":"Atopic dermatitis; Term (time); Dermatology; Medicine; Physics","score_opus":0.00559892539955492,"score_gpt":0.24772969753460658,"score_spread":0.24213077213505166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406295719","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966839,0.0017726402,0.000105466825,0.00006989045,0.000019161454,0.00018553215,0.00036752486,0.000011981547,0.0007839315],"genre_scores_gemma":[0.99775654,0.0003830005,0.00015432757,0.00015984704,0.00003512047,0.00013550423,0.00077175896,0.000003981559,0.0005999947],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9991015,0.00033316054,0.000092720074,0.0001652427,0.00015229477,0.00015515258],"domain_scores_gemma":[0.9983718,0.00031067923,0.0005959579,0.00018812458,0.00016364949,0.00036991414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027594746,0.00037292592,0.0009979858,0.00017093275,0.00043746224,0.0007463073,0.0003474556,0.0005409337,0.0020674986],"category_scores_gemma":[0.0014089382,0.00018163238,0.0016385994,0.00025566688,0.00029095728,0.0007051518,0.0004806973,0.0012133382,0.00056867074],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.37910897,0.0152848475,0.3628662,0.0014812953,0.0031293388,0.0006888358,0.0006304496,0.000910753,0.044904802,0.00009875212,0.0028823102,0.18801343],"study_design_scores_gemma":[0.023902575,0.20627294,0.7542085,0.00014400971,0.0020156838,0.0009225319,0.00026609297,0.0007254234,0.0059630345,0.00011736727,0.005402698,0.00005913191],"about_ca_topic_score_codex":0.00045256232,"about_ca_topic_score_gemma":0.0011066435,"teacher_disagreement_score":0.0027594746,"about_ca_system_score_codex":0.0004676781,"about_ca_system_score_gemma":0.00051465066,"threshold_uncertainty_score":0.014593661},"labels":[],"label_agreement":null},{"id":"W4406295765","doi":"10.25251/skin.9.supp.517","title":"Lebrikizumab vs Other Systemic Monotherapies for Moderate to Severe Atopic Dermatitis: Network Meta-analysis of Short-term Efficacy","year":2025,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"AstraZeneca; Bristol-Myers Squibb; Eli Lilly and Company; Argenx; Biogen; Amgen","keywords":"Atopic dermatitis; Medicine; Term (time); Meta-analysis; Dermatology; Internal medicine","score_opus":0.031819005665234025,"score_gpt":0.31437539098779166,"score_spread":0.2825563853225576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406295765","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06002899,0.9303891,0.0034405768,0.0009611699,0.0005476727,0.00060591067,0.0027643135,0.00014849137,0.0011137448],"genre_scores_gemma":[0.8663084,0.12440226,0.0037335767,0.0011723771,0.00036630288,0.0011578448,0.0021396712,0.00008368511,0.00063580275],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9832265,0.0121880295,0.0016553996,0.0017489325,0.0008994005,0.0002819088],"domain_scores_gemma":[0.967443,0.027096804,0.0031970278,0.0010529285,0.00077334594,0.0004369298],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.025040219,0.0026210358,0.011926754,0.0035393406,0.00044218625,0.0026995814,0.0018170686,0.0017322882,0.0033597096],"category_scores_gemma":[0.033724602,0.0011863026,0.044474393,0.0031698504,0.00062901597,0.0013948918,0.0014030241,0.0022339947,0.00027439996],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011802918,0.000030511503,0.0062045134,0.027337436,0.9457043,0.000054446453,0.000024846422,0.0018389608,0.00016706293,0.000101748185,0.00035374172,0.006379465],"study_design_scores_gemma":[0.0026560884,0.00047082803,0.004008652,0.0016523411,0.98884404,0.00005202196,0.000014968643,0.0011249944,0.000093186,0.00037479145,0.00069186056,0.000016220702],"about_ca_topic_score_codex":0.0044700135,"about_ca_topic_score_gemma":0.005658379,"teacher_disagreement_score":0.025040219,"about_ca_system_score_codex":0.0017668088,"about_ca_system_score_gemma":0.0014621455,"threshold_uncertainty_score":0.13242692},"labels":[],"label_agreement":null},{"id":"W4406296138","doi":"10.25251/skin.9.1.17","title":"Clinical Improvement of Necrobiosis Lipoidica Diabeticorum with Opzelura (Ruxolitinib) Cream: A Case Report","year":2025,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Skin Diseases and Diabetes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Necrobiosis lipoidica; Dermatology; Ruxolitinib; Medicine; Diabetes mellitus; Internal medicine; Myelofibrosis","score_opus":0.010899593492939943,"score_gpt":0.3138308872178585,"score_spread":0.30293129372491856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406296138","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9537001,0.016383296,0.0059080212,0.0038681857,0.00043315798,0.0003386956,0.0002843789,0.00029375547,0.018790394],"genre_scores_gemma":[0.9928241,0.0025820811,0.0013486992,0.00081240496,0.00033967997,0.000024689642,0.000065873704,0.000015574324,0.0019869814],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99950635,0.00006751114,0.000049393333,0.00013316197,0.00008507992,0.00015841254],"domain_scores_gemma":[0.9991672,0.00027436338,0.00019870997,0.000082222316,0.000053288903,0.00022428877],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000303622,0.0012363743,0.0010826339,0.0016197945,0.0014709115,0.0012822712,0.00082600093,0.0035354476,0.0017136111],"category_scores_gemma":[0.0014212121,0.00076851924,0.000942194,0.0010952725,0.0011472626,0.0013790814,0.0010143274,0.0023435648,0.00059200195],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000031423046,0.000036090285,0.0016749075,0.000024328901,0.0000068236486,0.9960393,0.00008202482,0.000030537343,0.00087286823,0.00006543668,0.000105120154,0.0010310583],"study_design_scores_gemma":[0.0000125571705,0.00005695169,0.0016969611,0.000010018948,0.000010269763,0.99701154,0.00005564365,0.00014684329,0.00051915145,0.000035624675,0.000438947,0.000005547682],"about_ca_topic_score_codex":0.0016842915,"about_ca_topic_score_gemma":0.0020194368,"teacher_disagreement_score":0.0035354476,"about_ca_system_score_codex":0.00093399605,"about_ca_system_score_gemma":0.00049853424,"threshold_uncertainty_score":0.006776631},"labels":[],"label_agreement":null},{"id":"W4408493760","doi":"10.25251/skin.10.supp.567","title":"Efficacy and Safety of Efinaconazole 10% Topical Solution for Onychomycosis Treatment in Older Adults","year":2025,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Nail Diseases and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mediprobe Research (Canada); University of Toronto","funders":"","keywords":"Dermatology; Medicine","score_opus":0.008574743314145362,"score_gpt":0.29102257769441076,"score_spread":0.2824478343802654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408493760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97127986,0.024975365,0.000316298,0.00025556423,0.00010020942,0.00081917853,0.0007095243,0.000026137599,0.0015178801],"genre_scores_gemma":[0.99356294,0.0044018226,0.00047083705,0.0003965276,0.00008776442,0.0004566672,0.00035045008,0.0000029352814,0.000270007],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9987041,0.0006516505,0.00019813563,0.00017216834,0.0001839727,0.000090085145],"domain_scores_gemma":[0.9984908,0.00037603627,0.00075509277,0.000052912386,0.00014760788,0.00017744715],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031080479,0.00053043524,0.0014571755,0.00045180286,0.0002609924,0.00051637366,0.00030145526,0.000862489,0.0020833951],"category_scores_gemma":[0.0027847385,0.00023282842,0.0015278595,0.00033010048,0.00030209686,0.00047857888,0.00031993448,0.00062574167,0.00019056335],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.58174485,0.009914048,0.04339056,0.009055789,0.013744285,0.00022065437,0.00045888848,0.0008018482,0.031454224,0.0001893407,0.0025435325,0.30648196],"study_design_scores_gemma":[0.20110951,0.47855955,0.2840194,0.0021568125,0.018659284,0.0006988172,0.00042952137,0.0010985275,0.0058945864,0.00037822436,0.0069031455,0.00009269671],"about_ca_topic_score_codex":0.00065135205,"about_ca_topic_score_gemma":0.0023787902,"teacher_disagreement_score":0.0031080479,"about_ca_system_score_codex":0.00038396177,"about_ca_system_score_gemma":0.00070956966,"threshold_uncertainty_score":0.016437173},"labels":[],"label_agreement":null},{"id":"W4408493853","doi":"10.25251/skin.10.supp.538","title":"Deucravacitinib in Psoriasis Patients with a History of Malignancy: Follow-up after 4 Years of Deucravacitinib Treatment in the POETYK PSO Program","year":2025,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"Incyte; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Psoriasis; Malignancy; Medicine; Dermatology; Internal medicine","score_opus":0.00954215173484367,"score_gpt":0.23473512960486337,"score_spread":0.22519297787001968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408493853","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968454,0.0011646701,0.00013076294,0.000057880625,0.000010491012,0.000052131305,0.0006509407,0.0000074872273,0.0010801784],"genre_scores_gemma":[0.9984156,0.00027165277,0.000070657006,0.00006237041,0.000017780518,0.00002501765,0.00086938625,0.0000016768455,0.00026586503],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994242,0.00011118969,0.00006464679,0.00016027801,0.0001384112,0.000101213984],"domain_scores_gemma":[0.9987581,0.000181514,0.0006423543,0.00006205747,0.00013959418,0.00021644453],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009337381,0.00013947573,0.0005702964,0.0006120201,0.00058172614,0.0006998339,0.0002756928,0.00033682547,0.001046131],"category_scores_gemma":[0.0014870048,0.00019257146,0.0007688466,0.00079708913,0.00013127342,0.00053061143,0.00031682933,0.0006982484,0.00023191894],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031073785,0.00022179369,0.98254377,0.000044770815,0.00022222263,0.00019319469,0.00006954173,0.0001277895,0.00051928597,0.000019661255,0.00042311236,0.012507524],"study_design_scores_gemma":[0.0001855605,0.0012230759,0.99569124,0.000023447663,0.0002615844,0.00073114753,0.00009825885,0.00035778075,0.00030534496,0.000037034242,0.0010763343,0.000009168909],"about_ca_topic_score_codex":0.0029476578,"about_ca_topic_score_gemma":0.004640346,"teacher_disagreement_score":0.0029476578,"about_ca_system_score_codex":0.00055054814,"about_ca_system_score_gemma":0.00052285014,"threshold_uncertainty_score":0.0058609843},"labels":[],"label_agreement":null},{"id":"W4408497907","doi":"10.25251/skin.10.supp.534","title":"Deucravacitinib in Plaque Psoriasis: Immune Response to and Safety of Pneumococcus and Tetanus Toxoid Vaccines in the POETYK LTE Trial","year":2025,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"","keywords":"Toxoid; Tetanus; Medicine; Immune system; Plaque psoriasis; Immunology; Psoriasis; Microbiology; Vaccination; Biology","score_opus":0.009630359305753027,"score_gpt":0.2599379885476756,"score_spread":0.25030762924192257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408497907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97939074,0.01081126,0.00029172213,0.00073874433,0.0001951006,0.0010053933,0.0010837511,0.000076680095,0.0064067333],"genre_scores_gemma":[0.99488384,0.0016369236,0.00018834454,0.00046699573,0.00013284605,0.000542971,0.00092579646,0.000006882435,0.0012154079],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9993724,0.00030443646,0.000048907797,0.0000799828,0.00007396769,0.00012025037],"domain_scores_gemma":[0.9994418,0.0001357221,0.00014497645,0.00004915351,0.00005542053,0.00017295865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016208483,0.00051734643,0.0010873439,0.00013374253,0.0003026463,0.0009791366,0.00035487098,0.00083933515,0.0028450314],"category_scores_gemma":[0.0011997159,0.00020021037,0.001290959,0.00015813466,0.0003285899,0.0007120394,0.0002997955,0.001911653,0.00047631672],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8417816,0.0051911813,0.011855494,0.0021388452,0.0034313204,0.00021727962,0.00017744776,0.0014078666,0.009599837,0.0004743163,0.006803247,0.116921656],"study_design_scores_gemma":[0.6926302,0.21008076,0.069002405,0.0004759625,0.0041281474,0.0012271659,0.00017842077,0.0027584021,0.004992499,0.0013132063,0.0131367985,0.00007613977],"about_ca_topic_score_codex":0.0005585132,"about_ca_topic_score_gemma":0.0013898059,"teacher_disagreement_score":0.0028450314,"about_ca_system_score_codex":0.0006808122,"about_ca_system_score_gemma":0.0006659625,"threshold_uncertainty_score":0.0095175505},"labels":[],"label_agreement":null},{"id":"W4408498262","doi":"10.25251/skin.10.supp.526","title":"Bimekizumab Maintenance of Response at Every Visit Over 4 Years in Patients with Psoriasis Achieving Clear Skin at Week 16: Results from Four Phase 3 Trials","year":2025,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Psoriasis; Medicine; Phase (matter); Dermatology; Internal medicine; Chemistry","score_opus":0.016137967611291333,"score_gpt":0.26463942600066387,"score_spread":0.24850145838937254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408498262","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9134575,0.07217217,0.0016073799,0.0011941091,0.00029716102,0.0041643465,0.00265351,0.00021142728,0.0042424044],"genre_scores_gemma":[0.9661963,0.021662427,0.0026058939,0.0015905972,0.00033389332,0.0034956848,0.002572635,0.000069320515,0.0014732766],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99741095,0.0013473678,0.00027921182,0.00030089426,0.0003599152,0.00030175466],"domain_scores_gemma":[0.99560416,0.0014926741,0.0013436496,0.00052513875,0.00046365478,0.0005707355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009754773,0.0011019402,0.0031120898,0.00049875735,0.00057166704,0.0019253386,0.0009931793,0.0014331492,0.002767817],"category_scores_gemma":[0.005437751,0.00049636135,0.0049862782,0.0009224438,0.00083695236,0.0012557349,0.0005006104,0.0032857896,0.0006256188],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.71307,0.015141424,0.011038819,0.0055598323,0.012100022,0.00013920786,0.00048776154,0.0016130315,0.011385699,0.00024484232,0.004875839,0.2243436],"study_design_scores_gemma":[0.6277315,0.30219078,0.045400348,0.0010191099,0.010097976,0.00052030315,0.00017171445,0.00089038635,0.0032941687,0.0006673871,0.007894324,0.00012195134],"about_ca_topic_score_codex":0.00094841607,"about_ca_topic_score_gemma":0.001938133,"teacher_disagreement_score":0.009754773,"about_ca_system_score_codex":0.0010471636,"about_ca_system_score_gemma":0.0014347476,"threshold_uncertainty_score":0.051588833},"labels":[],"label_agreement":null},{"id":"W4408498282","doi":"10.25251/skin.10.supp.531","title":"Long-Term Effectiveness of Guselkumab vs. Other Biologic Therapies Among Plaque Psoriasis Patients in the CorEvitas Psoriasis Registry","year":2025,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Psoriasis; Plaque psoriasis; Medicine; Dermatology; Term (time)","score_opus":0.01039560788878543,"score_gpt":0.25438247411742243,"score_spread":0.243986866228637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408498282","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961617,0.0011610056,0.00010786441,0.000091158014,0.000019005876,0.00012715656,0.0011747606,0.000010157426,0.0011471731],"genre_scores_gemma":[0.9973105,0.00033138334,0.00022332653,0.00008618178,0.00003909339,0.00015848974,0.0016333115,0.00000554605,0.00021212094],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9912204,0.0043667797,0.00076430687,0.0011713154,0.002017979,0.00045923385],"domain_scores_gemma":[0.9922421,0.002163975,0.0031284152,0.0007425219,0.00069795334,0.0010250193],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01121389,0.00025036905,0.001086469,0.00057604077,0.00054981525,0.0011621459,0.0007584777,0.00043646756,0.0014886708],"category_scores_gemma":[0.010009827,0.0001870187,0.0011764881,0.0009149933,0.00038466044,0.00088333746,0.000907254,0.00080686284,0.0002763934],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16083504,0.0043522767,0.75678533,0.00049785036,0.003453841,0.00009387084,0.0004003865,0.001198562,0.0014428052,0.0002762522,0.0022879506,0.06837583],"study_design_scores_gemma":[0.011333364,0.038406163,0.9382169,0.00014599519,0.003598621,0.00033750254,0.0004450133,0.0027064406,0.0014857231,0.00019650727,0.003057686,0.00006998648],"about_ca_topic_score_codex":0.0060995882,"about_ca_topic_score_gemma":0.011114212,"teacher_disagreement_score":0.01121389,"about_ca_system_score_codex":0.0017221541,"about_ca_system_score_gemma":0.0022763493,"threshold_uncertainty_score":0.05930537},"labels":[],"label_agreement":null},{"id":"W4409574408","doi":"10.25251/skin.10.supp.573","title":"Long-Term Safety and Efficacy of Tralokinumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis Treated for up to 6 Years","year":2025,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bausch Health; LEO Pharma; Galderma; Incyte; Regeneron Pharmaceuticals; Celgene; Sanofi; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Atopic dermatitis; Term (time); Medicine; Pediatrics; Dermatology; Physics","score_opus":0.005786183515752849,"score_gpt":0.2590034322650996,"score_spread":0.25321724874934676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409574408","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99651355,0.0024355869,0.00005507039,0.00006293808,0.000014143596,0.000059337017,0.00032047203,0.0000046748487,0.00053432886],"genre_scores_gemma":[0.99826187,0.00067861145,0.00010206102,0.00012150112,0.000023873936,0.000067423156,0.00043293668,0.0000013913269,0.00031019916],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996401,0.0000949378,0.00004215741,0.000071524075,0.000091370996,0.000059801932],"domain_scores_gemma":[0.9992242,0.00013397798,0.0003386633,0.000027714177,0.00009094568,0.00018444633],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000967325,0.00018091369,0.000534841,0.0001950929,0.00028550703,0.00047654883,0.00014981025,0.00033736406,0.0010641067],"category_scores_gemma":[0.001113541,0.00014077377,0.0006958453,0.00022234596,0.00016242171,0.00029274,0.00016236535,0.0007516694,0.00025968556],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04896796,0.0053022304,0.82093906,0.0007045423,0.0014689667,0.0007268033,0.00056477834,0.00051661365,0.008089953,0.00008244601,0.0020200026,0.11061662],"study_design_scores_gemma":[0.006043729,0.047334682,0.93781227,0.00019854163,0.0011123993,0.0016793405,0.00026190554,0.0005316874,0.0012819038,0.000047471553,0.00367666,0.0000194187],"about_ca_topic_score_codex":0.0010189586,"about_ca_topic_score_gemma":0.0023461182,"teacher_disagreement_score":0.0010641067,"about_ca_system_score_codex":0.0004298882,"about_ca_system_score_gemma":0.0005034049,"threshold_uncertainty_score":0.0051157475},"labels":[],"label_agreement":null},{"id":"W4412600394","doi":"10.25251/gdd40x24","title":"Long-term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-year Results from the ALLEGRO-LT Phase 3, Open-label Study","year":2025,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Hair Growth and Disorders","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"LEO Pharma; Eli Lilly and Company; Concert Pharmaceuticals; L'Oreal USA; Sanofi; Pfizer","keywords":"Alopecia areata; Open label; Dermatology; Medicine; Term (time); Pediatrics; Adverse effect; Internal medicine; Physics","score_opus":0.015270157276328807,"score_gpt":0.3098022576172259,"score_spread":0.2945321003408971,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412600394","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852276,0.010813762,0.00027341314,0.00023216689,0.00003782254,0.00021632866,0.0016353383,0.000031032672,0.0015325465],"genre_scores_gemma":[0.9950789,0.0018163775,0.000320068,0.00031872778,0.00005771973,0.00012211321,0.0018964923,0.000005538434,0.00038398567],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9993649,0.00023306166,0.000063626074,0.000095480806,0.00016635035,0.00007660283],"domain_scores_gemma":[0.9984823,0.0003106567,0.0006635884,0.00007295186,0.00019907378,0.00027152273],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022869566,0.00025487662,0.0008601738,0.00018636663,0.00026346353,0.0006714557,0.00024991474,0.00042884017,0.0012732926],"category_scores_gemma":[0.0009979968,0.00011874653,0.0011369815,0.00026076334,0.00020237917,0.00054382876,0.00018221365,0.000925138,0.00035062424],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1363704,0.008604329,0.4527326,0.0030514088,0.0058611133,0.0007445006,0.0008090033,0.0023980322,0.026187778,0.00018985497,0.010825532,0.3522255],"study_design_scores_gemma":[0.026833473,0.100296594,0.8516981,0.00032933382,0.002928304,0.0017893842,0.00020538265,0.0014012534,0.0040681986,0.0001347382,0.010253994,0.000061197665],"about_ca_topic_score_codex":0.00066648505,"about_ca_topic_score_gemma":0.002385199,"teacher_disagreement_score":0.0022869566,"about_ca_system_score_codex":0.00042401208,"about_ca_system_score_gemma":0.00044217423,"threshold_uncertainty_score":0.012094736},"labels":[],"label_agreement":null},{"id":"W4412600525","doi":"10.25251/2cx1vk07","title":"Real-World Ritlecitinib Treatment of Severe Alopecia Areata (AA) in the US: Patient Characteristics and Physician Satisfaction","year":2025,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Hair Growth and Disorders","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada)","funders":"Incyte; Sanofi; Pfizer","keywords":"Alopecia areata; Dermatology; Patient satisfaction; Medicine; Family medicine; Nursing","score_opus":0.00935563584456081,"score_gpt":0.2705095618040149,"score_spread":0.26115392595945414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412600525","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987374,0.00016281755,0.00003432668,0.00007148784,0.000002075697,0.000013034619,0.00063944573,0.0000020530254,0.00033745787],"genre_scores_gemma":[0.9992907,0.00008583121,0.00005503827,0.00006910281,0.0000056188574,0.0000134217535,0.00043257067,7.27507e-7,0.00004707201],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994911,0.00022101836,0.00007150359,0.000060187835,0.00008885434,0.00006724832],"domain_scores_gemma":[0.9977852,0.00040938062,0.0012920778,0.000048594313,0.00015694847,0.00030768724],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070723245,0.00009552807,0.00021789192,0.00042444418,0.00023433146,0.00034235904,0.000114490584,0.00024126751,0.0010833993],"category_scores_gemma":[0.0020580003,0.00009693424,0.00032379964,0.00080074184,0.00013485485,0.00030332193,0.00024091652,0.00025377647,0.00017013613],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026800012,0.00010826995,0.9948021,0.000027118906,0.00005169057,0.0000807321,0.00018366806,0.00005801488,0.000161001,0.000009081384,0.00055916316,0.0036912148],"study_design_scores_gemma":[0.000028926019,0.00025658886,0.9981396,0.000011250989,0.00002758582,0.0005032961,0.000405059,0.00018591303,0.000053357402,0.000007715005,0.00037613674,0.0000046713976],"about_ca_topic_score_codex":0.0035112598,"about_ca_topic_score_gemma":0.00758387,"teacher_disagreement_score":0.0035112598,"about_ca_system_score_codex":0.00030811562,"about_ca_system_score_gemma":0.00026463292,"threshold_uncertainty_score":0.0069816113},"labels":[],"label_agreement":null},{"id":"W4412600941","doi":"10.25251/ed52rz19","title":"Updated Integrated Safety Analysis of Ritlecitinib Over 72 Months In Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program","year":2025,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Hair Growth and Disorders","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Galderma; L'Oreal USA; LEO Pharma; Pfizer; Eli Lilly and Company","keywords":"Alopecia areata; Medicine; Dermatology; Clinical trial; Family medicine; Internal medicine","score_opus":0.012535400783838212,"score_gpt":0.32108735056964105,"score_spread":0.30855194978580286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412600941","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8352702,0.069490805,0.0069488743,0.002452559,0.00027345694,0.007977382,0.055579886,0.00067594287,0.021330997],"genre_scores_gemma":[0.9184282,0.0093402,0.0049141236,0.0026182136,0.00059861736,0.0043814247,0.056426898,0.00011802052,0.0031742868],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99238706,0.0032958188,0.00080500677,0.0008213082,0.0023235867,0.00036724674],"domain_scores_gemma":[0.98565257,0.0034540836,0.006181036,0.0010107409,0.0028739322,0.0008276676],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015001051,0.0006874612,0.0023970832,0.0012796798,0.00043905375,0.0019741904,0.0010306117,0.0007747828,0.004759426],"category_scores_gemma":[0.009130972,0.00039793435,0.0035237668,0.0018660635,0.0002944087,0.0014228575,0.0007988148,0.0017792551,0.0006854362],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30139923,0.003521609,0.12589389,0.010985536,0.05163922,0.00033664049,0.00040092465,0.007460648,0.013162062,0.0005891421,0.035066076,0.44954506],"study_design_scores_gemma":[0.117474556,0.07794441,0.66977906,0.0018470832,0.045984313,0.0023980604,0.00013777458,0.0052690534,0.006709348,0.0010360031,0.07118518,0.00023514939],"about_ca_topic_score_codex":0.0010366465,"about_ca_topic_score_gemma":0.003352776,"teacher_disagreement_score":0.015001051,"about_ca_system_score_codex":0.0012404309,"about_ca_system_score_gemma":0.0021174457,"threshold_uncertainty_score":0.07933402},"labels":[],"label_agreement":null},{"id":"W4416084832","doi":"10.25251/apx36v88","title":"Real-World Effectiveness of Upadacitinib in Moderate-to-Severe Atopic Dermatitis: Results from Longitudinal Analyses in 6- and 12-month Cohorts From the PPD CorEvitas Atopic Dermatitis Registry","year":2025,"lang":"","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Probity Medical Research; Queen's University","funders":"","keywords":"Eczema Area and Severity Index; Atopic dermatitis; Quality of life (healthcare); Clinical trial; Adverse effect; Rating scale","score_opus":0.021700364962630756,"score_gpt":0.3150602236048239,"score_spread":0.2933598586421931,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416084832","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98486614,0.0020763257,0.00035735383,0.00015543059,0.000031366013,0.00013804533,0.011510824,0.000021834821,0.00084276893],"genre_scores_gemma":[0.97882915,0.00066858734,0.0005512147,0.00014940398,0.00006580301,0.00022859822,0.01913652,0.000017678849,0.00035301058],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9934669,0.0027343521,0.00087540416,0.0012858408,0.0012144351,0.00042313454],"domain_scores_gemma":[0.9798696,0.0036852774,0.009574118,0.0030114003,0.002807373,0.0010522685],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010372302,0.00046244773,0.0009965721,0.0007775894,0.0005794413,0.0014848822,0.0008254109,0.00061240076,0.0010889445],"category_scores_gemma":[0.014725224,0.00038253542,0.0019008268,0.0016792621,0.00035452607,0.0008996371,0.0010002075,0.0011111689,0.00046476675],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0074548475,0.00040025878,0.97929734,0.0001931622,0.0029843075,0.000076610646,0.00012284216,0.00034106898,0.00024112416,0.000068101894,0.0018432669,0.006977126],"study_design_scores_gemma":[0.00059643347,0.0014622931,0.9932268,0.00006584929,0.001709632,0.0002774909,0.00010419035,0.00043106065,0.00022070187,0.000048179958,0.0018250602,0.0000322928],"about_ca_topic_score_codex":0.0058817603,"about_ca_topic_score_gemma":0.008113484,"teacher_disagreement_score":0.010372302,"about_ca_system_score_codex":0.0007982137,"about_ca_system_score_gemma":0.0009598945,"threshold_uncertainty_score":0.05485457},"labels":[],"label_agreement":null},{"id":"W4416084993","doi":"10.25251/0j9fht97","title":"Updated Integrated Safety Analysis of Ritlecitinib Up to ~5 Years in Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program","year":2025,"lang":"","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Hair Growth and Disorders","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Alopecia areata; Adverse effect; Incidence (geometry); Clinical trial; Safety profile; Pooled analysis","score_opus":0.015743953093950377,"score_gpt":0.33313335284524365,"score_spread":0.31738939975129327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416084993","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.715838,0.119869396,0.0131969815,0.0041176127,0.0004942613,0.011826215,0.10006005,0.0010841514,0.03351328],"genre_scores_gemma":[0.86374897,0.013760117,0.0085002445,0.004162215,0.0009165877,0.006933269,0.0970678,0.00018319773,0.0047275936],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98816675,0.004962984,0.0013281665,0.0011529938,0.0037267862,0.00066223467],"domain_scores_gemma":[0.97874486,0.005221102,0.008434556,0.0015596059,0.004935905,0.0011038688],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02123892,0.00077466836,0.0028685275,0.0018949738,0.00047295043,0.002403412,0.0012763366,0.0008783064,0.004918957],"category_scores_gemma":[0.013105499,0.00049480645,0.0047057117,0.0023386166,0.000293202,0.001750231,0.0011345191,0.0018458922,0.00078525575],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20857483,0.0021521146,0.1345997,0.012049885,0.056135885,0.00032897468,0.00039135868,0.009118229,0.011370228,0.0009770773,0.04619105,0.5181107],"study_design_scores_gemma":[0.07269934,0.058805116,0.66917497,0.0027021721,0.06225458,0.0023427182,0.00015934113,0.0062842784,0.006278923,0.0017387641,0.11726744,0.00029245557],"about_ca_topic_score_codex":0.0012413374,"about_ca_topic_score_gemma":0.004106451,"teacher_disagreement_score":0.02123892,"about_ca_system_score_codex":0.0015213926,"about_ca_system_score_gemma":0.0026721393,"threshold_uncertainty_score":0.11232352},"labels":[],"label_agreement":null},{"id":"W4416140151","doi":"10.25251/9zz14r68","title":"Real-World Comparative Effectiveness of Deucravacitinib vs Apremilast at 6 Months for Plaque Psoriasis: Skin Clearance Outcomes From the RePhlect Study","year":2025,"lang":"","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; SKiN Health","funders":"Janssen Pharmaceuticals; Genentech; LEO Pharma; Ortho Dermatologics; Bristol-Myers Squibb; Eli Lilly and Company; Chugai Pharmaceutical; Pfizer; National Psoriasis Foundation; Amgen","keywords":"Apremilast; Clinical trial; Plaque psoriasis; MEDLINE","score_opus":0.023430808397990298,"score_gpt":0.30673503431089494,"score_spread":0.28330422591290466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416140151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98649037,0.009289969,0.00024194461,0.0003740663,0.00018203954,0.00030534127,0.0020117788,0.000022452605,0.0010820462],"genre_scores_gemma":[0.99510753,0.0015154999,0.0003213542,0.00028136084,0.00018955866,0.0002293533,0.0018403898,0.000011166264,0.00050382764],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9968901,0.0017158877,0.000272936,0.0004990348,0.0002994327,0.0003225411],"domain_scores_gemma":[0.99561214,0.0014139593,0.0014770315,0.00045770901,0.00027373992,0.0007654015],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049145175,0.0012702612,0.003398592,0.00046575084,0.00043899723,0.001591429,0.0009980006,0.0016169323,0.0037868011],"category_scores_gemma":[0.004687314,0.00046997247,0.006203949,0.000651728,0.0010372224,0.0020072574,0.0006110872,0.0033353595,0.0007578199],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95215714,0.0030776686,0.008514126,0.0010258137,0.011552869,0.00009281101,0.00009110351,0.001281574,0.0013735574,0.00015534754,0.0009830035,0.019695101],"study_design_scores_gemma":[0.65784097,0.19722098,0.11194797,0.0003829805,0.024259496,0.00044914268,0.0003640576,0.0020562499,0.0013001291,0.00060585403,0.0033650624,0.00020704708],"about_ca_topic_score_codex":0.001814324,"about_ca_topic_score_gemma":0.0026173785,"teacher_disagreement_score":0.0049145175,"about_ca_system_score_codex":0.0015092876,"about_ca_system_score_gemma":0.0007636976,"threshold_uncertainty_score":0.025990784},"labels":[],"label_agreement":null},{"id":"W4416140208","doi":"10.25251/gmn1ta26","title":"Lebrikizumab Patients Treated in the Real World: First North American data from the PPD<sup>TM</sup> CorEvitas<sup>TM</sup> AD Registry","year":2025,"lang":"","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health; Probity Medical Research; Foothills Medical Centre; University of Calgary","funders":"Eli Lilly and Company","keywords":"MEDLINE; Disease; Epidemiology; Incidence (geometry); Data collection","score_opus":0.01739020930894231,"score_gpt":0.27928569984755447,"score_spread":0.26189549053861216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416140208","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9694792,0.0023845565,0.00032996773,0.00034310116,0.000032184038,0.00007839894,0.021081302,0.000032264743,0.0062391404],"genre_scores_gemma":[0.98013306,0.001220353,0.000276052,0.00034110848,0.000054005253,0.00007886381,0.01733853,0.000013489306,0.0005445585],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99930525,0.00019321866,0.00009072227,0.00014656132,0.00018322383,0.000081010505],"domain_scores_gemma":[0.9980716,0.00026899553,0.000953501,0.00020713956,0.0002986624,0.00020016453],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007326136,0.00015828945,0.00035792717,0.00048630615,0.00030980044,0.00085755583,0.00024670473,0.00026885042,0.0014934359],"category_scores_gemma":[0.0012276248,0.00024401612,0.00026544253,0.0014579986,0.00020870651,0.00061458675,0.00042136436,0.00057946343,0.0004649103],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00062740716,0.00010902598,0.9846768,0.000127805,0.00024402027,0.00016842721,0.00019902702,0.00016985493,0.00045930513,0.00010011907,0.005290282,0.007827873],"study_design_scores_gemma":[0.00011491177,0.00015210218,0.9921692,0.00005818155,0.00011871379,0.0005980664,0.0004487203,0.00020658471,0.00017760124,0.000052825224,0.0058891242,0.000013999639],"about_ca_topic_score_codex":0.008413204,"about_ca_topic_score_gemma":0.015801216,"teacher_disagreement_score":0.008413204,"about_ca_system_score_codex":0.0003977525,"about_ca_system_score_gemma":0.0004960187,"threshold_uncertainty_score":0.01672846},"labels":[],"label_agreement":null},{"id":"W4416140290","doi":"10.25251/vmn4mf70","title":"The Impact of Moderate-to-Severe Atopic Dermatitis on Sleep in Adolescent Patients from the Adelphi Real World Disease Specific Programme (DSP)<sup>TM</sup>","year":2025,"lang":"","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health; Probity Medical Research; Foothills Medical Centre; University of Calgary","funders":"","keywords":"Atopic dermatitis; Disease; Sleep (system call); MEDLINE; Population","score_opus":0.015322233882585974,"score_gpt":0.2784670552779415,"score_spread":0.26314482139535555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416140290","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99864084,0.00021544159,0.0000078727435,0.00006850896,0.000005748539,0.0000068391946,0.0003563812,9.588915e-7,0.000697372],"genre_scores_gemma":[0.9995258,0.00010309383,0.000010872903,0.00002411555,0.0000052956043,0.0000034034706,0.0002071792,6.421761e-7,0.00011968483],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997943,0.000058092886,0.000024145666,0.000026503556,0.000037901176,0.000059046557],"domain_scores_gemma":[0.99924004,0.0001170641,0.0002573781,0.000016459344,0.00006648803,0.0003025921],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023073431,0.00012430036,0.0001929742,0.00035026824,0.0003122545,0.00037730558,0.00017836023,0.00021079821,0.0019888852],"category_scores_gemma":[0.0011612274,0.00010379956,0.0003562951,0.0004142699,0.00015625582,0.00020978008,0.00033931847,0.00045319952,0.0001379366],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016929295,0.00005938379,0.99732757,0.00001976437,0.00003373244,0.000117394025,0.000100214784,0.000018559382,0.00010385459,0.000010497918,0.00013621738,0.0019034998],"study_design_scores_gemma":[0.0000025184668,0.00006666035,0.9995641,0.000005084867,0.0000099009785,0.000075810014,0.00019013195,0.000014582045,0.000008204466,0.0000027716374,0.000059226382,9.806205e-7],"about_ca_topic_score_codex":0.018981135,"about_ca_topic_score_gemma":0.043588642,"teacher_disagreement_score":0.018981135,"about_ca_system_score_codex":0.00038891812,"about_ca_system_score_gemma":0.0003793784,"threshold_uncertainty_score":0.037741303},"labels":[],"label_agreement":null},{"id":"W4416140380","doi":"10.25251/14pn6v71","title":"Lebrikizumab Dosed Every 8 Weeks as Maintenance Provides Long-Lasting Response in Patients with Moderate-to-Severe Atopic Dermatitis","year":2025,"lang":"","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Imputation (statistics); Atopic dermatitis; Dosing; Check List; Eczema Area and Severity Index; Medical record","score_opus":0.005441398379629446,"score_gpt":0.24390871564290686,"score_spread":0.2384673172632774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416140380","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982426,0.0009536667,0.00015025563,0.00008163602,0.000012236058,0.000061767016,0.0000711706,0.000012530792,0.00041410816],"genre_scores_gemma":[0.99899286,0.0002243367,0.00033434297,0.000078564306,0.000020846057,0.00004274234,0.00010307424,0.0000018215828,0.00020135992],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9994893,0.00025963597,0.000051009876,0.00007661566,0.00006937799,0.000054104858],"domain_scores_gemma":[0.99902785,0.00040159235,0.00026640634,0.00010008891,0.00006692152,0.00013711344],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020788377,0.0001909502,0.0006057425,0.00013164082,0.00017184758,0.00043588065,0.0002409087,0.0002452792,0.0010414658],"category_scores_gemma":[0.001673154,0.0001219753,0.000790442,0.00016116485,0.00016293157,0.00033583003,0.00022894697,0.00049469987,0.00016862607],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15808146,0.008891045,0.2831307,0.00096430053,0.0011099369,0.00044217726,0.0004791492,0.002294332,0.031310428,0.00018473677,0.0025238113,0.5105879],"study_design_scores_gemma":[0.06401629,0.22952695,0.6840316,0.00019684846,0.0010428568,0.0014027451,0.00040800148,0.0050424165,0.007646392,0.0004357053,0.0061987303,0.000051422787],"about_ca_topic_score_codex":0.00038700397,"about_ca_topic_score_gemma":0.0010975924,"teacher_disagreement_score":0.0020788377,"about_ca_system_score_codex":0.0002591874,"about_ca_system_score_gemma":0.00035533326,"threshold_uncertainty_score":0.010994017},"labels":[],"label_agreement":null},{"id":"W4416140478","doi":"10.25251/ta5v8k92","title":"Bimekizumab rates of oral candidiasis in patients with moderate to severe plaque psoriasis: Results from up to 4 years of five phase 3/3b studies","year":2025,"lang":"","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"","keywords":"Incidence (geometry); Adverse effect; Esophageal candidiasis; Nystatin; Oral microbiology; Mycosis","score_opus":0.01726677270135445,"score_gpt":0.2932623388721411,"score_spread":0.27599556617078663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416140478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9309501,0.060112927,0.001046041,0.00034615037,0.00009511727,0.0009824088,0.0034721848,0.00009374894,0.0029012836],"genre_scores_gemma":[0.98681414,0.00779561,0.00060924084,0.0004232752,0.00011660034,0.0004108248,0.0032644758,0.00002065888,0.0005452749],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99494153,0.0019113125,0.00071404217,0.0007436698,0.0012948631,0.0003946515],"domain_scores_gemma":[0.9918725,0.002046214,0.0033874833,0.00083697133,0.0010987191,0.0007581801],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015600071,0.00075597054,0.0018375954,0.0008593549,0.0006838823,0.0018958045,0.0008252547,0.0013463597,0.001473435],"category_scores_gemma":[0.0053705834,0.0005551335,0.0042488314,0.0012200251,0.0006457253,0.0010606085,0.00089155824,0.0014283967,0.00034778353],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24140936,0.0052148458,0.4846561,0.005488799,0.03768196,0.00032159337,0.0007579438,0.0017257194,0.012361165,0.00025970704,0.0047847363,0.20533806],"study_design_scores_gemma":[0.03780233,0.07248503,0.8489227,0.0010082595,0.02481339,0.0011488885,0.00028858794,0.00065983547,0.0038043947,0.00030440598,0.00861153,0.00015049858],"about_ca_topic_score_codex":0.0011502758,"about_ca_topic_score_gemma":0.0018732927,"teacher_disagreement_score":0.015600071,"about_ca_system_score_codex":0.00087835913,"about_ca_system_score_gemma":0.0010891063,"threshold_uncertainty_score":0.08250207},"labels":[],"label_agreement":null},{"id":"W4416140920","doi":"10.25251/2q1bnf78","title":"Real-World Effectiveness of Guselkumab in Patients With Psoriasis: Data From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)","year":2025,"lang":"","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Psoriasis; Psoriasis Area and Severity Index; Body surface area; Severity of illness; Longitudinal study; Disease; Clinical trial","score_opus":0.017512896759632787,"score_gpt":0.29013079450370094,"score_spread":0.27261789774406814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416140920","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9547375,0.0051533794,0.0014801786,0.00053121126,0.00004651234,0.00035331637,0.034350254,0.000058761907,0.0032889093],"genre_scores_gemma":[0.9644377,0.0013000737,0.0016592024,0.00032619375,0.00009923967,0.00072474574,0.031135917,0.000021944552,0.00029490882],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98505396,0.00871345,0.002639903,0.0013397821,0.0018849595,0.00036800298],"domain_scores_gemma":[0.96417326,0.010844305,0.019837061,0.0022576042,0.0020284853,0.000859277],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010950159,0.00027090733,0.0008472117,0.0011019575,0.00039908296,0.001215704,0.0005501694,0.00047083874,0.0015590978],"category_scores_gemma":[0.017465258,0.00023826055,0.0011730823,0.0021501286,0.00037063722,0.0012061415,0.0006519647,0.0007207601,0.0004176674],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0063340496,0.00036566606,0.97135395,0.00044621888,0.0012195009,0.000076922006,0.0001400602,0.0007191597,0.0002496191,0.00014921096,0.0024625116,0.016483096],"study_design_scores_gemma":[0.0013718539,0.0033419465,0.98370117,0.00022936345,0.0010928505,0.0006042435,0.00022852917,0.0012239993,0.00061862665,0.00020623495,0.0073260106,0.000055286815],"about_ca_topic_score_codex":0.0016858429,"about_ca_topic_score_gemma":0.0020623235,"teacher_disagreement_score":0.010950159,"about_ca_system_score_codex":0.0006936812,"about_ca_system_score_gemma":0.00081297685,"threshold_uncertainty_score":0.05791068},"labels":[],"label_agreement":null},{"id":"W4416140942","doi":"10.25251/sbrgz434","title":"Impact of Simultaneous Itch Relief and Substantial Skin Clearance With Lebrikizumab in Patients With Atopic Dermatitis: Post-hoc Analysis From ADvocate1/2","year":2025,"lang":"","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; SKiN Health; University of British Columbia","funders":"","keywords":"Clearance; Disease; MEDLINE; Clinical trial; Atopic dermatitis","score_opus":0.0029901312234496243,"score_gpt":0.24328544767987717,"score_spread":0.24029531645642754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416140942","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949003,0.0018685386,0.00043317996,0.00022338421,0.00020518701,0.00014772822,0.0009473357,0.000026243279,0.0012481586],"genre_scores_gemma":[0.9972236,0.00025166682,0.00028850883,0.00018492337,0.00013533425,0.00014639556,0.00084181986,0.00001953589,0.0009083586],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9955407,0.002136923,0.00026614667,0.00089683966,0.0003367295,0.000822645],"domain_scores_gemma":[0.9942537,0.0037549296,0.0006530378,0.00054593175,0.0002525334,0.0005397686],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043073213,0.0013329472,0.0031835882,0.00029514672,0.0005462762,0.0017035519,0.0010794243,0.00097545964,0.0069849747],"category_scores_gemma":[0.0066772155,0.00048664026,0.009607614,0.0003751615,0.0007358204,0.0019418261,0.0009877058,0.0028191535,0.0005605112],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.84773743,0.0013192255,0.09891366,0.0009080814,0.02663837,0.00029515015,0.00018590137,0.0010761912,0.0021021164,0.00023534022,0.0019019315,0.018686593],"study_design_scores_gemma":[0.12561868,0.17390497,0.5859323,0.00039238637,0.08714641,0.00080577936,0.0014121626,0.01058287,0.003801384,0.0014069428,0.008675383,0.00032075663],"about_ca_topic_score_codex":0.0017307122,"about_ca_topic_score_gemma":0.0024656726,"teacher_disagreement_score":0.0069849747,"about_ca_system_score_codex":0.0010057555,"about_ca_system_score_gemma":0.0013712001,"threshold_uncertainty_score":0.023367107},"labels":[],"label_agreement":null},{"id":"W4416140988","doi":"10.25251/0262jz84","title":"Lebrikizumab Treatment Improves Lichenification and Other Clinical Signs of Atopic Dermatitis in Adults and Adolescents with Moderate-to-Severe AD and Skin of Color","year":2025,"lang":"","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of British Columbia","funders":"Eli Lilly and Company; Amgen","keywords":"Phototype; Atopic dermatitis; Trunk; Eczema Area and Severity Index; Concomitant; Population; Clinical trial; Randomized controlled trial","score_opus":0.01108067746716104,"score_gpt":0.2914322233988284,"score_spread":0.2803515459316674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416140988","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990816,0.006504613,0.00016912856,0.00016295926,0.000050030747,0.00025521632,0.00047816383,0.00003921569,0.0015245761],"genre_scores_gemma":[0.9966306,0.0014646905,0.00042655162,0.00022383973,0.00006268261,0.00017370589,0.00040050072,0.0000035171133,0.0006138223],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9996859,0.00014891026,0.000028723096,0.00004721523,0.00004339015,0.000045957895],"domain_scores_gemma":[0.99964404,0.00008949331,0.00013549889,0.000017518858,0.00003641496,0.00007701574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001021673,0.00022353484,0.00075796293,0.00017585234,0.00012979782,0.00029056476,0.00017997771,0.00021079741,0.0025662244],"category_scores_gemma":[0.00068102696,0.000110568464,0.0007519593,0.000126279,0.00015297401,0.00018378721,0.00014228049,0.00051176036,0.00021319835],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25483954,0.014983168,0.16212988,0.0051422166,0.0039787353,0.0002813175,0.00036604467,0.0020120086,0.055715155,0.00031577674,0.006822791,0.49341327],"study_design_scores_gemma":[0.08662819,0.25075448,0.6352371,0.00065704214,0.0027493527,0.0010288946,0.00032830358,0.0022946226,0.010045222,0.00027951814,0.009957782,0.000039546187],"about_ca_topic_score_codex":0.00046340263,"about_ca_topic_score_gemma":0.00221178,"teacher_disagreement_score":0.0025662244,"about_ca_system_score_codex":0.0002532754,"about_ca_system_score_gemma":0.0003274672,"threshold_uncertainty_score":0.008584857},"labels":[],"label_agreement":null},{"id":"W4416141077","doi":"10.25251/ej4zcr36","title":"Estimated Conjunctivitis-Related Healthcare Cost Savings With Increased Tralokinumab Use Versus Other Biologics Among Patients With Moderate-Severe Atopic Dermatitis in the United States","year":2025,"lang":"","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"LEO Pharma","keywords":"Atopic dermatitis; Health care; MEDLINE; Cost analysis; Health economics","score_opus":0.016124761780484255,"score_gpt":0.26677901624789585,"score_spread":0.2506542544674116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416141077","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9255094,0.028249342,0.008964571,0.0011575117,0.00007532636,0.00031028967,0.029250184,0.000076562435,0.006406873],"genre_scores_gemma":[0.98914474,0.0029396527,0.0027094886,0.00017756173,0.000028611188,0.00014340015,0.00418937,0.000008631953,0.00065859884],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989416,0.0005859157,0.00014012938,0.00013315135,0.00013612396,0.000063051666],"domain_scores_gemma":[0.9985964,0.0008467147,0.00030463465,0.00003992109,0.00017770266,0.000034612043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019276151,0.00045749467,0.0005669308,0.0012267401,0.00010180656,0.0008426716,0.00036832882,0.00035001323,0.0025415004],"category_scores_gemma":[0.0066488683,0.0003216079,0.00301082,0.0015340479,0.00011293482,0.0006179449,0.00042330386,0.0004889442,0.00020239268],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006315485,0.0002820563,0.54427576,0.0033786546,0.01949748,0.0007917862,0.0002394057,0.28278768,0.0014320314,0.00559379,0.0061023277,0.12930353],"study_design_scores_gemma":[0.0010717959,0.0020552976,0.82052046,0.0022435244,0.015614416,0.0016740361,0.0006152538,0.13478509,0.0018970744,0.0056703957,0.013742367,0.00011029331],"about_ca_topic_score_codex":0.015635677,"about_ca_topic_score_gemma":0.019339029,"teacher_disagreement_score":0.015635677,"about_ca_system_score_codex":0.0019285198,"about_ca_system_score_gemma":0.0009015163,"threshold_uncertainty_score":0.031089306},"labels":[],"label_agreement":null},{"id":"W4416141089","doi":"10.25251/zkfhw160","title":"Demographics, Clinical, and Treatment Characteristics of Patients With Moderate to Severe Chronic Hand Eczema in the United States – A Retrospective Claims Analysis","year":2025,"lang":"","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Contact Dermatitis and Allergies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Retrospective cohort study; MEDLINE; Epidemiology; Population; Chronic disease","score_opus":0.00954346012523469,"score_gpt":0.2772124074548631,"score_spread":0.26766894732962837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416141089","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970059,0.0003128283,0.00006626369,0.000033414304,0.0000046665627,0.000017086582,0.0019191597,0.0000034316959,0.00063730037],"genre_scores_gemma":[0.9982198,0.0001158072,0.00004084669,0.00004396334,0.00000914509,0.000016681095,0.0014458868,0.0000017332259,0.00010609203],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993807,0.00009494177,0.00012471664,0.00018098099,0.00012613418,0.00009239665],"domain_scores_gemma":[0.9986528,0.00019538893,0.0007360131,0.00009904256,0.00014729938,0.00016950254],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046786916,0.00017630313,0.00035482718,0.00083770516,0.00045791682,0.00052721275,0.00033787603,0.00040286317,0.0016208707],"category_scores_gemma":[0.0012751835,0.00040575204,0.00046755729,0.001691105,0.00028292523,0.0005783855,0.00036701144,0.0005382013,0.00021863279],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008951712,0.000047620186,0.9987472,0.0000089221585,0.000054489967,0.000067450346,0.000034603574,0.000050114944,0.0000888971,0.000017931976,0.00021840201,0.000574787],"study_design_scores_gemma":[0.000007607475,0.00005062732,0.99906176,0.000008160804,0.000024664327,0.00029112428,0.00014160013,0.00019202326,0.000026497579,0.000013629953,0.00017824028,0.0000040270897],"about_ca_topic_score_codex":0.015575655,"about_ca_topic_score_gemma":0.014750274,"teacher_disagreement_score":0.015575655,"about_ca_system_score_codex":0.0005549325,"about_ca_system_score_gemma":0.00050080015,"threshold_uncertainty_score":0.030969977},"labels":[],"label_agreement":null},{"id":"W4416141127","doi":"10.25251/n1p8w126","title":"Integrated Safety Analysis of Abrocitinib in 3850 Patients With Moderate-To-Severe Atopic Dermatitis: Data From More Than 9600 Patient-Years With Up to 6.5 Years of Exposure","year":2025,"lang":"","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Pfizer","keywords":"Adverse effect; Incidence (geometry); Cohort; Population; Clinical trial; Janus kinase inhibitor; Cohort study","score_opus":0.00892148500178399,"score_gpt":0.25848724744308427,"score_spread":0.24956576244130027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416141127","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9458408,0.012649169,0.0024720726,0.00023614363,0.000053903368,0.0028091588,0.030193064,0.00014045539,0.005605243],"genre_scores_gemma":[0.9683215,0.0019300244,0.0014808337,0.000459533,0.00013403357,0.0019171922,0.024457304,0.000024591951,0.0012749841],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963593,0.0011852368,0.0005787991,0.00089921866,0.00080424227,0.00017320525],"domain_scores_gemma":[0.9951002,0.0010008333,0.0024176573,0.00062304764,0.0004506695,0.00040760788],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0064535215,0.000667276,0.0015965338,0.0006476899,0.00039282817,0.0012924039,0.0007100709,0.0005712566,0.0039625936],"category_scores_gemma":[0.003945047,0.0004211096,0.0025603836,0.0014508498,0.00039570435,0.0008600955,0.0007273316,0.0010299148,0.0007891084],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20537627,0.003183768,0.61513996,0.003896584,0.020382,0.0005100717,0.0002898656,0.0037201843,0.010464489,0.00032072683,0.010094303,0.1266218],"study_design_scores_gemma":[0.029376533,0.02873748,0.91531616,0.0003254421,0.008594306,0.0012621902,0.00008379482,0.001607405,0.002716291,0.00039647735,0.011493124,0.000090768204],"about_ca_topic_score_codex":0.000952936,"about_ca_topic_score_gemma":0.0017719031,"teacher_disagreement_score":0.0064535215,"about_ca_system_score_codex":0.000801716,"about_ca_system_score_gemma":0.0011261158,"threshold_uncertainty_score":0.034129918},"labels":[],"label_agreement":null},{"id":"W4416141135","doi":"10.25251/6g1c9m39","title":"Phase 2a Randomized, Double-Blinded, Placebo-Controlled Trial of a Topical Nitric Oxide Releasing Solution (NORS) for the Treatment of Plantar Warts (HPV-Warts-01)","year":2025,"lang":"","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Research & Development Corporation","funders":"","keywords":"Plantar warts; Nitric oxide; Placebo; Clinical endpoint; Foot (prosody); Clinical trial","score_opus":0.04270462571932358,"score_gpt":0.3759896381305963,"score_spread":0.33328501241127273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416141135","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94650066,0.005059594,0.0020674232,0.0017088151,0.0023761424,0.03366704,0.0039217086,0.00042199265,0.004276622],"genre_scores_gemma":[0.9278558,0.0036660659,0.005816997,0.0032903086,0.0011090155,0.047021873,0.0022737018,0.000078288416,0.008888025],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.999343,0.0002499836,0.000036169502,0.00018884712,0.00005335946,0.00012863401],"domain_scores_gemma":[0.9987919,0.00029781013,0.00025360967,0.000110718225,0.0001659597,0.0003800138],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019984895,0.0027698325,0.003494879,0.00051737844,0.0007966119,0.0015357375,0.0014390285,0.0031690504,0.012998564],"category_scores_gemma":[0.0024482638,0.0013371017,0.001544908,0.00038198355,0.0015762196,0.0018544411,0.00051670993,0.004105347,0.0019566976],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.968635,0.019668542,0.00025989045,0.0006121668,0.000465877,0.000030666342,0.00005102989,0.0001332751,0.0025634018,0.00012856665,0.0010799303,0.006371496],"study_design_scores_gemma":[0.9423279,0.056137696,0.00040226823,0.000025013147,0.00012361871,0.0000149038615,0.000015535432,0.00014083502,0.00019765367,0.00011122071,0.00049494003,0.000008367911],"about_ca_topic_score_codex":0.0008918666,"about_ca_topic_score_gemma":0.0022980627,"teacher_disagreement_score":0.012998564,"about_ca_system_score_codex":0.0007806579,"about_ca_system_score_gemma":0.0019021202,"threshold_uncertainty_score":0.04348451},"labels":[],"label_agreement":null},{"id":"W4416141136","doi":"10.25251/9k281951","title":"Tapinarof Cream 1% Once Daily: Consistent Efficacy Across Age Groups for Children Down to 2 Years of Age with Atopic Dermatitis in Two Pivotal Phase 3 Trials","year":2025,"lang":"","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Atopic dermatitis; Age groups; Oxidative stress; Aryl hydrocarbon receptor; Agonist; Clinical trial; Psoriasis","score_opus":0.019675538828943413,"score_gpt":0.3610051985971068,"score_spread":0.3413296597681634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416141136","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87836474,0.091040745,0.002181761,0.0026295723,0.001455085,0.0092622,0.0064917523,0.00062324683,0.007950952],"genre_scores_gemma":[0.9206309,0.04968595,0.0052810535,0.0055550295,0.00081813626,0.00584401,0.0054303077,0.00012118693,0.00663335],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99953604,0.00014824398,0.00004108907,0.00009977701,0.000077910925,0.00009693101],"domain_scores_gemma":[0.9991315,0.000225284,0.00021857234,0.000042779266,0.000106651525,0.00027529028],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019638902,0.0017120774,0.0033589513,0.00052236946,0.0004424198,0.0012261799,0.00084772776,0.0018701258,0.0063073495],"category_scores_gemma":[0.001754196,0.00054194574,0.0028742165,0.00040775808,0.0005846162,0.000969315,0.00034758283,0.0030191506,0.0009001666],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.74093735,0.028423304,0.0031444726,0.008522997,0.005027149,0.00042326213,0.00042067037,0.00062172295,0.026057191,0.00061998644,0.013752194,0.17204973],"study_design_scores_gemma":[0.82898813,0.1503839,0.008932189,0.0005080809,0.0014877316,0.00035229887,0.00009308082,0.00027240376,0.0020347042,0.0002815895,0.0066178525,0.00004815876],"about_ca_topic_score_codex":0.001141439,"about_ca_topic_score_gemma":0.00422423,"teacher_disagreement_score":0.0063073495,"about_ca_system_score_codex":0.0007018894,"about_ca_system_score_gemma":0.0009365638,"threshold_uncertainty_score":0.021100223},"labels":[],"label_agreement":null},{"id":"W4416141157","doi":"10.25251/6m5ykw66","title":"Successful In Vitro and In Vivo Treatment of Tinea Pedis with a Nitric Oxide-releasing Gel","year":2025,"lang":"","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Nail Diseases and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Research & Development Corporation","funders":"","keywords":"Trichophyton rubrum; Nitric oxide; In vivo; Trichophyton; Fungicide; Antifungal; Refractory (planetary science)","score_opus":0.00704809578985545,"score_gpt":0.26791084267878434,"score_spread":0.2608627468889289,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416141157","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99328846,0.0019068207,0.0028947054,0.00004050931,0.00005403191,0.00009427504,0.00014052942,0.000038263937,0.0015424639],"genre_scores_gemma":[0.99422544,0.00076008454,0.0036076426,0.00004308924,0.000011757507,0.00004598652,0.00010734382,0.000011130796,0.0011875007],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99983704,0.000038258768,0.000013647635,0.00003423817,0.000046572663,0.000030093355],"domain_scores_gemma":[0.99982494,0.00006052838,0.000035081186,0.000024286799,0.00003196141,0.000023289125],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003503661,0.0003465662,0.00021806816,0.00018517594,0.00014538212,0.00018280951,0.00017048318,0.00030536496,0.00096133107],"category_scores_gemma":[0.00025672503,0.00009109962,0.00028577854,0.00008629747,0.00016068334,0.00013924146,0.00015343828,0.00022210505,0.00013909402],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001431137,0.000116223644,0.00013938049,0.00010514249,0.000007521483,0.0001053347,0.000032246237,0.00014573026,0.9951068,0.000017583547,0.000040805844,0.004040135],"study_design_scores_gemma":[0.000034809684,0.0044209803,0.00223541,0.000015495807,0.000040283245,0.00041446395,0.00004025022,0.0011276602,0.9899483,0.000017319331,0.0016993142,0.0000057303932],"about_ca_topic_score_codex":0.00040495797,"about_ca_topic_score_gemma":0.0004951051,"teacher_disagreement_score":0.00096133107,"about_ca_system_score_codex":0.00010314559,"about_ca_system_score_gemma":0.00014857997,"threshold_uncertainty_score":0.0032159686},"labels":[],"label_agreement":null},{"id":"W4416141158","doi":"10.25251/gsd1c102","title":"Most Baricitinib Responders Achieved Full Scalp Hair Regrowth: Findings from Adult and Paediatric BRAVE-AA Trials","year":2025,"lang":"","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Hair Growth and Disorders","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"","keywords":"Scalp; Young adult; Clinical trial; Severity of illness; Randomized controlled trial","score_opus":0.014469191181411756,"score_gpt":0.2858461746513273,"score_spread":0.2713769834699155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416141158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89869654,0.07018725,0.0009546108,0.0020161716,0.0001205442,0.00071940257,0.012738898,0.000075386444,0.014491222],"genre_scores_gemma":[0.98118985,0.009969453,0.0005342491,0.0014279746,0.00010056081,0.00034898752,0.005326997,0.000024727884,0.0010772094],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99729973,0.0011701938,0.0003752204,0.00042100207,0.0004959001,0.00023800584],"domain_scores_gemma":[0.99404764,0.0023128074,0.0023225958,0.0003053064,0.0006412299,0.0003703904],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0053852727,0.00019712429,0.00078972225,0.00029894867,0.0002215621,0.0010035101,0.00037189192,0.00046127726,0.0028642972],"category_scores_gemma":[0.005973803,0.00014162254,0.00084912387,0.0006854996,0.0003702364,0.0007815005,0.00033122022,0.000684842,0.00055736216],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08217313,0.0005831769,0.520432,0.005948172,0.00836563,0.00034333146,0.0009038767,0.0012425082,0.009518908,0.0008683151,0.024668027,0.34495297],"study_design_scores_gemma":[0.009488317,0.012353613,0.9100823,0.0017508338,0.005265203,0.002381002,0.00067294395,0.0008218974,0.002464209,0.00050534756,0.054127116,0.00008719649],"about_ca_topic_score_codex":0.0012024615,"about_ca_topic_score_gemma":0.00505791,"teacher_disagreement_score":0.0053852727,"about_ca_system_score_codex":0.0003561545,"about_ca_system_score_gemma":0.0005652606,"threshold_uncertainty_score":0.02848041},"labels":[],"label_agreement":null},{"id":"W4416141167","doi":"10.25251/w6str133","title":"Long-Term Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 244-Week Results From the KEEPsAKE 2 Trial","year":2025,"lang":"","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Psoriatic arthritis; Adverse effect; Psoriasis; Placebo; Imputation (statistics); Drug","score_opus":0.01989010843082884,"score_gpt":0.29351688533544873,"score_spread":0.2736267769046199,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416141167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943093,0.0018218765,0.00028431645,0.00021452329,0.000060781764,0.00043880826,0.0013357027,0.000026036196,0.0015086115],"genre_scores_gemma":[0.99163085,0.0008767132,0.000604924,0.00036047155,0.00024184812,0.00085916906,0.0032213866,0.000017614107,0.0021869962],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9984629,0.0008965928,0.00011795986,0.00016920337,0.00022279151,0.00013050891],"domain_scores_gemma":[0.99740183,0.00063512893,0.0010292202,0.00035275373,0.00020355298,0.00037755872],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00464167,0.0008074062,0.0014806957,0.0001738691,0.00035250196,0.0009264483,0.00046955014,0.00072992296,0.0034824412],"category_scores_gemma":[0.0027472223,0.00034453726,0.0017968204,0.00022794702,0.0004894895,0.0008256036,0.0005210708,0.0017476835,0.00053716754],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9318941,0.006641685,0.017351514,0.00081194233,0.0031636716,0.00009210063,0.0001460433,0.0011943303,0.007192042,0.00011199227,0.00235727,0.029043363],"study_design_scores_gemma":[0.6000781,0.24092062,0.14095809,0.00019700847,0.005578697,0.00033861352,0.00012927625,0.0014328073,0.004573914,0.0003703175,0.005306608,0.000115871866],"about_ca_topic_score_codex":0.0002486202,"about_ca_topic_score_gemma":0.00071572437,"teacher_disagreement_score":0.00464167,"about_ca_system_score_codex":0.00034675442,"about_ca_system_score_gemma":0.00059131114,"threshold_uncertainty_score":0.024547756},"labels":[],"label_agreement":null},{"id":"W4416141170","doi":"10.25251/36zrjg92","title":"Tapinarof Cream 1% Once Daily: Maintenance of Low Disease Activity Including Pruritus Through End of the Treatment-freeInterval in a Long-term Extension Trial in Patients Down to 2 Years of Age with Atopic Dermatitis","year":2025,"lang":"","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"","keywords":"Atopic dermatitis; Discontinuation; Psoriasis; Skin barrier; Disease; Clinical trial","score_opus":0.01250357248406921,"score_gpt":0.28869931337164745,"score_spread":0.27619574088757826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416141170","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9811337,0.011637546,0.0003578391,0.0004577251,0.00057598465,0.0015451192,0.0008131033,0.00014251683,0.0033363565],"genre_scores_gemma":[0.9867532,0.005364638,0.0006675702,0.0009172108,0.00037773766,0.0011659621,0.0010915535,0.000019848383,0.0036422906],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9997055,0.00010671554,0.000016096417,0.000050554194,0.000033255204,0.00008784009],"domain_scores_gemma":[0.9995801,0.00007652191,0.00007347575,0.000029061426,0.000030046194,0.00021072697],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00103813,0.0011268568,0.0018565208,0.0003154745,0.00032933633,0.0008661745,0.00074333936,0.0011918588,0.005016478],"category_scores_gemma":[0.00071575405,0.00036314392,0.0014764449,0.00027516813,0.00053263863,0.00094773417,0.0003046981,0.0030110735,0.00081398955],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8850367,0.027586889,0.002028891,0.0013446622,0.001040741,0.00020985896,0.00016842777,0.00034183895,0.010839739,0.00027428754,0.0028212895,0.06830663],"study_design_scores_gemma":[0.72111684,0.26592147,0.009230333,0.00011510331,0.0003839896,0.00017677902,0.000052110463,0.0003647245,0.0009292894,0.00014873387,0.0015407607,0.000019858813],"about_ca_topic_score_codex":0.00076534774,"about_ca_topic_score_gemma":0.0025523943,"teacher_disagreement_score":0.005016478,"about_ca_system_score_codex":0.00044456954,"about_ca_system_score_gemma":0.0005907715,"threshold_uncertainty_score":0.016781807},"labels":[],"label_agreement":null},{"id":"W4416141214","doi":"10.25251/xdxsk580","title":"A Novel Topical Nitric Oxide Releasing Gel Demonstrates Effective Nail Penetration and Potent Antifungal Activity in Onychomycosis","year":2025,"lang":"","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Nail Diseases and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Research & Development Corporation; Mediprobe Research (Canada); University of Toronto","funders":"","keywords":"Ex vivo; Terbinafine; Nail plate; Penetration (warfare); In vivo; Antifungal; Trichophyton; Nail (fastener)","score_opus":0.008592733521409688,"score_gpt":0.27777260285696126,"score_spread":0.26917986933555155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416141214","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991422,0.0044424115,0.0026282745,0.00008218799,0.000057295973,0.000046780206,0.00007207515,0.0000427071,0.0012061835],"genre_scores_gemma":[0.9946163,0.0014640526,0.002685721,0.00005765044,0.0000128614665,0.000021571013,0.00007262069,0.000007670944,0.0010615796],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999143,0.000015966967,0.000007661692,0.000020074465,0.000028260789,0.000013729526],"domain_scores_gemma":[0.9999449,0.000013372899,0.000015039341,0.0000055193577,0.000009084474,0.000012151454],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014975198,0.00023829576,0.00021652837,0.0001323059,0.000076220065,0.00014827102,0.00018456148,0.00022091746,0.0006096776],"category_scores_gemma":[0.00011858278,0.00007991803,0.00015928951,0.000045508616,0.0001330413,0.00014920453,0.00013795121,0.00020592022,0.000100941],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001852045,0.00008053026,0.00016608227,0.0001354396,0.0000066904413,0.00016505043,0.000014486361,0.000052768428,0.9909513,0.000027569517,0.00005607306,0.008158754],"study_design_scores_gemma":[0.00012428925,0.00732448,0.0067642275,0.000038004247,0.00008289641,0.002761583,0.000058756184,0.001429156,0.9776169,0.000043576943,0.0037420255,0.000014132664],"about_ca_topic_score_codex":0.0002221381,"about_ca_topic_score_gemma":0.00047397247,"teacher_disagreement_score":0.0006096776,"about_ca_system_score_codex":0.00009211433,"about_ca_system_score_gemma":0.000110725145,"threshold_uncertainty_score":0.0020395517},"labels":[],"label_agreement":null},{"id":"W4416141241","doi":"10.25251/x2k3y515","title":"Amlitelimab Reduces Th2-, Th1-, and Th17/22-Related Cytokines and Chemokines in Adults With Moderate-to-Severe Atopic Dermatitis: Results From an Exploratory Analysis of the Phase 2b STREAM-AD Study","year":2025,"lang":"","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lynde Centre for Dermatology; University of Toronto","funders":"National Institute of Allergy and Infectious Diseases; National Institutes of Health; Sanofi","keywords":"Placebo; Chemokine; Exploratory analysis; Inflammation; Monoclonal antibody; Blockade; Atopic dermatitis; Multiplex","score_opus":0.008317057868066989,"score_gpt":0.2776039301126633,"score_spread":0.26928687224459635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416141241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960193,0.0024882283,0.00012939362,0.00011043806,0.000017434935,0.00036186475,0.0003943792,0.000023266286,0.00045570277],"genre_scores_gemma":[0.9964593,0.0010300024,0.000623666,0.00024505774,0.000053087897,0.00034279298,0.0007237375,0.0000059948948,0.00051637203],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99964213,0.00016918653,0.000026873096,0.000055338405,0.00005327662,0.00005315178],"domain_scores_gemma":[0.99965537,0.00006723218,0.00009993311,0.000020705367,0.000042844007,0.00011387116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013353913,0.0007478252,0.0010980055,0.0002618186,0.00020526607,0.0005769094,0.0003229869,0.00037916654,0.0013643217],"category_scores_gemma":[0.00052986573,0.00022198733,0.0009412993,0.00019351313,0.00032410506,0.00036263105,0.000246808,0.0007496707,0.0001863389],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.57509315,0.030748993,0.068405,0.0016887867,0.0032404223,0.0003786839,0.00028925756,0.0016154337,0.16113603,0.00021485948,0.0044760243,0.15271336],"study_design_scores_gemma":[0.2777734,0.49589047,0.1898024,0.00012347355,0.0027947407,0.0009202254,0.00017093628,0.0025153747,0.024466896,0.00025818794,0.0052283164,0.000055487373],"about_ca_topic_score_codex":0.00054200075,"about_ca_topic_score_gemma":0.0015421015,"teacher_disagreement_score":0.0013643217,"about_ca_system_score_codex":0.0005173479,"about_ca_system_score_gemma":0.00066307804,"threshold_uncertainty_score":0.007062316},"labels":[],"label_agreement":null},{"id":"W4416141242","doi":"10.25251/h3w8px06","title":"Efficacy, Safety, and Tolerability of Upadacitinib in Adults and Adolescents With Severe Alopecia Areata: Results From the Randomized, Placebo-Controlled, Double-Blind Phase 3 Program (UP-AA)","year":2025,"lang":"","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Hair Growth and Disorders","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lynde Centre for Dermatology; Probity Medical Research; SKiN Health; Queen's University","funders":"Incyte; Les Laboratories Pierre Fabre; National Alopecia Areata Foundation; L'Oreal USA; Sanofi; Pfizer; Concert Pharmaceuticals; Eli Lilly and Company","keywords":"Tolerability; Context (archaeology); Clinical trial; Adverse effect; Phases of clinical research","score_opus":0.011279431426697174,"score_gpt":0.2933219497264348,"score_spread":0.28204251829973764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416141242","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949049,0.0029359083,0.00018276511,0.00016412202,0.000043790358,0.0006074047,0.00041955337,0.000023857407,0.00071775477],"genre_scores_gemma":[0.9961002,0.0016511981,0.00048749358,0.0003094339,0.00006400222,0.000419653,0.00044160167,0.0000057959955,0.0005207343],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9997032,0.00014457843,0.000023298886,0.000034021163,0.000048214348,0.000046488647],"domain_scores_gemma":[0.9995409,0.000115086594,0.00013886754,0.00002344011,0.00004535468,0.00013632466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010618273,0.00032421818,0.00079357746,0.00017397758,0.00022820642,0.00039629437,0.00024268063,0.00048078346,0.0021266402],"category_scores_gemma":[0.00087035954,0.00014861015,0.00073447067,0.00017189725,0.00023622204,0.0004222506,0.00019840314,0.0013400485,0.0002537859],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5476771,0.041421656,0.016365727,0.0018199119,0.0017048866,0.0002877899,0.00043014664,0.0010078525,0.035400737,0.00020334274,0.005429446,0.34825134],"study_design_scores_gemma":[0.33028802,0.51610696,0.13752767,0.00025809358,0.001264638,0.00064227625,0.00030877691,0.001341484,0.006888749,0.00018474726,0.0051384014,0.000050120587],"about_ca_topic_score_codex":0.00064814463,"about_ca_topic_score_gemma":0.002038981,"teacher_disagreement_score":0.0021266402,"about_ca_system_score_codex":0.00034244635,"about_ca_system_score_gemma":0.0005138411,"threshold_uncertainty_score":0.007114291},"labels":[],"label_agreement":null},{"id":"W4416141277","doi":"10.25251/9es69b60","title":"Impact of Moderate-to-Severe Atopic Dermatitis on Daily Functioning among Adolescent Patients: A Real-World Study in the United States","year":2025,"lang":"","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Atopic dermatitis; Quality of life (healthcare); Mood; Disease; Activities of daily living; Alternative medicine; Mood swing; Primary care","score_opus":0.01225173217685616,"score_gpt":0.29928422111473846,"score_spread":0.2870324889378823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416141277","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9993499,0.00013858569,0.000013187297,0.00004461805,0.0000021530523,0.000009168278,0.00025681645,6.717812e-7,0.00018504217],"genre_scores_gemma":[0.9995659,0.00013675922,0.000027811468,0.0000414016,0.000003625046,0.0000084877465,0.00019483021,4.6518753e-7,0.00002082784],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993973,0.00025550186,0.000084499945,0.00007978168,0.000107307525,0.00007560518],"domain_scores_gemma":[0.9986638,0.00028431596,0.0006077004,0.0000530095,0.00012860556,0.00026251576],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007708586,0.00020259792,0.00031865478,0.00057084596,0.00042562786,0.00066410383,0.000243666,0.00035659957,0.00082879514],"category_scores_gemma":[0.0018324275,0.00019318462,0.00035221153,0.00090050546,0.00034268608,0.00053996884,0.00049839925,0.00057991006,0.00011520439],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000017896184,0.000036084464,0.998953,0.000008929708,0.000018287761,0.000049503135,0.00021551797,0.000010064568,0.00003257834,0.0000067548153,0.00008606872,0.0005653058],"study_design_scores_gemma":[0.0000042681318,0.00006979232,0.998577,0.000012587076,0.000012534357,0.00023532298,0.0008686088,0.000054653505,0.000015270707,0.0000056171903,0.00014248607,0.0000018862822],"about_ca_topic_score_codex":0.010316968,"about_ca_topic_score_gemma":0.01740273,"teacher_disagreement_score":0.010316968,"about_ca_system_score_codex":0.00051631336,"about_ca_system_score_gemma":0.0004558425,"threshold_uncertainty_score":0.020513833},"labels":[],"label_agreement":null},{"id":"W4416141304","doi":"10.25251/21ypnv28","title":"Treatment Patterns and Efficacy in Biologic-Exposed and Biologic-Naive Patients With Moderate-to-Severe Atopic Dermatitis: JADE REAL Post Hoc Analysis","year":2025,"lang":"","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; SKiN Health","funders":"Pfizer","keywords":"Post-hoc analysis; Eczema Area and Severity Index; Post hoc; Janus kinase inhibitor; JADE (particle detector); Concomitant; Ruxolitinib","score_opus":0.007916708921851867,"score_gpt":0.25394115425868813,"score_spread":0.24602444533683626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416141304","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952366,0.0005079003,0.0008367366,0.00007882118,0.00006240009,0.00050397735,0.0017708672,0.000028642804,0.0009740978],"genre_scores_gemma":[0.9948655,0.00009742058,0.0008281125,0.000112411144,0.00005541496,0.0009538355,0.0021209405,0.000022322274,0.0009441679],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9930958,0.0041012024,0.00056204107,0.0010362504,0.0006363881,0.00056816236],"domain_scores_gemma":[0.9901603,0.006758761,0.0011735717,0.0009066497,0.0005145456,0.0004862485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006943401,0.0007550404,0.0021855545,0.000777722,0.0003423907,0.0010850898,0.0010485871,0.00068078976,0.0051344666],"category_scores_gemma":[0.008423087,0.0003007032,0.0042356662,0.000542507,0.00050033873,0.001245858,0.0009959276,0.0015439711,0.00038766934],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4945703,0.005747405,0.44328004,0.0010923167,0.019342454,0.00047087137,0.0005787576,0.0051281047,0.0062004114,0.0004029597,0.0038248873,0.01936142],"study_design_scores_gemma":[0.019333554,0.12507331,0.79801464,0.00012573869,0.00987941,0.00075417716,0.0010050402,0.034246814,0.003380397,0.0007959889,0.0072380193,0.00015293826],"about_ca_topic_score_codex":0.0006416542,"about_ca_topic_score_gemma":0.0007167394,"teacher_disagreement_score":0.006943401,"about_ca_system_score_codex":0.00047885676,"about_ca_system_score_gemma":0.0006780176,"threshold_uncertainty_score":0.036720693},"labels":[],"label_agreement":null},{"id":"W4416141338","doi":"10.25251/czq0gz98","title":"Rationale and Design of a Phase 1b Trial Evaluating APG279, the Combination of Half-Life-Extended Anti-IL-13 and Anti-OX40L Monoclonal Antibodies, Compared With Dupilumab in Moderate-to-Severe Atopic Dermatitis","year":2025,"lang":"","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Dupilumab; Atopic dermatitis; Adverse effect; Monoclonal antibody; Pharmacodynamics; Clinical endpoint; Disease; Incidence (geometry)","score_opus":0.030026271463707354,"score_gpt":0.3234356889230727,"score_spread":0.29340941745936533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416141338","genre_codex":"protocol","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"protocol","genre_consensus":"protocol","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14057904,0.020861022,0.019413449,0.012448397,0.0048114704,0.7575147,0.009809196,0.0005822893,0.033980448],"genre_scores_gemma":[0.30258745,0.0061044805,0.026480481,0.015146588,0.0016005489,0.63370657,0.003506239,0.00009165405,0.010776117],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.9955693,0.002496837,0.00024626008,0.0007792696,0.00045292903,0.00045540827],"domain_scores_gemma":[0.9972832,0.0006116508,0.00047884972,0.00022456338,0.00031909219,0.0010825621],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011177078,0.002896796,0.002491611,0.0006347558,0.0009578039,0.0018205132,0.0020068972,0.004169393,0.0155548155],"category_scores_gemma":[0.0066199224,0.0013447489,0.0021042689,0.00062929926,0.0018472607,0.0017319524,0.0008006369,0.005884727,0.0051702987],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7442941,0.027739497,0.007896423,0.011256852,0.0028603696,0.0012339145,0.00047580127,0.0054013077,0.018421877,0.011829864,0.026037935,0.14255194],"study_design_scores_gemma":[0.7084074,0.18641211,0.0068517546,0.0018672297,0.0023552189,0.0007002182,0.00013624546,0.0030574955,0.0041969563,0.008342983,0.07753208,0.00014026825],"about_ca_topic_score_codex":0.00045278846,"about_ca_topic_score_gemma":0.0012929388,"teacher_disagreement_score":0.0155548155,"about_ca_system_score_codex":0.0015006363,"about_ca_system_score_gemma":0.0058016023,"threshold_uncertainty_score":0.05911076},"labels":[],"label_agreement":null},{"id":"W4416141346","doi":"10.25251/p6a0hd58","title":"C-206 Real-World Prospective Data Assessing the Long-Term Safety of Abrocitinib Treatment in Adults with Moderate to Severe Atopic Dermatitis (AD): Over Two Years of Experience from the CorEvitas AD Registry [1225]","year":2025,"lang":"","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Genentech; Sanofi; Pfizer","keywords":"Cohort; Incidence (geometry); Prospective cohort study; Poisson regression; Cohort study; Confidence interval; Atopic dermatitis; Observational study","score_opus":0.016281883786891178,"score_gpt":0.33728489574132264,"score_spread":0.3210030119544315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416141346","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87498784,0.0017498668,0.0014193373,0.00024784709,0.000041546355,0.0008897708,0.11523125,0.00011341468,0.00531926],"genre_scores_gemma":[0.90698117,0.00047421374,0.0016008388,0.00028383933,0.00006996158,0.0009464623,0.088625126,0.000022175669,0.0009961713],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9949751,0.0016283775,0.0011272538,0.0008343723,0.001234688,0.0002001998],"domain_scores_gemma":[0.97311497,0.004735293,0.012840542,0.00433346,0.003985342,0.000990448],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005984955,0.00032365366,0.0006249085,0.0010721735,0.00049804,0.0011345899,0.00076461106,0.00041003682,0.0034206293],"category_scores_gemma":[0.015202528,0.00029901706,0.00092387974,0.0028086677,0.00033062836,0.00061671674,0.0008116752,0.00047405492,0.0011834454],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042765173,0.00022372566,0.97884595,0.00039874512,0.0008246918,0.00009276633,0.00010587278,0.00032957373,0.00045098714,0.00012153294,0.0047598933,0.009569668],"study_design_scores_gemma":[0.00067867246,0.0008578193,0.9910294,0.0001078255,0.0004047378,0.00044578454,0.00009314014,0.0004314555,0.0004251098,0.00005442659,0.0054488447,0.000022774788],"about_ca_topic_score_codex":0.010119592,"about_ca_topic_score_gemma":0.009896428,"teacher_disagreement_score":0.010119592,"about_ca_system_score_codex":0.0008362114,"about_ca_system_score_gemma":0.0015148548,"threshold_uncertainty_score":0.031651855},"labels":[],"label_agreement":null},{"id":"W4416141358","doi":"10.25251/m10xva58","title":"Drug Survival of Risankizumab vs Other Biologics After 25 Months of Treatment Among Patients With Psoriatic Arthritis: An Interim Analysis of the VALUE Study","year":2025,"lang":"","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Pfizer","keywords":"Interim analysis; Concomitant; Post-hoc analysis; Psoriatic arthritis; Propensity score matching; Psoriasis; Observational study; Interim","score_opus":0.007972802628403415,"score_gpt":0.24529220213115632,"score_spread":0.2373193995027529,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416141358","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99406105,0.001103112,0.00085302675,0.00013845396,0.00006459009,0.00012790217,0.002683194,0.000020154628,0.0009484848],"genre_scores_gemma":[0.99347794,0.00014016696,0.0005544018,0.00015032759,0.00006114612,0.0002031819,0.004844346,0.00001314904,0.00055545627],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956316,0.0024507532,0.0002562824,0.000587471,0.0005318272,0.00054214435],"domain_scores_gemma":[0.9911869,0.0035306853,0.0024192173,0.0016836022,0.00044351426,0.0007360681],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0097766295,0.00046419178,0.0018541886,0.00050779944,0.0003623976,0.0013273743,0.00074828893,0.000672815,0.0024523456],"category_scores_gemma":[0.009639113,0.00035328232,0.004612993,0.00065921055,0.0003780583,0.0009212045,0.00087127683,0.002150979,0.00037386012],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42524716,0.0027277796,0.50951916,0.00044366872,0.015250107,0.0003115865,0.0002817782,0.004913511,0.0022448495,0.00072700693,0.0050455933,0.03328777],"study_design_scores_gemma":[0.024918048,0.102301024,0.81969357,0.00021885002,0.02360003,0.00070015475,0.00039710163,0.015999047,0.003475918,0.001628212,0.006910352,0.00015765926],"about_ca_topic_score_codex":0.00049207587,"about_ca_topic_score_gemma":0.00066085794,"teacher_disagreement_score":0.0097766295,"about_ca_system_score_codex":0.00057996734,"about_ca_system_score_gemma":0.00082994386,"threshold_uncertainty_score":0.051704407},"labels":[],"label_agreement":null},{"id":"W4416141382","doi":"10.25251/36mxmk39","title":"Integrated Safety Analysis of Ruxolitinib Cream: Data From 20 Clinical Studies in Inflammatory Dermatologic Conditions","year":2025,"lang":"","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"Incyte","keywords":"Ruxolitinib; Clinical trial; Safety profile; MEDLINE; Risk assessment","score_opus":0.09100882040484524,"score_gpt":0.43360308264627695,"score_spread":0.3425942622414317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416141382","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87547415,0.09272365,0.004291124,0.00035651968,0.00007358224,0.0025480394,0.017269034,0.00021528846,0.0070486297],"genre_scores_gemma":[0.97758055,0.008752055,0.0015947456,0.00046449061,0.00011217102,0.0008715771,0.009451195,0.00005761023,0.0011155745],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9918949,0.0034243907,0.001605451,0.00093306333,0.0018117419,0.00033039704],"domain_scores_gemma":[0.9879567,0.004787409,0.004466758,0.0010907409,0.0012865828,0.00041172904],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011536363,0.0009039553,0.00248135,0.0017078992,0.00034339086,0.0015758444,0.00049342104,0.00084740063,0.0038336872],"category_scores_gemma":[0.009665523,0.00035829094,0.0041029444,0.0018255397,0.0004883682,0.00077214005,0.0007994084,0.00093365443,0.00064593175],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32495147,0.0029934898,0.14896637,0.02049493,0.10881411,0.0007588213,0.0005643931,0.004217534,0.06213496,0.0006029832,0.0059326976,0.3195683],"study_design_scores_gemma":[0.06614786,0.095328994,0.63464415,0.0017772852,0.11672107,0.003438759,0.00028195063,0.0024295852,0.028399272,0.00090046006,0.049673364,0.00025722527],"about_ca_topic_score_codex":0.00023745748,"about_ca_topic_score_gemma":0.00062668254,"teacher_disagreement_score":0.011536363,"about_ca_system_score_codex":0.00066107686,"about_ca_system_score_gemma":0.0009758269,"threshold_uncertainty_score":0.061010838},"labels":[],"label_agreement":null},{"id":"W4416141399","doi":"10.25251/t4rkzz84","title":"Flexible Dosing of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Initial Results From the Real-World–Simulating Expanded Access Protocol Study, JADE REAL","year":2025,"lang":"","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health; Queen's University; Probity Medical Research","funders":"Pfizer","keywords":"Dosing; Adverse effect; Incidence (geometry); JADE (particle detector); Expanded access; Clinical trial","score_opus":0.023100562919750114,"score_gpt":0.356878933342599,"score_spread":0.3337783704228489,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416141399","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98422396,0.0018738239,0.0014022626,0.0003683165,0.00007172963,0.006959263,0.0024075743,0.000056480152,0.0026364704],"genre_scores_gemma":[0.98249924,0.001118699,0.0035325417,0.00062170805,0.00010415092,0.008542265,0.00276567,0.000020735482,0.00079504173],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9928865,0.005721548,0.00041195107,0.00044308894,0.000336291,0.00020068334],"domain_scores_gemma":[0.9939579,0.002222162,0.0017584699,0.0010810314,0.0004364514,0.00054407516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012526947,0.0007647583,0.0009506503,0.00031335434,0.00044134527,0.0012730858,0.00064118014,0.00079377065,0.0033315811],"category_scores_gemma":[0.009918908,0.00044251134,0.001993422,0.0004492118,0.00064194784,0.0011184542,0.00066331855,0.0014147048,0.0005716242],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.82053435,0.04219412,0.042315036,0.0017969975,0.0035945417,0.00043974328,0.00060372334,0.0038571216,0.009018554,0.0005238311,0.005718891,0.069403075],"study_design_scores_gemma":[0.5193567,0.32902485,0.12574184,0.00034781254,0.0026041926,0.0012792534,0.000302158,0.0058764587,0.002690017,0.00069358817,0.011932382,0.00015072878],"about_ca_topic_score_codex":0.0005215789,"about_ca_topic_score_gemma":0.00101739,"teacher_disagreement_score":0.012526947,"about_ca_system_score_codex":0.001042966,"about_ca_system_score_gemma":0.0015156852,"threshold_uncertainty_score":0.06624961},"labels":[],"label_agreement":null},{"id":"W4416195853","doi":"10.25251/64mgd212","title":"Red Light Photodynamic Therapy with 10% Aminolevulinic Acid Gel Showed Robust Efficacy for the Treatment of Superficial BCC in a Randomized, Vehicle-Controlled, Double-Blind, Multicenter Phase III Study","year":2025,"lang":"","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Nonmelanoma Skin Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bell (Canada)","funders":"","keywords":"Photodynamic therapy; Lesion; Basal cell carcinoma; Target lesion; Occlusion; Basal cell; Clinical trial","score_opus":0.03080565497281926,"score_gpt":0.33476288269899934,"score_spread":0.30395722772618006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416195853","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860373,0.0034073316,0.0022461135,0.00031233203,0.00027210874,0.005846466,0.00066531455,0.00016048706,0.0010524633],"genre_scores_gemma":[0.9853408,0.0023223246,0.003903125,0.00058374624,0.00019463748,0.0048383055,0.0008531133,0.000055196953,0.0019086958],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9989901,0.00051071827,0.000077207296,0.00019696423,0.000120213546,0.00010489331],"domain_scores_gemma":[0.9989625,0.00021694435,0.00029486566,0.00011433461,0.0001632276,0.00024809822],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004093554,0.0010869933,0.0020279817,0.00031922062,0.00045915946,0.0008877149,0.00077259785,0.001263658,0.0030822777],"category_scores_gemma":[0.001259519,0.00066873454,0.0013470614,0.0003803179,0.00082152325,0.00061290554,0.00025548195,0.0020150517,0.0005776957],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6726153,0.09858514,0.001737976,0.0019920445,0.0018043263,0.00009615693,0.00028625864,0.00083771365,0.16275446,0.0001735054,0.002329749,0.056787346],"study_design_scores_gemma":[0.37298185,0.6053698,0.005468228,0.00007813263,0.0011615125,0.000098652556,0.000041688305,0.00067744637,0.012022423,0.0000995806,0.0019690662,0.00003164301],"about_ca_topic_score_codex":0.0005964186,"about_ca_topic_score_gemma":0.0015228869,"teacher_disagreement_score":0.004093554,"about_ca_system_score_codex":0.00052930915,"about_ca_system_score_gemma":0.0018081452,"threshold_uncertainty_score":0.021649063},"labels":[],"label_agreement":null},{"id":"W4416195856","doi":"10.25251/9sm0xp66","title":"Safety and Efficacy of Photodynamic Therapy with Aminolevulinic Acid 10% Topical Gel Activated by Red Light versus Aminolevulinic Acid 20% Topical Solution Activated by Blue Light for the Treatment of Actinic Keratosis on the Upper Extremities: A Blinded Randomized Study","year":2025,"lang":"","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Nonmelanoma Skin Cancer Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Covenant Health","funders":"","keywords":"Photodynamic therapy; Actinic keratosis; Actinic keratoses; Intense pulsed light; Red light; Clinical endpoint; Blue light; Clinical trial","score_opus":0.021827952059749144,"score_gpt":0.3017234534958868,"score_spread":0.2798955014361377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416195856","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907479,0.0019433728,0.0007576723,0.00018198273,0.00034054468,0.004733646,0.0004313422,0.000047030433,0.000816545],"genre_scores_gemma":[0.9895865,0.0012095417,0.0016410992,0.00040073696,0.0005348148,0.0051569203,0.00035691043,0.000017894869,0.0010955216],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9960716,0.0023165438,0.0003503534,0.0006037119,0.0003576733,0.00030015167],"domain_scores_gemma":[0.99442333,0.0019426931,0.0017212933,0.0004423249,0.0005061823,0.0009642536],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0059787515,0.002021178,0.004372837,0.00068553124,0.0006702515,0.0015628507,0.0013593341,0.0027340178,0.0048829764],"category_scores_gemma":[0.0050061117,0.0012352496,0.0028924926,0.0005528358,0.0021268942,0.0014928699,0.0005733064,0.002821161,0.0009981053],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9834351,0.009510934,0.00048939517,0.00021855108,0.0005065863,0.000010955948,0.000027434324,0.00010576607,0.0019064674,0.00002222958,0.00008019598,0.0036863831],"study_design_scores_gemma":[0.71099305,0.28492832,0.0017180591,0.000025064295,0.0008358898,0.000018856494,0.000022413236,0.00035904723,0.0008115227,0.00006702629,0.0002018523,0.000018926325],"about_ca_topic_score_codex":0.00054683024,"about_ca_topic_score_gemma":0.00081213325,"teacher_disagreement_score":0.0059787515,"about_ca_system_score_codex":0.00092369004,"about_ca_system_score_gemma":0.0016982899,"threshold_uncertainty_score":0.031619012},"labels":[],"label_agreement":null}]}